<SEC-DOCUMENT>0001104659-23-049365.txt : 20230425
<SEC-HEADER>0001104659-23-049365.hdr.sgml : 20230425
<ACCEPTANCE-DATETIME>20230425092609
ACCESSION NUMBER:		0001104659-23-049365
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20230424
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230425
DATE AS OF CHANGE:		20230425

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Assertio Holdings, Inc.
		CENTRAL INDEX KEY:			0001808665
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				850598378
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39294
		FILM NUMBER:		23841983

	BUSINESS ADDRESS:	
		STREET 1:		100 S. SAUNDERS ROAD
		STREET 2:		SUITE 300
		CITY:			LAKE FOREST
		STATE:			IL
		ZIP:			60045
		BUSINESS PHONE:		(224) 419-7106

	MAIL ADDRESS:	
		STREET 1:		100 S. SAUNDERS ROAD
		STREET 2:		SUITE 300
		CITY:			LAKE FOREST
		STATE:			IL
		ZIP:			60045
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2313548d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:ASRT="http://assertiotx.com/20230424">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_030_ASRT_assertiotx.com_20230424 -->
<!-- Field: Set; Name: xdx; ID: xdx_044_20230424_20230424 -->
<!-- Field: Set; Name: xdx; ID: xdx_05B_edei%2D%2DEntityCentralIndexKey_0001808665 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2023-04-24to2023-04-24" name="dei:EntityCentralIndexKey">0001808665</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-04-24to2023-04-24" name="dei:AmendmentFlag">false</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="asrt-20230424.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2023-04-24to2023-04-24">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808665</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-24</xbrli:startDate>
        <xbrli:endDate>2023-04-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0">&#160;</p>



<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM&#160;<span id="xdx_90E_edei--DocumentType_c20230424__20230424_z1ZD59s6rHGg"><ix:nonNumeric contextRef="From2023-04-24to2023-04-24" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section 13 or 15(d) of the</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Securities Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_906_edei--DocumentPeriodEndDate_c20230424__20230424_zFj7tewWwMf5"><ix:nonNumeric contextRef="From2023-04-24to2023-04-24" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">April 24, 2023</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Date of Report (Date of earliest event reported)</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 20%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 20pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_902_edei--EntityRegistrantName_c20230424__20230424_zY1rBywWPhMb" style="font-size: 20pt"><ix:nonNumeric contextRef="From2023-04-24to2023-04-24" name="dei:EntityRegistrantName">ASSERTIO HOLDINGS,&#160;INC.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Exact name of registrant as specified in its
charter)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 20%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="vertical-align: top; width: 32%; text-align: center"><b><span id="xdx_906_edei--EntityIncorporationStateCountryCode_c20230424__20230424_zqn050ii6CG4"><ix:nonNumeric contextRef="From2023-04-24to2023-04-24" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></td>
    <td style="vertical-align: bottom; width: 2%">&#160;</td>
    <td style="vertical-align: top; width: 32%; text-align: center"><b><span id="xdx_906_edei--EntityFileNumber_c20230424__20230424_zFowtNuTJ0lg"><ix:nonNumeric contextRef="From2023-04-24to2023-04-24" name="dei:EntityFileNumber">001-39294</ix:nonNumeric></span></b></td>
    <td style="vertical-align: bottom; width: 2%">&#160;</td>
    <td style="vertical-align: top; width: 32%; text-align: center"><b><span id="xdx_906_edei--EntityTaxIdentificationNumber_c20230424__20230424_zIMoSLdDPM95"><ix:nonNumeric contextRef="From2023-04-24to2023-04-24" name="dei:EntityTaxIdentificationNumber">85-0598378</ix:nonNumeric></span></b></td></tr>
<tr>
    <td style="vertical-align: top; text-align: center"><b>(State or Other Jurisdiction of<br />
    Incorporation)</b></td>
    <td style="vertical-align: bottom"><b>&#160;</b></td>
    <td style="vertical-align: top; text-align: center"><b>(Commission<br />
    File Number)</b></td>
    <td style="vertical-align: bottom"><b>&#160;</b></td>
    <td style="vertical-align: top; text-align: center"><b>(IRS Employer <br />
    Identification Number)</b></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_90F_edei--EntityAddressAddressLine1_c20230424__20230424_zH7l2Le8ABYf"><b><ix:nonNumeric contextRef="From2023-04-24to2023-04-24" name="dei:EntityAddressAddressLine1">100
South Saunders Rd</ix:nonNumeric></b></span><b>., <span id="xdx_90C_edei--EntityAddressAddressLine2_c20230424__20230424_zi31TPhb19Dl"><ix:nonNumeric contextRef="From2023-04-24to2023-04-24" name="dei:EntityAddressAddressLine2">Suite
300</ix:nonNumeric></span></b><b> <br />
<span id="xdx_901_edei--EntityAddressCityOrTown_c20230424__20230424_zdXpzogdQeRf"><ix:nonNumeric contextRef="From2023-04-24to2023-04-24" name="dei:EntityAddressCityOrTown">Lake Forest</ix:nonNumeric></span></b><b>, <span id="xdx_90E_edei--EntityAddressStateOrProvince_c20230424__20230424_zom0FTD86Lp4"><ix:nonNumeric contextRef="From2023-04-24to2023-04-24" name="dei:EntityAddressStateOrProvince">IL</ix:nonNumeric></span></b><b> <span id="xdx_90E_edei--EntityAddressPostalZipCode_c20230424__20230424_zuMeHDV8uJae"><ix:nonNumeric contextRef="From2023-04-24to2023-04-24" name="dei:EntityAddressPostalZipCode">60045</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 90.65pt 0pt 91pt; text-align: center"><b>(Address of principal executive offices) (Zip Code)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>(<span id="xdx_90E_edei--CityAreaCode_c20230424__20230424_zxPJnsaGpgGa"><ix:nonNumeric contextRef="From2023-04-24to2023-04-24" name="dei:CityAreaCode">224</ix:nonNumeric></span>) <span id="xdx_904_edei--LocalPhoneNumber_c20230424__20230424_zejMoUZP4Y3j"><ix:nonNumeric contextRef="From2023-04-24to2023-04-24" name="dei:LocalPhoneNumber">419-7106</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>(Registrant&#8217;s telephone number, including area code)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>N/A</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Former Name or Former Address, if Changed Since Last Report)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Wingdings"><span style="font-family: Wingdings"><span id="xdx_907_edei--WrittenCommunications_c20230424__20230424_zxDSpksN9lA1"><ix:nonNumeric contextRef="From2023-04-24to2023-04-24" format="ixt:booleantrue" name="dei:WrittenCommunications">&#120;</ix:nonNumeric></span></span></span>&#160;&#160;&#160;&#160;&#160;Written communications
pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Wingdings"><span style="font-family: Wingdings"><span id="xdx_905_edei--SolicitingMaterial_c20230424__20230424_zoxu6V8uHsLf"><ix:nonNumeric contextRef="From2023-04-24to2023-04-24" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></span></span><span style="font-size: 10pt">&#160;&#160;&#160;&#160;&#160;</span>Soliciting
material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Wingdings"><span style="font-family: Wingdings"><span id="xdx_90B_edei--PreCommencementTenderOffer_c20230424__20230424_z250sa9lq4P2"><ix:nonNumeric contextRef="From2023-04-24to2023-04-24" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></span></span><span style="font-size: 10pt">&#160;&#160;&#160;&#160;&#160;</span>Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Wingdings"><span style="font-family: Wingdings"><span id="xdx_902_edei--PreCommencementIssuerTenderOffer_c20230424__20230424_zNsON3eGyRfd"><ix:nonNumeric contextRef="From2023-04-24to2023-04-24" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span></span><span style="font-size: 10pt">&#160;&#160;&#160;&#160;&#160;</span>Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Securities registered pursuant
to Section&#160;12(b)&#160;of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="text-align: center; width: 32%; padding-right: 5.4pt; padding-left: 5.4pt"><b>Title
    of each class</b></td>
    <td style="width: 2%"><b>&#160;</b></td>
    <td style="text-align: center; width: 26%; padding-right: 5.4pt; padding-left: 5.4pt"><b>Trading
    Symbol(s)</b></td>
    <td style="width: 2%"><b>&#160;</b></td>
    <td style="text-align: center; width: 38%; padding-right: 5.4pt; padding-left: 5.4pt"><b>Name
    of each exchange on which registered</b></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center; padding-right: 5.4pt; padding-left: 5.4pt"><span id="xdx_905_edei--Security12bTitle_c20230424__20230424_zEROzm3tQavh"><ix:nonNumeric contextRef="From2023-04-24to2023-04-24" name="dei:Security12bTitle">Common Stock, $0.0001 par value</ix:nonNumeric></span></td>
    <td>&#160;</td>
    <td style="text-align: center; padding-right: 5.4pt; padding-left: 5.4pt">
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_90F_edei--TradingSymbol_c20230424__20230424_zt8CjYhTLzK5"><ix:nonNumeric contextRef="From2023-04-24to2023-04-24" name="dei:TradingSymbol">ASRT</ix:nonNumeric></span></p></td>
    <td>&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">The <span id="xdx_900_edei--SecurityExchangeName_c20230424__20230424_zaPuJ8ufTMzb"><ix:nonNumeric contextRef="From2023-04-24to2023-04-24" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Capital Market</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Emerging growth company&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <span style="font-family: Wingdings"><span style="font-family: Wingdings"><span id="xdx_903_edei--EntityEmergingGrowthCompany_c20230424__20230424_zEk1qTBQQbjb"><ix:nonNumeric contextRef="From2023-04-24to2023-04-24" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section&#160;13(a)&#160;of the Exchange Act.&#160;&#160;&#160;&#160;&#160; <span style="font-family: Wingdings"><span style="font-family: Wingdings">&#168;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item&#160;1.01 Entry into a Material Definitive Agreement.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April&#160;24, 2023, Assertio Holdings,&#160;Inc., a Delaware corporation
(the &#8220;<span style="text-decoration: underline">Company</span>&#8221;), entered into an Agreement and Plan of Merger (the &#8220;<span style="text-decoration: underline">Merger Agreement</span>&#8221;), by and among
the Company, Spade Merger Sub 1,&#160;Inc., a Delaware corporation and wholly owned subsidiary of the Company (&#8220;<span style="text-decoration: underline">Merger Sub</span>&#8221;),
and Spectrum Pharmaceuticals,&#160;Inc., a Delaware corporation (&#8220;<span style="text-decoration: underline">Spectrum</span>&#8221;), pursuant to which, subject to the terms
and conditions set forth therein, Merger Sub will merge with and into Spectrum (the &#8220;<span style="text-decoration: underline">Merger</span>&#8221;), with Spectrum surviving
such Merger as a wholly owned subsidiary of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Merger Consideration</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the Merger Agreement, at the effective time of the Merger (the
&#8220;<span style="text-decoration: underline">Effective Time</span>&#8221;), each share of common stock, par value $0.001 per share, of Spectrum (the &#8220;<span style="text-decoration: underline">Spectrum Common
Stock</span>&#8221;) issued and outstanding immediately prior to the Effective Time (other than (i)&#160;treasury shares, (ii)&#160;any shares
of Spectrum Common Stock held directly by the Company or Merger Sub and (iii)&#160;shares of Spectrum Common Stock held by any holder
who properly demands appraisal of such shares in compliance with Section&#160;262 of the Delaware General Corporation Law) will be converted
into the right to receive (A)&#160;0.1783 (the &#8220;<span style="text-decoration: underline">Exchange Ratio</span>&#8221;) of a fully paid and non-assessable share of common
stock, par value $0.0001 per share, of the Company (the &#8220;<span style="text-decoration: underline">Company Common Stock</span>&#8221;) and, if applicable, cash in lieu of
fractional shares, subject to any applicable withholding (the &#8220;<span style="text-decoration: underline">Upfront Consideration</span>&#8221;), and (B)&#160;one contingent
value right (a &#8220;<span style="text-decoration: underline">CVR</span>&#8221;), which shall represent the right to receive the Milestone Payments (as defined below), at the
times and in the form provided for in the CVR Agreement (as defined below) (collectively, with the Upfront Consideration, the &#8220;<span style="text-decoration: underline">Merger
Consideration</span>&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At the Effective Time, Spectrum and a rights agent selected by Spectrum
and the Company (the &#8220;<span style="text-decoration: underline">Rights Agent</span>&#8221;) will enter into a contingent value rights agreement (the &#8220;<span style="text-decoration: underline">CVR Agreement</span>&#8221;),
a form of which is attached as an exhibit to the Merger Agreement, governing the terms of each CVR. Each CVR entitles the holder thereof
to receive a maximum of two contingent cash and/or Company Common Stock payments, as described below, with an aggregate maximum value
of $0.20, without interest, and subject to deduction for any required withholding of taxes (each, a &#8220;<span style="text-decoration: underline">Milestone Payment</span>&#8221;),
if the following milestones are achieved:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"></td><td style="text-align: justify; width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">If Net Sales (as defined in the CVR Agreement) of $175 million or more during the period commencing January&#160;1, 2024 and ending
December&#160;31, 2024 is achieved, such Milestone Payment will consist of a dollar amount per CVR equal to the lesser of (i)&#160;$0.10
and (ii)&#160;(A)&#160;0.249 <i>multiplied </i>by (B)&#160;(I)&#160;the Applicable Parent Stock Price (as defined in the CVR Agreement),
<i>multiplied </i>by (II)&#160;the Exchange Ratio (rounded down to the closest hundredth of a penny) (<span style="text-decoration: underline">provided</span> that such amount
shall not be less than $0) (the &#8220;<span style="text-decoration: underline">2024 Annual Net Sales Milestone Payment</span>&#8221;); and</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"></td><td style="text-align: justify; width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">If Net Sales of $225 million or more during the period commencing January&#160;1, 2025 and ending December&#160;31, 2025 is achieved,
such Milestone Payment will consist of a dollar amount per CVR equal to the lesser of (i)&#160;$0.10 and (ii)&#160;(A)&#160;0.249 <i>multiplied</i>
by (B)&#160;(I)&#160;the Applicable Parent Stock Price, <i>multiplied</i> by (II)&#160;the Exchange Ratio, <i>less </i>(III)&#160;the
2024 Annual Net Sales Milestone Payment (rounded down to the closest hundredth of a penny) (<span style="text-decoration: underline">provided</span> that such amount shall not
be less than $0).</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The foregoing description of the CVR Agreement does not purport to
be complete and is qualified in its entirety by reference to the full text of the CVR Agreement, a copy of which is included as an exhibit
to the Merger Agreement filed as Exhibit&#160;2.1 to this Current Report on Form&#160;8-K (this &#8220;<span style="text-decoration: underline">Current Report</span>&#8221;) and
incorporated by reference herein.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At the Effective Time, each option (other than an option under Spectrum&#8217;s
employee stock purchase plan) (each, a &#8220;<span style="text-decoration: underline">Spectrum Stock Option</span>&#8221;) to purchase Spectrum Common Stock granted under any
of Spectrum&#8217;s equity incentive plans, that is outstanding as of immediately prior to the Effective Time, shall, if unvested, become
vested, and automatically and without any required action on the part of the holder or Spectrum, be cancelled and treated as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"></td><td style="text-align: justify; width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">With respect to any Spectrum Stock Options with an exercise price per share that is less than the value of the Upfront Consideration,
converted into the right to receive (i)&#160;a number of shares of Company Common Stock, subject to certain exceptions with respect to
fractional shares and any applicable withholdings, that is equal to the quotient of (A)&#160;the product of (x)&#160;the total number
of Spectrum Common Stock underlying the Spectrum Stock Option multiplied by (y)&#160;the excess, if any, of the value of the Upfront Consideration
over the exercise price of such Spectrum Stock Option, divided by (B)&#160;the average of the daily volume-weighted average price per
share of Company Common Stock calculated based on the ten (10)&#160;consecutive trading days ending two trading days prior to the date
of the Merger Agreement and (ii)&#160;a number of CVRs equal to the number of Spectrum Common Stock underlying such Spectrum Stock Option.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">With respect to any Spectrum Stock Options with an exercise per share that is equal to or greater than the value of the Upfront Consideration
and less than the sum of the Upfront Consideration and the maximum amount payable under a CVR (each, a &#8220;<span style="text-decoration: underline">Contingent In-the-Money
Stock Option</span>&#8221;), converted into the right to receive a number of CVRs equal the number of Spectrum Common Stock underlying such
Spectrum Stock Option; provided, however, that the payment, if any, under each CVR shall be reduced by the amount by which the exercise
price per share exceeds the value of the Upfront Consideration; provided, further that, for the avoidance of doubt, such Contingent In-the-Money
Stock Option shall not entitle the holder thereof to receive any shares of Company Common Stock, cash or other consideration in connection
with the Effective Time.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"></td><td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td><td style="text-align: justify">With respect to any Spectrum Stock Options with an exercise price per share that is equal to or greater than the value of the Merger
Consideration (each, an &#8220;<span style="text-decoration: underline">Underwater Spectrum Stock Option</span>&#8221;), the holder of such Underwater Spectrum Stock Option will
receive no consideration and, effective as of immediately prior to the Effective Time, shall have no further rights thereto.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At the Effective Time, each Spectrum restricted stock unit (each, a
&#8220;<span style="text-decoration: underline">Spectrum RSU</span>&#8221;) with respect to Spectrum Common Stock granted under Spectrum&#8217;s equity incentive plans, whether
vested or unvested, that is outstanding immediately prior to the Effective Time shall become fully vested, and the holder of such Spectrum
RSUs shall, automatically and without any required action on the part of the holder thereof or Spectrum, receive the Merger Consideration.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At the Effective Time, each unvested restricted Spectrum Common Stock
granted under Spectrum&#8217;s equity incentive plans that is outstanding immediately prior to the Effective Time shall, automatically
and without any required action on the part of the holder thereof or Spectrum, fully vest and be treated like all other shares of Spectrum
Common Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At the Effective Time, each stock appreciation right with respect to
Spectrum Common Stock (each, a &#8220;<span style="text-decoration: underline">Spectrum SAR</span>&#8221;) granted under Spectrum equity incentive plans that is outstanding as
of immediately prior to the Effective Time, shall, if unvested, become vested, and automatically and without any required action on the
part of the holder or Spectrum be cancelled and:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"></td><td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td><td style="text-align: justify">With respect to any Spectrum SARs with an exercise price per share that is less than the value of the Upfront Consideration (each
such Spectrum SAR, an &#8220;<span style="text-decoration: underline">In-the-Money SAR</span>&#8221;), converted into the right to receive (i)&#160;a number of shares of Company
Common Stock, subject to certain terms with respect to fractional shares and any required withholding of taxes pursuant as described further
in the Merger Agreement, that is equal to the quotient of (A)&#160;the product of (x)&#160;the total number of Spectrum Common Stock underlying
the Spectrum SAR multiplied by (y)&#160;the excess, if any, of the value of the Upfront Consideration over the exercise price of such
Spectrum SAR, divided by (B)&#160;the average of the daily volume-weighted average price per share of Company Common Stock calculated
based on the ten (10)&#160;consecutive trading days ending two trading days prior to the date of the Merger Agreement and (ii)&#160;a
number of CVRs equal to the number of Spectrum Common Stock underlying such Spectrum SAR.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"></td><td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td><td style="text-align: justify">With respect to any Spectrum SARs with an exercise price per share that is equal to or greater than the value of the Upfront Consideration
and less than the sum of the Upfront Consideration and the maximum amount payable under a CVR (each, a &#8220;<span style="text-decoration: underline">Contingent In-the-Money
SAR</span>&#8221;), converted into the right to receive a number of CVRs equal the number of Spectrum Common Stock underlying such Spectrum SAR;
provided, however, that the payment, if any, under each CVR shall be reduced by the amount by which the exercise price per share exceeds
the value of the Upfront Consideration; provided, further that, for the avoidance of doubt, such Contingent In-the-Money SAR shall not
entitle the holder thereof to receive any shares of Company Common Stock, cash or other consideration in connection with the Effective
Time.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"></td><td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Symbol">&#183;</span></span></td><td style="text-align: justify">With respect to any Spectrum SAR with an exercise price per share that is equal to or greater than the value of the Merger Consideration
(each, an &#8220;<span style="text-decoration: underline">Underwater Spectrum SAR</span>&#8221;), the holder of such Underwater Spectrum SAR will receive no consideration and,
effective as of immediately prior to the Effective Time, shall have no further rights thereto.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To the extent the Company and any holder of a Spectrum Stock Option,
Spectrum RSU, share of unvested restricted Spectrum Common Stock or Spectrum SAR agree in writing to treatment different than as described
above, the terms of such written agreement will apply in lieu of the treatment described above.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At the Effective Time, upon the election of the holder of each Spectrum
warrant (the &#8220;<span style="text-decoration: underline">Spectrum Warrant</span>&#8221;), under that certain Warrant to Purchase Stock, dated as of September&#160;21, 2022,
by and between Spectrum and SLR Investment Corp., a Maryland corporation, that is outstanding immediately prior to the Effective Time
shall be cancelled and, in exchange therefor, Spectrum shall pay to each former holder of any such cancelled Spectrum Warrant as soon
as practicable following the Effective Time (i)&#160;a number of shares of Company Common Stock equal to the (A)&#160;product of (x)&#160;the
excess of $1.10 over the exercise price per Spectrum Common Stock under such Spectrum Warrant, and (y)&#160;the number of shares of Spectrum
Common Stock subject to such Spectrum Warrant, <i>multiplied by</i> (B)&#160;the Exchange Ratio, and (ii)&#160;one CVR for Spectrum Common
Stock underlying such Spectrum Warrant, in each case, without interest, and subject to deduction for any required withholding of taxes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Post-Closing Governance</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to applicable laws and the listing and corporate governance
rules&#160;and regulations of the Nasdaq Capital Market (&#8220;<span style="text-decoration: underline">Nasdaq</span>&#8221;) that are applicable to the Company, Spectrum shall
nominate one member of Spectrum&#8217;s board of directors (such individual, the &#8220;<span style="text-decoration: underline">Spectrum Board Designee</span>&#8221;) to the
Company&#8217;s board of directors prior to the Effective Time. The Spectrum Board Designee will be selected and designated to the Company&#8217;s
board of directors upon the Company&#8217;s consent (such consent not to be unreasonably withheld, conditions or delayed) effective as
of the Closing (as defined in the Merger Agreement). During the 12-month period following the Closing Date (as defined in the Merger Agreement),
the Company&#8217;s board of directors shall not propose to remove the Spectrum Board Designee other than for cause.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Conditions to the Merger</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The obligation of Spectrum and the Company to consummate the transactions
contemplated by the Merger Agreement is subject to the satisfaction or waiver of a number of customary conditions, including: (i)&#160;the
adoption of the Merger Agreement by Spectrum&#8217;s stockholders; (ii)&#160;approval of the issuance of shares of Company Common Stock
in the Merger by the Company&#8217;s stockholders; (iii)&#160;the Company&#8217;s registration statement on Form&#160;S-4 to be filed
in connection with the Merger having become effective and not subject of any stop order, and the shares of Company Common Stock issuable
in the Merger having been approved for listing on the Nasdaq, subject to official notice of issuance; (iv)&#160;the expiration of any
applicable waiting period, the absence of any pending agreement between the Company and any governmental entity not to close, and receipt
of any required approvals under the antitrust laws of the United States; (v)&#160;the absence of laws or orders restraining the consummation
of the Merger; (vi)&#160;the representations and warranties of Spectrum and the Company being true and correct, subject to the materiality
standards contained in the Merger Agreement, and Spectrum and the Company having complied in all material respects with their respective
obligations under the Merger Agreement; (vii)&#160;the absence of any effects that have constituted or resulted in, or would reasonably
be expected to constitute or result in, a material adverse effect for Spectrum or the Company; (viii)&#160;execution of the CVR Agreement
by the Company and the Rights Agent; and (ix)&#160;the receipt by Spectrum of a written opinion from Spectrum&#8217;s tax counsel that,
for U.S. federal income tax purposes, the Merger will qualify as a &#8220;reorganization&#8221; within the meaning of Section&#160;368(a)&#160;of
the Internal Revenue Code of 1986, as amended.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Representations and Warranties; Covenants</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Merger Agreement contains customary representations and warranties
given by Spectrum, the Company and Merger Sub. The Company and Spectrum have also each made customary covenants in the Merger Agreement,
including covenants by each of the parties relating to conduct of their business prior to the closing of the Merger. The parties have
generally agreed to use their respective reasonable best efforts to complete the Merger, including to obtain the required regulatory approvals
for the transaction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Merger Agreement also contains reciprocal covenants by Spectrum
and the Company not to solicit or participate in any discussions or negotiations with any person making an inquiry or proposal for an
alternative transaction, and requiring Spectrum&#8217;s and the Company&#8217;s respective boards of directors to recommend the transaction-related
proposals to their stockholders, in each case subject to certain exceptions. Prior to the approval of the transaction-related proposals
by their stockholders, the boards of directors of Spectrum and the Company, as applicable, may change their recommendation in response
to an unsolicited proposal for an alternative transaction, if the board of directors determines that the proposal constitutes a &#8220;Company
Superior Proposal&#8221; or &#8220;Parent Superior Proposal&#8221; (each as defined in the Merger Agreement), as applicable, and that
failure to take such action would reasonably be expected to be inconsistent with their fiduciary duties to their stockholders under applicable
law, subject to complying with certain procedures set forth in the Merger Agreement. Prior to the approval of the transaction-related
proposals by their stockholders, Spectrum&#8217;s and the Company&#8217;s respective boards of directors may also change their recommendation
if a &#8220;Company Intervening Event&#8221; or &#8220;Parent Intervening Event&#8221; (each as defined in the Merger Agreement), as applicable,
occurs, and the applicable board of directors determines, after consultation with its outside legal counsel and financial advisor, that
failing to change its recommendation would be reasonably likely to be inconsistent with their fiduciary duties, subject to complying with
certain procedures set forth in the Merger Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 4 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Termination and Termination Fees</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Merger Agreement contains customary mutual termination rights for
Spectrum and the Company, including if the Merger is not completed by October&#160;24, 2023 (the &#8220;<span style="text-decoration: underline">Outside Date</span>&#8221;); provided,
further, that if the satisfaction of the last to be satisfied or waived of the conditions set forth under Article&#160;VI of the Merger
Agreement occur less than two (2)&#160;business days prior to the Outside Date, the Outside Date shall be deemed extended to the extent
necessary to permit closing to occur. The Merger Agreement also contains customary termination rights for the benefit of each party, including
(i)&#160;if the board of directors of the other party changes its recommendation, (ii)&#160;if the board of directors of such party authorizes
entry into a definitive agreement relating to a superior proposal and (iii)&#160;if the other party breaches its representations, warranties
or covenants under the Merger Agreement in a way that would result in a failure of its condition to closing being satisfied (subject to
certain procedures and cure periods).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the Merger Agreement, Spectrum and the Company will be required
to pay a termination fee to the other party equal to $8,300,000, less the amount of previously paid expenses, if any, if the Merger Agreement
is terminated in certain circumstances, including if the board of directors of such party authorizes entry into a definitive agreement
relating to a superior proposal. If the Merger Agreement is terminated by either Spectrum or the Company due to the other party&#8217;s
failure to receive the requisite approval of its stockholders, then the party that failed to obtain such approval will be required to
reimburse the other party for up to $1,000,000 of reasonable and documented out-of-pocket fees and expenses incurred in connection with
the transaction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Additional Information</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The foregoing description of the Merger and the Merger Agreement does
not purport to be complete and is qualified in its entirety by reference to the full text of the Merger Agreement, which is filed as Exhibit&#160;2.1
to this Current Report and is incorporated herein by reference. A copy of the Merger Agreement has been included to provide investors
with information regarding its terms and is not intended to provide any factual information about Spectrum or the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Merger Agreement contains representations, warranties, covenants
and agreements, which were made only for purposes of such agreement and as of specified dates. The representations and warranties in the
Merger Agreement reflect negotiations between the parties to the Merger Agreement and are not intended as statements of fact to be relied
upon by stockholders, or any individual or other entity other than the parties. In particular, the representations, warranties, covenants
and agreements in the Merger Agreement may be subject to limitations agreed by the parties, including having been modified or qualified
by certain confidential disclosures that were made between the parties in connection with the negotiation of the Merger Agreement, and
having been made for purposes of allocating risk among the parties rather than establishing matters of fact. In addition, the parties
may apply standards of materiality in a way that is different from what may be viewed as material by investors. As such, the representations
and warranties in the Merger Agreement may not describe the actual state of affairs at the date they were made or at any other time and
you should not rely on them as statements of fact. Moreover, information concerning the subject matter of the representations and warranties
may change after the date of the Merger Agreement, and unless required by applicable law, the Company undertakes no obligation to update
such information.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 7.01 Regulation FD Disclosure.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April&#160;25, 2023, the Company and Spectrum
announced that they had entered into the Merger Agreement. A copy of the joint press release is attached hereto as Exhibit&#160;99.1 and
incorporated by reference herein.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information in Item 7.01 of this Current Report
(including Exhibit&#160;99.1) is being furnished pursuant to Item 7.01 and shall not be deemed to be &#8220;filed&#8221; for purposes
of Section&#160;18 of Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated
by reference in any filing under the Securities Act of 1933, as amended.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 5 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Forward Looking Statements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The statements in this communication include forward-looking statements
concerning the Company the proposed transactions and other matters. Forward-looking statements may discuss goals, intentions and expectations
as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs and involve numerous
risks and uncertainties that could cause actual results to differ materially from expectations. Forward-looking statements speak only
as of the date they are made or as of the dates indicated in the statements and should not be relied upon as predictions of future events,
as there can be no assurance that the events or circumstances reflected in these statements will be achieved or will occur. Forward-looking
statements can often, but not always, be identified by the use of forward-looking terminology including &#8220;believes,&#8221; &#8220;expects,&#8221;
&#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;seeks,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;pro
forma,&#8221; &#8220;estimates,&#8221; &#8220;anticipates,&#8221; &#8220;designed,&#8221; or the negative of these words and phrases,
other variations of these words and phrases or comparable terminology. The forward-looking statements in this communication relate to,
among other things: failure to obtain applicable regulatory or stockholder approvals in a timely manner or otherwise; failure to satisfy
other closing conditions to the proposed transactions; risks that the new businesses will not be integrated successfully or that the combined
company will not realize estimated cost savings, value of certain tax assets, synergies and growth, or that such benefits may take longer
to realize than expected; failure to realize anticipated benefits of the combined operations; risks relating to unanticipated costs of
integration; demand for the combined company&#8217;s products; the growth, change and competitive landscape of the markets in which the
combined company participates; expected industry trends, including pricing pressures and managed healthcare practices; variations in revenues
obtained from commercialization agreements, including contingent milestone payments, royalties, license fees and other contract revenues,
including non-recurring revenues, and the accounting treatment with respect thereto; the Company&#8217;s ability to obtain and maintain
intellectual property protection for its products and operate its business without infringing the intellectual property rights of others;
the commercial success and market acceptance of the Company&#8217;s products, including the coverage of the Company&#8217;s products by
payors and pharmacy benefit managers; the entry and sales of generics of the Company&#8217;s products, including Indocin products which
are not patent protected and may face generic competition at any time; the outcome of, and the Company&#8217;s intentions with respect
to, any litigation or investigations, including antitrust litigation, opioid-related investigations, opioid-related litigation and related
claims for negligence and breach of fiduciary duty against the Company&#8217;s former insurance broker, and other disputes and litigation,
and the costs and expenses associated therewith; the ability of the Company&#8217;s third-party manufacturers to manufacture adequate
quantities of commercially salable inventory and active pharmaceutical ingredients for each of the Company&#8217;s products, and the Company&#8217;s
ability to maintain its supply chain, which relies on single-source suppliers; and our counterparties&#8217; compliance or non-compliance
with their obligations under our agreements. These forward-looking statements involve risks and uncertainties that could cause actual
results to differ materially from those contemplated by the statements. These risks, as well as other risks related to the proposed transaction,
will be included in the registration statement on Form&#160;S-4 and joint proxy statement/prospectus that will be filed with the Securities
and Exchange Commission (the &#8220;<span style="text-decoration: underline">SEC</span>&#8221;) in connection with the proposed transaction. For a discussion of factors that could
cause actual results to differ materially from those contemplated by forward-looking statements, see the sections captioned &#8220;Risk
Factors&#8221; in the Company&#8217;s Annual Report on Form&#160;10-K for the year ended December&#160;31, 2022, subsequent Quarterly
Reports on Form&#160;10-Q and other filings with the SEC. Many of these risks and uncertainties may be exacerbated by the COVID-19 pandemic
and any worsening of the global business and economic environment as a result. The Company does not assume, and hereby disclaims, any
obligation to update forward-looking statements, except as may be required by law.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>No Offer or Solicitation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This communication is not intended to and shall not constitute an offer
to buy or sell or the solicitation of an offer to buy or sell any securities, or a solicitation of any vote or approval, nor shall there
be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification
under the securities laws of any such jurisdiction. No offering of securities shall be made, except by means of a prospectus meeting the
requirements of Section&#160;10 of the U.S. Securities Act of 1933, as amended.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Additional Information about the Merger and Where to Find It</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the proposed transaction, the Company intends to
file with the SEC a registration statement on Form&#160;S-4 that will include a joint proxy statement of the Company and Spectrum and
that also constitutes a prospectus of the Company. Each of the Company and Spectrum may also file other relevant documents with the SEC
regarding the proposed transaction. This document is not a substitute for the joint proxy statement/prospectus or registration statement
or any other document that the Company or Spectrum may file with the SEC. The definitive joint proxy statement/prospectus (if and when
available) will be mailed to stockholders of the Company and Spectrum. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE REGISTRATION
STATEMENT, JOINT PROXY STATEMENT/PROSPECTUS AND ANY OTHER RELEVANT DOCUMENTS THAT MAY&#160;BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS
OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY IF AND WHEN THEY BECOME AVAILABLE BECAUSE THEY CONTAIN OR WILL CONTAIN
IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Investors and security holders will be able to obtain free copies of the registration
statement and joint proxy statement/prospectus (if and when available) and other documents containing important information about the
Company, Spectrum and the proposed transaction, once such documents are filed with the SEC through the website maintained by the SEC at
<i>http://www.sec.gov</i>. Copies of the documents filed with the SEC by the Company will be available free of charge on the Company&#8217;s
website at <i>www.assertiotx.com </i>or by contacting the Company&#8217;s Investor Relations Department by email at investor@assertiotx.com.
Copies of the documents filed with the SEC by Spectrum will be available free of charge on Spectrum&#8217;s website at <i>www.sppirx.com
</i>or by contacting the Company&#8217;s Investor Relations Department atir@sppirx.com.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 6 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Participants in the Solicitation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company and Spectrum and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies
from their respective stockholders in respect of the proposed transactions contemplated by the joint proxy statement/prospectus. Information
regarding the persons who are, under the rules&#160;of the SEC, participants in the solicitation of the stockholders of the Company and
Spectrum in connection with the proposed transactions, including a description of their direct or indirect interests, by security holdings
or otherwise, will be set forth in the joint proxy statement/prospectus when it is filed with the SEC. Information regarding the Company&#8217;s
directors and executive officers</span>, including a description of their direct and indirect interests, is contained in its Annual Report
on Form&#160;10-K for the year ended December&#160;31, 2022 and its Proxy Statement on Schedule 14A, dated April&#160;3, 2023, which are
filed with the SEC. Information regarding Spectrum&#8217;s directors and executive officers, including a description of their direct and
indirect interests, by security holdings or otherwise, is available in its Annual Report on Form&#160;10-K for the year ended December&#160;31,
2022 and its Proxy Statement on Schedule 14A, dated April&#160;27, 2022, which are filed with the SEC. Other information regarding the
participants in the proxy solicitations and a description of their direct and indirect interests, by security holdings or otherwise, will
be contained in the joint proxy statement/prospectus and other relevant materials to be filed with the SEC regarding the proposed transaction
when such materials become available. Investors should read the joint proxy statement/prospectus carefully when it becomes available before
making any voting or investment decisions. You may obtain free copies of these documents from the Company or Spectrum using the sources
indicated above.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>Item&#160;9.01 Financial Statements and
Exhibits.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr>
    <td style="width: 4%">&#160;</td>
    <td style="vertical-align: top; width: 4%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td colspan="3">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration: underline">EXHIBIT&#160;INDEX</span></b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3pt">&#160;</p></td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 14%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit&#160;No.</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: justify; width: 85%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="vertical-align: top">
    <td><a href="tm2313548d1_ex2-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</span></a></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="tm2313548d1_ex2-1.htm" style="-sec-extract: exhibit">Agreement and Plan of Merger, dated April&#160;24, 2023, by and among Assertio Holdings,&#160;Inc., Spade Merger Sub 1,&#160;Inc. and Spectrum Pharmaceuticals,&#160;Inc. (Form&#160;of CVR Agreement included as Exhibit&#160;B thereto)*</a></td></tr>
  <tr style="vertical-align: top">
    <td><a href="tm2313548d1_ex99-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></a></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="tm2313548d1_ex99-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joint Press Release of Assertio Holdings,&#160;Inc. and Spectrum Pharmaceuticals,&#160;Inc., dated April&#160;25, 2023</span></a></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page&#160;Interactive Data File (embedded within the Inline XBRL document)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">* Certain exhibits and schedules have been omitted pursuant to Item
601(b)(2)&#160;of Regulation S-K. The Company hereby undertakes to furnish supplemental copies of any of the omitted exhibits and schedules
upon request by the SEC; <i>provided</i>, <i>however</i>, that the Company may request confidential treatment pursuant to Rule&#160;24b-2
of the Securities Exchange Act of 1934, as amended, for any exhibits or schedules so furnished.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 7 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this Current Report to be signed on its behalf by the undersigned
hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: April&#160;25, 2023</span></td>
    <td colspan="2" style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ASSERTIO HOLDINGS,&#160;INC.</b></span></td>
    </tr>
  <tr style="vertical-align: bottom">
    <td style="width: 50%">&#160;</td>
    <td style="width: 5%">&#160;</td>
    <td style="width: 45%">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>By:</b></span></td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>/s/ Daniel A. Peisert </i></b></span></td>
    </tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name:</b></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Daniel A. Peisert</b></span></td>
    </tr>
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title:</b></span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>President and Chief Executive Officer</b></span></td>
    </tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 8; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>



</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjd0KgkAQhZ/Adxj2WvyjILxMSiKLEIlulxxjSXdkdq18pN6yTYmGgWHmzHeOEL7IaataZLisywIq7PpWWoQSG2TUV3Qf2W6fgpsl3pSxLLWd1h+YkWPQMctgeXX36fOhDNYpxEkYL8IkgmiVxis4HYT31TPSjapRWyVbkLqGE1PPCq3kcXao5Is0deOUdEY2irSzC6JZfkMSxQkc6SGfxHcDRZEJz5/KEznT0H9jBmOpg02LncsyM/pv7wPgo0ke -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.1
<SEQUENCE>2
<FILENAME>tm2313548d1_ex2-1.htm
<DESCRIPTION>EXHIBIT 2.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><B>Exhibit 2.1</B></P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AGREEMENT AND PLAN OF MERGER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">among</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ASSERTIO HOLDINGS,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SPADE MERGER SUB 1,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SPECTRUM PHARMACEUTICALS,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Dated as of April&nbsp;24, 2023</P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in"><U>Page</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Article&nbsp;I THE Merger</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">2</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; width: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;1.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Merger</FONT></TD>
    <TD STYLE="text-align: right; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;1.2</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Closing; Effective Time</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;1.3</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effects of the Merger</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;1.4</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Incorporation and Bylaws</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;1.5</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors; Officers</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;1.6</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsequent Actions</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Article&nbsp;II EFFECT OF THE Merger ON THE CAPITAL STOCK OF THE CONSTITUENT CORPORATIONS; EXCHANGE OF CERTIFICATES</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">3</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;2.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conversion of Capital Stock</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;2.2</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exchange and Payment</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;2.3</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Treatment of Options and Other Equity-Based Awards</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;2.4</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Treatment of Warrant</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;2.5</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No Fractional Shares</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;2.6</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax Withholding</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;2.7</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dissenting Shares</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Article&nbsp;III REPRESENTATIONS AND WARRANTIES OF THE COMPANY</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">12</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Organization, Standing and Power</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.2</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capital Stock</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.3</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authority</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.4</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No Conflict; Consents and Approvals</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.5</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SEC Reports; Financial Statements</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.6</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No Undisclosed Liabilities</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.7</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain Information</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.8</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Absence of Certain Changes or Events</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.9</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Litigation</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.10</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compliance with Laws</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.11</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Benefit Plans</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.12</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Labor Matters</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.13</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Environmental Matters</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.14</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taxes</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.15</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contracts</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.16</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insurance</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.17</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Properties</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">29</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.18</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intellectual Property</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">29</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.19</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Health Care Regulatory Matters</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; width: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.20</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Data Privacy</FONT></TD>
    <TD STYLE="text-align: right; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">34</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.21</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain Payments</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">35</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.22</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">State Takeover Statutes</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.23</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Affiliate Transactions</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.24</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brokers</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.25</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion of Financial Advisor</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.26</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No Other Representations or Warranties</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">37</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.27</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No Reliance</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">37</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Article&nbsp;IV REPRESENTATIONS AND WARRANTIES OF PARENT and MERGER SUB</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">38</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Organization, Standing and Power</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">38</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.2</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capital Stock</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">38</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.3</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authority</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">39</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.4</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No Conflict; Consents and Approvals</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">40</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.5</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SEC Reports; Financial Statements</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">41</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.6</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No Undisclosed Liabilities</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">42</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.7</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain Information</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.8</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Absence of Certain Changes or Events</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.9</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Litigation</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.10</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compliance with Laws</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.11</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Benefit Plans</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">44</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.12</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Labor Matters</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">46</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.13</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Environmental Matters</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">46</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.14</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taxes</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">47</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.15</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insurance</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">49</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.16</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Properties</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">49</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.17</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intellectual Property</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.18</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Health Care Regulatory Matters</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">51</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.19</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain Payments</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.20</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">State Takeover Statutes</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.21</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Affiliate Transactions</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.22</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brokers</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.23</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion of Financial Advisor</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.24</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No Prior Activities</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.25</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No Other Representations or Warranties</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.26</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No Reliance</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Article&nbsp;V COVENANTS</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">55</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conduct of Business of the Company</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">55</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.2</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conduct of Business of Parent</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.3</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No Control of Other Party&rsquo;s Business</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.4</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No Solicitation by the Company</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.5</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No Solicitation by Parent</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">66</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; width: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.6</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preparation of Form&nbsp;S-4 and Joint Proxy Statement/Prospectus; Stockholders&rsquo; Meetings</FONT></TD>
    <TD STYLE="text-align: right; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">71</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.7</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Access to Information; Confidentiality</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">74</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.8</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further Action; Efforts</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">75</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.9</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment and Employee Benefits Matters; Other Plans</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">77</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.10</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Takeover Laws</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">79</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.11</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock Exchange Listing</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">79</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.12</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock Exchange Delisting</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">79</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.13</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indemnification, Exculpation and Insurance</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">79</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.14</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rule&nbsp;16b-3</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">81</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.15</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Public Announcements</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">81</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.16</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obligations of Merger Sub</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">82</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.17</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notices of Certain Events</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">82</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.18</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholder Litigation</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">82</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.19</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain Tax Matters.</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">83</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.20</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Governance Matters</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">84</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.21</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Term Loan Credit Facility</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">84</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Article&nbsp;VI CONDITIONS PRECEDENT</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">85</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;6.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conditions to Each Party&rsquo;s Obligation to Effect the Merger</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">85</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;6.2</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conditions to the Obligations of the Company</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">85</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;6.3</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conditions to the Obligations of Parent and Merger Sub.</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">86</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;6.4</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Frustration of Closing Conditions</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">87</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Article&nbsp;VII TERMINATION, AMENDMENT AND WAIVER</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">87</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Termination</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">87</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.2</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effect of Termination</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">89</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.3</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fees and Expenses</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">90</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.4</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment or Supplement</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">93</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.5</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Extension of Time; Waiver</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">93</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Article&nbsp;VIII GENERAL PROVISIONS</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">93</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;8.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nonsurvival of Representations and Warranties and Pre-Closing Covenants</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">93</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;8.2</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notices</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">94</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;8.3</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain Definitions</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">95</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;8.4</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interpretation</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;8.5</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Entire Agreement</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;8.6</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parties in Interest</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;8.7</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Governing Law</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;8.8</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Submission to Jurisdiction</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;8.9</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assignment; Successors</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;8.10</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Specific Performance</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;8.11</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currency</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; width: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;8.12</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Severability</FONT></TD>
    <TD STYLE="text-align: right; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;8.13</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Waiver of Jury Trial</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;8.14</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Counterparts</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">102</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;8.15</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Facsimile or .pdf Signature</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">102</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;8.16</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No Presumption Against Drafting Party</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">102</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;8.17</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Recourse</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">102</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Exhibits</U></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Exhibit&nbsp;A</U></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Form&nbsp;of Certificate of Merger</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Exhibit&nbsp;B</U></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Form&nbsp;of CVR Agreement</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INDEX OF DEFINED TERMS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><U>Definition</U></TD>
    <TD STYLE="text-align: right"><U>Section</U></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 83%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Action</FONT></TD>
    <TD STYLE="width: 17%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.9</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreement</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preamble</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anti-Corruption Laws</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.21</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Antitrust Law</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.8(h)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Book-Entry Shares</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;2.2(c)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cancelled Shares</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;2.1(a)(ii)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Merger</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;1.2(b)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificates</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;2.2(b)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Closing</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;1.2(a)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Closing Date</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;1.2(a)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">COBRA</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.11(c)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Code</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recitals</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preamble</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company 401(k)&nbsp;Plan</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.9(d)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company Acquisition Proposal</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.4(i)(i)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company Adverse Recommendation Change</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.4(c)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company Alternative Acquisition Agreement</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.4(c)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company Board</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recitals</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company Board Designee</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.20(a)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company Board Recommendation</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.3</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company Bylaws</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.1(b)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company Charter</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.1(b)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company Data Partners</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.20(a)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company Disclosure Letter</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article&nbsp;III</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company Equity Plans</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;2.3(a)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company ESPP</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;2.3(f)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company Expenses</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.3(e)</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"><FONT STYLE="background-color: White">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: White"><B>INDEX
OF DEFINED TERMS<BR>
(Continued)</B></FONT></P>



<P STYLE="margin: 0"><FONT STYLE="background-color: White">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="background-color: White"><U>Definition</U></FONT></TD>
    <TD STYLE="text-align: right"><U>Section</U></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>


<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 83%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company Intellectual Property</FONT></TD>
    <TD STYLE="text-align: right; width: 17%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.18(a)</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 82%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company Intervening Event</FONT></TD>
    <TD STYLE="text-align: right; width: 18%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.4(i)(ii)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company Leased Real Property</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.17(a)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company Material Adverse Effect</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;6.3(a)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company Plan</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.11(a)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company Products</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.19(c)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company Real Property Leases</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.17(a)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company Registered IP</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.18(b)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company RSU</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;2.3(b)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company Safety Notices</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.19(g)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company SAR</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;2.3(d)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company SEC Documents</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.5(a)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company Shares</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;2.1(a)(i)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company Stock Option</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;2.3(a)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company Stockholder Approval</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.3</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company Stockholders Meeting</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.6(a)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company Superior Proposal</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.4(i)(iii)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company Superior Proposal Notice</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.4(d)(ii)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company Termination Fee</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.3(b)(iii)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company Warrant</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;2.4</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidentiality Agreement</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.7</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Continuation Period</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.9(a)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contract</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.4(a)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Covered Employees</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.9(a)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current ESPP Offering Period</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;2.3(f)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CVR</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;2.1(a)(i)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred Compensation Plan</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.9(e)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred Compensation Plan Termination</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.9(e)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delaware Secretary of State</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;1.2(b)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DGCL</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recitals</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dissenting Shares</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.6</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective Time</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;1.2(b)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Laws</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.12(b)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Environmental Laws</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.13(c)(i)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Environmental Permits</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.13(c)(ii)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ERISA</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.11(a)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ERISA Affiliate</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.11(d)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exchange Act</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.4(b)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exchange Agent</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;2.2(a)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exchange Fund</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;2.2(b)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expense Reimbursement Cap</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.3(c)(iii)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.19(c)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA Ethics Policy</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.19(i)</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->v<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"><FONT STYLE="background-color: White">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: White"><B>INDEX
OF DEFINED TERMS<BR>
(Continued)</B></FONT></P>



<P STYLE="margin: 0"><FONT STYLE="background-color: White">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="background-color: White"><U>Definition</U></FONT></TD>
    <TD STYLE="text-align: right"><U>Section</U></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>


<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDCA</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.19(a)</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 82%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;S-4</FONT></TD>
    <TD STYLE="text-align: right; width: 18%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.7</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fractional Share Cash Consideration</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;2.5(b)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">GAAP</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.5(b)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Government Official</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.21</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Governmental Entity</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.4(b)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Health Care Laws</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.19(a)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HSR Act</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.4(b)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indemnified Parties</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.13(a)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intended Tax Treatment</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recitals</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IRS</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.11(a)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joint Proxy Statement/Prospectus</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.6(a)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Labor Agreement</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.12(a)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Law</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.4(a)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liens</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.2(c)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Material Contract</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.15(a)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Materials of Environmental Concern</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.13(c)(iii)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maximum Annual Premium</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.13(c)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Measurement Date</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.2(a)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Merger</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recitals</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Merger Consideration</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;2.1(a)(i)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Merger Sub</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preamble</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Merger Sub Board</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recitals</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nasdaq</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.4(b)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preamble</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent Acquisition Proposal</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.5(i)(i)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent Adverse Recommendation Change</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.5(c)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent Alternative Acquisition Agreement</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.5(c)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent Board</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recitals</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent Board Recommendation</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.3</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent Bylaws</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.1(b)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent Charter</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.1(b)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent Closing Price</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;2.3(a)(i)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent Common Stock</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recitals</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent Disclosure Letter</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article&nbsp;IV</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent ERISA Affiliate</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.11(d)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent Expenses</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.3(d)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent Financial Partners</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.23)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent Intervening Event</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.5(i)(ii)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent Material Adverse Effect</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;6.2(a)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent Plan</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.11(a)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent Products</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.18(c)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent Registered IP</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.17(b)</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->vi<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"><FONT STYLE="background-color: White">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: White"><B>INDEX
OF DEFINED TERMS<BR>
(Continued)</B></FONT></P>



<P STYLE="margin: 0"><FONT STYLE="background-color: White">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="background-color: White"><U>Definition</U></FONT></TD>
    <TD STYLE="text-align: right"><U>Section</U></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>


<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 82%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent Safety Notices</FONT></TD>
    <TD STYLE="text-align: right; width: 18%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.18(g)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent SEC Documents</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.5(a)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent Signing Price</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;2.3(a)(i)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent Stock Issuance</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recitals</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent Stock Options</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.2(a)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent Stockholder Approval</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.3</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent Stockholders Meeting</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.6(a)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent Superior Proposal</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.5(i)(iii)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent Superior Proposal Notice</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.5(d)(ii)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent Termination Fee</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.3(c)(iii)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payoff Letter</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.21</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Permits</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.10</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Personal Information</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.20(a)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preferred Stock</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.2(a)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Privacy Requirements</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.20(a)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">R&amp;D Sponsor</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.18(g)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Relevant Legal Restraint</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;6.1(b)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Representatives</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.4(a)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SEC</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.5(a)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities Act</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.5(a)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Security Incident</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.20(c)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Surviving Corporation</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recitals</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Takeover Laws</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.22</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax Returns</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.14(d)(i)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taxes</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.14(d)(ii)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Term Loan Amendment</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.21</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Term Loan Collateral Agent</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.21</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Term Loan Credit Facility</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.21</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Term Loan Required Lenders</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.21</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Termination Date</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.1(b)(i)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third Party</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.4(a)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upfront Consideration</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;2.1(a)(i)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->vii<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AGREEMENT AND PLAN OF MERGER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This AGREEMENT AND PLAN OF
MERGER (this &ldquo;<U>Agreement</U>&rdquo;), dated as of April&nbsp;24, 2023, is made by and among Assertio Holdings,&nbsp;Inc., a Delaware
(&ldquo;<U>Parent</U>&rdquo;), Spade Merger Sub 1,&nbsp;Inc., a Delaware corporation and a wholly-owned Subsidiary of Parent (&ldquo;<U>Merger
Sub</U>&rdquo;), and Spectrum Pharmaceuticals,&nbsp;Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>RECITALS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, upon the terms and
subject to the conditions of this Agreement and in accordance with the General Corporation Law of the State of Delaware (the &ldquo;<U>DGCL</U>&rdquo;),
Parent, Merger Sub and the Company have agreed to enter into a business combination transaction pursuant to which Merger Sub will merge
with and into the Company (the &ldquo;<U>Merger</U>&rdquo;), with the Company being the surviving corporation (the Company, in its capacity
as the surviving corporation of the Merger, is sometimes referred to as the &ldquo;<U>Surviving Corporation</U>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, for U.S. federal
income Tax purposes, the parties hereto intend that (i)&nbsp;the Merger will qualify as a &ldquo;reorganization&rdquo; within the meaning
of Section&nbsp;368(a)&nbsp;of the Internal Revenue Code of 1986, as amended (the &ldquo;<U>Code</U>&rdquo;) (the &ldquo;<U>Intended Tax
Treatment</U>&rdquo;), and (ii)&nbsp;this Agreement is, and hereby is adopted as, a &ldquo;plan of reorganization&rdquo; for purposes
of Sections 354, 361 and the 368 of the Code and within the meaning of Treasury Regulations Sections 1.368-2(g)&nbsp;and 1.368-3(a);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the board of directors
of the Company (the &ldquo;<U>Company Board</U>&rdquo;) (a)&nbsp;determined that the terms of this Agreement and the transactions contemplated
hereby, including the Merger, are fair to, and in the best interests of, the Company and its stockholders, (b)&nbsp;determined that it
is in the best interests of the Company and its stockholders, and declared it advisable, to enter into this Agreement, (c)&nbsp;approved
the execution and delivery by the Company of this Agreement, the performance by the Company of its covenants and agreements contained
herein and the consummation of the Merger and the other transactions contemplated hereby upon the terms and subject to the conditions
contained herein and (d)&nbsp;subject to <U>&lrm;Section&nbsp;5.4</U>, resolved to recommend that the Company&rsquo;s stockholders vote
to adopt this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the board of directors
of Parent (the &ldquo;<U>Parent Board</U>&rdquo;) (a)&nbsp;determined that the terms of this Agreement and the transactions contemplated
hereby, including the Merger, are fair to, and in the best interests of, Parent and its stockholders, (b)&nbsp;determined that it is in
the best interests of Parent and its stockholders, and declared it advisable, to enter into this Agreement, (c)&nbsp;approved the execution
and delivery by Parent of this Agreement, the performance by Parent of its covenants and agreements contained herein and the consummation
of the Merger and the other transactions contemplated hereby upon the terms and subject to the conditions contained herein and (d)&nbsp;subject
to <U>&lrm;Section&nbsp;5.5</U>, determined to recommend that the stockholders of Parent approve the issuance of common stock, par value
$0.0001 per share, of Parent (&ldquo;<U>Parent Common Stock</U>&rdquo;) pursuant to the Merger as contemplated by, and subject to the
terms and conditions set forth in, this Agreement and the CVR Agreement (the &ldquo;<U>Parent Stock Issuance</U>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the board of directors
of Merger Sub (the &ldquo;<U>Merger Sub Board</U>&rdquo;) (a)&nbsp;approved this Agreement and declared its advisability and (b)&nbsp;resolved
to recommend the adoption of this Agreement by the sole stockholder of Merger Sub;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, Parent, as the sole
stockholder of Merger Sub, shall adopt this Agreement immediately following the execution of this Agreement upon the recommendation of
the Merger Sub Board; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, Parent, Merger Sub
and the Company desire to make certain representations, warranties, covenants and agreements in connection with the Merger and the other
transactions contemplated by this Agreement and also to prescribe certain terms and conditions to the Merger as specified herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, in consideration
of the premises, and of the representations, warranties, covenants and agreements contained herein, and intending to be legally bound
hereby, Parent, Merger Sub and the Company hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase; color: #010000"><B>Article&nbsp;I</B></FONT><B><FONT STYLE="text-transform: uppercase"><BR>
THE Merger</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;1.1</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>The
Merger</U>. Upon the terms and subject to the conditions of this Agreement, at the Effective Time and in accordance with the DGCL, Merger
Sub shall be merged with and into the Company pursuant to which (i)&nbsp;the separate corporate existence of Merger Sub shall cease, (ii)&nbsp;the
Company shall be the Surviving Corporation in the Merger and shall continue its corporate existence under the laws of the State of Delaware
as a direct, wholly owned Subsidiary of Parent and (iii)&nbsp;all of the properties, rights, privileges, powers and franchises of the
Company and Merger Sub will vest in the Surviving Corporation, and all of the debts, liabilities, restrictions, obligations and duties
of the Company will become the debts, liabilities, restrictions, obligations and duties of the Surviving Corporation, all as provided
under the DGCL.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;1.2</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Closing;
Effective Time</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
closing of the Merger (the &ldquo;<U>Closing</U>&rdquo;) shall take place at 9:00 a.m., Eastern time, no later than the second Business
Day following the satisfaction or, to the extent permitted hereunder and by applicable Law, waiver of the last to be satisfied or waived
of all conditions to the parties&rsquo; respective obligations to effect the Merger set forth in <B><U>&lrm;</U></B><U>Article&nbsp;</U>VI
(other than those conditions that by their nature are to be satisfied at the Closing, but subject to the satisfaction or, to the extent
permitted hereunder and by applicable Law, waiver of those conditions at the Closing), at the offices of Gibson, Dunn&nbsp;&amp; Crutcher
LLP, 200 Park Avenue, New York, NY 10166, unless another date, time or place is agreed to in writing by Parent and the Company; <U>provided</U>,
that the Closing may occur remotely via electronic exchange of required Closing documentation in lieu of an in-person Closing, and the
parties shall cooperate in connection therewith. The date on which the Closing actually occurs is referred to in this Agreement as the
 &ldquo;<U>Closing Date</U>.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Subject
to the provisions of this Agreement, at the Closing, the parties shall cause a certificate of merger with respect to the Merger in the
form set forth as <U>Exhibit&nbsp;A</U> hereto (the &ldquo;<U>Certificate of Merger</U>&rdquo;) to be duly executed and filed with the
Secretary of State of the State of Delaware (the &ldquo;<U>Delaware Secretary of State</U>&rdquo;), in accordance with the relevant provisions
of the DGCL. The Merger shall become effective upon the filing of the Certificate of Merger with the Delaware Secretary of State or at
such other time as the parties may mutually agree to in writing and as shall be specified in the Certificate of Merger. The date and time
when the Merger shall become effective is herein referred to as the &ldquo;<U>Effective Time</U>.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;1.3</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Effects
of the Merger</U>. The Merger shall have the effects provided for in this Agreement and in the applicable provisions of the DGCL.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;1.4</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Certificate
of Incorporation and Bylaws</U>. From and after the Effective Time, subject to </FONT><FONT STYLE="font-size: 13pt"><B><U>&lrm;</U></B></FONT><U><FONT STYLE="font-size: 10pt">Section&nbsp;5.12</FONT></U><FONT STYLE="font-size: 10pt">,
the certificate of incorporation and the bylaws of Merger Sub as in effect immediately prior to the Effective Time shall be the certificate
of incorporation and bylaws, respectively, of the Surviving Corporation until thereafter changed or amended as provided therein or by
applicable Law (and subject to the provisions of </FONT><FONT STYLE="font-size: 13pt"><B><U>&lrm;</U></B></FONT><U><FONT STYLE="font-size: 10pt">Section&nbsp;5.12)</FONT></U><FONT STYLE="font-size: 10pt">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;1.5</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Directors;
Officers</U>. From and after the Effective Time, (i)&nbsp;the directors of Merger Sub immediately prior to the Effective Time shall be
the directors of the Surviving Corporation until the earlier of their resignation or removal or until their respective successors are
duly elected and qualified and (ii)&nbsp;the officers of Merger Sub immediately prior to the Effective Time shall be the officers of the
Surviving Corporation until the earlier of their resignation or removal or until their respective successors are duly elected and qualified.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;1.6</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Subsequent
Actions</U>. If, at any time after the Effective Time the Surviving Corporation shall consider or be advised that any deeds, bills of
sale, assignments, assurances or any other actions or things are necessary or desirable to vest, perfect or confirm of record or otherwise
in the Surviving Corporation its right, title or interest in, to or under any of the rights, properties or assets of the Company or Merger
Sub, as applicable, acquired or to be acquired by the Surviving Corporation as a result of or in connection with the Merger or otherwise
to carry out this Agreement, the officers and directors of the Surviving Corporation shall be authorized to execute and deliver, in the
name of and on behalf of either the Company or Merger Sub, all such deeds, bills of sale, assignments and assurances and to take and do,
in the name and on behalf of each of such corporations or otherwise, all such other actions and things as may be necessary or desirable
to vest, perfect or confirm any and all right, title and interest in, to and under such rights, properties or assets in the Surviving
Corporation, or otherwise to carry out this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase; color: #010000"><B>Article&nbsp;II</B></FONT><B><FONT STYLE="text-transform: uppercase"><BR>
EFFECT OF THE Merger ON THE CAPITAL STOCK OF THE CONSTITUENT CORPORATIONS; EXCHANGE OF CERTIFICATES</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;2.1</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Conversion
of Capital Stock</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Subject
to the terms and conditions of this Agreement, at the Effective Time, automatically, by virtue of the Merger and without any action on
the part of the Company, Parent, Merger Sub or the holders of any shares of capital stock of the Company, Parent or Merger Sub, and subject
to the provisions of this <B><U>&lrm;</U></B><U>Article&nbsp;II:</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">each
share of common stock, par value $0.001 per share, of the Company (such shares, collectively, the &ldquo;<U>Company Shares</U>&rdquo;)
issued and outstanding immediately prior to the Effective Time (other than Cancelled Shares and any Dissenting Shares), shall be converted
automatically into and shall thereafter represent the right to receive (A)&nbsp;a number of validly issued, fully paid and nonassessable
shares of Parent Common Stock equal to the Exchange Ratio, subject to <B><I><U>&lrm;</U></I></B><U>Section&nbsp;2.5</U> with respect to
fractional shares and any required withholding of Taxes pursuant to <B><I><U>&lrm;</U></I></B><U>Section&nbsp;2.6</U> (the &ldquo;<U>Upfront
Consideration</U>&rdquo;), and (B)&nbsp;one contingent value right per share (a &ldquo;<U>CVR</U>&rdquo;) which shall represent the right
to receive the Milestone Payments (as defined in the CVR Agreement), at the times and in the form provided for in the CVR Agreement (the
Upfront Consideration plus one CVR, collectively, the &ldquo;<U>Merger Consideration</U>&rdquo;). Each CVR issued as a portion of the
Merger Consideration hereunder will be issued in book-entry form pursuant to Section&nbsp;2.3 of the CVR Agreement and will not be evidenced
by a certificate or other instrument.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">each
Company Share held in the treasury of the Company or held directly by Parent, Merger Sub, the Company or any wholly-owned Subsidiary of
the Company immediately prior to the Effective Time shall automatically be cancelled and shall cease to exist, and no consideration shall
be delivered in exchange therefor (such shares, the &ldquo;<U>Cancelled Shares</U>&rdquo;); and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">each
share of common stock, par value $0.01 per share, of Merger Sub issued and outstanding immediately prior to the Effective Time shall be
converted into and become one validly issued, fully paid and non-assessable share of common stock, par value $0.01 per share, of the Surviving
Corporation with the same rights, powers, and privileges as the shares so converted and shall constitute the only outstanding shares of
capital stock of the Surviving Corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">If
at any time during the period between the date of this Agreement and the Effective Time (and as permitted by <B><U>&lrm;</U></B><U>Article&nbsp;V</U>),
any change in the outstanding shares of capital stock of Parent or the Company, or securities convertible into or exchangeable into or
exercisable for shares of such capital stock, shall occur as a result of any reclassification, recapitalization, stock split (including
a reverse stock split) or subdivision or combination, exchange or readjustment of shares, or any stock dividend or stock distribution
with a record date during such period, merger or other similar transaction, then the Merger Consideration and any other amounts payable
pursuant to this Agreement or the CVR Agreement shall be adjusted to the extent appropriate to provide the same economic effect as contemplated
by this Agreement prior to such action; provided that nothing in this <B><U>&lrm;</U></B><U>Section&nbsp;2.1</U> shall be construed to
permit the Company or Parent to take any action with respect to its securities that is prohibited by the terms of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;2.2</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Exchange
and Payment</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Appointment
of Exchange Agent</U>. Prior to the mailing of the Joint Proxy Statement/Prospectus, Parent shall enter into an agreement (in a form reasonably
acceptable to the Company) with a commercial bank or trust company (reasonably acceptable to the Company (it being agreed that either
of the existing transfer agents for the Company and Parent shall be deemed reasonably acceptable)) to act as an exchange agent (the &ldquo;<U>Exchange
Agent</U>&rdquo;) for the purpose of paying the Upfront Consideration and the Exchange Agent&rsquo;s other responsibilities under this
Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Prior
to the Effective Time, Parent shall deposit (or cause to be deposited) with the Exchange Agent (i)&nbsp;the aggregate Fractional Share
Cash Consideration payable in the Merger to holders of Company Shares and (ii)&nbsp;evidence of Parent Common Stock in book-entry form
representing the number of shares of Parent Common Stock sufficient to deliver the aggregate Upfront Consideration payable in the Merger
to holders of Company Shares (such cash and book-entry shares, together with any dividends or distributions with respect thereto, the
 &ldquo;<U>Exchange Fund</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Exchange Fund shall not be used for any purpose other than to fund payments in respect of Company Shares converted into Upfront Consideration
pursuant to <B><U>&lrm;</U></B><U>Section&nbsp;2.1(a)</U>, except as provided in this Agreement (including payment of the Fractional Share
Cash Consideration). For the avoidance of doubt, Parent shall not be required to deposit any funds or shares of Parent Common Stock related
to any CVR with the Rights Agent unless and until such deposit is required pursuant to the terms of the CVR Agreement. Parent shall pay
all charges and expenses of the Exchange Agent incurred by it in connection with the exchange of Company Shares for the Upfront Consideration.
At or prior to the Effective Time, Parent shall duly authorize, execute and deliver, and shall ensure that the Rights Agent duly authorizes,
executes and delivers, the CVR Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">As
promptly as reasonably practicable after the Effective Time, the Surviving Corporation shall cause the Exchange Agent to mail to each
holder of record of an outstanding certificate or outstanding certificates (&ldquo;<U>Certificates</U>&rdquo;) that immediately prior
to the Effective Time represented outstanding Company Shares that were converted into the right to receive the Merger Consideration with
respect thereto pursuant to <B><U>&lrm;</U></B><U>Section&nbsp;2.1(a)</U>, (i)&nbsp;a form of letter of transmittal (which shall specify
that delivery shall be effected, and risk of loss and title to the Certificates held by such Person shall pass, only upon proper delivery
of the Certificates to the Exchange Agent) and (ii)&nbsp;instructions for use in effecting the surrender of such Certificates in exchange
for the Merger Consideration payable with respect thereto pursuant to <B><U>&lrm;</U></B><U>Section&nbsp;2.1(a)</U>, the Fractional Share
Cash Consideration payable pursuant to <B><U>&lrm;</U></B><U>Section&nbsp;2.5</U> and any dividends or other distributions such holder
is entitled to receive pursuant to <B><U>&lrm;</U></B><U>Section&nbsp;2.2(k)</U>&nbsp;below. Upon surrender of a Certificate to the Exchange
Agent, together with such letter of transmittal, duly completed and validly executed in accordance with the instructions thereto, the
holder of such Certificate shall be entitled to receive in exchange therefor the Merger Consideration for each Company Share formerly
represented by such Certificate (subject to deduction for any required withholding Tax), and the Certificate so surrendered shall forthwith
be cancelled and any shares of Parent Common Stock issued in connection with the foregoing shall be in non-certificated book-entry form.
As promptly as reasonably practicable after the Effective Time, the Surviving Corporation shall cause the Exchange Agent to deliver to
each holder of record immediately prior to the Effective Time of (1)&nbsp;uncertificated Company Shares represented by book entry (&ldquo;<U>Book-Entry
Shares</U>&rdquo;) and (2)&nbsp;Certificates, the Merger Consideration payable with respect thereto pursuant to <B><U>&lrm;</U></B><U>Section&nbsp;2.1(a)</U>,
the Fractional Share Cash Consideration payable pursuant to <B><U>&lrm;</U></B><U>Section&nbsp;2.5</U>, any dividends or other distributions
such holder is entitled to receive pursuant to <B><U>&lrm;</U></B><U>Section&nbsp;2.2(k)</U>&nbsp;below, in each case without the need
for receipt of any further documentation, including any &ldquo;agent&rsquo;s message&rdquo; or other evidence of surrender. The shares
of Parent Common Stock issued in connection with the foregoing shall be in non-certificated book-entry form. No interest will be paid
or accrued for the benefit of holders of Certificates or Book-Entry Shares on the Merger Consideration payable in respect of Certificates
or Book-Entry Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">If
payment of the Merger Consideration or Fractional Share Cash Consideration is to be made to a Person other than the Person in whose name
the surrendered Certificate or Book-Entry Share is registered, it shall be a condition of payment that such Certificate so surrendered
shall be properly endorsed or shall be otherwise in proper form for transfer or such Book-Entry Share shall be properly transferred and
that the Person requesting such payment shall have paid any transfer and other Taxes required by reason of the payment of the Merger Consideration
to a Person other than the registered holder of the Certificate or Book-Entry Share surrendered or shall have established to the satisfaction
of Parent that such Tax either has been paid or is not applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Until
surrendered as contemplated hereby, each Certificate or Book-Entry Share shall be deemed at any time after the Effective Time to represent
only book-entry shares representing the aggregate Merger Consideration that such holder has the right to receive pursuant to <B><U>&lrm;</U></B><U>Section&nbsp;2.1(a)</U>&nbsp;and
this <B><U>&lrm;</U></B><U>Article&nbsp;II</U>, the Fractional Share Cash Consideration payable pursuant to <B><U>&lrm;</U></B><U>Section&nbsp;2.5</U>
and any dividends or other distributions such holder is entitled to receive pursuant to <B><U>&lrm;</U></B><U>Section&nbsp;2.2(k)</U>&nbsp;below,
in each case, in respect of Company Shares theretofore represented by such Certificate or Book-Entry Shares, as applicable, without any
interest thereon.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Merger Consideration, the Fractional Share Cash Consideration and any dividends or other distributions payable pursuant to <B><U>&lrm;</U></B><U>Section&nbsp;2.2(k)</U>&nbsp;paid
upon the surrender of Certificates or Book-Entry Shares in accordance with the terms of this <B><U>&lrm;</U></B><U>Article&nbsp;II</U>
shall be deemed to have been paid in full satisfaction of all rights pertaining to the Company Shares formerly represented by such Certificates
or Book-Entry Shares. At the Effective Time, the stock transfer books of the Company shall be closed and there shall be no further registration
of transfers on the stock transfer books of the Surviving Corporation of the Company Shares that were outstanding immediately prior to
the Effective Time. If, after the Effective Time, Certificates are presented to the Surviving Corporation or the Exchange Agent for transfer
or transfer is sought for Book-Entry Shares, such Certificates or Book-Entry Shares shall be cancelled and exchanged as provided in this
<B><U>&lrm;</U></B><U>Article&nbsp;II</U>, subject to applicable Law in the case of Dissenting Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Exchange Agent shall invest any cash included in the Exchange Fund as directed by Parent, on a daily basis; <U>provided</U>, that any
investment of such cash shall in all events be in short-term obligations of the United States of America with maturities of no more than
30 days or guaranteed by the United States of America and backed by the full faith and credit of the United States of America or in commercial
paper obligations rated A-1 or P-1 or better by Moody&rsquo;s Investors Service,&nbsp;Inc. or Standard&nbsp;&amp; Poor&rsquo;s Corporation,
respectively. If for any reason (including investment losses) the cash in the Exchange Fund is insufficient to fully satisfy all of the
payment obligations to be made in cash by the Exchange Agent hereunder, Parent shall cause the Surviving Corporation to promptly deposit
cash into the Exchange Fund in an amount which is equal to the deficiency in the amount of cash required to fully satisfy such cash payment
obligations. Any interest and other income resulting from such investments shall be payable to the Surviving Corporation or such other
party as may be determined by Parent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">At
any time following the date that is 12 months after the Effective Time, the Surviving Corporation shall be entitled to require the Exchange
Agent to deliver to it any funds (including any interest received with respect thereto) which have been made available to the Exchange
Agent and which have not been disbursed to holders of Certificates or Book-Entry Shares, and thereafter such holders shall be entitled
to look to Parent and the Surviving Corporation (subject to abandoned property, escheat or other similar Laws) only as general creditors
thereof with respect to the Merger Consideration (and any dividends or other distributions payable with respect thereto pursuant to <B><U>&lrm;</U></B><U>Section&nbsp;2.2(k)</U>&nbsp;and
Fractional Share Cash Consideration payable with respect thereto pursuant to <B><U>&lrm;</U></B><U>Section&nbsp;2.5</U>) payable upon
due surrender of their Certificate or Book-Entry Shares. Notwithstanding the foregoing, neither the Surviving Corporation nor Parent shall
be liable to any holder of Company Shares for any amounts paid to a public official pursuant to applicable abandoned property, escheat,
or similar Laws. Any amounts remaining unclaimed by holders of the Company Shares two years after the Effective Time, or such earlier
date, immediately prior to such time when the amounts would otherwise escheat to or become property of any Governmental Entity shall become,
to the extent permitted by applicable Law, the property of the Surviving Corporation (or, at the option of Parent, Parent) free and clear
of any claims or interest of any Person previously entitled thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">If
any Certificate shall have been lost, stolen or destroyed, upon the holder&rsquo;s compliance with the replacement requirements established
by the Exchange Agent, including, if necessary, an indemnity by such Person for any claim that may be made against it or the Surviving
Corporation with respect to such Certificate, the Exchange Agent will deliver in exchange for such lost, stolen or destroyed Certificate
the Merger Consideration, the Fractional Share Cash Consideration and any dividends or other distributions payable with respect thereto
pursuant to <B><U>&lrm;</U></B><U>Section&nbsp;2.2(k)</U>, payable in respect thereof pursuant to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">No
dividends or other distributions with respect to shares of Parent Common Stock with a record date after the Effective Time shall be paid
to the holder of any unsurrendered Certificate or Book-Entry Share with respect to the shares of Parent Common Stock that the holder thereof
has the right to receive upon the surrender thereof, and no cash payment in lieu of fractional shares of Parent Common Stock shall be
paid to any such holder pursuant to <B><U>&lrm;</U></B><U>Section&nbsp;2.5</U>, in each case until the holder of such Certificate or Book-Entry
Share shall have surrendered such Certificate or Book-Entry Share in accordance with this <B><U>&lrm;</U></B><U>Article&nbsp;II</U>. Following
the surrender of any Certificate or Book-Entry Share, there shall be paid to the holder of the Certificate or Book-Entry Share representing
shares of Parent Common Stock issued in exchange therefor, without interest, (i)&nbsp;at the time of such surrender, the amount of dividends
or other distributions with a record date after the Effective Time theretofore paid with respect to such shares of Parent Common Stock
and the amount of any cash payable in lieu of a fractional share of Parent Common Stock to which such holder is entitled pursuant to <B><U>&lrm;</U></B><U>Section&nbsp;2.5</U>
and (ii)&nbsp;at the appropriate payment date, the amount of dividends or other distributions with a record date after the Effective Time
but prior to such surrender and a payment date subsequent to such surrender payable with respect to such shares of Parent Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;2.3</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Treatment
of Options and Other Equity-Based Awards</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">At
the Effective Time, each option (other than an option under the Company ESPP) (each, a &ldquo;<U>Company Stock Option</U>&rdquo;) to purchase
Company Shares granted under the Company&rsquo;s 2009 Equity Incentive Plan, 2018 Equity Incentive Plan, 2022 Employment Inducement Incentive
Award Plan or any other equity incentive plan or arrangement (the &ldquo;<U>Company Equity Plans</U>&rdquo;), that is outstanding as of
immediately prior to the Effective Time, shall, if unvested, become vested, and automatically and without any required action on the part
of the holder or the Company (other than as provided in <B><U>&lrm;</U></B><U>Section&nbsp;2.3(h)</U>&nbsp;hereof), be cancelled and:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">With
respect to any Company Stock Options with an exercise price per share that is less than the value of the Upfront Consideration (each such
Company Stock Option, an &ldquo;<U>In-the-Money Stock Option</U>&rdquo;), converted into the right to receive (i)&nbsp;a number of shares
of Parent Common Stock, subject to <B><I><U>&lrm;</U></I></B><U>Section&nbsp;2.5</U> with respect to fractional shares and any required
withholding of Taxes pursuant to <B><I><U>&lrm;</U></I></B><U>Section&nbsp;2.6</U>, that is equal to the quotient of (A)&nbsp;the product
of (x)&nbsp;the total number of Company Shares underlying the Company Stock Option multiplied by (y)&nbsp;the excess, if any, of the value
of the Upfront Consideration over the exercise price of such Company Stock Option, divided by (B)&nbsp;the average of the daily volume-weighted
average price per share of Parent Common Stock calculated based on the ten (10)&nbsp;consecutive trading days ending two trading days
prior to the date of this Agreement (the &ldquo;<U>Parent Signing Price</U>&rdquo;) and (ii)&nbsp;a number of CVRs equal to the number
of Company Shares underlying such Company Stock Option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">With
respect to any Company Stock Options with an exercise price per share that is equal to or greater than the value of the Upfront Consideration
and less than the sum of the Upfront Consideration and the maximum amount payable under a CVR (each, a &ldquo;<U>Contingent In-the-Money
Stock Option</U>&rdquo;), converted into the right to receive a number of CVRs equal the number of Company Shares underlying such Company
Stock Option; provided, however, that the payment, if any, under each CVR shall be reduced by the amount by which the exercise price per
share exceeds the value of the Upfront Consideration; provided, further that, for the avoidance of doubt, such Contingent In-the-Money
Stock Option shall not entitle the holder thereof to receive any shares of Parent Common Stock, cash or other consideration in connection
with the Effective Time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">With
respect to any Company Stock Options with an exercise price per share that is equal to or greater than the value of the Merger Consideration
(each, an &ldquo;<U>Underwater Company Stock Option</U>&rdquo;), the holder of such Underwater Company Stock Option receive no consideration
and, effective as of immediately prior to the Effective Time, shall have no further rights thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">At
the Effective Time, each restricted stock unit (each, a &ldquo;<U>Company RSU</U>&rdquo;) with respect to Company Shares granted under
the Company Equity Plans, whether vested or unvested, that is outstanding immediately prior to the Effective Time shall become fully vested,
and the holder of such Company RSUs shall, automatically and without any required action on the part of the holder thereof or the Company,
receive the Merger Consideration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">At
the Effective Time, each unvested restricted Company Share granted under the Company Equity Plans that is outstanding immediately prior
to the Effective Time shall automatically and without any required action on the part of the holder thereof or the Company fully vest
and be treated as specified in <B><U>&lrm;</U></B><U>Section&nbsp;2.1</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">At
the Effective Time, each stock appreciation right (each, a &ldquo;<U>Company SAR</U>&rdquo;) with respect to Company Shares granted under
any Company Equity Plan that is outstanding as of immediately prior to the Effective Time, shall, if unvested, become vested, and automatically
and without any required action on the part of the holder or the Company (other than as provided in <B><U>&lrm;</U></B><U>Section&nbsp;2.3(h)</U>&nbsp;hereof),
be cancelled and:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">With
respect to any Company SARs with an exercise price per share that is less than the value of the Upfront Consideration (each such Company
SAR, an &ldquo;<U>In-the-Money SAR</U>&rdquo;), converted into the right to receive (i)&nbsp;a number of shares of Parent Common Stock,
subject to <B><I><U>&lrm;</U></I></B><U>Section&nbsp;2.5</U> with respect to fractional shares and any required withholding of Taxes pursuant
to <B><I><U>&lrm;</U></I></B><U>Section&nbsp;2.6</U>, that is equal to the quotient of (A)&nbsp;the product of (x)&nbsp;the total number
of Company Shares underlying the Company SAR multiplied by (y)&nbsp;the excess, if any, of the value of the Upfront Consideration over
the exercise price of such Company SAR, divided by (B)&nbsp;the <U>Parent Signing Price</U> and (ii)&nbsp;a number of CVRs equal to the
number of Company Shares underlying such Company SAR.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">With
respect to any Company SARs with an exercise price per share that is equal to or greater than the value of the Upfront Consideration and
less than the sum of the Upfront Consideration and the maximum amount payable under a CVR (each, a &ldquo;<U>Contingent In-the-Money SAR</U>&rdquo;),
converted into the right to receive a number of CVRs equal the number of Company Shares underlying such Company SAR; provided, however,
that the payment, if any, under each CVR shall be reduced by the amount by which the exercise price per share exceeds the value of the
Upfront Consideration; provided, further that, for the avoidance of doubt, such Contingent In-the-Money SAR shall not entitle the holder
thereof to receive any shares of Parent Common Stock, cash or other consideration in connection with the Effective Time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">With
respect to any Company SAR with an exercise price per share that is equal to or greater than the value of the Merger Consideration (each,
an &ldquo;<U>Underwater Company SAR</U>&rdquo;), the holder of such Underwater Company SAR receive no consideration and, effective as
of immediately prior to the Effective Time, shall have no further rights thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Surviving Corporation shall pay the holders of Company Stock Options, Company RSUs and Company SARs the cash payments described in this
<B><U>&lrm;</U></B><U>Section&nbsp;2.3</U> (with respect to fractional shares) through the Surviving Corporation&rsquo;s payroll system
(or, for individuals who are not current or former employees, directly to such individuals) promptly after the Effective Time, but in
any event not later than the first regularly scheduled pay date that is at least three (3)&nbsp;Business Days after the Effective Time.
Parent shall cause its transfer agent to issue to the holders of Company Stock Options, Company RSUs, and Company SARs, the shares of
Parent Common Stock and the CVRs, as applicable, as described in this <B><U>&lrm;</U></B><U>Section&nbsp;2.3</U> and the CVR Agreement,
as applicable, promptly after the Effective Time, but in any event not later than the third Business Day after the Effective Time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">As
soon as practicable following the date hereof, the Company shall take all actions with respect to the Company&rsquo;s Employee Stock Purchase
Plan (the &ldquo;<U>Company ESPP</U>&rdquo;) that are necessary to provide that: (i)&nbsp;with respect to any offering period in effect
as of the date hereof (the &ldquo;<U>Current ESPP Offering Period</U>&rdquo;), no employee who is not a participant in the Company ESPP
as of the date hereof may become a participant in the Company ESPP and no participant may increase the percentage amount of his or her
payroll deduction election from that in effect on the date hereof for the Current ESPP Offering Period; (ii)&nbsp;subject to the consummation
of the Merger, the Company ESPP shall terminate effective immediately prior to the Effective Time; (iii)&nbsp;the Company ESPP shall be
suspended and no new offering period shall be commenced under the Company ESPP prior to the termination of this Agreement; and (iv)&nbsp;if
any Current ESPP Offering Period is still in effect at the Effective Time, then the last day of such Current ESPP Offering Period shall
be accelerated to a date before the Closing Date determined by the Company Board (or relevant committee thereof) in its discretion and
the final settlement or purchase of Company Shares thereunder shall be made on that day and such Company Shares shall be treated as specified
in <B><U>&lrm;</U></B><U>Section&nbsp;2.1</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Prior
to the Effective Time, the Company shall adopt such resolutions and take all other action (including, as applicable, providing advance
notice to holders of Company Stock Options and Company SARs) as may be reasonably required to effectuate the provisions of this <B><U>&lrm;</U></B><U>Section&nbsp;2.3</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Notwithstanding
the foregoing, to the extent Parent and any holder of Company Stock Options, Company RSUs, unvested restricted Company Shares, or Company
SARs agree in writing to different treatment of such Company Stock Options, Company RSUs, unvested restricted Company Shares, or Company
SARs, as applicable, then the terms of such written agreement shall apply in lieu of the treatment described in this <B><U>&lrm;</U></B><U>Section&nbsp;2.3</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;2.4</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Treatment
of Warrant</U>. At the Effective Time, each Warrant (the &ldquo;<U>Company Warrant</U>&rdquo;), under that certain Warrant to Purchase
Stock, dated as of September&nbsp;21, 2022, by and between the Company and SLR Investment Corp., a Maryland corporation, that is outstanding
immediately prior to the Effective Time shall be cancelled and, in exchange therefor, the Surviving Corporation shall pay to each former
holder of any such cancelled Company Warrant as soon as practicable following the Effective Time (i)&nbsp;a number of shares of Parent
Common Stock equal to (A)&nbsp;the product of (x)&nbsp;the excess of $1.10 over the exercise price per Company Share under such Company
Warrant, and (y)&nbsp;the number of Company Shares subject to such Company Warrant, multiplied by (B)&nbsp;the Exchange Ratio, and (ii)&nbsp;one
CVR for Company Share underlying such Company Warrant, in each case, without interest, and subject to deduction for any required withholding
Tax.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;2.5</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>No
Fractional Shares</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">No
fractional shares of Parent Common Stock shall be issued in connection with the Merger, and no certificate or scrip representing fractional
shares of Parent Common Stock shall be issued upon the surrender for exchange of Certificates or Book-Entry Shares or any other provision
of <B><U>&lrm;</U></B><U>Article&nbsp;II</U>, and such fractional share interests shall not entitle the owner thereof to vote or to any
other rights of a stockholder of Parent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Notwithstanding
any other provision of this Agreement, each holder of Company Shares converted pursuant to the Merger who would otherwise be entitled
to receive a fraction of a share of Parent Common Stock (or holder of other equity interests of the Company who would otherwise have been
entitled to receive a fraction of a share of Parent Common Stock pursuant to the provisions of <B><U>&lrm;</U></B><U>Section&nbsp;2.3</U>)
(after aggregating all fractional shares of Parent Common Stock otherwise issuable to such holder pursuant to <B><U>&lrm;</U></B><U>Section&nbsp;2.1(a)</U>)
shall, in lieu thereof and upon surrender of such holder&rsquo;s Certificates and Book-Entry Shares, as applicable, be paid in cash the
dollar amount (rounded to the nearest whole cent), without interest and subject to any required tax withholding, determined by multiplying
such fraction by the average of the daily volume-weighted average price per share of Parent Common Stock calculated based on the ten (10)&nbsp;consecutive
trading days ending two trading days prior to the date of this Agreement (the &ldquo;<U>Fractional Share Cash Consideration</U>&rdquo;).
No such holder shall be entitled to dividends, voting rights or any other rights in respect of any fractional share of Parent Common Stock
that would otherwise have been issuable as part of the Merger Consideration. As soon as practicable after the determination of the amount
of the Fractional Share Cash Consideration, if any, to be paid to holders of the Company Shares in respect of any fractional shares, the
Exchange Agent shall make available such amounts to the holders of the Company Shares entitled to receive such cash. The payment of Fractional
Share Cash Consideration in lieu of fractional share interests pursuant to this <B><U>&lrm;</U></B><U>Section&nbsp;2.5(b)</U>&nbsp;is
not a separately bargained-for consideration but merely represents a mechanical rounding-off of the fractions in the exchange.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;2.6</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Tax
Withholding</U>. Each of Parent, the Exchange Agent, the Rights Agent, Merger Sub, the Company, the Surviving Corporation, and their respective
Affiliates, as applicable, shall be entitled to deduct and withhold from any amounts otherwise payable pursuant to this Agreement or the
CVR Agreement, any amounts as are required to be deducted and withheld with respect to the making of such payment pursuant to the Code
or any other applicable tax Law. In the event any such deduction and withholding are required to be made in respect of Parent Common Stock
to be received by a holder of Company Shares in the Merger, such deduction and withholding shall be satisfied by reducing the number of
shares of Parent Common Stock to which such holder otherwise would be entitled under this Agreement by a number of shares equal to (x)&nbsp;the
dollar amount of such deduction and withholding, divided by (y)&nbsp;the Parent Signing Price. To the extent that amounts are so deducted
or withheld and paid over or remitted to the appropriate Governmental Entity, such amounts shall be treated for all purposes of this Agreement
or the CVR Agreement, as applicable, as having been paid to the Person in respect of which such deduction and withholding were made.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;2.7</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Dissenting
Shares</U>. Notwithstanding anything in this Agreement to the contrary, Company Shares issued and outstanding immediately prior to the
Effective Time (other than, for the avoidance of doubt, any Cancelled Shares) that are held by any holder who is entitled to demand and
properly demands appraisal of such Company Shares pursuant to, and complies in all respects with, Section&nbsp;262 of the DGCL (&ldquo;<U>Dissenting
Shares</U>&rdquo;) shall not be converted into or be exchangeable for the right to receive the Merger Consideration, but instead at the
Effective Time shall become entitled to payment of the fair value of such shares in accordance with the provisions of Section&nbsp;262
of the DGCL, and at the Effective Time all Dissenting Shares shall no longer be outstanding and shall automatically be canceled and cease
to exist, and each holder (or beneficial owner) of Dissenting Shares shall cease to have any rights with respect thereto, except the right
to receive the fair value of such Dissenting Shares in accordance with the provisions of Section&nbsp;262 of the DGCL. Dissenting Shares
shall be treated in accordance with Section&nbsp;262 of the DGCL. If any such holder fails to perfect or waives, withdraws or loses any
such right to appraisal, each such Company Share of such holder shall thereupon cease to constitute Dissenting Shares and the right of
such holder to be paid the fair value of such holder&rsquo;s Dissenting Shares under Section&nbsp;262 of the DGCL shall be forfeited and
cease. If such forfeiture shall occur, following the Effective Time, each such Company Share of such holder shall be converted into and
become exchangeable only for the right to receive the Merger Consideration in accordance with <U>&lrm;Section&nbsp;2.1(a)</U>, without
interest. The Company shall serve prompt notice to Parent of any demands received by the Company for appraisal of any Company Shares,
and Parent shall have the right to, and the Company shall provide Parent the opportunity to, participate in all negotiations and proceedings
with respect to such demands and the exercise of any appraisal rights under the DGCL. The Company shall not, without the prior written
consent of Parent, make any payment with respect to, offer to compromise or settle or compromise or settle, or approve any withdrawal
of any such demands.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase; color: #010000"><B>Article&nbsp;III</B></FONT><B><FONT STYLE="text-transform: uppercase"><BR>
REPRESENTATIONS AND WARRANTIES OF THE COMPANY</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except (a)&nbsp;as disclosed
or reflected in the Company SEC Documents filed and publicly available after January&nbsp;1, 2021 but at least one Business Day prior
to the date of this Agreement (but excluding any risk factor disclosures contained under the heading &ldquo;Risk Factors,&rdquo; any disclosure
of risks included in any &ldquo;forward-looking statements&rdquo; disclaimer or any other statements that are similarly predictive or
forward-looking in nature, in each case, other than any specific factual information contained therein), or (b)&nbsp;as set forth in the
disclosure letter delivered by the Company to Parent concurrently with the execution of this Agreement (the &ldquo;<U>Company Disclosure
Letter</U>&rdquo;) (it being agreed that disclosure of any information in a particular section&nbsp;or subsection&nbsp;of the Company
Disclosure Letter shall be deemed disclosure with respect to any other section&nbsp;or subsection&nbsp;of this Agreement to the extent
to which the relevance of such information is reasonably apparent on the face of such disclosure that such disclosure also qualifies or
applies to such other subsections), the Company represents and warrants to Parent and Merger Sub as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;3.1</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Organization,
Standing and Power</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Company (i)&nbsp;is a corporation duly organized, validly existing and in good standing under the Laws of the State of Delaware, (ii)&nbsp;has
all requisite corporate power and authority to own, lease and operate its properties and to carry on its business as it is now being conducted
and (iii)&nbsp;is duly qualified or licensed to do business and is in good standing(with respect to jurisdictions that recognize such
concept) in each jurisdiction in which the nature of its business or the ownership, leasing or operation of its properties makes such
qualification or licensing necessary, except, with respect to clauses&nbsp;(ii)&nbsp;and (iii), for any such failure to have such power
and authority or to be so qualified or licensed or in good standing that, individually or in the aggregate, has not constituted or resulted
in, and would not reasonably be expected to constitute or result in, a Company Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Company has previously furnished or otherwise made available to Parent a true and complete copy of the Company&rsquo;s certificate of
incorporation (the &ldquo;<U>Company Charter</U>&rdquo;) and bylaws (the &ldquo;<U>Company Bylaws</U>&rdquo;), in each case as amended
to the date of this Agreement, and each as so delivered is in full force and effect. The Company is not in violation of any provision
of the Company Charter or Company Bylaws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Each
of the Company&rsquo;s Subsidiaries (i)&nbsp;is an entity duly organized, validly existing and in good standing (with respect to jurisdictions
that recognize such concept) under the Laws of the jurisdiction of its organization, (ii)&nbsp;has all requisite corporate or similar
power and authority to own, lease and operate its properties and to carry on its business as now being conducted and (iii)&nbsp;is duly
qualified or licensed to do business and is in good standing (with respect to jurisdictions that recognize such concept) in each jurisdiction
in which the nature of its business or the ownership, leasing or operation of its properties makes such qualification or licensing necessary,
except in each case of clauses (i), (ii)&nbsp;and (iii), that, individually or in the aggregate, has not constituted or resulted in, and
would not reasonably be expected to constitute or result in, a Company Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Company has previously furnished or otherwise made available to Parent a true and complete copy of the Organizational Documents of each
Subsidiary of the Company, in each case as amended to the date of this Agreement, and each such Organizational Document as so delivered
is in full force and effect. Except as, individually or in the aggregate, has not constituted or resulted in, and would not reasonably
be expected to constitute or result in, a Company Material Adverse Effect, no such Subsidiary is in violation of any of the provisions
of such Organizational Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;3.2</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Capital
Stock</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
authorized capital stock of the Company consists of (i)&nbsp;300,000,000 Company Shares and (ii)&nbsp;5,000,000 shares of preferred stock,
par value $0.001 per share (the &ldquo;<U>Preferred Stock</U>&rdquo;). As of April&nbsp;21, 2023 (the &ldquo;<U>Measurement Date</U>&rdquo;),
(1)&nbsp;205,284,506 Company Shares were issued and outstanding, all of which were validly issued, fully paid and nonassessable and were
free of preemptive rights, (2)&nbsp;1,489,315 of such Company Shares were unvested restricted shares, (3)&nbsp;no Company Shares were
held in treasury, (4)&nbsp;no shares of Preferred Stock were outstanding, (5)&nbsp;454,545 Company Shares were issuable upon exercise
of the Company Warrant, (6)&nbsp;an aggregate of 5,516,641 Company Shares were subject to or otherwise deliverable in connection with
outstanding Company RSUs (at the target level of performance), (7)&nbsp;18,368,256 (vested and unvested) Company Shares were issuable
upon the exercise of outstanding Company Stock Options, (8)&nbsp;2,664,213 Company Shares were subject to outstanding Company SARs, (9)&nbsp;636,473
Company Shares were issuable pursuant to the Current ESPP Offering Period assuming the fair market value of a Company Share on the last
day of the Current ESPP Offering Period is $0.31, the Current ESPP Offering Period ends on its regularly scheduled date, all current elections
to participate remain in effect and no new elections to participate are permitted and (10)&nbsp;4,361,610 Company Shares were available
for issuance of future awards under any other Company equity compensation plan or arrangement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Except
as set forth above and except for changes since the Measurement Date resulting from the exercise of Company Stock Options outstanding
on such date, as of the date of this Agreement, (1)&nbsp;there are not outstanding or authorized any (A)&nbsp;shares of capital stock
or other voting securities of the Company, (B)&nbsp;securities of the Company convertible into or exchangeable for shares of capital stock
or voting securities of the Company or (C)&nbsp;options or other rights to acquire from the Company, and no obligation of the Company
to issue, any capital stock, voting securities or securities convertible into or exchangeable for capital stock or voting securities of
the Company, (2)&nbsp;there are no outstanding obligations of the Company or any Subsidiary of the Company to repurchase, redeem or otherwise
acquire any capital stock, voting securities or securities convertible into or exchangeable for capital stock or voting securities of
the Company or Subsidiary of the Company, (3)&nbsp;there are no other options, calls, warrants, rights of first refusal or other rights,
agreements, arrangements or commitments of any character relating to the issued or unissued capital stock of the Company or any of its
Subsidiaries to which the Company or any of its Subsidiaries is a party, (4)&nbsp;there are no bonds, debentures, notes or other indebtedness
of the Company or any Subsidiary of the Company issued and outstanding having the right to vote (or convertible or exercisable or exchangeable
for securities having the right to vote) on any matters on which stockholders of the Company may vote, and (5)&nbsp;there is no Contract
to which the Company or its Subsidiaries is a party relating to the voting or registration of, or restricting any Person from purchasing,
selling, pledging or otherwise disposing of (or from granting any option or similar right with respect to), any Company Shares or capital
or other equity interests of any Subsidiary of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Each
of the outstanding shares of capital stock of each of the Company&rsquo;s Subsidiaries is duly authorized, validly issued, fully paid
and nonassessable and all such shares are owned by the Company or another wholly-owned Subsidiary of the Company and are owned free and
clear of all security interests, liens, claims, pledges, agreements, limitations in voting rights, charges or other encumbrances (collectively,
other than encumbrances under applicable securities Laws, &ldquo;<U>Liens</U>&rdquo;) of any nature whatsoever, except where any such
failure to own any such shares free and clear, individually or in the aggregate, has not constituted or resulted in, and would not reasonably
be expected to constitute or result in, a Company Material Adverse Effect. <B><U>&lrm;&lrm;</U></B><U>Section&nbsp;3.2(c)</U>&nbsp;of
the Company Disclosure Letter sets forth a true and complete list of each Subsidiary of the Company and its jurisdiction of incorporation
or organization.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">With
respect to each Company RSU, Company Stock Option, Company SAR, and unvested restricted Company Share granted under the Company Equity
Plans (each, a &ldquo;<U>Company Award</U>&rdquo;), <U>Section&nbsp;3.2(d)</U>&nbsp;of the Company Disclosure Letter sets forth (i)&nbsp;the
name or identification number of each holder of such Company Award; (ii)&nbsp;the type of Company Award; (iii)&nbsp;the name of the relevant
Company Equity Plan under which the Company Award was issued; (iv)&nbsp;the date of grant; (v)&nbsp;the number of Company Shares covered
by such Company Award and any portion of the Company Award, if applicable, that has been forfeited, cancelled or exercised; and (vi)&nbsp;the
cash exercise price per Company Share of such Company Award, if applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">All
Company Awards were issued under the Company&rsquo;s 2009 Equity Incentive Plan, 2018 Equity Incentive Plan and 2022 Employment Inducement
Incentive Award Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;3.3</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Authority</U>.
The Company has all necessary corporate power and authority to execute and deliver this Agreement, to perform its obligations hereunder
and, subject to the adoption and approval of this Agreement by the holders of at least a majority in combined voting power of the Company
Shares issued and outstanding on the record date for the Company Stockholder Meeting and entitled to vote on the proposal to adopt this
Agreement (the &ldquo;<U>Company Stockholder Approval</U>&rdquo;), to consummate the transactions contemplated hereby. The execution,
delivery and performance of this Agreement by the Company and the consummation by the Company of the transactions contemplated hereby
have been duly authorized by all necessary corporate action on the part of the Company and no other corporate proceedings on the part
of the Company are necessary to approve this Agreement or to consummate the transactions contemplated hereby, subject, in the case of
the consummation of the Merger, to obtaining the Company Stockholder Approval. This Agreement has been duly executed and delivered by
the Company and, assuming the due authorization, execution and delivery by Parent and Merger Sub constitutes a valid and binding obligation
of the Company, enforceable against the Company in accordance with its terms (except to the extent that enforceability may be limited
by applicable bankruptcy, insolvency, moratorium, reorganization or similar Laws affecting the enforcement of creditors&rsquo; rights
generally or by general principles of equity). As of the date hereof, the Company Board has approved and declared advisable this Agreement
and the transactions contemplated hereby and, subject to <U>&lrm;Section&nbsp;5.4</U>, has directed that this Agreement be submitted to
a vote of the Company&rsquo;s stockholders, resolved to recommend that the Company&rsquo;s stockholders adopt and approve this Agreement
and the transactions contemplated hereby (the &ldquo;<U>Company Board Recommendation</U>&rdquo;) and resolved to include the Company Board
Recommendation in the Joint Proxy Statement/Prospectus. The Company Stockholder Approval is the only vote or consent of the holders of
any class or series of capital stock of the Company necessary to approve this Agreement or the Merger or the other transactions contemplated
hereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;3.4</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>No
Conflict; Consents and Approvals</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
execution, delivery and performance of this Agreement by the Company, and the consummation by the Company of the transactions contemplated
hereby, do not and will not (i)&nbsp;conflict with or violate the Company Charter or Company Bylaws or the equivalent Organizational Documents
of any of the Company&rsquo;s Subsidiaries, (ii)&nbsp;assuming that all consents, approvals and authorizations contemplated by clauses&nbsp;(i)&nbsp;through
(v)&nbsp;of <U>subsection&nbsp;<B>&lrm;</B>(b)</U>&nbsp;below have been obtained and all filings described in such clauses have been made,
conflict with or violate any law, rule, regulation, order, judgment or decree (collectively, &ldquo;<U>Law</U>&rdquo;) applicable to the
Company or any of its Subsidiaries or by which any of their respective properties are bound or (iii)&nbsp;result in any breach or violation
of, or constitute a default (or an event which with notice or lapse of time or both would become a default), or result in the loss of
a benefit under, or give rise to any right of termination, cancellation, amendment or acceleration of, any note, bond, mortgage, indenture,
contract, agreement, lease, license, permit or other instrument or obligation (each, a &ldquo;<U>Contract</U>&rdquo;) to which the Company
or any of its Subsidiaries is a party or by which the Company or any of its Subsidiaries or any of their respective properties are bound,
except, in the case of clauses&nbsp;(ii)&nbsp;and (iii), for any such conflict, breach, violation, default, loss, right or other occurrence
that, individually or in the aggregate, has not constituted or resulted in, and would not reasonably be expected to constitute or result
in, a Company Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
execution, delivery and performance of this Agreement by the Company, and the consummation by the Company of the transactions contemplated
hereby, do not and will not require any consent, approval, authorization or permit of, action by, filing with or notification to, any
governmental or regulatory (including stock exchange) authority, agency, court commission, or other governmental body (each, a &ldquo;<U>Governmental
Entity</U>&rdquo;), except for (i)&nbsp;such filings as may be required under applicable requirements of the Securities Exchange Act of
1934, as amended (the &ldquo;<U>Exchange Act</U>&rdquo;) and the rules&nbsp;and regulations promulgated thereunder, and under state securities,
takeover and &ldquo;blue sky&rdquo; laws, (ii)&nbsp;the filings required under the Hart-Scott-Rodino Antitrust Improvements Act of 1976,
as amended (the &ldquo;<U>HSR Act</U>&rdquo;), (iii)&nbsp;such filings as necessary to comply with the applicable requirements of The
Nasdaq Stock Market (&ldquo;<U>Nasdaq</U>&rdquo;), (iv)&nbsp;the filing with the Secretary of State of the State of Delaware of the Certificate
of Merger as required by the DGCL and (v)&nbsp;any such consent, approval, authorization, permit, action, filing or notification, in each
case with respect to a Governmental Entity, the failure of which to make or obtain that, individually or in the aggregate, has not constituted
or resulted in, and would not reasonably be expected to constitute or result in, a Company Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;3.5</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>SEC
Reports; Financial Statements</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Company has timely filed, furnished or otherwise transmitted all forms, reports, statements, certifications and other documents (including
all exhibits, amendments and supplements thereto) required to be filed by it with the U.S. Securities and Exchange Commission (the &ldquo;<U>SEC</U>&rdquo;)
since January&nbsp;1, 2021 (all such forms, reports, statements, certificates and other documents filed since January&nbsp;1, 2021 and
prior to the date hereof, collectively, the &ldquo;<U>Company SEC Documents</U>&rdquo;). As of their respective dates, or, if amended,
as of the date of the last such amendment, each of the Company SEC Documents complied as to form in all material respects with the applicable
requirements of the Securities Act of 1933, as amended (the &ldquo;<U>Securities Act</U>&rdquo;) and the Exchange Act, and the applicable
rules&nbsp;and regulations promulgated thereunder, as the case may be, each as in effect on the date so filed. As of their respective
filing dates (or, if amended or superseded by a subsequent filing prior to the date hereof, as of the date of such amendment or superseding
filing), none of the Company SEC Documents contained any untrue statement of a material fact or omitted to state a material fact required
to be stated or incorporated by reference therein or necessary in order to make the statements therein, in the light of the circumstances
under which they were made, not misleading. No Subsidiary of the Company has been required to file any forms, reports or other documents
with the SEC at any time since January&nbsp;1, 2021. Since January&nbsp;1, 2021 no executive officer of the Company has failed in any
respect to make the certifications required of him or her under Section&nbsp;302 or 906 of the Sarbanes-Oxley Act. Neither the Company
nor any of its executive officers has received notice from any Governmental Entity challenging or questioning the accuracy, completeness,
form or manner of filing of such certifications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
audited consolidated financial statements of the Company (including any related notes thereto) included in or incorporated by reference
in the Company SEC Documents (i)&nbsp;complied as to form in all material respects with the published rules&nbsp;and regulations of the
SEC applicable thereto; (ii)&nbsp;have been prepared in accordance with United States generally accepted accounting principles (&ldquo;<U>GAAP</U>&rdquo;)
applied on a consistent basis throughout the periods involved (except as may be indicated in the notes thereto or, in the case of unaudited
statements, as permitted by Form&nbsp;10-Q or any successor form under the Exchange Act, and except that unaudited financial statements
may not contain footnotes and are subject to normal and recurring year-end adjustments); (iii)&nbsp;fairly present in all material respects
the consolidated financial position of the Company and its Subsidiaries at the respective dates thereof and the results of their operations
and cash flows for the periods indicated subject, with respect to unaudited interim statements, to normal and recurring year-end adjustments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Company maintains, and at all times since January&nbsp;1, 2021 has maintained, disclosure controls and procedures required by Rule&nbsp;13a-15
or 15d-15 under the Exchange Act. Such disclosure controls and procedures are designed to ensure that information required to be disclosed
by the Company in its filings with the SEC under the Exchange Act is recorded and reported on a timely basis to the individuals responsible
for the preparation of the Company&rsquo;s filings with the SEC under the Exchange Act. The Company maintains internal control over financial
reporting (as defined in Rule&nbsp;13a-15 or 15d-15, as applicable, under the Exchange Act). Such internal control over financial reporting
is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
for external purposes in accordance with GAAP. The Company&rsquo;s management has completed an assessment of the effectiveness of the
Company&rsquo;s system of internal control over financial reporting in compliance with the requirements of Section&nbsp;404 of the Sarbanes-Oxley
Act for the fiscal year ended December&nbsp;31, 2022, and such assessment concluded that such controls were effective and the Company&rsquo;s
independent registered accountant has issued an attestation report concluding that the Company maintained effective internal control over
financial reporting as of December&nbsp;31, 2022. The Company has disclosed, based on the most recent evaluation of its Chief Executive
Officer and its Chief Financial Officer prior to the date of this Agreement, to the Company&rsquo;s auditors and the audit committee of
the Company Board (i)&nbsp;any significant deficiencies and material weaknesses in the design or operation of its internal controls over
financial reporting and (ii)&nbsp;any fraud, whether or not material, that involves management or other employees who have a significant
role in the Company&rsquo;s internal control over financial reporting, and each such deficiency, weakness and fraud so disclosed to auditors,
if any, has been disclosed to Parent prior to the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Since
January&nbsp;1, 2021, (i)&nbsp;none of the Company or any Subsidiary of the Company nor, to the knowledge of the Company, any director
or officer of the Company or any Subsidiary of the Company has received or otherwise had or obtained knowledge of any material complaint,
allegation, assertion or claim, whether written or oral, regarding accounting, internal accounting controls or auditing practices, procedures,
methodologies or methods of the Company or any Subsidiary of the Company or any material complaint, allegation, assertion or claim from
employees of the Company or any Subsidiary of the Company regarding questionable accounting or auditing matters with respect to the Company
or any Subsidiary of the Company, and (ii)&nbsp;to the knowledge of the Company, no attorney representing the Company or any Subsidiary
of the Company, whether or not employed by the Company or any Subsidiary of the Company, has reported evidence of a material violation
of securities Laws, breach of fiduciary duty or similar violation by the Company, any Subsidiary of the Company or any of their respective
officers, directors, employees or agents to the Company Board or any committee thereof, or to the General Counsel or Chief Executive Officer
of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">As
of the date hereof, the Company is in compliance in all material respects with all current listing requirements of Nasdaq.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Neither
the Company nor any Subsidiary of the Company is a party to, or has a commitment to effect, enter into or create, any joint venture, or
 &ldquo;off-balance sheet arrangement&rdquo; (as defined in Item 303(a)&nbsp;of Regulation S-K under the Exchange Act).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">As
of the date of this Agreement, there are no outstanding or unresolved comments in comment letters received from the SEC with respect to
the Company SEC Documents, and none of the Company SEC Documents is, to the knowledge of the Company, the subject of ongoing SEC review
or investigation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;3.6</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>No
Undisclosed Liabilities</U>. Neither the Company nor any of its Subsidiaries has any liabilities or obligations of any nature, whether
or not accrued, absolute, determined, contingent or otherwise, and whether due or to become due, that would be required by GAAP to be
reflected on a consolidated balance sheet (or the notes thereto) of the Company and its Subsidiaries, except for liabilities and obligations
(a)&nbsp;reflected or reserved against in the Company&rsquo;s consolidated balance sheet as of December&nbsp;31, 2022 (or the notes thereto)
included in the Company SEC Documents, (b)&nbsp;incurred in the ordinary course of business since January&nbsp;1, 2023, (c)&nbsp;incurred
pursuant to the transactions contemplated by this Agreement or the CVR Agreement and (d)&nbsp;that, individually or in the aggregate,
has not constituted or resulted in, and would not reasonably be expected to constitute or result in, a Company Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;3.7</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Certain
Information</U>. The information supplied or to be supplied by the Company specifically for inclusion in the registration statement on
Form&nbsp;S-4 to be filed by Parent in connection with the Parent Stock Issuance (as amended or supplemented from time to time, the &ldquo;<U>Form&nbsp;S-4</U>&rdquo;)
shall not, at the time that the Form&nbsp;S-4 is declared effective by the SEC, contain any untrue statement of a material fact or omit
to state any material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances
under which they were made, not misleading, except that no representation or warranty is made by the Company with respect to statements
made therein based on information supplied by or on behalf of Parent or Merger Sub specifically for inclusion in the Form&nbsp;S-4. The
Joint Proxy Statement/Prospectus will not, at the date the Joint Proxy Statement/Prospectus is first mailed to the stockholders of the
Company and at the time of the Company Stockholders Meeting, contain any untrue statement of a material fact or omit to state any material
fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they
were made, not misleading, except that, in each case, no representation or warranty is made by the Company with respect to statements
made therein based on information supplied by or on behalf of Parent or Merger Sub specifically for inclusion in the Joint Proxy Statement/Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;3.8</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Absence
of Certain Changes or Events</U>. Since January&nbsp;1, 2023 through the date of this Agreement, (a)&nbsp;the businesses of the Company
and its Subsidiaries have been conducted in the ordinary course of business in all material respects and in a manner consistent with past
practice, and neither the Company nor any of its Subsidiaries has undertaken any action that if proposed to be taken after the date of
this Agreement would require Parent&rsquo;s consent pursuant to <U>&lrm;Section&nbsp;5.1(b)&lrm;(iii)</U>, <U>(v)</U>, <U>(viii)</U>,
<U>(xi)</U>, <U>&lrm;(xii)</U>, <U>(xv)</U>&nbsp;or, as it relates solely to any of the foregoing clauses, <U>Section&nbsp;5.1(b)(xx)</U>,
and (b)&nbsp;there has not been any Effect that has constituted or resulted in, or that would reasonably be expected to constitute or
result in, a Company Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;3.9</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Litigation</U>.
Except as, individually or in the aggregate, has not constituted or resulted in, and would not reasonably be expected to constitute or
result in, a Company Material Adverse Effect, (a)&nbsp;there is no suit, claim, action, proceeding, arbitration, mediation or investigation,
whether civil, legal or administrative, before any court or public or private body or tribunal or other Governmental Entity (each, an
 &ldquo;<U>Action</U>&rdquo;) pending or, to the knowledge of the Company, threatened against the Company or any of its Subsidiaries or
any of their respective properties or assets, (b)&nbsp;neither the Company nor any of its Subsidiaries nor any of their respective properties
or assets is or are subject to any judgment, order, injunction, rule&nbsp;or decree of any Governmental Entity and (c)&nbsp;there are
no subpoenas, civil investigative demands or other written requests for information issued to the Company or any of its Subsidiaries relating
to potential or actual violations of any Law that are pending or, to the knowledge of the Company, threatened, or any investigations or
claims against or affecting the Company or any of its Subsidiaries, or any of their respective properties or assets, relating to potential
or actual violations of any Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;3.10</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Compliance
with Laws</U>. Except as provided in <U>&lrm;Section&nbsp;3.10</U> of the Company Disclosure Letter, the Company and each of its Subsidiaries
are in compliance with all Laws applicable to them or by which any of their respective properties are bound, except where any non-compliance,
individually or the aggregate, has not constituted or resulted in, and would not reasonably be expected to constitute or result in, a
Company Material Adverse Effect. Neither the Company nor any of its Subsidiaries has, during the three-year period prior to the date of
this Agreement: (i)&nbsp;to the knowledge of the Company, received any written notice or verbal notice from any Governmental Entity regarding
any potential or actual material violation by the Company or any of its Subsidiaries of any Law; or (ii)&nbsp;provided any notice to any
Governmental Entity regarding any potential or actual material violation by the Company or any of its Subsidiaries of any Law. The Company
and its Subsidiaries have in effect all permits, registrations, licenses, exemptions, authorizations, franchises, orders, clearances and
approvals of all Governmental Entities (collectively, &ldquo;<U>Permits</U>&rdquo;) necessary for them to own, lease or operate their
properties and to carry on their businesses as now conducted, except for any Permits the absence of which, individually or in the aggregate,
has not constituted or resulted in, and would not reasonably be expected to constitute or result in, a Company Material Adverse Effect.
Except, individually or in the aggregate, has not constituted or resulted in, and would not reasonably be expected to constitute or result
in, a Company Material Adverse Effect, (x)&nbsp;all Permits are valid and in full force and effect and are not subject to any administrative
or judicial proceeding that could result in any modification, termination or revocation thereof and, to the knowledge of the Company,
no suspension or cancellation of any such Permit is threatened, (y)&nbsp;all fees and assessments due and payable in connection with the
Permits have been timely paid, and (z)&nbsp;the Company and each of its Subsidiaries is in compliance with the terms and requirements
of all Company Permits.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;3.11</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Benefit
Plans</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B><U>&lrm;&lrm;</U></B><U>Section&nbsp;3.11(a)</U>&nbsp;of
the Company Disclosure Letter sets forth a true and complete list of each material Company Plan. For purposes of this Agreement, &ldquo;<U>Company
Plan</U>&rdquo; means each &ldquo;employee benefit plan&rdquo; (within the meaning of section&nbsp;3(3)&nbsp;of the Employee Retirement
Income Security Act of 1974, as amended (&ldquo;<U>ERISA</U>&rdquo;)), each &ldquo;multiemployer plans&rdquo; (within the meaning of ERISA
section&nbsp;3(37)), and each stock purchase, stock option, severance, employment, change-in-control, fringe benefit, bonus, incentive,
deferred compensation and all other plans, agreements, programs, policies or other arrangements providing compensation or benefits, whether
or not subject to ERISA (including any funding mechanism therefor now in effect or required in the future as a result of the transactions
contemplated by this Agreement or otherwise), whether formal or informal, written, legally binding or not, under which any employee or
former employee of the Company or its Subsidiaries has any present or future right to benefits or the Company or its Subsidiaries has
had or has any present or future material liability or which is sponsored, maintained or contributed to by the Company or its Subsidiaries.
With respect to each material Company Plan, the Company has furnished or made available to Parent a current, accurate and complete copy
thereof (or, in the case of an unwritten Company Plan, a summary of the material terms and conditions thereof) and, to the extent applicable:
(i)&#8239;&#8239;any related trust agreement or other funding instrument (including insurance contracts), (ii)&nbsp;the most recent determination,
advisory or opinion letter from the Internal Revenue Service (the &ldquo;<U>IRS</U>&rdquo;), (iii)&nbsp;any summary plan description and
summary of material modifications thereto and other equivalent written communications by the Company or its Subsidiaries to their employees
concerning the extent of the benefits provided under a Company Plan; (iv)&nbsp;for the three most recent years (A)&nbsp;the Form&nbsp;5500
and attached schedules, (B)&nbsp;audited financial statements, (C)&nbsp;actuarial valuation reports, (D)&nbsp;attorney&rsquo;s response
to an auditor&rsquo;s request for information and (E)&nbsp;nondiscrimination and other testing results for 2020, 2021 and 2022; and (v)&nbsp;copies
of all material non-routine correspondence with any Governmental Entity in the past three years (including any filings under the Company
Plans&rsquo; &ldquo;Compliance Resolution System&rdquo; or the Department of Labor Delinquent Filer Program).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">With
respect to the Company Plans:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">except
as, individually or in the aggregate, has not constituted or resulted in, and would not reasonably be expected to constitute or result
in Company Material Adverse Effect, each Company Plan is now and has at all times been established, maintained, funded and administered
in accordance with its terms and in compliance with all applicable Laws, including the applicable provisions of ERISA and the Code, and
no prohibited transaction, as described in Section&nbsp;406 of ERISA or Section&nbsp;4975 of the Code, has occurred with respect to any
Company Plan, and except as, individually or in the aggregate, has not constituted or resulted in, and would not reasonably be expected
to constitute or result in a Parent Material Adverse Effect, all contributions required to be made under the terms of any Company Plan
or applicable Law have been timely made;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">each
Company Plan intended to be qualified under Section&nbsp;401(a)&nbsp;of the Code has received a currently effective, favorable determination,
advisory and/or opinion letter, as applicable, from the IRS that it is so qualified (or the deadline for obtaining such a letter has not
expired as of the date of this Agreement) and, to the knowledge of the Company, nothing has occurred that would reasonably be expected
to cause the loss, or failure to have, such qualified status of such Company Plan; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">there
are no (and in the past three (3)&nbsp;years have not been any) material Actions (including any investigation, audit or other administrative
proceeding) or other claims by the Department of Labor, the Pension Benefit Guaranty Corporation, the IRS or any other Governmental Entity
or by any plan participant, beneficiary or other Person pending, or to the knowledge of the Company, threatened relating to the Company
Plans, any fiduciaries thereof with respect to their duties to the Company Plans or the assets of any of the trusts under any of the Company
Plans (other than routine claims for benefits).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Except
as, individually or in the aggregate, has not constituted or resulted in, and would not reasonably be expected to constitute or result
in Company Material Adverse Effect, the Company and its Subsidiaries do not maintain any Company Plan, or otherwise have any liability
with respect to a plan, that is a &ldquo;group health plan&rdquo; (as such term is defined in Section&nbsp;5000(b)(1)&nbsp;of the Code)
that has not been administered and operated in all respects in compliance with the applicable requirements of Part&nbsp;6 of Subtitle
B of Title I of ERISA and Section&nbsp;4980B(b)&nbsp;of the Code (&ldquo;<U>COBRA</U>&rdquo;), and the Company and its Subsidiaries are
not subject to any liability, including additional contributions, fines, penalties or loss of tax deduction as a result of such administration
and operation. The Company and its Subsidiaries do not have any material liability under Chapter 43 of the Code (whether or not assessed).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">No
Company Plan is, and none of the Company, any of its Subsidiaries or any ERISA Affiliate maintains, sponsors or contributes to (or has
any liability, including on account of previously maintaining, sponsoring or contributing to), a plan that is subject to Section&nbsp;302
or Title IV of ERISA or Section&nbsp;412 of the Code. For purposes of this section, &ldquo;<U>ERISA Affiliate</U>&rdquo; means any trade
or business (whether or not incorporated) which is (or to the extent the Company or any Subsidiary could have any outstanding liability
on account of a prior affiliation, was) treated as a single employer along with the Company or any of its Subsidiaries for purposes of
Section&nbsp;4001 of ERISA or Section&nbsp;414 of the Code. No Company Plan is, and none of the Company or its Subsidiaries has any liability
with respect to a plan that is, a &ldquo;multiemployer plan&rdquo; within the meaning of Section&nbsp;3(37) of ERISA or a &ldquo;multiple
employer welfare arrangement&rdquo; within the meaning of Section&nbsp;3(40) of ERISA. None of any Company Plan, the Company or any of
its Subsidiaries provides or has any obligation to provide health, death or other welfare benefits following the termination of an employee&rsquo;s
employment with the Company or its Subsidiaries, except to the extent required by COBRA or other similar Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Neither
the execution of this Agreement, nor the consummation of any of the transactions contemplated hereby (either alone or in combination with
any other event) could reasonably be expected to result in the payment of a benefit or compensation, the increase of a benefit or compensation
amount, the payment of a contingent benefit or the acceleration of the payment, funding or vesting of a benefit or compensation with respect
to any current or former employee or other individual service provider of the Company or its Subsidiaries. Neither the execution of this
Agreement, nor the consummation of any of the transactions contemplated hereby (either alone or in combination with any other event) could
reasonably be expected to result in any payment or benefit being nondeductible pursuant to Section&nbsp;280G of the Code or subject to
a Tax under Section&nbsp;4999 of the Code. The Company has no obligation to indemnify any individual for, or provide a gross-up, make-whole
or similar payment in respect of, any Tax incurred pursuant to Section&nbsp;409A or 4999 of the Code or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;3.12</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Labor
Matters</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Company has provided to Parent a document, entitled &ldquo;Signing Date Schedule of Company Service Providers&rdquo; current as of the
date hereof, (i)&nbsp;Part&nbsp;I of which includes the following information: a list of each employee of the Company or its Subsidiaries
(each, a &ldquo;<U>Company Employee</U>&rdquo;), and with respect to each such Company Employee, the Company Employee&rsquo;s (i)&nbsp;(A)&nbsp;name,
(B)&nbsp;primary work location, (C)&nbsp;employer, (D)&nbsp;hire date, (E)&nbsp;title, (F)&nbsp;exempt/non-exempt status, (G)&nbsp;full
or part-time status, (H)&nbsp;salaried/hourly status, or other compensation structure, (I)&nbsp;current base salary or wage rate and (J)&nbsp;current
annual incentive compensation opportunity and structure, and (ii)&nbsp;Part&nbsp;II of which includes the following information: a list
of each independent contractor of the Company or its Subsidiaries (each, a &ldquo;<U>Company Contractor</U>&rdquo;), which includes, with
respect to each such Company Contractor, such Company Contractor&rsquo;s (A)&nbsp;name, (B)&nbsp;date of retention, (C)&nbsp;date of contract
expiration, (D)&nbsp;location, (E)&nbsp;contracting entity, (F)&nbsp;rate and frequency of remuneration, and (G)&nbsp;type of services.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Except
as set forth on <B><U>&lrm;&lrm;</U></B><U>Section&nbsp;3.12(b)</U>&nbsp;of the Company Disclosure Letter, the Company is not a party
to or otherwise bound by any collective bargaining agreement, Contract or other labor-related agreement, arrangement or understanding
with a labor or trade union, labor organization, employee representative body or works council (each, a &ldquo;<U>Labor Agreement</U>&rdquo;),
nor is any such Labor Agreement presently being negotiated, nor, to the knowledge of the Company, are there any employees of the Company
or any of its Subsidiaries represented by a labor or trade union, employee representative body, labor organization or works council. The
Company has made available to Parent a true and complete copy of each Labor Agreement and all material amendments thereto. To the knowledge
of the Company, there are no organizing activities, representation campaigns, certification proceedings or petitions seeking a representation
proceeding pending or threatened by or with respect to any of the employees of the Company or any of its Subsidiaries. Since January&nbsp;1,
2020, there has not been any, and there are no pending or, to the knowledge of the Company, threatened strikes, walkouts, lockouts, slowdowns
or other labor stoppages&nbsp;against or affecting the Company or its Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Company and its Subsidiaries are, and since January&nbsp;1, 2020 have been, in compliance in all material respects with the terms of the
Company Plans, any applicable Labor Agreement and all applicable Laws respecting or relating to recruitment, employment and employment
practices, and agency and other workers, including all Laws respecting terms and conditions of employment, health and safety, wages and
hours, worker classification, child labor, immigration, employment discrimination, disability rights or benefits, equal opportunity, plant
closures and layoffs, affirmative action, workers&rsquo; compensation, labor relations, employee leave issues and unemployment insurance
(collectively &ldquo;<U>Employment Laws</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Except
as set forth on <B><U>&lrm;&lrm;</U></B><U>Section&nbsp;3.12(d)</U>&nbsp;of the Company Disclosure Letter, there are no material Actions
or claims pending or, to Company&rsquo;s knowledge, threatened, relating to Employment Law, or unfair labor practice or payment of compensation
to any current or former service provider of the Company or any of its Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">During
the three (3)-year period immediately prior to the date of this Agreement, neither the Company nor its Subsidiaries have implemented any
 &ldquo;plant closing&rdquo; or &ldquo;mass layoff&rdquo; (in each case, as defined under the Worker Adjustment and Retraining Notification
Act of 1988, as amended, or any similar applicable foreign, state or local Law) with respect to which there is any remaining liability
or obligation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;3.13</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Environmental
Matters</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Except
as, individually or in the aggregate, has not constituted or resulted in, and would not reasonably be expected to constitute or result
in, a Company Material Adverse Effect: (i)&nbsp;the Company and each of its Subsidiaries are, and during the past three (3)&nbsp;years
have been, in compliance with all applicable Environmental Laws, and possess and are, and during the past three (3)&nbsp;years have been,
in compliance with all applicable Environmental Permits required under such Environmental Laws to operate the business; (ii)&nbsp;there
has been no release, discharge or disposal of Materials of Environmental Concern that could reasonably be expected to result in a violation
by, or result in a liability of the Company and each of its Subsidiaries under, any Environmental Laws (A)&nbsp;on, under, in or at any
owned or leased real property, or to the knowledge of the Company, (B)&nbsp;on, under, in or at any real property formerly owned or leased
by the Company or its Subsidiaries or at any third party waste disposal location used by the Company or its Subsidiaries; (iii)&nbsp;neither
the Company nor any of its Subsidiaries have received any written request for information pursuant to section&nbsp;104(e)&nbsp;of the
Comprehensive Environmental Response, Compensation and Liability Act or similar state statute, concerning any release or threatened release
of Materials of Environmental Concern at any location; (iv)&nbsp;within the last three (3)&nbsp;years, neither the Company nor any of
its Subsidiaries has received any written notice, claim or complaint, or is presently subject to any action or proceeding, relating to
actual or alleged noncompliance with, or liability arising under, Environmental Laws or any other liabilities pursuant to Environmental
Laws that is unresolved, and to the knowledge of the Company, no such matter has been threatened in writing; and (v)&nbsp;the Company
has provided Parent reasonable access to all material environmental investigations, studies, audits, analyses or other reports (including
any Phase I or Phase II reports) to the extent in the possession, custody or control of the Company or its Subsidiaries relating to the
Company or each of its Subsidiaries compliance with Environmental Law or the presence of contamination by Materials of Environmental Concern
on, under, in or at any property currently or formerly owned, leased, operated or occupied by the Company or its Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Notwithstanding
any other representations and warranties in this Agreement, the representations and warranties in this <B><U>&lrm;</U></B><U>Section&nbsp;3.13</U>
are the only representations and warranties in this Agreement with respect to Environmental Laws or Materials of Environmental Concern.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">For
purposes of this Agreement, the following terms shall have the meanings assigned below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<U>Environmental
Laws</U>&rdquo; means all foreign, federal, tribal, state, or local statutes, regulations, ordinances, codes, or decrees protecting the
quality of the environment and natural resources, including the ambient air, soil, surface water or groundwater, and human health and
safety (in relation to exposure to Materials of Environmental Concern).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<U>Environmental
Permits</U>&rdquo; means all permits, licenses, franchises, approvals, consents, registrations, and other authorizations required under
applicable Environmental Laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<U>Materials
of Environmental Concern</U>&rdquo; means any pollutant, contaminant, waste, or chemical or any radioactive, ignitable, corrosive, reactive,
hazardous, acutely hazardous, or toxic substance or waste defined and regulated as such, or which could give rise to liability, under
applicable Environmental Laws, including the Comprehensive Environmental Response, Compensation and Liability Act or the Resource Conservation
and Recovery Act (or their state law equivalents) or any substance, waste or material having or displaying any of the foregoing characteristics,
including per- and polyfluoroalkyl substances, polychlorinated biphenyls and petroleum, its derivatives, by products and other hydrocarbons.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;3.14</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Taxes</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Except
as, individually or in the aggregate, has not constituted or resulted in, and would not reasonably be expected to constitute or result
in, a Company Material Adverse Effect:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">All
Tax Returns required by applicable Law to be filed by or on behalf of the Company or any of its Subsidiaries have been timely filed in
accordance with all applicable Laws (after giving effect to any extensions of time in which to make such filings), and all such Tax Returns
are true, correct and complete.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Company and its Subsidiaries have timely paid in full to the appropriate Governmental Entity all Taxes required to be paid by any of them
(whether or not shown on any Tax Return). The Company has established adequate accruals and reserves in accordance with GAAP on the financial
statements included in the Company SEC Documents for all Taxes payable by the Company and its applicable Subsidiaries with respect to
all taxable periods (and portions thereof) through the date of such financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Each
of the Company and its Subsidiaries has (i)&nbsp;timely deducted, withheld and collected all amounts required to be deducted, withheld
or collected by any of them with respect to any payment owing to, or received from, their employees, creditors, independent contractors,
customers and other third parties and have timely paid or remitted over any amounts so withheld, deducted or collected to the appropriate
Governmental Entity and (ii)&nbsp;otherwise complied with all applicable Laws relating to the withholding, collection and remittance of
Taxes (including information reporting requirements).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">There
are no Liens for Taxes with respect to any assets or properties of the Company or any of its Subsidiaries, except for statutory Liens
for Taxes not yet due and payable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">No
claim has been made in writing by any Tax authority in a jurisdiction where the Company or any of its Subsidiaries has not filed a Tax
Return of a particular type that the Company or its applicable Subsidiary, as the case may be, is or may be subject to Tax by, or required
to file Tax Returns in, such jurisdiction with respect to Taxes that are the subject of such Tax Return.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Neither
the Company nor any its Subsidiaries (A)&nbsp;is or has been a member of any affiliated, combined, consolidated, unitary or similar group
for purposes of filing Tax Returns or paying Taxes for which the statute of limitations is open (except for any such group of which the
Company is the common parent) or (B)&nbsp;has any liability for Taxes of any Person (other than the Company or any of its Subsidiaries)
under Treasury Regulations Section&nbsp;1.1502-6 (or&nbsp;any similar state, local or non-U.S. Law) or as a transferee or successor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Neither
the Company nor any of its Subsidiaries is a party to or bound by, or has any obligation under, any Tax indemnity, sharing, allocation,
or reimbursement agreement or arrangement, other than (A)&nbsp;customary Tax provisions in ordinary course commercial agreements, the
principal purpose of which is not related to Taxes and (B)&nbsp;any agreement or arrangement solely between or among the Company and/or
any of its Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(viii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">No
audits or other proceedings are currently ongoing or pending, or threatened or proposed in writing, against or with respect to the Company
or any of its Subsidiaries with respect to any Tax or Tax Return. No deficiencies for any amount of Taxes have been asserted or assessed
in writing against the Company or any of its Subsidiaries that have not been paid in full by any of them or that are not being contested
in good faith and for which adequate accruals or reserves for such deficiency have not been established in accordance with GAAP on the
financial statements included in the Company SEC Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ix)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Neither
the Company nor any of its Subsidiaries will be required to include any item of income in, or exclude any item of deduction from, taxable
income for any taxable period (or any portion thereof) ending after the Closing Date as a result of (A)&nbsp;any installment sale or other
open transaction disposition made prior to the Closing, (B)&nbsp;any adjustment under Section&nbsp;481(a)&nbsp;of the Code (or any comparable,
analogous or similar provision under any U.S. state or local or non-U.S. Law) or change in method of accounting initiated prior to the
Closing, (C)&nbsp;the use of an improper method of accounting for any taxable period (or portion thereof) ending on or prior to the Closing
Date, (D)&nbsp;any &ldquo;closing agreement&rdquo; as described in Section&nbsp;7121 of the Code (or any comparable, analogous or similar
provision under any U.S. state or local or non-U.S. Law) executed prior to the Closing, (E)&nbsp;any prepaid amount or deferred revenue
received or accrued prior to the Closing, (F)&nbsp;having entered into a &ldquo;gain recognition agreement&rdquo; within the meaning of
Treasury Regulation Section&nbsp;1.367(a)-8 or (G)&nbsp;pursuant to Section&nbsp;965 of the Code. Neither the Company nor any of its Subsidiaries
has made an election pursuant to Section&nbsp;965(h)&nbsp;of the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(x)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Neither
the Company nor any of its Subsidiaries (A)&nbsp;has filed any extension of time within which to file any Tax Returns that have not been
filed, except in the ordinary course of business, (B)&nbsp;has entered into any agreement or other arrangement waiving or extending the
statute of limitations or the period of assessment or collection of any Taxes for which the statute of limitations is open, (C)&nbsp;has
granted any power of attorney that is in force with respect to any matters relating to any Taxes, except in the ordinary course of business
(D)&nbsp;has applied for a ruling from any Tax authority relating to any Taxes that has not been granted or has proposed to enter into
an agreement with a Tax authority that is pending or (E)&nbsp;has been issued any private letter rulings, technical advice memoranda or
similar agreement or rulings by any Tax authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xi)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Neither
the Company nor any of its Subsidiaries has participated in any &ldquo;listed transaction&rdquo; within the meaning of Treasury Regulations
Section&nbsp;1.6011-4(b)(2)&nbsp;(or any similar state, local or non-U.S. Law).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Company has not been a &ldquo;United States real property holding corporation&rdquo; within the meaning of Section&nbsp;897(c)(2)&nbsp;of
the Code during the applicable period specified in Section&nbsp;897(c)(1)(A)(ii)&nbsp;of the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Neither
the Company nor any of its Subsidiaries has constituted a &ldquo;distributing corporation&rdquo; or a &ldquo;controlled corporation&rdquo;
(within the meaning of Section&nbsp;355(a)(1)(A)&nbsp;of the Code) in a distribution of stock intended to qualify for Tax-free treatment
under Section&nbsp;355 of the Code (or any similar provision of state, local, or non-U.S. Law) or otherwise as part of a plan (or series
of related transactions), within the meaning of Section&nbsp;355(e)&nbsp;of the Code, that includes the Merger, in the two years prior
to the date of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Neither
the Company nor any of its Subsidiaries has knowledge of any facts, agreements, plans or other circumstances or has taken or agreed to
take any action, in each case that is not contemplated by this Agreement, that would reasonably be expected to prevent or impede the Merger
from qualifying for the Intended Tax Treatment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">As
used in this Agreement:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<U>Tax
Returns</U>&rdquo; means any and all U.S. and non-U.S. (whether national, federal, state, provincial, local or otherwise) returns, declarations,
forms, statements, reports or other documents filed or required to be filed with any Governmental Entity with respect to Taxes, including
any schedules or attachments thereto and any amendments thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<U>Taxes</U>&rdquo;
means any and all U.S. federal, state and local and non-U.S. taxes, assessments, levies, duties, tariffs, imposts and other charges and
fees of any kind whatsoever similar to, or in the nature of, a tax imposed by a Governmental Entity, including any income, franchise,
windfall or other profits, gross receipts, premiums, property, sales, use, net worth, capital stock, payroll, employment, social security,
workers&rsquo; compensation, unemployment compensation, excise, withholding, ad valorem, stamp, transfer, value-added, and license, registration
and documentation fees, severance, occupation, environmental, disability, real property, personal property, escheat or unclaimed property
obligations, registration, alternative or add-on minimum or estimated taxes, together with any interest, penalties and additions imposed
with respect thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;3.15</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Contracts</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Except
for this Agreement and except as filed with the SEC as an exhibit to any Company SEC Document, as of the date hereof, neither the Company
nor any of its Subsidiaries is a party to or is bound by any of the following categories of Contracts (each such Contract required to
be filed as an exhibit to any Company SEC Document or required to be listed in <B>&lrm;</B><U>Section&nbsp;3.15(a)</U>&nbsp;of the Company
Disclosure Letter, a &ldquo;<U>Material Contract</U>&rdquo;):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">any
Contract required to be filed by the Company as a &ldquo;material contract&rdquo; pursuant to Item 601(b)(10)&nbsp;of Regulation S-K under
the Securities Act that has not been so filed (except for a Company Plan listed in <B><I><U>&lrm;</U></I></B><U>Section&nbsp;3.11(a)</U>&nbsp;of
the Company Disclosure Letter);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">any
Contract to which the Company is a party that (a)&nbsp;restricts the ability of the Company or its Subsidiaries to (x)&nbsp;engage in
or compete in any geographic area or line of business, market or field, (y)&nbsp;transaction with any Person or (z)&nbsp;solicit any client
or customer, in each case in any manner that is material to the Company or that would restrict in any material respect Parent or its Subsidiaries
following the Closing, (b)&nbsp;requires the Company or its Subsidiaries to conduct any business on a &ldquo;most favored nations&rdquo;
basis with any third party that restricts in any material respect the business of the Company or that would restrict in any material respect
Parent or its Subsidiaries following the Closing, or (c)&nbsp;provides for &ldquo;exclusivity,&rdquo; rights of first refusal or offer
or any similar requirement or right in favor of any third party that restricts in any material respect the business of the Company or
that would restrict in any material respect Parent or its Subsidiaries following the Closing;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">any
Contract to which the Company is a party that provides for payments to or from the Company in excess of $1,000,000 in the aggregate annually;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">any
Contract creating, guaranteeing or securing indebtedness for borrowed money of the Company, in each case in excess of $1,000,000;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">any
Contract with respect to the creation, formation, governance or control of any material partnerships, joint ventures or joint ownership
arrangements with third parties;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">any
Contract, other than in the ordinary course of business, that (A)&nbsp;relates to the acquisition of material assets or capital stock
or other securities (by merger, capital contribution or otherwise) of any Person after the date of this Agreement with a total consideration
of more than $1,000,000 in the aggregate, (B)&nbsp;relates to the disposition (after the date of this Agreement), directly or indirectly,
of material assets of the Company or its Subsidiaries or any capital stock or other securities (by merger, capital contribution or otherwise)
of the Company or its Subsidiaries or (C)&nbsp;contains a put, call, right of first refusal or similar right pursuant to which the Company
or its Subsidiaries could be required to purchase or sell, as applicable, any of the foregoing;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">any
Contract that relates to the sale, transfer or other disposition of a business or assets by the Company pursuant to which the Company
has any continuing indemnification, guarantee, &ldquo;earnout&rdquo; or other contingent, deferred or fixed payment obligations;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(viii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">any
Contract pursuant to which Company or its Subsidiaries exclusively licenses from or to another Person rights to material intellectual
property;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ix)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">any
Contract with a term exceeding one year after the date of this Agreement which is a financial derivative interest rate hedge;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(x)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">each
Contract that grants any right of first refusal or right of first offer or similar right with respect to any material assets, rights or
properties of the Company or its Subsidiaries;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xi)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">each
collective bargaining or other labor or works council agreement covering Company Employees;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">any
Contract with a Governmental Entity;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xiii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">each
Contract (other than any Organizational Document) between the Company or any of its Subsidiaries, on the one hand, and any director, officer
or Affiliate (other than a wholly owned Subsidiary of the Company) of the Company or any of its Subsidiaries or any of their respective
 &ldquo;associates&rdquo; or &ldquo;immediate family&rdquo; members (as such terms are defined in Rule&nbsp;12b-2 and Rule&nbsp;16a-1 of
the Exchange Act), on the other hand, including (but not limited to) any Contract pursuant to which the Company or any of its Subsidiaries
has an obligation to indemnify such director, officer, Affiliate or &ldquo;associate&rdquo; or &ldquo;immediate family&rdquo; member,
but excluding any Company Plan;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xiv)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">each
Contract expressly limiting or restricting the ability of the Company or its Subsidiaries (i)&nbsp;to make distributions or declare or
pay dividends in respect of their capital stock, partnership interests, membership interests or other equity interests, as the case may
be, (ii)&nbsp;to pledge their capital stock or other equity interests, (iii)&nbsp;to issue any guaranty, (iv)&nbsp;to make loans to the
Company or its Subsidiaries, or (v)&nbsp;to grant liens on the property of the Company or its Subsidiaries; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xv)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">each
Contract that obligates the Company or its Subsidiaries to make any loans, advances or capital contributions to, or investments in, any
Person, except for (i)&nbsp;loans or advances for indemnification, attorneys&rsquo; fees, or travel and other business expenses in the
ordinary course of business, or (ii)&nbsp;loans, advances or capital contributions to, or investments in, any Person that is not an Affiliate
or Company Employee not in excess of $500,000 individually;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xvi)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">that
are (A)&nbsp;bid bonds, payment bonds, performance bonds, Tax bonds, licensing bonds, reclamation bonds, surety bonds or any similar undertaking
or financial security arrangements or (B)&nbsp;indemnity or underwriting agreements or other contracts with a surety, in each case in
excess of $1,000,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Each
Material Contract has not been terminated prior to the date of this Agreement, is valid and binding on the Company and each of its Subsidiaries
party thereto and, to the knowledge of the Company, any other party thereto, except for such failures to be valid and binding or to be
in full force and effect that, individually or in the aggregate, has not constituted or resulted in, and would not reasonably be expected
to constitute or result in, Company Material Adverse Effect. Except as, individually or in the aggregate, has not constituted or resulted
in, and would not reasonably be expected to constitute or result in, a Company Material Adverse Effect, there is no existing breaches
or defaults under any Material Contract or Company Real Property Lease by the Company or any of its Subsidiaries party thereto or, to
the knowledge of the Company, any other party thereto, and no event or action has occurred or failed to occur that with the lapse of time
or the giving of notice or both would constitute a default thereunder by the Company or any of its Subsidiaries party thereto or, to the
knowledge of the Company, any other party thereto. Prior to the date of this Agreement, the Company has made available to Parent accurate
and complete copies of each Material Contract in effect as of the date of this Agreement, together with all material amendments and supplements
thereto in effect as of the date of this Agreement. Prior to the date of this Agreement, no counterparty to a Material Contract or Company
Real Property Lease has canceled, terminated or substantially curtailed its relationship with the Company or its Subsidiaries, given notice
to the Company or its Subsidiaries of any intention to cancel, terminate or substantially curtail its relationship with the Company or
its Subsidiaries, or, to the knowledge of the Company, threatened to do any of the foregoing or, to the knowledge of the Company, been
threatened with bankruptcy or insolvency.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;3.16</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Insurance</U>.
Except as, individually or in the aggregate, has not constituted or resulted in, and would not reasonably be expected to constitute or
result in, a Company Material Adverse Effect, (a)&nbsp;all insurance policies of the Company and its Subsidiaries are in full force and
effect and provide insurance in such amounts and against such risks as is, in all material respects, commercially reasonable, (b)&nbsp;neither
the Company nor any of its Subsidiaries is in breach or default, and neither the Company nor any of its Subsidiaries has taken any action
or failed to take any action which, with notice or the lapse of time, would constitute such a breach or default, or permit termination
or modification of, any of such insurance policies and (c)&nbsp;since the earlier of the most recent renewal date and January&nbsp;1,
2021, as of the date hereof, the Company has not received any written notice (i)&nbsp;threatening termination of, or premium increases
with respect to, or material alteration of coverage under, any such policies, other than premium increases or alterations of coverage
occurring in the ordinary course during the renewal process for any such policies, (ii)&nbsp;refusal of any coverage or rejection of any
material claim under any insurance policy held by the Company or any of its Subsidiaries. As of the date of this Agreement, there is no
pending material claim by the Company or its Subsidiaries against any insurance carrier under any insurance policy held by the Company
or its Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;3.17</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Properties</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B><U>&lrm;&lrm;</U></B><U>Section&nbsp;3.17(a)</U>&nbsp;of
the Company Disclosure Letter sets forth a true and complete list of all the leased real property that the Company or a Subsidiary leases,
subleases or otherwise occupies (the &ldquo;<U>Company Leased Real Property</U>&rdquo;) pursuant to which the Company or a Subsidiary
is a tenant, subtenant, or otherwise occupies such Company Leased Real Property (individually and collectively, the &ldquo;<U>Company
Real Property Leases</U>&rdquo;) and the parties to such agreement. The Company Real Property Leases are in full force and effect and
constitute a legal, valid and binding obligation on the Company or the applicable Subsidiary which is a party to it, enforceable in accordance
with its terms. There are no subleases, licenses, occupancy agreements, consents, assignments, purchase agreements, or other contracts
granting to any person (other than the Company or a Subsidiary) the right to use or occupy the Company Leased Real Property, and no other
Person (other than the Company and its Subsidiaries) is in possession of the Company Leased Real Property. There are no outstanding options,
rights of first offer or rights of first refusal in favor of any other party to purchase or lease the Company Leased Real Property or
any portion thereof or interest therein. The Company or a Subsidiary has provided a true and complete copy of each such Company Real Property
Lease. The Company or its Subsidiaries have a valid leasehold estate in all Company Leased Real Property, free and clear of all Encumbrances,
other than Permitted Encumbrances. The Company or a Subsidiary has performed all obligations required to be performed by it to date under
such Company Real Property Lease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Except
as, individually or in the aggregate, has not constituted or resulted in, and would not reasonably be expected to constitute or result
in, a Company Material Adverse Effect, the Company or a Subsidiary of the Company owns and has good and valid title to all of its tangible
personal property. No representation is made under this <B><U>&lrm;</U></B><U>Section&nbsp;3.17</U> with respect to any intellectual property
or intellectual property rights, which are the subject of <B><U>&lrm;</U></B><U>Section&nbsp;3.18</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Company does not own any real property.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;3.18</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Intellectual
Property</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Company or its Subsidiaries own, or have the right pursuant to valid and enforceable licenses to use, all (i)&nbsp;trademarks (including
service marks, trade names, business marks, brand names, certification marks, trade dress, logos, corporate names, trade styles, and other
indications of origin, and the goodwill associated with the foregoing, in each case in any jurisdiction), (ii)&nbsp;domain names, (iii)&nbsp;patents
(including any national or multinational statutory invention registrations, patents and patent applications issued or applied for in any
jurisdiction, including all certificates of invention, provisionals, nonprovisionals, substitutions, divisionals, continuations, continuations-in-part,
reissues, renewals, extensions, supplementary protection certificates, reexaminations, patents of addition, utility models, inventors&rsquo;
certificates and the equivalents of any of the foregoing, in each case in any jurisdiction), (iv)&nbsp;copyrights (including with respect
to literary, pictorial and graphic works in any jurisdiction), and (v)&nbsp;know-how and trade secrets and other intellectual property
rights, including for each case (i)-(iv), any pending applications to register, used in or necessary for the business of Company and its
Subsidiaries as currently conducted (collectively &ldquo;<U>Company Intellectual Property</U>&rdquo;). (i)&nbsp;all Company Intellectual
Property will be owned or continue to be available for use, following the consummation of the transactions contemplated by this Agreement,
on substantially the same terms (including with respect to payment obligations) as they were owned or available for use by Company and
its Subsidiaries immediately prior to the Effective Time; (ii)&nbsp;neither Company nor any of its Subsidiaries have&nbsp;transferred
ownership of, or granted any exclusive license of or exclusive right to use, or authorized the retention of any exclusive rights to use
or joint ownership of, any Company Intellectual Property, to any other Person; and (iii)&nbsp;no Person has notified Company or any of
its Subsidiaries in writing that it is claiming any ownership of or right to use any Company Intellectual Property that is owned by or
exclusively licensed to the Company or one of its Subsidiaries (other than the right to use Company Intellectual Property expressly granted
to such Person under a Contract with the Company or any of its Subsidiaries).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 37; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B>&lrm;<U>&lrm;</U></B><U>Section&nbsp;3.18(b)</U>&nbsp;of
the Company Disclosure Letter sets forth a true and complete list of all material Company Intellectual Property that is owned by or exclusively
licensed to the Company or one of its Subsidiaries and is registered or issued under the authority of any Governmental Entity or Internet
domain name registrar (collectively, &ldquo;<U>Company Registered IP</U>&rdquo;), including (i)&nbsp;the name of the applicant/registrant
(including, if different, the legal owner(s)&nbsp;and beneficial owner(s)&nbsp;of such item), (ii)&nbsp;any other co-owners, (iii)&nbsp;the
date and jurisdiction of application/registration, (iv)&nbsp;the application or registration number, and (v)&nbsp;the status of such item.
Except as, individually or in the aggregate has not constituted or resulted in, and would not reasonably be expected to constitute or
result in, a Company Material Adverse Effect, (i)&nbsp;all Company Registered IP (other than pending applications thereof) are valid,
subsisting and, to the knowledge of Company, enforceable and (ii)&nbsp;no Company Registered IP is involved in any interference, reissue,
reexamination, opposition, cancellation or similar proceeding and, to the knowledge of Company, no such action is or has been threatened
with respect to any of the Company Registered IP. All Company Registered IP is owned by or licensed to Company or one its Subsidiaries
free and clear of all Liens. Neither Company nor any of its Subsidiaries has received any written notice or claim in the three (3)&nbsp;years
prior to the date hereof challenging the validity or enforceability or inventorship or ownership of any Company Registered IP. To the
knowledge of the Company, no trademark (including service marks, trade names, business marks, brand names, certification marks, trade
dress, logos, corporate names, and trade styles) or domain names owned, used, or applied for by the Company conflicts or interferes with
any trademark or domain name owned, used, and applied for by any other Person for the same class of goods or services.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Each
employee, director, independent contractor or consultant of the Company or any of its Subsidiaries who is or was involved in the creation
or development of any intellectual property on behalf of the Company or any of its Subsidiaries, pursuant to such individual&rsquo;s activities
on behalf of the Company or any of its Subsidiaries, has signed a valid and enforceable written agreement containing (i)&nbsp;an irrevocable
present assignment to the Company or its Subsidiaries of all intellectual property rights developed by such Person during such Person&rsquo;s
employment or engagement with the Company or its Subsidiaries, and (ii)&nbsp;appropriate confidentiality provisions protecting the Company
Intellectual Property owned by or exclusively licensed to the Company or its Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Except
as, individually or in the aggregate, has not constituted or resulted in, and would not reasonably be expected to constitute or result
in, a Company Material Adverse Effect, each of the Company and its Subsidiaries has taken commercially reasonable steps to maintain the
confidentiality of all information of the Company or its Subsidiaries that derives economic value (actual or potential) from not being
generally known to other Persons who can obtain economic value from its disclosure or use, including taking commercially reasonable steps
to safeguard any such information that is accessible through computer systems or networks, and to the knowledge of the Company, such information
have not been used by or disclosed to any Person except pursuant to written, valid and appropriate non-disclosure agreements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 38; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Except
as, individually or in the aggregate, has not constituted or resulted in, and would not reasonably be expected to constitute or result
in, a Company Material Adverse Effect, to the knowledge of the Company (i)&nbsp;the Company and its Subsidiaries are not infringing upon
or misappropriating any patents, copyrights, trademarks, trade secrets or other intellectual property rights of any third party in connection
with the conduct of their respective businesses, (ii)&nbsp;no third party is misappropriating or infringing any Company Intellectual Property
owned by or exclusively licensed to the Company or one of its Subsidiaries and (iii)&nbsp;no Company Intellectual Property owned by or
exclusively licensed to the Company or one of its Subsidiaries is subject to any outstanding order, judgment, decree or stipulation restricting
or limiting in any material respect the use or licensing thereof by the Company or any of its Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Neither
this Agreement nor the transactions contemplated by this Agreement, including the assignment to, or assumption by, Parent by operation
of law or otherwise of any Contracts to which the Company or any of its Subsidiaries is a party, will result in: (i)&nbsp;Parent or any
of its Affiliates granting to any other Person any right to or with respect to any intellectual property rights owned by, or licensed
to, Parent or any of its Affiliates (other than rights granted by the Company or any of its Subsidiaries prior to the Closing Date to
Company Intellectual Property), (ii)&nbsp;Parent or any of its Affiliates being bound by, or subject to, any non-compete or other material
restriction on the operation or scope of their respective businesses (excluding any non-compete or other material restriction that arises
from any agreement to which the Company or any of its Subsidiaries is not a party), (iii)&nbsp;Parent or any of its Affiliates being obligated
to pay any royalties or other material amounts, or offer any discounts, to any other Person pursuant to any Contract to which the Company
is a party in excess of those payable by, or required to be offered by, the Company in the absence of this Agreement or the transactions
contemplated hereby or (iv)&nbsp;a loss of, or Lien on, any Company Intellectual Property.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">No
funding, facilities or personnel of any Governmental Entity or any university, college, research institute or other educational institution
(each a &ldquo;<U>R&amp;D Sponsor</U>&rdquo;) has been or is being used in the development of any Company Intellectual Property that is
owned by or exclusively licensed to the Company or one of its Subsidiaries except for any such funding or use of facilities or personnel
that has not and would not reasonably be expected to result in such R&amp;D Sponsor obtaining any ownership rights to (or the right to
obtain any ownership rights to) such Company Intellectual Property, or any rights to receive royalties or other rights to use or exploit
any Company Intellectual Property that is owned by or exclusively licensed to the Company or one of its Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 39; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;3.19</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Health
Care Regulatory Matters</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Company, and to the knowledge of the Company, each of its directors, officers, management employees, agents (while acting in such capacity),
contract manufacturers, suppliers, and distributors are, and at all times prior hereto were, in material compliance with all health care
laws to the extent applicable to the Company or any of its products or activities, including, but not limited to the following: the Federal
Food, Drug, and Cosmetic Act (&ldquo;<U>FDCA</U>&rdquo;); the Public Health Service Act (42 U.S.C. &sect; 201 et seq.), including the
Clinical Laboratory Improvement Amendments of 1988 (42 U.S.C. &sect; 263a); the Federal Trade Commission Act (15 U.S.C. &sect; 41 et seq.);
the Controlled Substances Act (21 U.S.C. &sect; 801 et seq.); the federal Anti-Kickback Statute (42 U.S.C. &sect; 1320a-7b(b)); the Physician
Payment Sunshine Act (42 U.S.C. &sect; 1320a-7h); the civil monetary penalties law (42 U.S.C. &sect; 1320a-7a); the civil False Claims
Act (31 U.S.C. &sect; 3729 et seq.); the administrative False Claims Law (42 U.S.C. &sect;&nbsp;1320a-7b(a)); the Stark law (42 U.S.C.
 &sect; 1395nn); the Criminal Health Care Fraud Statute (18 U.S.C. &sect; 1347) and all other criminal laws relating to health care fraud
and abuse, including but not limited to 18 U.S.C. &sect;&sect; 286, 287, 1035, 1349; the Health Insurance Portability and Accountability
Act of 1996 (42 U.S.C. &sect; 1320d et seq.), as amended by the Health Information Technology for Economic and Clinical Health Act (42
U.S.C. &sect; 17921 et seq.); the exclusion laws (42 U.S.C. &sect; 1320a-7); Medicare (Title XVIII of the Social Security Act), Medicaid
(Title XIX of the Social Security Act) and any other law pertaining to a government sponsored or funded healthcare program, including
the collection and reporting requirements, and the processing of any applicable rebate, chargeback or adjustment, under applicable rules&nbsp;and
regulations relating to the Medicaid Drug Rebate Program (42 U.S.C. &sect; 1396r-8) and any state supplemental rebate program, Medicare
average sales price reporting (42 U.S.C. &sect; 1395w-3a), the Public Health Service Act (42 U.S.C. &sect; 256b), the VA Federal Supply
Schedule (38 U.S.C. &sect; 8126) or under any state pharmaceutical assistance program or U.S. Department of Veterans Affairs agreement,
and any successor government programs; and the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education
Reconciliation Act of 2010 (42 U.S.C. &sect;&nbsp;18001 et seq.); any regulations promulgated pursuant to such laws; and any other state,
federal or ex-U.S. laws, accreditation standards, or regulations governing the manufacturing, development, testing, labeling, advertising,
marketing or distribution of pharmaceutical or biological products, kickbacks, patient or program charges, record-keeping, claims process,
documentation requirements, medical necessity, referrals, the hiring of employees or acquisition of services or supplies from those who
have been excluded from government health care programs, quality, safety, privacy, security, licensure, accreditation or any other aspect
of providing health care, clinical laboratory or diagnostic products or services (&ldquo;<U>Health Care Laws</U>&rdquo;). To the knowledge
of the Company, there are no facts or circumstances that reasonably would be expected to give rise to any material liability under any
Health Care Laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Company is not party to any corporate integrity agreements, monitoring agreements, deferred or non-prosecution agreements, consent decrees,
settlement orders, or similar agreements with or imposed by any Governmental Entity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">All
applications, notifications, submissions, information, claims, reports and statistical analyses, and other data and conclusions derived
therefrom, utilized as the basis for or submitted in connection with any and all requests for a Permit from the U.S. Food and Drug Administration
(&ldquo;<U>FDA</U>&rdquo;) or other Governmental Entity relating to products that are regulated as drugs, medical devices, or other healthcare
products under Health Care Laws, including biological and drug candidates, compounds or products being researched, tested, stored, developed,
labeled, manufactured, packed and/or distributed by the Company or any of its Subsidiaries (&ldquo;<U>Company Products</U>&rdquo;), including,
without limitation, investigational new drug applications, when submitted to the FDA or other Governmental Entity were true, complete
and correct in all material respects as of the date of submission and any necessary or required updates, changes, corrections or modification
to such applications, submissions, information and data have been submitted to the FDA or other Governmental Entity. The Company does
not have knowledge of any facts or circumstances that would be reasonably likely to lead to the revocation, suspension, limitation, or
cancellation of a Permit required under Health Care Laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 40; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">All
preclinical studies and clinical trials conducted by or, to the knowledge of the Company, on behalf of the Company have been, and if still
pending are being, conducted in material compliance with research protocols and all applicable Health Care Laws, including, but not limited
to, the FDCA and its applicable implementing regulations at 21 C.F.R. Parts 50, 54, 56, 58, 312, 314 and 601. No clinical trial conducted
by or on behalf of the Company has been conducted using any clinical investigators who have been disqualified, debarred or excluded from
healthcare programs. No clinical trial conducted by or on behalf of the Company has been terminated or suspended prior to completion,
and no clinical investigator who has participated or is participating in, or institutional review board that has or has had jurisdiction
over, a clinical trial conducted by or on behalf of the Company has placed a partial or full clinical hold order on, or otherwise terminated,
delayed or suspended, such a clinical trial at a clinical research site based on an actual or alleged lack of safety or efficacy of any
Company Product or a failure to conduct such clinical trial in compliance with applicable Health Care Laws, their implementing regulations
and good clinical practices. The Company has not identified or received notice of instances or allegations of research misconduct (defined
as falsification or fabrication of data, or plagiarism, as those terms are defined in 42 C.F.R. Part&nbsp;93) involving research conducted
by, or on behalf of the Company, that could compromise or affect the integrity, reliability, completeness, or accuracy of the data collected
in such research, or the rights, safety, or welfare of the research subjects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">All
manufacturing operations conducted by or, to the knowledge of the Company, for the benefit of the Company have been and are being conducted
in material compliance with all Permits under applicable Health Care Laws, all applicable provisions of the FDA&rsquo;s current good manufacturing
practice (cGMP) regulations for pharmaceuticals and biological products at 21 C.F.R. Parts 210, 211, 600 and 610 and all comparable foreign
regulatory requirements of any Governmental Entity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Company has not received any written communication that relates to an alleged violation or noncompliance with any Health Care Laws, including
any notification of any pending or threatened claim, suit, proceeding, hearing, enforcement, investigation, arbitration, import detention
or refusal, FDA Warning Letter or Untitled Letter, or any action by a Governmental Entity relating to any Health Care Laws. All Warning
Letters, Form&nbsp;FDA-483 observations, or comparable findings from other Governmental Entities listed in <B><U>&lrm;</U></B><U>Section&nbsp;3.19</U>
of the Company Disclosure Letter have been resolved and closed out to the satisfaction of the applicable Governmental Entity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">There
have been no seizures, withdrawals, recalls, detentions, or suspensions of manufacturing, testing, or distribution relating to the Company
Products required or requested by a Governmental Entity, or other notice of action relating to an alleged lack of safety, efficacy, or
regulatory compliance of the Company Products, or any adverse experiences relating to the Company Products that have been reported to
FDA or other Governmental Entity (&ldquo;<U>Company Safety Notices</U>&rdquo;), and, to the knowledge of the Company, there are no facts
or circumstances that reasonably would be expected to give rise to a Company Safety Notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 41; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">There
are no unresolved Company Safety Notices, and to the knowledge the Company, there are no facts that would be reasonably likely to result
in a material Company Safety Notice or a termination or suspension of developing and testing of any of the Company Products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Neither
the Company, nor, to the knowledge of the Company, any officer, employee, agent, or distributor of the Company has made an untrue statement
of a material fact or fraudulent or misleading statement to a Governmental Entity, failed to disclose a material fact required to be disclosed
to a Governmental Entity, or committed an act, made a statement, or failed to make a statement that would reasonably be expected to provide
a basis for the FDA to invoke its policy respecting the &ldquo;Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities&rdquo;
Final Policy set forth in 56 Fed. Reg. 46191 (September&nbsp;10, 1991) and any amendments thereto (the &ldquo;<U>FDA Ethics Policy</U>&rdquo;).
To the knowledge of the Company, none of the aforementioned is or has been under investigation resulting from any allegedly untrue, fraudulent,
misleading, or false statement or omission, including data fraud, or had any action pending or threatened relating to the FDA Ethics Policy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">All
reports, documents, claims, Permits and notices required to be filed, maintained or furnished to the FDA or any Governmental Entity by
the Company have been so filed, maintained or furnished, except where failure to file, maintain or furnish such reports, documents, claims,
Permits or notices has not constituted or resulted in and would not reasonably be expected to constitute or result in, individually or
in the aggregate, a Company Material Adverse Effect. All such reports, documents, claims, Permits and notices were true and complete in
all material respects on the date filed (or were corrected in or supplemented by a subsequent filing).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Neither
the Company nor, to the knowledge of the Company, any officer, employee, agent, or distributor of the Company has committed any act, made
any statement or failed to make any statement that violates the Federal Anti-Kickback Statute, 28 U.S.C. &sect; 1320a-7b, the Federal
False Claims Act, 31 U.S.C. &sect; 3729, other Health Care Laws, or any other similar federal, state, or ex-U.S. law applicable in the
jurisdictions in which the Company Products are sold or intended to be sold.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Neither
the Company nor, to the knowledge of the Company, any officer, employee, agent, or distributor of the Company has been convicted of any
crime or engaged in any conduct that has resulted, or would reasonably be expected to result, in debarment under applicable Law, including,
without limitation, 21 U.S.C. &sect; 335a, or exclusion under 42 U.S.C. &sect; 1320a-7, or any other statutory provision or similar law
applicable in other jurisdictions in which the Company Products are sold or intended to be sold. None of the Company, any officer, employee
or, to the knowledge of the Company, agent or distributor of the Company, has been debarred, suspended or excluded from participation
in any federal health care program or convicted of any crime or engaged in any conduct for which such Person could be excluded from participating
in any federal health care program under Section&nbsp;1128 of the Social Security Act of 1935, as amended, or any similar Health Care
Law or program.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section&nbsp;3.20</FONT><FONT STYLE="color: #010000">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Data
Privacy.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Company and, to the knowledge of the Company, all vendors, processors, or other third parties processing information or data, in any form,
that is capable, directly or indirectly, of being associated with, related to or linked to, or used to identify, describe, contact or
locate, a natural Person, including name, address, telephone number, email address, billing information, health information, driver&rsquo;s
license number, other government-issued identifier, vehicle identification number, online identifier, device identifier,&nbsp;IP address,
browsing history, search history and/or other data that is considered &ldquo;personally identifiable information,&rdquo; &ldquo;personal
information,&rdquo; &ldquo;personal data,&rdquo; or any similar term by any applicable Privacy Requirements (&ldquo;<U>Personal Information</U>&rdquo;)
by or for, and/or sharing Personal Information with, the Company (collectively, &ldquo;<U>Company Data Partners</U>&rdquo;), comply and
have since January&nbsp;1,&nbsp;2020, complied in all material respects with (i)&nbsp;Laws relating to the privacy, security, or processing
of Personal Information, data breach notification, website and mobile application privacy policies and practices, processing and security
of payment card information, and email, text message, or telephone communications, (ii)&nbsp;policies, notices, and/or statements related
to Personal Information, and (iii)&nbsp;contractual commitments related to the processing of Personal Information applicable to the Company
(collectively, the &ldquo;<U>Privacy Requirements</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 42; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
execution, delivery, and performance of this Agreement and the Merger will not: (i)&nbsp;conflict with or result in a material violation
or breach of any Privacy Requirements; (ii)&nbsp;require the consent of or provision of notice to any Person concerning such Person&rsquo;s
Personal Information; (iii)&nbsp;give rise to any right of termination or other right to impair or limit the Parent&rsquo;s rights to
own and process any Personal Information used in or necessary for the operation of the Company&rsquo;s business; or (iv)&nbsp;otherwise
prohibit the transfer of Personal Information to the Parent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Company has implemented, maintained and complied with, and has required the Company Data Partners processing material Personal Information
to implement, maintain and comply with, in all material respects, commercially reasonable technical, physical, and organizational measures,
plans, procedures, controls, and programs, (i)&nbsp;protect Personal Information against any accidental, unlawful or unauthorized access,
use, loss, disclosure, alteration, destruction, compromise, or cyberattack,&#8239;including a ransomware attack or a denial-of-service
attack (each, a &ldquo;<U>Security Incident</U>&rdquo;), and (ii)&nbsp;identify and address internal and external risks to the privacy
and security of Personal Information. Neither the Company and to the knowledge of the Company, any of the Company Data Partners has experienced
any material Security Incidents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">In
relation to any Security Incident and/or Privacy Requirement, the Company has not (i)&nbsp;notified or been required to notify any customer,
consumer, employee, Governmental Entity, or other Person, or (ii)&nbsp;received any notice, inquiry, request, claim, complaint, correspondence
or other communication from, or been the subject of any investigation or enforcement action by, any Governmental Entity or other Person.
To the knowledge of the Company, there are no facts or circumstances that could give rise to the occurrence of (i)&nbsp;or (ii).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;3.21</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Certain
Payments</U>. Neither the Company nor any of its Subsidiaries nor any director, officer, employee, agent or other person acting on behalf
of the Company or its Subsidiaries has, directly or indirectly, (a)&nbsp;violated or taken any action that could potentially result in
a violation of any provision of the Foreign Corrupt Practices Act of 1977, as amended, the UK Bribery Act of 2010 or its predecessor laws,
or any other Laws concerning corrupt payments applicable to the Company or its Subsidiaries (collectively, the &ldquo;<U>Anti-Corruption
Laws</U>&rdquo;) or (b): (i)&nbsp;used, offered to use or authorized the use of any funds of the Company or any of its Subsidiaries for
unlawful contributions, unlawful gifts or unlawful entertainment, or for other unlawful payments, related to political activity or otherwise;
(ii)&nbsp;made, offered to make or authorized any unlawful payment to foreign or domestic Government Officials or employees or to foreign
or domestic political parties or campaigns from funds of the Company or its Subsidiaries; (iii)&nbsp;established or maintained any unlawful
fund of monies or other assets of the Company or its Subsidiaries; (iv)&nbsp;made any inaccurate entry on the books or records of the
Company or its Subsidiaries; (v)&nbsp;made, offered to make or authorized any bribe, unlawful rebate, unlawful payoff, unlawful influence
payment, unlawful kickback or other unlawful payment to any person, private or public, in any form or (vi)&nbsp;engaged in or facilitated
any transaction or dealing in property or interests in property of, received from or made any contribution of funds, goods or services
to or for the benefit of, provided any payments or material assistance to, or otherwise engage in or facilitated any transactions with
any Prohibited Person. Neither the Company nor any of its Subsidiaries is or within the past five years has been (i)&nbsp;under external
or internal investigation by any Governmental Entity for any potential or actual violation of any Anti-Corruption Laws or (ii)&nbsp;has
received any written or other notice from any Governmental Entity regarding any potential or actual violation of, or potential or actual
failure to comply with, any Anti-Corruption Laws. Since January&nbsp;1,&nbsp;2018, neither the Company nor any of its Subsidiaries has
made any disclosure (voluntary or otherwise) to any Governmental Entity with respect to any alleged irregularity, misstatement or omission
or other potential violation or liability arising under or relating to any Anti-Corruption Laws. &ldquo;<U>Government Official</U>&rdquo;
means any person employed by or that is an agent of any Governmental Entity or any political party or that is a candidate for Governmental
Entity office, or the family member or close affiliate of any of these.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 43; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;3.22</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>State
Takeover Statutes</U>. No &ldquo;fair price,&rdquo; &ldquo;moratorium,&rdquo; &ldquo;control share acquisition&rdquo; or similar antitakeover
Law (collectively, &ldquo;<U>Takeover Laws</U>&rdquo;) enacted under of any state Laws in the United States apply to this Agreement, the
CVR Agreement or any of the transactions contemplated hereby and thereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;3.23</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Affiliate
Transactions</U>. Except (i)&nbsp;as set forth on <U>&lrm;&lrm;Section&nbsp;3.23</U> of the Company Disclosure Letter or (ii)&nbsp;for
directors&rsquo; and employment-related Material Contracts filed or incorporated by reference as an exhibit to a Company SEC Document
filed by the Company prior to the date hereof and for any intercompany agreements, as of the date hereof, no executive officer or director
of the Company is a party to any Material Contract with or binding upon the Company or any of its Subsidiaries or any of their respective
properties or assets or has any material interest in any material property owned by the Company or any of its Subsidiaries or has engaged
in any material transaction with any of the foregoing since January&nbsp;1, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;3.24</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Brokers</U>.
No broker, investment banker, financial advisor or other Person, other than Guggenheim Securities, LLC, is entitled to any broker&rsquo;s,
finder&rsquo;s, financial advisor&rsquo;s or other similar fee or commission in connection with the transactions contemplated by this
Agreement based upon arrangements made by or on behalf of the Company or any of its Subsidiaries. The Company has made available to Parent
true, correct and complete copies of all engagement, fee and similar Contracts between the Company (or any Subsidiary of the Company)
and Guggenheim Securities, LLC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;3.25</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Opinion
of Financial Advisor</U>. Guggenheim Securities, LLC has delivered to the Company Board its written opinion (or oral opinion to be confirmed
in writing), dated as of the date of this Agreement, to the effect that, as of the date of this Agreement and based upon and subject to
the assumptions, qualifications, limitations and other matters set forth therein, the Exchange Ratio pursuant to this Agreement and the
consideration payable pursuant to the CVR Agreement is fair, from a financial point of view, to the holders of Company Shares. The Company
will make available to Parent a copy of such opinion as soon as practicable following the execution of this Agreement for information
purposes only.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 44; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;3.26</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>No
Other Representations or Warranties</U>. Except for the representations and warranties contained in <U>&lrm;Article&nbsp;IV</U> or in
any certificate delivered pursuant to this Agreement, the Company acknowledges that none of Parent, Merger Sub nor any other Person on
behalf of Parent or Merger Sub makes any other express or implied representation or warranty with respect to Parent or Merger Sub with
respect to any other information provided to the Company in connection with the transactions contemplated by this Agreement. Neither Parent
nor any other Person will have or be subject to any liability to the Company, its Subsidiaries or any other Person resulting from the
distribution to the Company or its Subsidiaries, or the Company&rsquo;s or its Subsidiaries&rsquo; use of, any such information, including
any information, documents, projections, forecasts or other material made available to the Company or its Subsidiaries in certain &ldquo;data
rooms&rdquo; or management presentations in expectation of, or in connection with, the transactions contemplated by this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;3.27</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>No
Reliance</U>. The Company acknowledges and agrees that it has had an opportunity to discuss and ask questions regarding the business of
Parent and its Subsidiaries with the management of Parent, has received sufficient responses to its requests for information regarding
Parent, and&nbsp;has conducted its own independent investigation of Parent and its Subsidiaries and the transactions contemplated hereby,
and has not relied on any representation or warranty by any Person on behalf of Parent or any of its Subsidiaries, except for the representations
and warranties set forth in <U>&lrm;Article&nbsp;IV</U> or in any certificate delivered in connection with this Agreement. Without limiting
the foregoing, except for the representations and warranties set forth in <U>&lrm;Article&nbsp;IV</U> of this Agreement or in any certificate
delivered in connection with this Agreement, each of Parent and Merger Sub further acknowledges and agrees that none of the Parent or
Merger Sub or any of their respective stockholders, directors, officers, employees, Affiliates, advisors, agents or other Representatives
has made any representation or warranty concerning any estimates, projections, forecasts, business plans or other forward-looking information
regarding Parent, its Subsidiaries or their respective businesses and operations. The Company hereby acknowledges that there are uncertainties
inherent in attempting to develop such estimates, projections, forecasts, business plans and other forward-looking information with which
the Company is familiar, that except for the representations and warranties set forth in <U>&lrm;Article&nbsp;IV</U> or in any certificate
delivered in connection with this Agreement, the Company are taking full responsibility for making their own evaluation of the adequacy
and accuracy of all estimates, projections, forecasts, business plans and other forward-looking information furnished to them (including
the reasonableness of the assumptions underlying such estimates, projections, forecasts, business plans and other forward-looking information),
and the Company will have no claim against the Parent or Merger Sub or any of their respective stockholders, directors, officers, employees,
Affiliates, advisors, agents or other Representatives with respect thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 45; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase; color: #010000"><B>Article&nbsp;IV</B></FONT><B><FONT STYLE="text-transform: uppercase"><BR>
REPRESENTATIONS AND WARRANTIES OF PARENT and MERGER SUB</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except (a)&nbsp;as disclosed
or reflected in the Parent SEC Documents filed and publicly available after January&nbsp;1, 2021 but at least one Business Day prior to
the date of this Agreement (but excluding any risk factor disclosures contained under the heading &ldquo;Risk Factors,&rdquo; any disclosure
of risks included in any &ldquo;forward-looking statements&rdquo; disclaimer or any other statements that are similarly predictive or
forward-looking in nature, in each case, other than any specific factual information contained therein), or (b)&nbsp;as set forth in the
disclosure letter delivered by Parent to the Company concurrently with the execution of this Agreement (the &ldquo;<U>Parent Disclosure
Letter</U>&rdquo;) (it being agreed that disclosure of any information in a particular section&nbsp;or subsection&nbsp;of the Parent Disclosure
Letter shall be deemed disclosure with respect to any other section&nbsp;or subsection&nbsp;of this Agreement to the extent to which the
relevance of such information is reasonably apparent on the face of such disclosure that such disclosure also qualifies or applies to
such other subsections), Parent and Merger Sub represent and warrant to the Company as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;4.1</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Organization,
Standing and Power</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Each
of Parent, its Subsidiaries and Merger Sub (i)&nbsp;is an entity duly organized, validly existing and in good standing under the Laws
of the State of Delaware, (ii)&nbsp;has all requisite organizational power and authority to own, lease and operate its properties and
to carry on its business as it is now being conducted and (iii)&nbsp;is duly qualified or licensed to do business and is in good standing
(with respect to jurisdictions that recognize such concept) in each jurisdiction in which the nature of its business or the ownership,
leasing or operation of its properties makes such qualification or licensing necessary, except, with respect to clauses&nbsp;(ii)&nbsp;and
(iii), for any such failure to have such power and authority or to be so qualified or licensed or in good standing that, individually
or in the aggregate, has not constituted or resulted in, and would not reasonably be expected to constitute or result in, a Parent Material
Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Parent
has previously furnished or otherwise made available to the Company a true and complete copy of Parent&rsquo;s certificate of incorporation
(the &ldquo;<U>Parent Charter</U>&rdquo;) and bylaws (the &ldquo;<U>Parent Bylaws</U>&rdquo;), in each case as amended to the date of
this Agreement, and each as so delivered is in full force and effect. Parent is not in violation of any provision of the Parent Charter
or the Parent Bylaws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;4.2</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Capital
Stock</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
authorized capital stock of Parent consists of (i)&nbsp;200,000,000 shares of Parent Common Stock and (ii)&nbsp;5,000,000 shares of preferred
stock, par value $0.0001 per share. As of the Measurement Date, (1)&nbsp;55,664,293 shares of Parent Common Stock were issued and outstanding,
all of which were validly issued, fully paid and nonassessable and were free of preemptive rights, (2)&nbsp;none of such shares were unvested
restricted shares, (3)&nbsp;no shares were held in treasury, (4)&nbsp;no shares of Preferred Stock were outstanding, (5)&nbsp;an aggregate
of 2,924,143 shares of Parent Common Stock were subject to or otherwise deliverable in connection with outstanding restricted stock units
that vest solely based on the passage of time, (6)&nbsp;an aggregate of 1,000,000 shares of Parent Common Stock were subject to or otherwise
deliverable in connection with outstanding restricted stock units that vest based in whole or in part on performance metrics (at the target
level of performance), (7)&nbsp;an aggregate of 4,817,222 shares of Parent Common Stock were subject to or otherwise deliverable in connection
with the exercise of outstanding options to purchase Parent Common Stock (of which 3,817,222 vest solely based on the passage of time
and 1,000,000 vest based in whole or in part on performance metrics (at the target level of performance)) (&ldquo;<U>Parent Stock Options</U>&rdquo;),
(8)&nbsp;528,854 shares of Parent Common Stock were available for issuance of future awards under the Parent&rsquo;s equity incentive
plans and (9)&nbsp;9,768,012 shares of Parent Common Stock subject to or otherwise deliverable in connection with the exercise of outstanding
convertible notes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 46; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Except
as set forth above and except for changes since the Measurement Date resulting from the exercise of Parent Stock Options outstanding on
such date, as of the date of this Agreement, (i)&nbsp;there are not outstanding or authorized any (A)&nbsp;shares of capital stock or
other voting securities of Parent, (B)&nbsp;securities of Parent convertible into or exchangeable for shares of capital stock or voting
securities of Parent or (C)&nbsp;options or other rights to acquire from Parent, and no obligation of Parent to issue, any capital stock,
voting securities or securities convertible into or exchangeable for capital stock or voting securities of Parent, (ii)&nbsp;there are
no outstanding obligations of Parent or any Subsidiary of Parent to repurchase, redeem or otherwise acquire any capital stock, voting
securities or securities convertible into or exchangeable for capital stock or voting securities of Parent or any Subsidiary of Parent
and (iii)&nbsp;there are no other options, calls, warrants, rights of first refusal or other rights, agreements, arrangements or commitments
of any character relating to the issued or unissued capital stock of Parent or any of its Subsidiaries to which Parent or any of its Subsidiaries
is a party (iv)&nbsp;there are no bonds, debentures, notes or other indebtedness of Parent or any Subsidiary of Parent issued and outstanding
having the right to vote (or convertible or exercisable or exchangeable for securities having the right to vote) on any matters on which
stockholders of Parent may vote, and (v)&nbsp;there is no Contract to which Parent or its Subsidiaries is a party relating to the voting
or registration of, or restricting any Person from purchasing, selling, pledging or otherwise disposing of (or from granting any option
or similar right with respect to), any shares or capital or other equity interests of any Subsidiary of Parent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Each
of the outstanding shares of capital stock of each of Parent&rsquo;s Subsidiaries is duly authorized, validly issued, fully paid and nonassessable
and all such shares are owned by Parent or another wholly-owned Subsidiary of Parent and are owned free and clear of all Liens of any
nature whatsoever, except where any such failure to own any such shares free and clear that, individually or in the aggregate, has not
constituted or resulted in and would not reasonably be expected to constitute or result in, a Parent Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">All
of the issued and outstanding capital stock of Merger Sub is owned, directly or indirectly, by Parent. Merger Sub has no outstanding options,
warrants, rights or any other agreements pursuant to which any Person other than Parent may acquire any equity security of Merger Sub.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;4.3</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Authority</U>.
Each of Parent and Merger Sub has all necessary corporate power and authority to execute and deliver this Agreement and the CVR Agreement,
to perform its obligations hereunder and, subject to (a)&nbsp;the approval of this Agreement and the CVR Agreement by Parent as the sole
stockholder of Merger Sub, and (b)&nbsp;the approval of the Parent Stock Issuance by the holders of at least a majority of the issued
and outstanding shares of Parent Common Stock present in person or by proxy at the Parent Stockholder Meeting and entitled to vote on
the proposal to approve the Parent Stock Issuance (the &ldquo;<U>Parent Stockholder Approval</U>&rdquo;), to consummate the transactions
contemplated hereby. The execution, delivery and performance of this Agreement by Parent and Merger Sub and the consummation by Parent
and Merger Sub of the transactions contemplated hereby have been duly authorized by all necessary corporate action on the part of Parent
and no other corporate proceedings on the part of Parent or Merger Sub are necessary to approve this Agreement and the CVR Agreement or
to consummate the transactions contemplated hereby and thereby, subject, in the case of the consummation of the Merger, to obtaining the
Parent Stockholder Approval. This Agreement has been, and as of the Effective Time the CVR Agreement will have been, duly executed and
delivered by Parent and Merger Sub and, assuming the due authorization, execution and delivery by Parent and Merger Sub, constitutes a
valid and binding obligation of each of Parent and Merger Sub, enforceable against each of Parent and Merger Sub in accordance with its
terms (except to the extent that enforceability may be limited by applicable bankruptcy, insolvency, moratorium, reorganization or similar
Laws affecting the enforcement of creditors&rsquo; rights generally or by general principles of equity). As of the date hereof, the Parent
Board has approved and declared advisable this Agreement and the transactions contemplated hereby and, subject to <U>&lrm;Section&nbsp;5.5</U>,
has directed that this Agreement be submitted to a vote of Parent&rsquo;s stockholders, resolved to recommend that Parent&rsquo;s stockholders,
adopt and approve the Parent Stock Issuance contemplated hereby (the &ldquo;<U>Parent Board Recommendation</U>&rdquo;) and resolved to
include the Parent Board Recommendation in the Joint Proxy Statement/Prospectus. The Parent Stockholder Approval is the only vote or consent
of the holders of any class or series of capital stock of Parent necessary to approve this Agreement or the Merger or the other transactions
contemplated hereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 47; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;4.4</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>No
Conflict; Consents and Approvals</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
execution, delivery and performance of this Agreement and the CVR Agreement by each of Parent and Merger Sub and the consummation by each
of Parent and Merger Sub of the transactions contemplated hereby and thereby, do not and will not (i)&nbsp;conflict with or violate the
Parent Charter or Parent Bylaws or the equivalent Organizational Documents of any of Parent&rsquo;s Subsidiaries or Merger Sub (ii)&nbsp;assuming
that all consents, approvals and authorizations contemplated by clauses&nbsp;(i)&nbsp;through (v)&nbsp;of <U>subsection <B>&lrm;</B>(b)</U>&nbsp;below
have been obtained and all filings described in such clauses have been made, conflict with or violate any Law applicable to Parent, any
of its Subsidiaries or Merger Sub, or by which any of their respective properties are bound or (iii)&nbsp;result in any breach or violation
of, or constitute a default (or an event which with notice or lapse of time or both would become a default), or result in the loss of
a benefit under, or give rise to any right of termination, cancellation, amendment or acceleration of, any Contract to which Parent, any
of its Subsidiaries or Merger Sub is a party or by which Parent, any of its Subsidiaries, Merger Sub or any of their respective properties
are bound, except, in the case of clauses&nbsp;(ii)&nbsp;and (iii), for any such conflict, breach, violation, default, loss, right or
other occurrence that that, individually or in the aggregate, has not constituted or resulted in, and would not reasonably be expected
to constitute or result in, a Parent Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
execution, delivery and performance of this Agreement by each of Parent or Merger Sub and the consummation by each of Parent or Merger
Sub of the transactions contemplated hereby, do not and will not require any consent, approval, authorization or permit of, action by,
filing with or notification to, any Governmental Entity, except for (i)&nbsp;such filings as may be required under applicable requirements
of the Exchange Act and the rules&nbsp;and regulations promulgated thereunder, and under state securities, takeover and &ldquo;blue sky&rdquo;
laws, (ii)&nbsp;the filings required under the HSR Act, (iii)&nbsp;such filings as necessary to comply with the applicable requirements
of Nasdaq, (iv)&nbsp;the filing with the Secretary of State of the State of Delaware of the Certificate of Merger as required by the DGCL
and (v)&nbsp;any such consent, approval, authorization, permit, action, filing or notification, in each case with respect to a Governmental
Entity, the failure of which to make or obtain that, individually or in the aggregate, has not constituted or resulted in, and would not
reasonably be expected to constitute or result in, a Parent Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 48; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;4.5</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>SEC
Reports; Financial Statements</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Parent
has timely filed, furnished or otherwise transmitted all forms, reports, statements, certifications and other documents (including all
exhibits, amendments and supplements thereto) required to be filed by it with the SEC since January&nbsp;1, 2021 (all such forms, reports,
statements, certificates and other documents filed since January&nbsp;1, 2021 and prior to the date hereof, collectively, the &ldquo;<U>Parent
SEC Documents</U>&rdquo;). As of their respective dates, or, if amended, as of the date of the last such amendment, each of the Parent
SEC Documents complied as to form in all material respects with the applicable requirements of the Securities Act and the Exchange Act,
and the applicable rules&nbsp;and regulations promulgated thereunder, as the case may be, each as in effect on the date so filed. As of
their respective filing dates (or, if amended or superseded by a subsequent filing prior to the date hereof, as of the date of such amendment
or superseding filing), none of the Parent SEC Documents contained any untrue statement of a material fact or omitted to state a material
fact required to be stated or incorporated by reference therein or necessary in order to make the statements therein, in the light of
the circumstances under which they were made, not misleading. No Subsidiary of Parent has been required to file any forms, reports or
other documents with the SEC at any time since January&nbsp;1, 2021. Since January&nbsp;1, 2021 no executive officer of Parent has failed
in any respect to make the certifications required of him or her under Section&nbsp;302 or 906 of the Sarbanes-Oxley Act. Neither Parent
nor any of its executive officers has received notice from any Governmental Entity challenging or questioning the accuracy, completeness,
form or manner of filing of such certifications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
audited consolidated financial statements of Parent (including any related notes thereto) included in or incorporated by reference in
the Parent SEC Documents (i)&nbsp;complied as to form in all material respects with the published rules&nbsp;and regulations of the SEC
applicable thereto; (ii)&nbsp;have been prepared in accordance with GAAP applied on a consistent basis throughout the periods involved
(except as may be indicated in the notes thereto or, in the case of unaudited statements, as permitted by Form&nbsp;10-Q or any successor
form under the Exchange Act, and except that unaudited financial statements may not contain footnotes and are subject to normal and recurring
year-end adjustments); (iii)&nbsp;fairly present in all material respects the consolidated financial position of Parent and its Subsidiaries
at the respective dates thereof and the results of their operations and cash flows for the periods indicated subject, with respect to
unaudited interim statements, to normal and recurring year-end adjustments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Parent
maintains, and at all times since January&nbsp;1, 2021 has maintained, disclosure controls and procedures required by Rule&nbsp;13a-15
or 15d-15 under the Exchange Act. Such disclosure controls and procedures are designed to ensure that information required to be disclosed
by Parent in its filings with the SEC under the Exchange Act is recorded and reported on a timely basis to the individuals responsible
for the preparation of Parent&rsquo;s filings with the SEC under the Exchange Act. Parent maintains internal control over financial reporting
(as defined in Rule&nbsp;13a-15 or 15d-15, as applicable, under the Exchange Act). Such internal control over financial reporting is designed
to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with GAAP. Parent&rsquo;s management has completed an assessment of the effectiveness of Parent&rsquo;s system
of internal control over financial reporting in compliance with the requirements of Section&nbsp;404 of the Sarbanes-Oxley Act for the
fiscal year ended December&nbsp;31, 2022, and such assessment concluded that such controls were effective and Parent&rsquo;s independent
registered accountant has issued an attestation report concluding that Parent maintained effective internal control over financial reporting
as of December&nbsp;31, 2022. Parent has disclosed, based on the most recent evaluation of its Chief Executive Officer and its Chief Financial
Officer prior to the date of this Agreement, to Parent&rsquo;s auditors and the audit committee of the Parent Board (i)&nbsp;any significant
deficiencies and material weaknesses in the design or operation of its internal controls over financial reporting and (ii)&nbsp;any fraud,
whether or not material, that involves management or other employees who have a significant role in Parent&rsquo;s internal control over
financial reporting, and each such deficiency, weakness and fraud so disclosed to auditors, if any, has been disclosed to the Company
prior to the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 49; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Since
January&nbsp;1, 2021, (i)&nbsp;none of Parent or any Subsidiary of Parent nor, to the knowledge of Parent, any director or officer of
Parent or any Subsidiary of Parent has received or otherwise had or obtained knowledge of any material complaint, allegation, assertion
or claim, whether written or oral, regarding accounting, internal accounting controls or auditing practices, procedures, methodologies
or methods of Parent or any Subsidiary of Parent or any material complaint, allegation, assertion or claim from employees of Parent or
any Subsidiary of Parent regarding questionable accounting or auditing matters with respect to Parent or any Subsidiary of Parent, and
(ii)&nbsp;to the knowledge of Parent, no attorney representing Parent or any Subsidiary of Parent, whether or not employed by Parent or
any Subsidiary of Parent, has reported evidence of a violation of securities Laws, breach of fiduciary duty or similar violation by Parent,
any Subsidiary of Parent or any of their respective officers, directors, employees or agents to Parent Board or any committee thereof,
or to the General Counsel or Chief Executive Officer of Parent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">As
of the date hereof, Parent is in compliance in all material respects with all current listing requirements of Nasdaq.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Neither
Parent nor any Subsidiary of Parent is a party to, or has a commitment to effect, enter into or create, any joint venture, or &ldquo;off-balance
sheet arrangement&rdquo; (as defined in Item 303(a)&nbsp;of Regulation S-K under the Exchange Act).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">As
of the date of this Agreement, there are no outstanding or unresolved comments in comment letters received from the SEC with respect to
Parent SEC Documents, and none of Parent SEC Documents is, to the knowledge of Parent, the subject of ongoing SEC review or investigation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;4.6</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>No
Undisclosed Liabilities</U>. Neither Parent nor any of its Subsidiaries has any liabilities or obligations of any nature, whether or not
accrued, absolute, determined, contingent or otherwise, and whether due or to become due, that would be required by GAAP to be reflected
on a consolidated balance sheet (or the notes thereto) of Parent and its Subsidiaries, except for liabilities and obligations (a)&nbsp;reflected
or reserved against in Parent&rsquo;s consolidated balance sheet as of December&nbsp;31, 2022 (or the notes thereto) included in the Parent
SEC Documents, (b)&nbsp;incurred in the ordinary course of business since January&nbsp;1, 2023, (c)&nbsp;incurred pursuant to the transactions
contemplated by this Agreement and (d)&nbsp;that, individually or in the aggregate, has not constituted or resulted in, and would not
reasonably be expected to constitute or result in, a Parent Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 50; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;4.7</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Certain
Information</U>. The information supplied or to be supplied by Parent and Merger Sub specifically for inclusion in the Form&nbsp;S-4 shall
not, at the time that the Form&nbsp;S-4 is declared effective by the SEC, contain any untrue statement of a material fact or omit to state
any material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under
which they were made, not misleading, except that no representation or warranty is made by Parent with respect to statements made therein
based on information supplied by or on behalf of the Company specifically for inclusion in the Form&nbsp;S-4. The Joint Proxy Statement/Prospectus
will not, at the date the Joint Proxy Statement/Prospectus is first mailed to the stockholders of Parent and at the time of the Parent
Stockholders Meeting, contain any untrue statement of a material fact or omit to state any material fact required to be stated therein
or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading, except
that, in each case, no representation or warranty is made by Parent with respect to statements made therein based on information supplied
by or on behalf of the Company specifically for inclusion in the Joint Proxy Statement/Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;4.8</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Absence
of Certain Changes or Events</U>. Since January&nbsp;1, 2023 through the date of this Agreement, (a)&nbsp;the businesses of Parent and
its Subsidiaries have been conducted in the ordinary course of business in all material respects and in a manner consistent with past
practice, and (b)&nbsp;there has not been any Effect that has constituted or resulted in, or that would reasonably be expected to constitute
or result in, a Parent Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;4.9</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Litigation</U>.
Except as, individually or in the aggregate, has not constituted or resulted in, and would not reasonably be expected to constitute or
result in, a Parent Material Adverse Effect, (a)&nbsp;there is no Action pending or, to the knowledge of Parent, threatened against Parent
or any of its Subsidiaries or any of their respective properties or assets, and (b)&nbsp;neither Parent nor any of its Subsidiaries nor
any of their respective properties or assets is or are subject to any judgment, order, injunction, rule&nbsp;or decree of any Governmental
Entity and (c)&nbsp;there are no subpoenas, civil investigative demands or other written requests for information issued to Parent or
any of its Subsidiaries relating to potential or actual violations of any Law that are pending or, to the knowledge of Parent, threatened,
or any investigations or claims against or affecting Parent or any of its Subsidiaries, or any of their respective properties or assets,
relating to potential or actual violations of any Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;4.10</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Compliance
with Laws</U>. Except as provided in Section&nbsp;4.10 of the Parent Disclosure Letter, Parent and each of its Subsidiaries are in compliance
with all Laws applicable to them or by which any of their respective properties are bound, except where any non-compliance, individually
or the aggregate, has not constituted or resulted in, and would not reasonably be expected to constitute or result in, a Parent Material
Adverse Effect. Neither Parent nor any of its Subsidiaries has, during the three-year period prior to the date of this Agreement: (i)&nbsp;to
the knowledge of the Parent, received any written notice or verbal notice from any Governmental Entity regarding any potential or actual
material violation by Parent or any of its Subsidiaries of any Law; or (ii)&nbsp;provided any notice to any Governmental Entity regarding
any potential or actual material violation by Parent or any of its Subsidiaries of any Law. Parent and its Subsidiaries have in effect
all Permits necessary for them to own, lease or operate their properties and to carry on their businesses as now conducted, except for
any Permits the absence of which, individually or in the aggregate, has not constituted or resulted in, and would not reasonably be expected
to constitute or result in, a Parent Material Adverse Effect. Except as, individually or in the aggregate, has not constituted or resulted
in, and would not reasonably be expected to constitute or result in, a Parent Material Adverse Effect, (x)&nbsp;all Permits are valid
and in full force and effect and are not subject to any administrative or judicial proceeding that could result in any modification, termination
or revocation thereof and, to the knowledge of Parent, no suspension or cancellation of any such Permit is threatened, (y)&nbsp;all fees
and assessments due and payable in connection with the Permits have been timely paid, and (z)&nbsp;Parent and each of its Subsidiaries
is in compliance with the terms and requirements of all Parent Permits.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 51; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;4.11</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Benefit
Plans</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">For
purposes of this Agreement, &ldquo;<U>Parent Plan</U>&rdquo; means each &ldquo;employee benefit plan&rdquo; (within the meaning of ERISA),
each &ldquo;multiemployer plans&rdquo; (within the meaning of ERISA section 3(37)), and each stock purchase, stock option, severance,
employment, change-in-control, fringe benefit, bonus, incentive, deferred compensation and all other plans, agreements, programs, policies
or other arrangements providing compensation or benefits, whether or not subject to ERISA (including any funding mechanism therefor now
in effect or required in the future as a result of the transactions contemplated by this Agreement or otherwise), whether formal or informal,
written, legally binding or not, under which any employee or former employee of Parent or its Subsidiaries has any present or future right
to benefits or Parent or its Subsidiaries has had or has any present or future material liability or which is sponsored, maintained or
contributed to by Parent or its Subsidiaries. With respect to each material Parent Plan, Parent has furnished or made available to the
Company a current, accurate and complete copy thereof (or, in the case of an unwritten Parent Plan, a summary of the material terms and
conditions thereof) and, to the extent applicable: (i)&nbsp; any related trust agreement or other funding instrument (including insurance
contracts), (ii)&nbsp;the most recent determination, advisory or opinion letter from the IRS, (iii)&nbsp;any summary plan description
and summary of material modifications thereto and other equivalent written communications by the Parent or its Subsidiaries to their employees
concerning the extent of the benefits provided under a Parent Plan; (iv)&nbsp;for the three most recent years (A)&nbsp;the Form&nbsp;5500
and attached schedules, (B)&nbsp;audited financial statements, (C)&nbsp;actuarial valuation reports, (D)&nbsp;attorney&rsquo;s response
to an auditor&rsquo;s request for information and (E)&nbsp;nondiscrimination and other testing results for 2020, 2021 and 2022; and (v)&nbsp;copies
of all material non-routine correspondence with any Governmental Entity in the past three years (including any filings under the Parent
Plans Compliance Resolution System or the Department of Labor Delinquent Filer Program).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">With
respect to the Parent Plans:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Except
as, individually or in the aggregate, has not constituted or resulted in, and would not reasonably be expected to constitute or result
in a Parent Material Adverse Effect, each Parent Plan is now and has at all times been established, maintained, funded and administered
in accordance with its terms and in compliance with all applicable Laws, including the applicable provisions of ERISA and the Code, and
no prohibited transaction, as described in Section&nbsp;406 of ERISA or Section&nbsp;4975 of the Code, has occurred with respect to any
Parent Plan, and except as, individually or in the aggregate, has not constituted or resulted in, and would not reasonably be expected
to constitute or result a Parent Material Adverse Effect, all contributions required to be made under the terms of any Parent Plan or
applicable Law have been timely made;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 52; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">each
Parent Plan intended to be qualified under Section&nbsp;401(a)&nbsp;of the Code has received a currently effective, favorable determination,
advisory and/or opinion letter, as applicable, from the IRS that it is so qualified (or the deadline for obtaining such a letter has not
expired as of the date of this Agreement) and, to the knowledge of Parent, nothing has occurred that would reasonably be expected to cause
the loss, or failure to have, such qualified status of such Parent Plan; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">there
are no (and in the past three (3)&nbsp;years have not been any) material Actions (including any investigation, audit or other administrative
proceeding) or other claims by the Department of Labor, the Pension Benefit Guaranty Corporation, the IRS or any other Governmental Entity
or by any plan participant, beneficiary or other Person pending, or to the knowledge of Parent, threatened relating to the Parent Plans,
any fiduciaries thereof with respect to their duties to the Parent Plans or the assets of any of the trusts under any of the Parent Plans
(other than routine claims for benefits).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Except
as, individually or in the aggregate, has not constituted or resulted in, and would not reasonably be expected to constitute or result
in a Parent Material Adverse Effect, Parent and its Subsidiaries do not maintain any Parent Plan, or otherwise have any liability with
respect to a plan, that is a &ldquo;group health plan&rdquo; (as such term is defined in Section&nbsp;5000(b)(1)&nbsp;of the Code) that
has not been administered and operated in all respects in compliance with the applicable requirements of COBRA and the Parent and its
Subsidiaries are not subject to any material liability, including additional contributions, fines, penalties or loss of tax deduction
as a result of such administration and operation. Parent and its Subsidiaries do not have any material liability under Chapter 43 of the
Code (whether or not assessed).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">No
Parent Plan is, and none of the Parent, any of its Subsidiaries or any Parent ERISA Affiliate maintains, sponsors or contributes to (or
has any liability, including on account of previously maintaining, sponsoring or contributing to), a plan that is subject to Section&nbsp;302
or Title IV of ERISA or Section&nbsp;412 of the Code. For purposes of this section, &ldquo;<U>Parent ERISA Affiliate</U>&rdquo; means
any trade or business (whether or not incorporated) which is (or to the extent the Parent or any Subsidiary could have any outstanding
liability on account of a prior affiliation, was) treated as a single employer along with Parent or any of its Subsidiaries for purposes
of Section&nbsp;4001 of ERISA or Section&nbsp;414 of the Code. No Parent Plan is, and none of Parent or its Subsidiaries has any liability
with respect to a plan that is, a &ldquo;multiemployer plan&rdquo; within the meaning of Section&nbsp;3(37) of ERISA or a &ldquo;multiple
employer welfare arrangement&rdquo; within the meaning of Section&nbsp;3(40) of ERISA. None of any Parent Plan, Parent or any of its Subsidiaries
provides or has any obligation to provide health, death or other welfare benefits following the termination of an employee&rsquo;s employment
with Parent or its Subsidiaries, except to the extent required by COBRA or other similar Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 53; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Neither
the execution of this Agreement, nor the consummation of any of the transactions contemplated hereby (either alone or in combination with
any other event) could reasonably be expected to result in the payment of a benefit or compensation, the increase of a benefit or compensation
amount, the payment of a contingent benefit or the acceleration of the payment, funding or vesting of a benefit or compensation with respect
to any current or former employee or other individual service provider of Parent or its Subsidiaries. Neither the execution of this Agreement,
nor the consummation of any of the transactions contemplated hereby (either alone or in combination with any other event) could reasonably
be expected to result in any payment or benefit being nondeductible pursuant to Section&nbsp;280G of the Code or subject to a Tax under
Section&nbsp;4999 of the Code. The Parent has no obligation to indemnify any individual for, or provide a gross-up, make-whole or similar
payment in respect of, any Tax incurred pursuant to Section&nbsp;409A or 4999 of the Code or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section&nbsp;4.12</FONT><FONT STYLE="color: #010000">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Labor
Matters</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Parent
and its Subsidiaries are, and since January&nbsp;1, 2020 have been, in all material respects, in compliance with the terms of the Parent
Plans, any applicable Labor Agreement and all applicable Laws respecting or relating to recruitment, employment and employment practices,
and agency and other workers, including all Employment Laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Except
as set forth on <B><U>&lrm;&lrm;</U></B><U>Section&nbsp;4.12(c)</U>&nbsp;of the Parent Disclosure Letter, there are no material Actions
or claims pending or, to Parent&rsquo;s knowledge, threatened, relating to Employment Law, or unfair labor practice or payment of compensation
to any current or former service provider of the Parent or any of its Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">During
the three (3)-year period immediately prior to the date of this Agreement, neither Parent nor its Subsidiaries have implemented any &ldquo;plant
closing&rdquo; or &ldquo;mass layoff&rdquo; (in each case, as defined under the Worker Adjustment and Retraining Notification Act of 1988,
as amended, or any similar applicable foreign, state or local Law) with respect to which there is any remaining liability or obligation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;4.13</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Environmental
Matters</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Except
as, individually or in the aggregate, has not constituted or resulted in, and would not reasonably be expected to constitute or result
in, a Parent Material Adverse Effect: (i)&nbsp;Parent and each of its Subsidiaries are, and during the past three (3)&nbsp;years have
been, in compliance with all applicable Environmental Laws, and possess and are, and during the past three (3)&nbsp;years have been, in
compliance with all applicable Environmental Permits required under such Environmental Laws to operate the business; (ii)&nbsp;there has
been no release, discharge or disposal of Materials of Environmental Concern that could reasonably be expected to result in a violation
by, or result in a liability of Parent and each of its Subsidiaries under, any Environmental Laws (A)&nbsp;on, under, in or at any owned
or leased real property, or to the knowledge of Parent, (B)&nbsp;on, under, in or at any real property formerly owned or leased by Parent
or its Subsidiaries or at any third party waste disposal location used by the Parent or its Subsidiaries; (iii)&nbsp;neither Parent nor
any of its Subsidiaries have received any written request for information pursuant to section&nbsp;104(e)&nbsp;of the Comprehensive Environmental
Response, Compensation and Liability Act or similar state statute, concerning any release or threatened release of Materials of Environmental
Concern at any location; and (iv)&nbsp;within the last three (3)&nbsp;years, neither Parent nor any of its Subsidiaries haves received
any written notice, claim or complaint, or is presently subject to any action or proceeding, relating to actual or alleged noncompliance
with, or liability arising under, Environmental Laws or any other liabilities pursuant to Environmental Laws that is unresolved, and to
the knowledge of Parent, no such matter has been threatened in writing; and (v)&nbsp;the Parent has provided Company reasonable access
to all material environmental investigations, studies, audits, analyses or other reports (including any Phase I or Phase II reports) to
the extent in the possession, custody or control of the Parent or its Subsidiaries relating to the Parent or each of its Subsidiaries
compliance with Environmental Law or the presence of contamination by Materials of Environmental Concern on, under, in or at any property
currently or formerly owned, leased, operated or occupied by the Parent or its Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 54; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Notwithstanding
any other representations and warranties in this Agreement, the representations and warranties in this <B><U>&lrm;</U></B><U>Section&nbsp;4.13</U>
are the only representations and warranties in this Agreement with respect to Environmental Laws or Materials of Environmental Concern.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;4.14</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Taxes</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Except
as, individually or in the aggregate, has not constituted or resulted in, and would not reasonably be expected to constitute or result
in, a Parent Material Adverse Effect:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">All
Tax Returns required by applicable Law to be filed by or on behalf of Parent or any of its Subsidiaries have been timely filed in accordance
with all applicable Laws (after giving effect to any extensions of time in which to make such filings), and all such Tax Returns are true,
correct and complete.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Parent
and its Subsidiaries have timely paid in full to the appropriate Governmental Entity all Taxes required to be paid by any of them (whether
or not shown on any Tax Return). Parent has established adequate accruals and reserves in accordance with GAAP on the financial statements
included in the Parent SEC Documents for all Taxes payable by Parent and its applicable Subsidiaries with respect to all taxable periods
(and portions thereof) through the date of such financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Each
of Parent and its Subsidiaries has (i)&nbsp;timely deducted, withheld and collected all amounts required to be deducted, withheld or collected
by any of them with respect to any payment owing to, or received from, their employees, creditors, independent contractors, customers
and other third parties and have timely paid or remitted over any amounts so withheld, deducted or collected to the appropriate Governmental
Entity and (ii)&nbsp;otherwise complied with all applicable Laws relating to the withholding, collection and remittance of Taxes (including
information reporting requirements).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">There
are no Liens for Taxes with respect to any assets or properties of Parent or any of its Subsidiaries, except for statutory Liens for Taxes
not yet due and payable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 55; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">No
claim has been made in writing by any Tax authority in a jurisdiction where Parent or any of its Subsidiaries has not filed a Tax Return
of a particular type that Parent or its applicable Subsidiary, as the case may be, is or may be subject to Tax by, or required to file
Tax Returns in, such jurisdiction with respect to Taxes that are the subject of such Tax Return.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Neither
Parent nor any its Subsidiaries (i)&nbsp;is or has been a member of any affiliated, combined, consolidated, unitary or similar group for
purposes of filing Tax Returns or paying Taxes for which the statute of limitations is open (except for any such group of which Parent
is the common parent) or (ii)&nbsp;has any liability for Taxes of any Person (other than Parent or any of its Subsidiaries) under Treasury
Regulations Section&nbsp;1.1502-6 (or&nbsp;any similar state, local or non-U.S. Law) or as a transferee or successor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Neither
Parent nor any of its Subsidiaries is a party to or bound by, or has any obligation under, any Tax indemnity, sharing, allocation, or
reimbursement agreement or arrangement, other than (A)&nbsp;customary Tax provisions in ordinary course commercial agreements, the principal
purpose of which is not related to Taxes and (B)&nbsp;any agreement or arrangement solely between or among Parent and/or any of its Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(viii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">No
audits or other proceedings are currently ongoing or pending, or threatened or proposed in writing, against or with respect to Parent
or any of its Subsidiaries with respect to any Tax or Tax Return. No deficiencies for any amount of Taxes have been asserted or assessed
in writing against Parent or any of its Subsidiaries that have not been paid in full by any of them or that are not being contested in
good faith and for which adequate accruals or reserves for such deficiency have not been established in accordance with GAAP on the financial
statements included in the Parent SEC Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ix)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Neither
Parent nor any of its Subsidiaries will be required to include any item of income in, or exclude any item of deduction from, taxable income
for any taxable period (or any portion thereof) ending after the Closing Date as a result of (A)&nbsp;any installment sale or other open
transaction disposition made prior to the Closing, (B)&nbsp;any adjustment under Section&nbsp;481(a)&nbsp;of the Code (or any comparable,
analogous or similar provision under any U.S. state or local or non-U.S. Law) or change in method of accounting initiated prior to the
Closing, (C)&nbsp;the use of an improper method of accounting for any taxable period (or portion thereof) ending on or prior to the Closing
Date, (D)&nbsp;any &ldquo;closing agreement&rdquo; as described in Section&nbsp;7121 of the Code (or any comparable, analogous or similar
provision under any U.S. state or local or non-U.S. Law) executed prior to the Closing, (E)&nbsp;any prepaid amount or deferred revenue
received or accrued prior to the Closing, (F)&nbsp;having entered into a &ldquo;gain recognition agreement&rdquo; within the meaning of
Treasury Regulation Section&nbsp;1.367(a)-8 or (G)&nbsp;pursuant to Section&nbsp;965 of the Code. Neither Parent nor any of its Subsidiaries
has made an election pursuant to Section&nbsp;965(h)&nbsp;of the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(x)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Neither
Parent nor any of its Subsidiaries (A)&nbsp;has filed any extension of time within which to file any Tax Returns that have not been filed,
except in the ordinary course of business, (B)&nbsp;has entered into any agreement or other arrangement waiving or extending the statute
of limitations or the period of assessment or collection of any Taxes for which the statute of limitations is open, (C)&nbsp;has granted
any power of attorney that is in force with respect to any matters relating to any Taxes, except in the ordinary course of business (D)&nbsp;has
applied for a ruling from any Tax authority relating to any Taxes that has not been granted or has proposed to enter into an agreement
with a Tax authority that is pending or (E)&nbsp;has been issued any private letter rulings, technical advice memoranda or similar agreement
or rulings by any Tax authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 56; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xi)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Neither
Parent nor any of its Subsidiaries has participated in any &ldquo;listed transaction&rdquo; within the meaning of Treasury Regulations
Section&nbsp;1.6011-4(b)(2)&nbsp;(or any similar state, local or non-U.S. Law).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Neither
Parent nor any of its Subsidiaries has constituted a &ldquo;distributing corporation&rdquo; or a &ldquo;controlled corporation&rdquo;
(within the meaning of Section&nbsp;355(a)(1)(A)&nbsp;of the Code) in a distribution of stock intended to qualify for Tax-free treatment
under Section&nbsp;355 of the Code (or any similar provision of state, local, or non-U.S. Law) or otherwise as part of a plan (or series
of related transactions), within the meaning of Section&nbsp;355(e)&nbsp;of the Code, that includes the Merger, in the two years prior
to the date of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Neither
Parent nor any of its Subsidiaries has knowledge of any facts, agreements, plans or other circumstances or has taken or agreed to take
any action, in each case that is not contemplated by this Agreement, that would reasonably be expected to prevent or impede the Merger
from qualifying for the Intended Tax Treatment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;4.15</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Insurance</U>.
Except as, individually or in the aggregate, has not constituted or resulted in, and would not reasonably be expected to constitute or
result in, a Parent Material Adverse Effect, (a)&nbsp;all insurance policies of Parent and its Subsidiaries are in full force and effect
and provide insurance in such amounts and against such risks as is, in all material respects, commercially reasonable, (b)&nbsp;neither
Parent nor any of its Subsidiaries is in breach or default, and neither Parent nor any of its Subsidiaries has taken any action or failed
to take any action which, with notice or the lapse of time, would constitute such a breach or default, or permit termination or modification
of, any of such insurance policies and (c)&nbsp;since the earlier of the most recent renewal date and January&nbsp;1, 2021, as of the
date hereof, Parent has not received any written notice (i)&nbsp;threatening termination of, or premium increases with respect to, or
material alteration of coverage under, any such policies, other than premium increases or alterations of coverage occurring in the ordinary
course during the renewal process for any such policies, (ii)&nbsp;refusal of any coverage or rejection of any material claim under any
insurance policy held by Parent or any of its Subsidiaries. As of the date of this Agreement, there is no pending material claim by Parent
or its Subsidiaries against any insurance carrier under any insurance policy held by Parent or its Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;4.16</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Properties</U>.
Except as, individually or in the aggregate, has not constituted or resulted in, and would not reasonably be expected to constitute or
result in, a Parent Material Adverse Effect, Parent or a Subsidiary of Parent owns and has (i)&nbsp;good and valid title to all of its
tangible personal property and (ii)&nbsp;a valid leasehold estate in all of its leased real property, free and clear of Encumbrances other
than Permitted Encumbrances. No representation is made under this <U>&lrm;Section&nbsp;4.16</U> with respect to any intellectual property
or intellectual property rights, which are the subject of <U>&lrm;Section&nbsp;4.17</U>. Parent or a Subsidiary of Parent does not own
any real property.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 57; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;4.17</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Intellectual
Property</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Except
as, individually or in the aggregate, has not constituted or resulted in and would not reasonably be expected to constitute or result
in a Parent Material Adverse Effect, Parent or its Subsidiaries own, or have the right pursuant to valid and enforceable licenses to use,
all (i)&nbsp;trademarks (including service marks, trade names, business marks, brand names, certification marks, trade dress, logos, corporate
names, trade styles, and other indications of origin, and the goodwill associated with the foregoing, in each case in any jurisdiction),
(ii)&nbsp;domain names, (iii)&nbsp;patents (including any national or multinational statutory invention registrations, patents and patent
applications issued or applied for in any jurisdiction, including all certificates of invention, provisionals, nonprovisionals, substitutions,
divisionals, continuations, continuations-in-part, reissues, renewals, extensions, supplementary protection certificates, reexaminations,
patents of addition, utility models, inventors&rsquo; certificates and the equivalents of any of the foregoing, in each case in any jurisdiction),
(iv)&nbsp;copyrights (including with respect to literary, pictorial and graphic works in any jurisdiction), and (v)&nbsp;all know-how
and trade secrets and other intellectual property rights, including for each case (i)-(iv), any pending applications to register, used
in or necessary for the business of Parent and its Subsidiaries as currently conducted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Except
as, individually or in the aggregate, has not constituted or resulted in and would not reasonably be expected to constitute or result
in a Parent Material Adverse Effect, (i)&nbsp;all registered marks, patents, copyrights and domain names owned or purported to be owned
(in whole or in part) by Parent or any of its Subsidiaries (collectively, &ldquo;<U>Parent Registered IP</U>&rdquo;) are valid, subsisting
and, to the knowledge of Parent, enforceable. No Parent Registered IP is involved in any interference, reissue, reexamination, opposition,
cancellation or similar proceeding and, to the knowledge of Parent, no such action is or has been threatened with respect to any of the
Parent Registered IP.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Except
as, individually or in the aggregate, has not constituted or resulted in and would not reasonably be expected to constitute or result
in a Parent Material Adverse Effect, each of Parent and its Subsidiaries has taken commercially reasonable steps to maintain the confidentiality
of all information of Parent or its Subsidiaries that derives economic value (actual or potential) from not being generally known to other
Persons who can obtain economic value from its disclosure or use, including taking commercially reasonable steps to safeguard any such
information that is accessible through computer systems or networks, and to the knowledge of Parent, such information have not been used
by or disclosed to any Person except pursuant to written, valid and appropriate non-disclosure agreements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Except
as, individually or in the aggregate, has not constituted or resulted in and would not reasonably be expected to constitute or result
in a Parent Material Adverse Effect, to the knowledge of Parent, (i)&nbsp;Parent and its Subsidiaries are not infringing upon or misappropriating
intellectual property of any third party in connection with the conduct of their respective businesses, (ii)&nbsp;no third party is misappropriating
or infringing any intellectual property owned by Parent or any of its Subsidiaries and (iii)&nbsp;no intellectual property owned by Parent
or any of its Subsidiaries is subject to any outstanding order, judgment, decree or stipulation restricting or limiting in any material
respect the use or licensing thereof by Parent or any of its Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 58; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;4.18</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Health
Care Regulatory Matters</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Parent,
and to the knowledge of Parent, each of its directors, officers, management employees, agents (while acting in such capacity), contract
manufacturers, suppliers, and distributors are, and at all times prior hereto were, in material compliance with all Health Care Laws to
the extent applicable to Parent or any of its products or activities. To the knowledge of Parent, there are no facts or circumstances
that reasonably would be expected to give rise to any material liability under any Health Care Laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Parent
is not party to any corporate integrity agreements, monitoring agreements, deferred or non-prosecution agreements, consent decrees, settlement
orders, or similar agreements with or imposed by any Governmental Entity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">All
applications, notifications, submissions, information, claims, reports and statistical analyses, and other data and conclusions derived
therefrom, utilized as the basis for or submitted in connection with any and all requests for a Permit from the FDA or other Governmental
Entity relating to products that are regulated as drugs, medical devices, or other healthcare products under Health Care Laws, including
biological and drug candidates, compounds or products being researched, tested, stored, developed, labeled, manufactured, packed and/or
distributed by Parent or any of its Subsidiaries (&ldquo;<U>Parent Products</U>&rdquo;), including, without limitation, investigational
new drug applications, when submitted to the FDA or other Governmental Entity were true, complete and correct in all material respects
as of the date of submission and any necessary or required updates, changes, corrections or modification to such applications, submissions,
information and data have been submitted to the FDA or other Governmental Entity. Parent does not have knowledge of any facts or circumstances
that would be reasonably likely to lead to the revocation, suspension, limitation, or cancellation of a Permit required under Health Care
Laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">All
preclinical studies and clinical trials conducted by or, to the knowledge of Parent, on behalf of Parent have been, and if still pending
are being, conducted in material compliance with research protocols and all applicable Health Care Laws, including, but not limited to,
the FDCA and its applicable implementing regulations at 21 C.F.R. Parts 50, 54, 56, 58, 312 and , 314 and 601. No clinical trial conducted
by or on behalf of Parent has been conducted using any clinical investigators who have been disqualified, debarred or excluded from healthcare
programs. No clinical trial conducted by or on behalf of Parent has been terminated or suspended prior to completion, and no clinical
investigator who has participated or is participating in, or institutional review board that has or has had jurisdiction over, a clinical
trial conducted by or on behalf of Parent has placed a partial or full clinical hold order on, or otherwise terminated, delayed or suspended,
such a clinical trial at a clinical research site based on an actual or alleged lack of safety or efficacy of any Parent Product or a
failure to conduct such clinical trial in compliance with applicable Health Care Laws, their implementing regulations and good clinical
practices. Parent has not identified or received notice of instances or allegations of research misconduct (defined as falsification or
fabrication of data, or plagiarism, as those terms are defined in 42 C.F.R. Part&nbsp;93) involving research conducted by, or on behalf
of Parent, that could compromise or affect the integrity, reliability, completeness, or accuracy of the data collected in such research,
or the rights, safety, or welfare of the research subjects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 59; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">All
manufacturing operations conducted by or, to the knowledge of Parent, for the benefit of Parent have been and are being conducted in material
compliance with all Permits under applicable Health Care Laws, all applicable provisions of the FDA&rsquo;s current good manufacturing
practice (cGMP) regulations for pharmaceuticals and biological products at 21 C.F.R. Parts 210, 211, 600 and 610 and all comparable foreign
regulatory requirements of any Governmental Entity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Parent
has not received any written communication that relates to an alleged violation or noncompliance with any Health Care Laws, including
any notification of any pending or threatened claim, suit, proceeding, hearing, enforcement, investigation, arbitration, import detention
or refusal, FDA Warning Letter or Untitled Letter, or any action by a Governmental Entity relating to any Health Care Laws. All Warning
Letters, Form&nbsp;FDA-483 observations, or comparable findings from other Governmental Entities listed in <B><U>&lrm;</U></B><U>Section&nbsp;4.18</U>
of Parent Disclosure Letter have been resolved and closed out to the satisfaction of the applicable Governmental Entity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">There
have been no seizures, withdrawals, recalls, detentions, or suspensions of manufacturing, testing, or distribution relating to the Parent
Products required or requested by a Governmental Entity, or other notice of action relating to an alleged lack of safety, efficacy, or
regulatory compliance of the Parent Products, or any adverse experiences relating to the Parent Products that have been reported to FDA
or other Governmental Entity (&ldquo;<U>Parent Safety Notices</U>&rdquo;), and, to the knowledge of Parent, there are no facts or circumstances
that reasonably would be expected to give rise to a Parent Safety Notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">There
are no unresolved Parent Safety Notices, and to the knowledge Parent, there are no facts that would be reasonably likely to result in
a material Parent Safety Notice or a termination or suspension of developing and testing of any of the Parent Products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Neither
Parent, nor, to the knowledge of Parent, any officer, employee, agent, or distributor of Parent has made an untrue statement of a material
fact or fraudulent or misleading statement to a Governmental Entity, failed to disclose a material fact required to be disclosed to a
Governmental Entity, or committed an act, made a statement, or failed to make a statement that would reasonably be expected to provide
a basis for the FDA to invoke its FDA Ethics Policy. To the knowledge of Parent, none of the aforementioned is or has been under investigation
resulting from any allegedly untrue, fraudulent, misleading, or false statement or omission, including data fraud, or had any action pending
or threatened relating to the FDA Ethics Policy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">All
reports, documents, claims, Permits and notices required to be filed, maintained or furnished to the FDA or any Governmental Entity by
Parent have been so filed, maintained or furnished, except where failure to file, maintain or furnish such reports, documents, claims,
Permits or notices that, individually or in the aggregate, has not constituted or resulted in, and would not reasonably be expected to
constitute or result in, a Parent Material Adverse Effect. All such reports, documents, claims, Permits and notices were true and complete
in all material respects on the date filed (or were corrected in or supplemented by a subsequent filing).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Neither
Parent nor, to the knowledge of Parent, any officer, employee, agent, or distributor of Parent has committed any act, made any statement
or failed to make any statement that violates the Federal Anti-Kickback Statute, 28 U.S.C. &sect; 1320a-7b, the Federal False Claims Act,
31 U.S.C. &sect; 3729, other Health Care Laws, or any other similar federal, state, or ex-U.S. law applicable in the jurisdictions in
which the Parent Products are sold or intended to be sold.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 60; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Neither
Parent nor, to the knowledge of Parent, any officer, employee, agent, or distributor of Parent has been convicted of any crime or engaged
in any conduct that has resulted, or would reasonably be expected to result, in debarment under applicable Law, including, without limitation,
21 U.S.C. &sect; 335a, or exclusion under 42 U.S.C. &sect; 1320a-7, or any other statutory provision or similar law applicable in other
jurisdictions in which the Parent Products are sold or intended to be sold. None of Parent nor any officer, employee, or to the knowledge
of Parent, agent or distributor of Parent, has been debarred, suspended or excluded from participation in any federal health care program
or convicted of any crime or engaged in any conduct for which such Person could be excluded from participating in any federal health care
program under Section&nbsp;1128 of the Social Security Act of 1935, as amended, or any similar Health Care Law or program.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;4.19</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Certain
Payments</U>. Neither Parent nor any of its Subsidiaries nor any director, officer, employee, agent or other person acting on behalf of
Parent or its Subsidiaries has, directly or indirectly, (a)&nbsp;violated or taken any action that could potentially result in a violation
of any Anti-Corruption Laws or (b): (i)&nbsp;used, offered to use or authorized the use of any funds of Parent or any of its Subsidiaries
for unlawful contributions, unlawful gifts or unlawful entertainment, or for other unlawful payments, related to political activity or
otherwise; (ii)&nbsp;made, offered to make or authorized any unlawful payment to foreign or domestic Government Officials or employees
or to foreign or domestic political parties or campaigns from funds of Parent or its Subsidiaries; (iii)&nbsp;established or maintained
any unlawful fund of monies or other assets of Parent or its Subsidiaries; (iv)&nbsp;made any inaccurate entry on the books or records
of Parent or its Subsidiaries; (v)&nbsp;made, offered to make or authorized any bribe, unlawful rebate, unlawful payoff, unlawful influence
payment, unlawful kickback or other unlawful payment to any person, private or public, in any form or (vi)&nbsp;engaged in or facilitated
any transaction or dealing in property or interests in property of, received from or made any contribution of funds, goods or services
to or for the benefit of, provided any payments or material assistance to, or otherwise engage in or facilitated any transactions with
any Prohibited Person. Neither Parent nor any of its Subsidiaries is or within the past five years has been (i)&nbsp;under external or
internal investigation by any Governmental Entity for any potential or actual violation of any Anti-Corruption Laws or (ii)&nbsp;has received
any written or other notice from any Governmental Entity regarding any potential or actual violation of, or potential or actual failure
to comply with, any Anti-Corruption Laws. Neither Parent nor any of its Subsidiaries has made any disclosure (voluntary or otherwise)
to any Governmental Entity with respect to any alleged irregularity, misstatement or omission or other potential violation or liability
arising under or relating to any Anti-Corruption Laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;4.20</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>State
Takeover Statutes</U>. No Takeover Laws enacted under of any state Laws in the United States apply to this Agreement or the CVR Agreement
or any of the transactions contemplated hereby and thereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;4.21</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Affiliate
Transactions</U>. Except for directors&rsquo; and employment-related Material Contracts filed or incorporated by reference as an exhibit
to a Parent SEC Document filed by Parent prior to the date hereof and for any intercompany agreements, as of the date hereof, no executive
officer or director of Parent is a party to any Material Contract with or binding upon Parent or any of its Subsidiaries or any of their
respective properties or assets or has any material interest in any material property owned by Parent or any of its Subsidiaries or has
engaged in any material transaction with any of the foregoing that would be required to be disclosed under Item 404 of Regulation S-K
promulgated by the SEC since January&nbsp;1, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 61; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;4.22</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Brokers</U>.
No broker, investment banker, financial advisor or other Person, other than SVB Securities LLC and H.C. Wainwright&nbsp;&amp; Co., LLC
(together, the &ldquo;<U>Parent Financial Advisors</U>&rdquo;), is entitled to any broker&rsquo;s, finder&rsquo;s, financial advisor&rsquo;s
or other similar fee or commission in connection with the transactions contemplated by this Agreement based upon arrangements made by
or on behalf of Parent, its Subsidiaries, or Merger Sub. Parent has made available to the Company true, correct and complete copies of
all engagement, fee and similar Contracts between Parent (or any Subsidiary of Parent) and the Parent Financial Advisors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;4.23</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Opinion
of Financial Advisor</U>. Each of the Parent Financial Advisors has delivered to the Parent Board its written opinion (or oral opinion
to be confirmed in writing), dated as of the date of this Agreement, to the effect that, as of the date of this Agreement and based upon
and subject to the assumptions, qualifications, limitations and other matters set forth therein, the Merger Consideration proposed to
be paid by Parent pursuant to this Agreement is fair, from a financial point of view, to Parent. Parent will make available to the Company
a copy of each such opinion as soon as practicable following the execution of this Agreement for information purposes only.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;4.24</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>No
Prior Activities</U>. Except for obligations incurred in connection with its organization and the transactions contemplated hereby, Merger
Sub has not incurred any obligation or liability nor engaged in any business or activity of any type or kind whatsoever or entered into
any Contract with any Person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;4.25</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>No
Other Representations or Warranties</U>. Except for the representations and warranties contained in <U>&lrm;Article&nbsp;</U>III or in
any certificate delivered pursuant to this Agreement, each of Parent and Merger Sub acknowledges that neither the Company nor any other
Person on behalf of the Company makes any other express or implied representation or warranty with respect to the Company or any of its
Subsidiaries with respect to any other information provided to Parent or Merger Sub in connection with the transactions contemplated by
this Agreement. Neither the Company nor any other Person will have or be subject to any liability to Parent or Merger Sub or any other
Person resulting from the distribution to Parent or Merger Sub, or Parent&rsquo;s or Merger Sub&rsquo;s use of, any such information,
including any information, documents, projections, forecasts or other material made available to Parent or Merger Sub in certain &ldquo;data
rooms&rdquo; or management presentations in expectation of, or in connection with, the transactions contemplated by this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;4.26</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>No
Reliance</U>. Each of Parent, and Merger Sub acknowledges and agrees that it (a)&nbsp;has had an opportunity to discuss and ask questions
regarding the business of the Company and its Subsidiaries with the management of the Company, (b)&nbsp;has had access to the books and
records of the Company, the &ldquo;data room&rdquo; maintained by the Company for purposes of the transactions contemplated by this Agreement
and such other information as it has desired or requested to review and has received sufficient responses to its requests for information
regarding the Company and (c)&nbsp;has conducted its own independent investigation of the Company and its Subsidiaries and the transactions
contemplated hereby, and has not relied on any representation or warranty by any Person on behalf of the Company or any of its Subsidiaries,
except for the representations and warranties set forth in <U>&lrm;Article&nbsp;</U>III or in any certificate delivered in connection
with this Agreement. Without limiting the foregoing, except for the representations and warranties set forth in <U>&lrm;Article&nbsp;III</U>
of this Agreement or in any certificate delivered in connection with this Agreement, each of Parent and Merger Sub further acknowledges
and agrees that none of the Company or any of its stockholders, directors, officers, employees, Affiliates, advisors, agents or other
Representatives has made any representation or warranty concerning any estimates, projections, forecasts, business plans or other forward-looking
information regarding the Company, its Subsidiaries or their respective businesses and operations. Each of Parent and Merger Sub hereby
acknowledges that there are uncertainties inherent in attempting to develop such estimates, projections, forecasts, business plans and
other forward-looking information with which Parent and Merger Sub are familiar, that except for the representations and warranties set
forth in <U>&lrm;Article&nbsp;III</U> or in any certificate delivered in connection with this Agreement, Parent and Merger Sub are taking
full responsibility for making their own evaluation of the adequacy and accuracy of all estimates, projections, forecasts, business plans
and other forward-looking information furnished to them (including the reasonableness of the assumptions underlying such estimates, projections,
forecasts, business plans and other forward-looking information), and that Parent and Merger Sub will have no claim against the Company
or any of its stockholders, directors, officers, employees, Affiliates, advisors, agents or other Representatives with respect thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 62; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase; color: #010000"><B>Article&nbsp;V</B></FONT><B><FONT STYLE="text-transform: uppercase"><BR>
COVENANTS</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;5.1</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Conduct
of Business of the Company</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Company covenants and agrees that, during the period from the date hereof until the Effective Time, except (i)&nbsp;as expressly required
by this Agreement, (ii)&nbsp;as disclosed in <B><U>&lrm;</U></B><U>Section&nbsp;5.1(a)</U>&nbsp;of the Company Disclosure Letter, (iii)&nbsp;as
required by applicable Law (including any Public Health Measures) or with respect to commercially reasonable actions taken by the Company
or any of its Subsidiaries in response to Public Health Measures that are taken in good faith and are consistent with practices in the
industry and geographic regions in which the Company operates in response to COVID-19 or (iv)&nbsp;to the extent Parent shall otherwise
consent in writing (which consent shall not be unreasonably withheld, conditioned or delayed), the Company shall, and shall cause each
of its Subsidiaries to, (w)&nbsp;conduct their respective business in the ordinary course of business in all material respects and (x)&nbsp;use
reasonable best efforts to preserve substantially intact their respective business organizations and material assets, to keep available
the services of its and its Subsidiaries&rsquo; current officers and key employees, to preserve their respective present relationships
with material customers and material suppliers and comply in all material respects with all applicable Laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Without
limiting the generality of the foregoing, between the date of this Agreement and the Effective Time, except (w)&nbsp;as expressly required
by this Agreement, (x)&nbsp;as disclosed in <B><U>&lrm;&lrm;</U></B><U>Section&nbsp;5.1(b)</U>&nbsp;of the Company Disclosure Letter,
(y)&nbsp;as required by applicable Law (including any Public Health Measures) or (z)&nbsp;to the extent Parent shall otherwise consent
in writing (which consent shall not be unreasonably withheld, conditioned or delayed), the Company shall not, and the Company shall cause
each of its Subsidiaries not to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 63; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">amend
or otherwise change its Organizational Documents;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">issue,
deliver, sell, pledge, grant, dispose of or encumber any shares of capital stock, or grant to any Person any right to acquire any additional
shares of, or securities convertible or exchangeable for, or options, warrants or rights to acquire, any shares of its capital stock or
other equity interests, except pursuant to the exercise of Company Stock Options or settlement of other awards (including, but not limited
to Company RSUs) outstanding as of the date hereof (or permitted hereunder to be granted after the date hereof) and in accordance with
the terms of such instruments;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">declare,
set aside, make or pay any dividend or other distribution, payable in cash, stock, property or otherwise, with respect to any of its capital
stock (except for any dividend or distribution by a Subsidiary of the Company to the Company or to other Subsidiaries);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">(A)&nbsp;adjust,
split, combine, exchange, redeem, repurchase or otherwise acquire any shares of capital stock or equity interests, or any other securities
or obligations convertible (currently or after the passage of time or the occurrence of certain events) into or exchangeable for any shares
of the Company&rsquo;s or any of its Subsidiaries&rsquo; capital stock or equity interests, except in connection with the cashless exercises
or similar transactions pursuant to the exercise of Company Stock Options or settlement of Company RSUs or other awards or obligations
outstanding as of the date hereof or permitted to be granted after the date hereof or through the Company&rsquo;s existing or previously
announced repurchase program, redemptions or exchanges, or (B)&nbsp;reclassify, combine, split, subdivide or otherwise amend the terms
of its capital stock or equity interests, or any other securities or obligations convertible (currently or after the passage of time or
the occurrence of certain events) into or exchangeable for any shares of the Company&rsquo;s or any of its Subsidiaries&rsquo; capital
stock or equity interests;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">(A)&nbsp;acquire
(whether by merger, consolidation or acquisition of stock or assets or otherwise) any corporation, partnership or other business organization
or division thereof or any assets other than (x)&nbsp;such acquisitions set forth on <B><I><U>&lrm;</U></I></B><U>Section&nbsp;5.1(b)(v)</U>&nbsp;of
the Company Disclosure Letter, (y)&nbsp;purchases of inventory and other assets in the ordinary course of business or pursuant to existing
Contracts; (B)&nbsp;sell, assign, transfer, lease, license, encumber or otherwise dispose of (whether by merger, consolidation or acquisition
of stock or assets or otherwise) any corporation, partnership or other business organization or division thereof or any assets, other
than, in each case, (x)&nbsp;sales of inventory, goods or services in the ordinary course of business or of obsolete equipment or assets
in the ordinary course of business; (C)&nbsp;as security for any borrowings permitted by <B><I><U>&lrm;</U></I></B><U>Section&nbsp;5.1(b)(viii)</U>;
or (D)&nbsp;licenses granted to customers or other third parties in the ordinary course of business; or (E)&nbsp;dispositions of assets
which do not constitute Company Intellectual Property, and with respect to which the fair market value of all such assets does not exceed
$500,000 in the aggregate;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">except
in the ordinary course of business, (x)&nbsp;materially amend or terminate any Material Contract (other than terminations pursuant to
the expiration of the existing term of any Material Contract or without penalty and loss of material benefit to the Company), (y)&nbsp;waive,
release or assign any material rights under any Material Contract or (z)&nbsp;enter into any Contract or agreement that, if in effect
on the date of this Agreement, would constitute a Material Contract;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 64; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">make,
or agree or commit to make, any capital expenditure, except (A)&nbsp;for capital expenditures in the ordinary course in an amount not
to exceed $300,000, (B)&nbsp;capital expenditures related to operational emergencies or (C)&nbsp;as required by Law or a Governmental
Entity; provided, that in the case of clauses (B)&nbsp;and (C), the Company shall provide Parent with notice of such action taken as soon
as reasonably practicable thereafter;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(viii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">fail
to maintain compliance in all material respects with the material terms of the Term Loan Credit Facility;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ix)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">(A)&nbsp;make
any loans, advances or capital contributions to, or investments in, any other Person (other than a Subsidiary of the Company), (B)&nbsp;incur,
redeem, repurchase, prepay, defease, or cancel any indebtedness for borrowed money, guarantee any such indebtedness, issue or sell any
debt securities or rights to acquire any debt securities (directly, contingently or otherwise) or make any loans or advances or capital
contributions to any other Person, except for: (1)&nbsp;subject to <B><I><U>&lrm;</U></I></B><U>Section&nbsp;5.21</U>, repayment of the
amounts outstanding under the Term Loan Credit Facility when due in accordance with their terms; (2)&nbsp;any indebtedness among the Company
and its Subsidiaries or among Subsidiaries of the Company (and guarantees by the Company or its Subsidiaries in respect thereof) and (3)&nbsp;purchase
money financings and capital leases entered into in the ordinary course of business in an aggregate amount not to exceed $50,000 at any
time outstanding, (C)&nbsp;assume, guarantee, endorse or otherwise become liable or responsible for the indebtedness or other obligations
of another Person (other than a guaranty by the Company on behalf of its Subsidiaries) or (D)&nbsp;incur any Encumbrance on any of its
material property or assets, except Permitted Encumbrances;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(x)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">except
to the extent required by applicable Law or any Company Plan in effect as of the date hereof, (A)&nbsp;materially increase or decrease
the compensation or benefits of any director or any Company Employee with annual base compensation in excess of $200,000, (B)&nbsp;enter
into, establish, amend, terminate or materially modify (including by exercising discretion to accelerate vesting or the time of payment
or funding) any Company Plan, or any arrangement that would be a Company Plan if in effect as of the date of this Agreement; (C)&nbsp;hire
any individual as an employee (except, with respect to any individual whose annual base compensation does not exceed $200,000, to fill
a vacancy); (D)&nbsp;terminate the employment of any Company Employee with annual base compensation in excess of $200,000 (other than
for cause); or (E)&nbsp;enter into any collective bargaining agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xi)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">implement
or adopt any material change in its methods of accounting, except as may be required to conform to changes in statutory or regulatory
accounting rules&nbsp;or GAAP or regulatory requirements with respect thereto;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">adopt
a plan of (A)&nbsp;complete or partial liquidation of the Company or any Subsidiary of the Company or (B)&nbsp;dissolution, merger, consolidation,
division, restructuring, recapitalization or other reorganization, other than, in the case of clause (B), transactions between or among
direct or indirect wholly owned Subsidiaries of the Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 65; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xiii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">enter
into any Company Real Property Leases;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xiv)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">commence,
compromise, settle or agree to settle any Action (including any Action relating to this Agreement or the transactions contemplated hereby),
or consent to the same, other than compromises, settlements or agreements in the ordinary course of business that (A)&nbsp;involve only
the payment of money damages (1)&nbsp;for an amount (in excess of insurance proceeds) for each such compromise or settlement that is,
individually, less than $50,000 and for all such compromises or settlements that is, in the aggregate, less than $100,000 or (2)&nbsp;consistent
with the reserves reflected in the Company&rsquo;s balance sheet at December&nbsp;31, 2022, (B)&nbsp;do not impose any restriction on
the Company&rsquo;s business or the business of its Subsidiaries, (C)&nbsp;do not relate to any litigation, claim, suit, action or proceeding
by the Company&rsquo;s stockholders in connection with this Agreement or the Merger and (D)&nbsp;do not include an admission of liability
or fault on the part of the Company or any of its Subsidiaries;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xv)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">(A)&nbsp;make,
change or revoke any material Tax election, (B)&nbsp;change or adopt any material Tax accounting period or material method of Tax accounting,
(C)&nbsp;amend or refile any material Tax Return, (D)&nbsp;file any material Tax Return prepared in a manner materially inconsistent with
past practice, (E)&nbsp;settle or compromise any material liability for Taxes or any audit, claim or other proceeding relating to a material
amount of Taxes, (F)&nbsp;enter into any &ldquo;closing agreement&rdquo; within the meaning of Section&nbsp;7121 of the Code (or any similar
state, local or non-U.S. Law), (G)&nbsp;request any ruling from any Governmental Entity relating to Taxes, (H)&nbsp;surrender any right
to claim a material refund of Taxes or (I)&nbsp;other than in the ordinary course of business, agree to an extension or waiver of the
statute of limitations with respect to a material amount of Taxes;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xvi)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">sell,
transfer, assign, license, or otherwise dispose of (by merger, consolidation, operation of law, division or otherwise), or grant a Lien
on, covenant not to sue in respect of, mortgage, encumber or exchange any material Company Intellectual Property owned, or purported to
be owned, by, or exclusively license to, the Company or any Subsidiary of the Company (other than the grant of non-exclusive licenses
to customers in the ordinary course of business, to the extent such licenses are necessary for the respective customer&rsquo;s use or
receipt of Company Products and subject to terms and conditions (including as to confidentiality) that are consistent with past practice);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xvii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">materially
reduce the amount of insurance coverage or fail to renew or maintain any material existing insurance policies;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xviii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">(A)&nbsp;amend
any Permits in a manner that adversely impacts the Company&rsquo;s ability to conduct its business in any material respect or (B)&nbsp;terminate
or knowingly allow to lapse any material Permits;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xix)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">with
respect to Intellectual Property, (A)&nbsp;sell, assign, license, sublicense, encumber, fail to maintain, transfer or otherwise dispose
of any right, title or interest of the Company in any Company Intellectual Property, (B)&nbsp;grant, extend, amend, or waive, cancel or
modify any rights in or to the Company Intellectual Property, (C)&nbsp;fail to use diligent efforts to file and prosecute any patent applications
included in the Company Intellectual Property; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 66; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xx)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">agree
to take or otherwise authorize, approve or enter into any agreement or make any commitment to take any of the actions described in <U>Sections
<B><I>&lrm;</I></B>5.1(b)(i)</U>&nbsp;through (xix).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;5.2</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Conduct
of Business of Parent</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Parent
covenants and agrees that, during the period from the date hereof until the Effective Time, except (i)&nbsp;as expressly required by this
Agreement, (ii)&nbsp;as disclosed in <B><U>&lrm;</U></B><U>Section&nbsp;5.2(a)</U>&nbsp;of the Parent Disclosure Letter, (iii)&nbsp;as
required by applicable Law (including any Public Health Measures) or with respect to commercially reasonable actions taken by Parent or
any of its Subsidiaries in response to Public Health Measures that are taken in good faith and are consistent with practices in the industry
and geographic regions in which Parent operates in response to COVID-19 or (iv)&nbsp;to the extent the Company shall otherwise consent
in writing (which consent shall not be unreasonably withheld, conditioned or delayed), Parent shall, and shall cause each of its Subsidiaries
to (w)&nbsp;conduct their respective business in the ordinary course of business in all material respects and (x)&nbsp;use reasonable
best efforts to preserve substantially intact their respective business organizations and material assets, to keep available the services
of its and its Subsidiaries&rsquo; current officers and key employees, to preserve their respective present relationships with material
customers and material suppliers and comply in all material respects with all applicable Laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Without
limiting the generality of the foregoing, between the date of this Agreement and the Effective Time, except (w)&nbsp;as expressly required
by this Agreement, (x)&nbsp;as disclosed in <B><U>&lrm;&lrm;</U></B><U>Section&nbsp;5.2(b)</U>&nbsp;of the Parent Disclosure Letter, (y)&nbsp;as
required by applicable Law (including any Public Health Measures), or (z)&nbsp;to the extent the Company shall otherwise consent in writing
(which consent shall not be unreasonably withheld, conditioned or delayed), Parent shall not and shall cause each of its Subsidiaries
not to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">amend
or otherwise change the Organizational Documents of Parent or Merger Sub in any manner that would be adverse in any material respect to
the holders of Company Shares (after giving effect to the Merger) relative to other holders of Parent Common Stock;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">issue,
deliver, sell, grant or otherwise permit to become outstanding any shares of capital stock, or grant to any Person any right to acquire
any additional shares of, or securities convertible or exchangeable for, or options, warrants or rights to acquire, any shares of its
capital stock or other equity interests, except (A)&nbsp;pursuant to the exercise of Parent Stock Options or settlement of other equity
awards issued pursuant to a Parent Plan; (B)&nbsp;shares of Parent Common Stock issuable upon exercise or exchange of any outstanding
convertible notes or warrants; (C)&nbsp;compensatory awards in the ordinary course of business; or (D)&nbsp;to any of the Company and
its Subsidiaries;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">declare,
set aside, make or pay any dividend or other distribution, payable in cash, stock, property or otherwise, with respect to any of its capital
stock (except for any dividend or distribution by a Subsidiary of Parent to Parent or to other Subsidiaries);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 67; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">(A)&nbsp;adjust,
split, combine, exchange, redeem, repurchase or otherwise acquire any shares of Parent Common Stock, except (w)&nbsp;in connection with
the cashless exercises or similar transactions pursuant to the exercise of Parent Stock Options or settlement of other awards or obligations
outstanding as of the date hereof or permitted to be granted after the date hereof, (x)&nbsp;shares of Parent Common Stock repurchased
from employees or consultants or former employees or consultants of Parent pursuant to the exercise of repurchase rights; (y)&nbsp;shares
of Parent Common Stock accepted as payment for the exercise price of Parent&rsquo;s equity awards or for withholding Taxes incurred in
connection with the exercise, vesting or settlement of equity awards, as applicable, in accordance with the terms of the applicable award;
or (z)&nbsp;through Parent&rsquo;s existing or previously announced repurchase program, redemptions or exchanges, or (B)&nbsp;reclassify,
combine, split, subdivide or otherwise amend the terms of its capital stock or equity interests, or any other securities or obligations
convertible (currently or after the passage of time or the occurrence of certain events) into or exchangeable for any shares of Parent&rsquo;s
or any of its Subsidiaries&rsquo; capital stock or equity interests;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">implement
or adopt any material change in its methods of accounting, except as may be required to conform to changes in statutory or regulatory
accounting rules&nbsp;or GAAP or regulatory requirements with respect thereto;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">adopt
a plan of (A)&nbsp;complete or partial liquidation of Parent or Merger Sub or (B)&nbsp;dissolution, merger, consolidation, division, restructuring,
recapitalization or other reorganization, other than, in the case of clause (B), transactions between or among Parent and any direct or
indirect wholly owned Subsidiaries of Parent; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">agree
to take or otherwise authorize, approve or enter into any agreement or make any commitment to take any of the actions described in <B><I><U>&lrm;</U></I></B><U>Section&nbsp;5.2(b)(i)</U>&nbsp;through
<U>Section&nbsp;5.2(b)(vi)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;5.3</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>No
Control of Other Party&rsquo;s Business</U>. Nothing contained in this Agreement (including anything in <U>&lrm;Section&nbsp;5.1(b)</U>)
shall give Parent, directly or indirectly, the right to control or direct the Company&rsquo;s or its Subsidiaries&rsquo; operations prior
to the Effective Time, and nothing contained in this Agreement (including anything in <U>&lrm;Section&nbsp;5.2(b)</U>) shall give the
Company, directly or indirectly, the right to control or direct Parent&rsquo;s or its Subsidiaries&rsquo; operations prior to the Effective
Time. Prior to the Effective Time, each of the Company and Parent shall exercise, consistent with the terms and conditions of this Agreement,
complete control and supervision over its and its Subsidiaries&rsquo; respective operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;5.4</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>No
Solicitation by the Company</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">From
the date of this Agreement until the earlier of the Effective Time and the valid termination of this Agreement in accordance with <B><U>&lrm;</U></B><U>Section&nbsp;7.1</U>,
except as expressly permitted by this <B><U>&lrm;</U></B><U>Section&nbsp;5.4</U>, the Company agrees that it shall not, and shall cause
its Subsidiaries and direct its and their respective directors, officers, employees, investment bankers, attorneys, consultants, accountants
and other advisors, agents or representatives (collectively, &ldquo;<U>Representatives</U>&rdquo;) not to, directly or indirectly, (i)&nbsp;initiate,
solicit, knowingly assist, knowingly induce or knowingly encourage or facilitate (including by providing information) any inquiries, proposals
or offers with respect to, or the making, submission, announcement or completion of, any proposal or offer that constitutes, or would
be reasonably expected to lead to, a Company Acquisition Proposal or (ii)&nbsp;engage in, continue or participate in any negotiations
or discussions with any Persons other than Parent, Merger Sub and their respective Affiliates and Representatives to the extent acting
on behalf of Parent or Merger Sub (any such Person, a &ldquo;<U>Third Party</U>&rdquo;) (other than to refer the inquiring Person to this
<B><U>&lrm;</U></B><U>Section&nbsp;5.4</U>) concerning any Company Acquisition Proposal or any inquiry, proposal or offer that would reasonably
be expected to lead to any Company Acquisition Proposal, (iii)&nbsp;furnish or provide or cause to be furnished or provided any non-public
information or data relating to the Company or any of its Subsidiaries in connection with, or for the purpose of soliciting, initiating,
encouraging or facilitating, or in response to, any inquiry, proposal or offer that constitutes of would reasonably be expected to lead
to a Company Acquisition Proposal, or (iv)&nbsp;resolve or agree to do any of the foregoing. The Company agrees that it will, and will
cause its Subsidiaries and direct its and their respective Representatives to, (x)&nbsp;immediately cease and cause to be terminated any
existing activities, discussions or negotiations with any Third Party conducted heretofore with respect to any Company Acquisition Proposal,
(y)&nbsp;deliver a written notice to any such Third Party explicitly stating that the Company is terminating all discussions and negotiations
with such Third Party with respect to any Company Acquisition Proposal, and requesting that such Third Party promptly return or destroy
all confidential or proprietary information concerning the Company and its Subsidiaries, and (z)&nbsp;promptly terminate access of any
such Third Party to any due diligence or electronic or physical data room with respect to any Company Acquisition Proposal; <U>provided</U>,
that nothing in this Agreement shall restrict the Company from permitting a Person to request the waiver of a &ldquo;standstill&rdquo;
or similar obligation or from granting such a waiver, in each case to the extent necessary to comply with fiduciary duties under applicable
Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 68; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Notwithstanding
anything to the contrary in <B><U>&lrm;</U></B><U>Section&nbsp;5.4(a</U>), at any time prior to obtaining the Company Stockholder Approval,
in response to an unsolicited bona fide written Company Acquisition Proposal from a Third Party made after the date hereof that (x)&nbsp;did
not result from a material breach of <B><U>&lrm;</U></B><U>Section&nbsp;5.4(a</U>)&nbsp;or <B><U>&lrm;</U></B><U>Section&nbsp;5.4(c)</U>&nbsp;by
the Company, any of its Subsidiaries or any of its or their respective Representatives, and (y)&nbsp;the Company Board determines in good
faith, after consultation with the Company&rsquo;s outside legal counsel and its financial advisor, constitutes or may reasonably be expected
to lead to a Company Superior Proposal and that failure to engage in such discussions or negotiations, or provide such information, would
reasonably be expected to be inconsistent with the Company Board&rsquo;s fiduciary duties to the Company and its stockholders under applicable
Law, the Company and its Representatives may, following receipt of an executed customary confidentiality agreement with nondisclosure
provisions that are at least as restrictive of such Third Party as the Confidentiality Agreement (except for such changes specifically
necessary in order for the Company to be able to comply with its obligations under this Agreement) and that does not prohibit compliance
by the Company with this <B><U>&lrm;</U></B><U>Section&nbsp;5.4</U>: (i)&nbsp;furnish information with respect to the Company and its
Subsidiaries to such Third Party making such Company Acquisition Proposal and (ii)&nbsp;participate in discussions or negotiations with
such Third Party and its Representatives regarding such Company Acquisition Proposal; <U>provided</U>, that the Company shall promptly
(and in no event later than 24 hours after its receipt of such Company Acquisition Proposal) provide or make available to Parent any material
non-public information concerning the Company or any of its Subsidiaries that is provided to the Person making such Company Acquisition
Proposal or its Representatives which was not previously provided or made available to Parent. If the Company receives a Company Acquisition
Proposal, then the Company shall promptly (and in no event later than 24 hours after its receipt of such Company Acquisition Proposal)
notify Parent in writing of such Company Acquisition Proposal (which notification shall include the identity of the Person making or submitting
such request or Company Acquisition Proposal and an unredacted copy of any such written request or proposal (or, if not in writing, a
written summary of the material terms and conditions thereof)), together with copies of any proposed transaction agreements, and the Company
shall thereafter keep Parent reasonably informed in writing, on a current basis (and, in any event, within 24 hours), of the status of
such Company Acquisition Proposal, including informing Parent of any material change to the terms of such Company Acquisition Proposal,
and the status of any negotiations, including any change in its intentions as previously notified.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 69; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Subject
to the permitted actions contemplated by clauses <B><U>&lrm;</U></B><U>(d)</U>&nbsp;and <B><U>&lrm;</U></B><U>(e)</U>&nbsp;below, and
<B><U>&lrm;</U></B><U>Section&nbsp;7.1(c)(ii</U>), neither the Company Board nor any committee thereof shall (i)&nbsp;withdraw, change,
qualify, withhold, amend or modify in a manner adverse to Parent or Merger Sub, or publicly propose to withdraw, change, qualify, withhold,
amend or modify in a manner adverse to Parent or Merger Sub, the Company Board Recommendation, (ii)&nbsp;adopt, approve, recommend, or
publicly propose to adopt, approve or recommend, any Company Acquisition Proposal or Company Alternative Acquisition Agreement, (iii)&nbsp;fail
to include the Company Board Recommendation in the Joint Proxy Statement/Prospectus, (iv)&nbsp;in the event a tender offer that constitutes
a Company Acquisition Proposal subject to Regulation 14D under the Exchange Act is commenced, fail to recommend against such Company Acquisition
Proposal in any solicitation or recommendation statement made on Schedule 14D-9 within ten (10)&nbsp;Business Days of such commencement
(and in no event later than one (1)&nbsp;Business Day prior to the date of the Company Stockholder Meeting, as it may be postponed or
adjourned pursuant to <B><U>&lrm;</U></B><U>Section&nbsp;5.6(b)</U>), or (v)&nbsp;if requested by Parent, fail to issue, within ten (10)&nbsp;Business
Days after a Company Acquisition Proposal is publicly announced (and in no event later than one (1)&nbsp;Business Day prior to the date
of the Company Stockholder Meeting, as it may be postponed or adjourned pursuant to <B><U>&lrm;</U></B><U>Section&nbsp;5.6(b)</U>), a
press release reaffirming the Company Board Recommendation (any of such action in clauses (i)-(v), an &ldquo;<U>Company Adverse Recommendation
Change</U>&rdquo;), (vi)&nbsp;cause or permit the Company or any of its Subsidiaries to enter into or agree to any letter of intent, memorandum
of understanding or similar document, agreement in principle, acquisition agreement, merger agreement, or other similar agreement or commitment
(other than a confidentiality agreement referred to in <B><U>&lrm;</U></B><U>Section&nbsp;5.4(b)</U>&nbsp;entered into in compliance with
<B><U>&lrm;</U></B><U>Section&nbsp;5.4(b)</U>) relating to any Company Acquisition Proposal (a &ldquo;<U>Company Alternative Acquisition
Agreement</U>&rdquo;) or (vii)&nbsp;take any action to make the provisions of any anti-takeover or similar statute or regulation inapplicable
to any Company Acquisition Proposal or counterparty thereto; <U>provided</U>, that delivery of a written notice to Parent as contemplated
by paragraph <B><U>&lrm;</U></B><U>(d)</U>&nbsp;below, or public disclosure that such notice has been delivered to Parent, shall not be
deemed to constitute an Company Adverse Recommendation Change or otherwise a violation of this clause (c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Notwithstanding
anything to the contrary set forth in this <B><U>&lrm;</U></B><U>Section&nbsp;5.4</U>, following receipt of a written Company Acquisition
Proposal by the Company after the date of this Agreement that did not result from a breach of this <B><U>&lrm;</U></B><U>Section&nbsp;5.4</U>,
and that has not been withdrawn, the Company Board may, at any time prior to the Company Stockholders Meeting, make a Company Adverse
Recommendation Change and authorize the Company to terminate this Agreement to enter into a Company Alternative Acquisition Agreement
with respect to such Company Superior Proposal in accordance with <B><U>&lrm;</U></B><U>Section&nbsp;7.1(c)(ii)</U>, or authorize, resolve,
agree or propose publicly to take any such action, if all of the following conditions are met prior to making such Company Adverse Recommendation
Change:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 70; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">the
Company Board determines in good faith, after consultation with the Company&rsquo;s outside legal counsel and its financial advisor, that
such Company Acquisition Proposal constitutes a Company Superior Proposal and that failure to take such action would reasonably be expected
to be inconsistent with the Company Board&rsquo;s fiduciary duties to its stockholders under applicable Law;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">(A)&nbsp;the
Company shall have provided to Parent five Business Days&rsquo; prior written notice (the &ldquo;<U>Company Superior Proposal Notice</U>&rdquo;),
which shall state expressly (1)&nbsp;that it has received a written Company Acquisition Proposal that constitutes a Company Superior Proposal,
(2)&nbsp;an unredacted copy of such Company Acquisition Proposal (or, if not in writing, the material terms and conditions thereof, including
the consideration offered therein and the identity of the Person or group making the Company Acquisition Proposal) and shall have contemporaneously
provided an unredacted copy of the Company Alternative Acquisition Agreement and all other documents (other than immaterial documents)
related to the Company Superior Proposal (it being understood and agreed that any amendment to the financial terms or any other material
term or condition of such Company Superior Proposal shall require a new notice and an additional two Business Day period) and (3)&nbsp;that,
subject to <U>clause <B><I>&lrm;</I></B>(iii)</U>&nbsp;below, the Company Board has determined to make a Company Adverse Recommendation
Change or to terminate this Agreement in accordance with <B><I><U>&lrm;</U></I></B><U>Section&nbsp;7.1(c)(ii)</U>&nbsp;in order to enter
into the Company Alternative Acquisition Agreement, as applicable and (B)&nbsp;prior to making such Company Adverse Recommendation Change
or terminating this Agreement in accordance with <B><I><U>&lrm;</U></I></B><U>Section&nbsp;7.1(c)(ii)</U>, as applicable, (x)&nbsp;the
Company shall have used commercially reasonable efforts to engage in good faith with Parent (to the extent Parent wishes to engage) during
such notice period commencing on the delivery of the Company Superior Proposal Notice, to consider any adjustments proposed by Parent
to the terms and conditions of this Agreement such that the Company Alternative Acquisition Agreement ceases to constitute a Company Superior
Proposal and (y)&nbsp;in determining whether to make an Company Adverse Recommendation Change or to effect a termination in accordance
with <B><I><U>&lrm;</U></I></B><U>Section&nbsp;7.1(c)(ii)</U>, the Company Board shall have taken into account any changes to the terms
of this Agreement proposed by Parent and any other information provided by Parent in response to such notice; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">following
the end of such five Business Day period (as such period may be extended in accordance with clause <B><I>&lrm;</I></B>(ii)&nbsp;above),
the Company Board shall have determined, in good faith, after consultation with its financial advisors and outside legal counsel, that,
in light of such Company Superior Proposal and taking into account any revised terms proposed by Parent, such Company Superior Proposal
continues to constitute a Company Superior Proposal and that the failure to make such Company Adverse Recommendation Change or to so terminate
this Agreement in accordance with <B><I><U>&lrm;</U></I></B><U>Section&nbsp;7.1(c)(ii)</U>, as applicable, would reasonably be expected
to be inconsistent with the directors&rsquo; fiduciary duties under applicable Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Notwithstanding
anything to the contrary set forth in this <B><I><U>&lrm;</U></I></B><U>Section&nbsp;5.4</U>, upon the occurrence of any Company Intervening
Event, the Company Board may, at any time prior to the Company Stockholders Meeting, make a Company Adverse Recommendation Change that
is not related to a Company Acquisition Proposal if all of the following conditions are met:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 71; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">prior
to making such Company Adverse Recommendation Change, (1)&nbsp;the Company Board determines in good faith, after consultation with its
outside legal counsel and its financial advisor, that, in light of such Company Intervening Event, a failure to effect a Company Adverse
Recommendation Change would be reasonably expected to be inconsistent with the Company Board&rsquo;s fiduciary duties to its stockholders
under applicable Law, (2)&nbsp;the Company shall have (A)&nbsp;provided to Parent five Business Days&rsquo; prior written notice, which
shall (1)&nbsp;set forth in reasonable detail information describing the Company Intervening Event and the rationale for the Company Adverse
Recommendation Change and (2)&nbsp;state expressly that, subject to <U>clause <B><I>&lrm;</I></B>(ii)</U>&nbsp;below, the Company Board
has determined to make an Company Adverse Recommendation Change and (B)&nbsp;prior to making such an Company Adverse Recommendation Change,
used commercially reasonable efforts to engage in good faith with Parent (to the extent Parent wishes to engage) during such five Business
Day period to consider any adjustments proposed by Parent to the terms and conditions of this Agreement such that the failure of the Company
Board to make an Company Adverse Recommendation Change in response to the Company Intervening Event in accordance with <U>clause <B><I>&lrm;</I></B>(ii)</U>&nbsp;below
would no longer reasonably be expected to be inconsistent with the directors&rsquo; fiduciary duties under applicable Law; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">following
the end of such five Business Day period, the Company Board shall have determined in good faith, after consultation with its outside legal
counsel, that in light of such Company Intervening Event and taking into account any revised terms proposed by Parent, the failure to
make a Company Adverse Recommendation Change would reasonably be expected to be inconsistent with the directors&rsquo; fiduciary duties
under applicable Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Company promptly (and in any event within 48 hours) shall advise Parent orally and in writing of (i)&nbsp;any written Company Acquisition
Proposal, (ii)&nbsp;any written request for non-public information relating to the Company or its Subsidiaries, other than requests for
information not reasonably expected to be related to a Company Acquisition Proposal and (iii)&nbsp;any written inquiry or request for
discussion or negotiation regarding a Company Acquisition Proposal, including in each case the identity of the Person making any such
Company Acquisition Proposal, inquiry or request and the material terms of any such Company Acquisition Proposal, inquiry or request and
thereafter shall keep Parent informed, on a current basis, of the status and terms of any such proposals or offers and the status of any
such discussions or negotiations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Nothing
set forth in this Agreement shall prevent the Company or the Company Board from (i)&nbsp;taking and disclosing to its stockholders a position
contemplated by Rule&nbsp;14e-2(a), Rule&nbsp;14d-9 or Item 1012(a)&nbsp;of Regulation M-A promulgated under the Exchange Act (or any
similar communication to stockholders in connection with the making or amendment of a tender offer or exchange offer) or from (ii)&nbsp;making
any required disclosure to the Company&rsquo;s stockholders if, in the good faith judgment of the Company Board, after consultation with
outside counsel, failure to disclose such information would reasonably be expected to violate its obligations under applicable Law; <I>provided</I>,
<I>however</I>, that in the case of either clause (i)&nbsp;or clause (ii), no such communication or statement that would constitute a
Company Adverse Recommendation Change shall be permitted, made or taken except in accordance with <B><I><U>&lrm;</U></I></B><U>Section&nbsp;5.4(d)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 72; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Any
breach of the restrictions contained in this <B><I><U>&lrm;</U></I></B><U>Section&nbsp;5.4</U> by any of the Company&rsquo;s Subsidiaries,
or any Representatives of the Company or any of its Subsidiaries, shall be deemed to be a breach of this <B><I><U>&lrm;</U></I></B><U>Section&nbsp;5.4</U>
by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">As
used in this Agreement:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<U>Company
Acquisition Proposal</U>&rdquo; means any inquiry, proposal or offer from any Person or group of Persons other than Parent or one of its
Subsidiaries for (A)&nbsp;a merger, reorganization, consolidation, share exchange, business combination, recapitalization, liquidation,
dissolution or similar transaction involving an acquisition of the Company (or any Subsidiary or Subsidiaries of the Company whose business
constitutes 20% or more of the net revenues, net income or assets of the Company and its Subsidiaries, taken as a whole) or (B)&nbsp;the
acquisition in any manner, directly or indirectly, of over 20% of the equity securities, voting power or consolidated total assets of
the Company and its Subsidiaries, in each case other than the Merger and the other transactions contemplated by this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<U>Company
Intervening Event</U>&rdquo; means an Effect that arises following the date hereof that (A)(x)&nbsp;was not known to, or reasonably foreseeable
by, the Company Board prior to the execution of this Agreement (or if known or reasonably foreseeable, the material consequences of which
were not known or reasonably foreseeable), which Effect becomes known to, or reasonably foreseeable by, the Company Board prior to the
Company Stockholders Meeting, and (y)&nbsp;is material to the Company and its Subsidiaries (taken as a whole), and (B)&nbsp;does not relate
to (x)&nbsp;a Company Acquisition Proposal or a Company Superior Proposal or any inquiry or communications relating thereto, any matter
relating thereto or consequences thereof, and (y)&nbsp; in each case in and of itself, any changes in the market price or trading volume
of Company Shares or the fact that the Company meets, fails to meet or exceeds any internal or published projections, forecasts or estimates
of its revenue, earnings or other financial performance or results of operations for any period (it&nbsp;being understood, however, that
any underlying cause of any of the foregoing may be taken into account unless excluded pursuant to clause (A)).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<U>Company
Superior Proposal</U>&rdquo; means any bona fide written Company Acquisition Proposal (A)&nbsp;on terms which the Company Board determines
in good faith, after consultation with the Company&rsquo;s outside legal counsel and financial advisors, to be more favorable from a financial
point of view (including taking into account payment by the Company of the Company Termination Fee) to the holders of Company Shares than
the Merger and the other transactions contemplated by this Agreement (after giving effect to any revisions to the terms of the Agreement
committed to in writing by Parent in response to such Company Acquisition Proposal pursuant to <B><I><U>&lrm;</U></I></B><U>Section&nbsp;5.4(d)</U>),
taking into account all the terms and conditions of such proposal, including the timing, likelihood of consummation, confidentiality,
legal, financial, regulatory, financing and other aspects of such Company Acquisition Proposal, and this Agreement and (B)&nbsp;that the
Company Board believes in good faith, after consultation with the Company&rsquo;s outside legal counsel and financial advisors, is reasonably
capable of being completed on the terms proposed, taking into account all financial, regulatory, legal and other aspects of such proposal;
<U>provided</U>, that for purposes of the definition of &ldquo;Company Superior Proposal,&rdquo; the references to &ldquo;20%&rdquo; in
the definition of Company Acquisition Proposal shall be deemed to be references to &ldquo;50%.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 73; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;5.5</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>No
Solicitation by Parent</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">From
the date of this Agreement until the earlier of the Effective Time and the valid termination of this Agreement in accordance with <B><U>&lrm;</U></B><U>Section&nbsp;7.1</U>,
except as expressly permitted by this <B><U>&lrm;</U></B><U>Section&nbsp;5.5</U>, Parent agrees that neither it nor any of its Subsidiaries
shall, and that it shall not, and shall cause its Subsidiaries and direct its and their respective Representatives not to, directly or
indirectly, (i)&nbsp;initiate, solicit, knowingly assist, knowingly induce or knowingly encourage or facilitate (including by providing
information) any inquiries, proposals or offers with respect to, or the making, submission, announcement or completion of, any proposal
or offer that constitutes, or would be reasonably expected to lead to, a Parent Acquisition Proposal or (ii)&nbsp;engage in, continue
or participate in any negotiations or discussions with any Third Party (other than to refer the inquiring Person to this <B><U>&lrm;</U></B><U>Section&nbsp;5.5</U>)
concerning any Parent Acquisition Proposal or any inquiry, proposal or offer that would reasonably be expected to lead to any Parent Acquisition
Proposal, (iii)&nbsp;furnish or provide or cause to be furnished or provided any non-public information or data relating to Parent or
any of its Subsidiaries in connection with, or for the purpose of soliciting, initiating, encouraging or facilitating, or in response
to, any inquiry, proposal or offer that constitutes of would reasonably be expected to lead to a Parent Acquisition Proposal, or (iv)&nbsp;resolve
or agree to do any of the foregoing. Parent agrees that it will, and will cause its Subsidiaries and direct its and their respective Representatives
to, (x)&nbsp;immediately cease and cause to be terminated any existing activities, discussions or negotiations with any Third Party conducted
heretofore with respect to any Parent Acquisition Proposal, (y)&nbsp;deliver a written notice to any such Third Party explicitly stating
that Parent is terminating all discussions and negotiations with such Third Party with respect to any Parent Acquisition Proposal, and
requesting that such Third Party promptly return or destroy all confidential or proprietary information concerning Parent and its Subsidiaries,
and (z)&nbsp;promptly terminate access of any such Third Party to any due diligence or electronic or physical data room with respect to
any Parent Acquisition Proposal; <U>provided</U>, that nothing in this Agreement shall restrict Parent from permitting a Person to request
the waiver of a &ldquo;standstill&rdquo; or similar obligation or from granting such a waiver, in each case to the extent necessary to
comply with fiduciary duties under applicable Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Notwithstanding
anything to the contrary in <B><U>&lrm;</U></B><U>Section&nbsp;5.5(a)</U>, at any time prior to obtaining the Parent Stockholder Approval,
in response to an unsolicited bona fide written Parent Acquisition Proposal from a Third Party made after the date hereof that (x)&nbsp;did
not result from a material breach of <B><U>&lrm;</U></B><U>Section&nbsp;5.5(a</U>)&nbsp;or <B><U>&lrm;</U></B><U>Section&nbsp;5.5(c)</U>&nbsp;by
Parent, any of its Subsidiaries or any of its or their respective Representatives, and (y)&nbsp;Parent Board determines in good faith,
after consultation with Parent&rsquo;s outside legal counsel and its financial advisor, constitutes or may reasonably be expected to lead
to a Parent Superior Proposal and that failure to engage in such discussions or negotiations, or provide such information, would reasonably
be expected to be inconsistent with Parent Board&rsquo;s fiduciary duties to Parent and its stockholders under applicable Law, Parent
and its Representatives may, following receipt of an executed customary confidentiality agreement with nondisclosure provisions that are
at least as restrictive of such Third Party as the Confidentiality Agreement (except for such changes specifically necessary in order
for Parent to be able to comply with its obligations under this Agreement) and that does not prohibit compliance by Parent with this <B><U>&lrm;</U></B><U>Section&nbsp;5.5(b)</U>&nbsp;(i)&nbsp;furnish
information with respect to Parent and its Subsidiaries such Third Party making such Parent Acquisition Proposal and (ii)&nbsp;participate
in discussions or negotiations with such Third Party and its Representatives regarding such Parent Acquisition Proposal; <U>provided</U>,
that Parent shall promptly (and in no event later than 24 hours after its receipt of such Parent Acquisition Proposal) provide or make
available to the Company any material non-public information concerning Parent or any of its Subsidiaries prior to or substantially concurrently
with the provision of such information to the Person making such Parent Acquisition Proposal or its Representatives which was not previously
provided or made available to the Company. If Parent receives a Parent Acquisition Proposal, then Parent shall promptly (and in no event
later than 24 hours after its receipt of such Parent Acquisition Proposal) notify the Company in writing of such Parent Acquisition Proposal
(which notification shall include the identity of the Person making or submitting such request or Parent Acquisition Proposal and an unredacted
copy of any such written request or proposal (or, if not in writing, a written summary of the material terms and conditions thereof)),
together with copies of any proposed transaction agreements, and Parent shall thereafter keep the Company reasonably informed in writing,
on a current basis (and, in any event, within 24 hours), of the status of such Parent Acquisition Proposal, including informing the Company
of any material change to the terms of such Parent Acquisition Proposal, and the status of any negotiations, including any change in its
intentions as previously notified.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 74; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Subject
to the permitted actions contemplated by clauses <B>&lrm;</B>(d)&nbsp;and <B>&lrm;</B>(e)&nbsp;below, and <B><U>&lrm;</U></B><U>Section&nbsp;7.1(d)(ii</U>),
neither the Parent Board nor any committee thereof shall (i)&nbsp;withdraw, change, qualify, withhold, amend or modify in a manner adverse
to the Company, or publicly propose to withdraw, change, qualify, withhold, amend or modify in a manner adverse to the Company, the Parent
Board Recommendation, (ii)&nbsp;adopt, approve, recommend, or publicly propose to adopt, approve or recommend, any Parent Acquisition
Proposal or Parent Alternative Acquisition Agreement, (iii)&nbsp;fail to include the Parent Board Recommendation in the Joint Proxy Statement/Prospectus,
(iv)&nbsp;in the event a tender offer that constitutes a Parent Acquisition Proposal subject to Regulation 14D under the Exchange Act
is commenced, fail to recommend against such Parent Acquisition Proposal in any solicitation or recommendation statement made on Schedule
14D09 within (10)&nbsp;Business Days of such commencement (and in no event later than one (1)&nbsp;Business Day prior to the date of the
Parent Stockholder Meeting, as it may be postponed or adjourned pursuant to <B><U>&lrm;</U></B><U>Section&nbsp;5.6(c</U>)) or (v)&nbsp;if
requested by the Company, fail to issue, within ten (10)&nbsp;Business Days after a Parent Acquisition Proposal is publicly announced
(and in no event later than one (1)&nbsp;Business Day prior to the date of the Parent Stockholder Meeting, as it may be postponed or adjourned
pursuant to <B><U>&lrm;</U></B><U>Section&nbsp;5.6(c</U>)), a press release reaffirming the Parent Board Recommendation (any of such action
in clauses (i)-(v), a &ldquo;<U>Parent Adverse Recommendation Change</U>&rdquo;); (vi)&nbsp;cause or permit Parent or any of its Subsidiaries
to enter into or agree to any letter of intent, memorandum of understanding or similar document, agreement in principle, acquisition agreement,
merger agreement, or other similar agreement or commitment (other than a confidentiality agreement referred to in <B><U>&lrm;</U></B><U>Section&nbsp;5.5(b</U>)&nbsp;entered
into in compliance with <B><U>&lrm;</U></B><U>Section&nbsp;5.5(b</U>)) relating to any Parent Acquisition Proposal (a &ldquo;<U>Parent
Alternative Acquisition Agreement</U>&rdquo;) or (vii)&nbsp;take any action to make the provisions of any anti-takeover or similar statute
or regulation inapplicable to any Parent Acquisition Proposal or counterparty thereto; provided, that delivery of a written notice to
the Company as contemplated by paragraph <B>&lrm;</B>(d)&nbsp;below, or public disclosure that such notice has been delivered to the Company,
shall not be deemed to constitute a Parent Adverse Recommendation Change or otherwise a violation of this clause (c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Notwithstanding
anything to the contrary set forth in this <B><U>&lrm;</U></B><U>Section&nbsp;5.5</U>, following receipt of a written Parent Acquisition
Proposal by Parent after the date of this Agreement that did not result from a breach of this <B><U>&lrm;</U></B><U>Section&nbsp;5.5</U>
and has not been withdrawn the Parent Board may, at any time prior to the Parent Stockholders Meeting, make a Parent Adverse Recommendation
Change and authorize Parent to terminate this Agreement to enter into a Parent Alternative Acquisition Agreement with respect to such
Parent Superior Proposal in accordance with <B><U>&lrm;</U></B><U>Section&nbsp;7.1(d)(ii)</U>, or authorize, resolve, agree or propose
publicly to take any such action, if all of the following conditions are met prior to making such Parent Adverse Recommendation Change:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 75; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">the
Parent Board determines in good faith, after consultation with the Parent&rsquo;s outside legal counsel and its financial advisor, that
such Parent Acquisition Proposal constitutes a Parent Superior Proposal and that failure to take such action would reasonably be expected
to be inconsistent with the Parent Board&rsquo;s fiduciary duties to its stockholders under applicable Law;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">(A)&nbsp;Parent
shall have provided to the Company five Business Days&rsquo; prior written notice (the &ldquo;<U>Parent Superior Proposal Notice</U>&rdquo;),
which shall state expressly (1)&nbsp;that it has received a written Parent Acquisition Proposal that constitutes a Parent Superior Proposal,
(2)&nbsp;an unredacted copy of such Parent Acquisition Proposal (or, if not in writing, the material terms and conditions thereof including
the consideration offered therein and the identity of the Person or group making the Parent Acquisition Proposal) and shall have contemporaneously
provided an unredacted copy of the Parent Alternative Acquisition Agreement and all other documents (other than immaterial documents)
related to the Parent Superior Proposal (it being understood and agreed that any amendment to the financial terms or any other material
term or condition of such Parent Superior Proposal shall require a new notice and an additional two Business Day period) and (3)&nbsp;that,
subject to clause <B><I>&lrm;</I></B>(iii)&nbsp;below, the Parent Board has determined to make an Parent Adverse Recommendation Change
or to terminate this Agreement in accordance with <B><I><U>&lrm;</U></I></B><U>Section&nbsp;7.1(d)(ii)</U>&nbsp;in order to enter into
the Parent Alternative Acquisition Agreement, as applicable and (B)&nbsp;prior to making such Parent Adverse Recommendation Change or
terminating this Agreement in accordance with <B><I><U>&lrm;</U></I></B><U>Section&nbsp;7.1(d)(ii)</U>, as applicable, (x)&nbsp;Parent
shall have used commercially reasonable efforts to engage in good faith with the Company (to the extent the Company wishes to engage)
during such notice period commencing on the delivery of the Parent Superior Proposal Notice, to consider any adjustments proposed by the
Company to the terms and conditions of this Agreement such that the Parent Alternative Acquisition Agreement ceases to constitute a Parent
Superior Proposal and (y)&nbsp;in determining whether to make a Parent Adverse Recommendation Change or to effect a termination in accordance
with <B><I><U>&lrm;</U></I></B><U>Section&nbsp;7.1(d)(ii)</U>, the Parent Board shall have taken into account any changes to the terms
of this Agreement proposed by the Company and any other information provided by the Company in response to such notice; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">following
the end of such five Business Day period (as such period may be extended in accordance with clause <B><I>&lrm;</I></B>(ii)&nbsp;above),
the Parent Board shall have determined, in good faith, after consultation with its financial advisors and outside legal counsel, that,
in light of such Parent Superior Proposal and taking into account any revised terms proposed by the Company, such Parent Superior Proposal
continues to constitute a Parent Superior Proposal and that the failure to make such Parent Adverse Recommendation Change or to so terminate
this Agreement in accordance with <B><I><U>&lrm;</U></I></B><U>Section&nbsp;7.1(d)(ii)</U>, as applicable, would reasonably be expected
to be inconsistent with the directors&rsquo; fiduciary duties under applicable Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 76; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Notwithstanding
anything to the contrary set forth in this <B><U>&lrm;</U></B><U>Section&nbsp;5.5</U>, upon the occurrence of any Parent Intervening Event,
the Parent Board may, at any time prior to the Parent Stockholders Meeting, make a Parent Adverse Recommendation Change that is not related
to a Parent Acquisition Proposal if all of the following conditions are met:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">prior
to making such Parent Adverse Recommendation Change, (1)&nbsp;the Parent Board determines in good faith, after consultation with its outside
legal counsel and its financial advisor, that, in light of such Parent Intervening Event, a failure to effect a Parent Adverse Recommendation
Change would be reasonably expected to be inconsistent with the Parent Board&rsquo;s fiduciary duties to its stockholders under applicable
Law, (2)&nbsp;Parent shall have (A)&nbsp;provided to the Company five Business Days&rsquo; prior written notice, which shall (1)&nbsp;set
forth in reasonable detail information describing the Parent Intervening Event and the rationale for the Parent Adverse Recommendation
Change and (2)&nbsp;state expressly that, subject to clause <B><I>&lrm;</I></B>(ii)&nbsp;below, the Parent Board has determined to make
a Parent Adverse Recommendation Change and (B)&nbsp;prior to making such a Parent Adverse Recommendation Change, used commercially reasonable
efforts to engage in good faith with the Company (to the extent the Company wishes to engage) during such five Business Day period to
consider any adjustments proposed by the Company to the terms and conditions of this Agreement such that the failure of the Parent Board
to make a Parent Adverse Recommendation Change in response to the Parent Intervening Event in accordance with clause <B><I>&lrm;</I></B>(ii)&nbsp;below
would no longer reasonably be expected to be inconsistent with the directors&rsquo; fiduciary duties under applicable Law; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">following
the end of such five Business Day period, the Parent Board shall have determined in good faith, after consultation with its outside legal
counsel, that in light of such Parent Intervening Event and taking into account any revised terms proposed by the Company, the failure
to make a Parent Adverse Recommendation Change would reasonably be expected to be inconsistent with the directors&rsquo; fiduciary duties
under applicable Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Parent
promptly (and in any event within 48 hours) shall advise the Company orally and in writing of (i)&nbsp;any written Parent Acquisition
Proposal, (ii)&nbsp;any written request for non-public information relating to Parent or its Subsidiaries, other than requests for information
not reasonably expected to be related to a Parent Acquisition Proposal and (iii)&nbsp;any written inquiry or request for discussion or
negotiation regarding a Parent Acquisition Proposal, including in each case the identity of the Person making any such Parent Acquisition
Proposal, inquiry or request and the material terms of any such Parent Acquisition Proposal, inquiry or request and thereafter shall keep
the Company informed, on a current basis, of the status and terms of any such proposals or offers and the status of any such discussions
or negotiations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Nothing
set forth in this Agreement shall prevent Parent or the Parent Board from (i)&nbsp;taking and disclosing to its stockholders a position
contemplated by Rule&nbsp;14e-2(a), Rule&nbsp;14d-9 or Item 1012(a)&nbsp;of Regulation M-A promulgated under the Exchange Act (or any
similar communication to stockholders in connection with the making or amendment of a tender offer or exchange offer) or from (ii)&nbsp;making
any required disclosure to Parent&rsquo;s stockholders if, in the good faith judgment of the Parent Board, after consultation with outside
counsel, failure to disclose such information would reasonably be expected to violate its obligations under applicable Law; <I>provided</I>,
<I>however</I>, that in the case of either clause (i)&nbsp;or clause (ii), no such communication or statement that would constitute a
Parent Adverse Recommendation Change shall be permitted, made or taken except in accordance with <B><U>&lrm;</U></B><U>Section&nbsp;5.5(d)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 77; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Any
breach of the restrictions contained in this <B><U>&lrm;</U></B><U>Section&nbsp;5.5</U> by any of the Parent&rsquo;s Subsidiaries, or
any Representatives of the Parent or any of its Subsidiaries, shall be deemed to be a breach of this <B><U>&lrm;</U></B><U>Section&nbsp;5.5</U>
by Parent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">As
used in this Agreement:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<U>Parent
Acquisition Proposal</U>&rdquo; means any inquiry, proposal or offer from any Person or group of Persons other than the Company or one
of its Subsidiaries for (A)&nbsp;a merger, reorganization, consolidation, share exchange, business combination, recapitalization, liquidation,
dissolution or similar transaction involving an acquisition of Parent (or any Subsidiary or Subsidiaries of Parent whose business constitutes
20% or more of the net revenues, net income or assets of Parent and its Subsidiaries, taken as a whole) or (B)&nbsp;the acquisition in
any manner, directly or indirectly, of over 20% of the equity securities, voting power or consolidated total assets of Parent and its
Subsidiaries, in each case other than the Merger and the other transactions contemplated by this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<U>Parent
Intervening Event</U>&rdquo; means an Effect that arises following the date hereof that (A)&nbsp;(x)&nbsp;was not known to, or reasonably
foreseeable by, the Parent Board prior to the execution of this Agreement (or if known or reasonably foreseeable, the material consequences
of which were not known or reasonably foreseeable), which Effect becomes known to, or reasonably foreseeable by, the Parent Board prior
to the Parent Stockholders Meeting, and (y)&nbsp;is material to Parent and its Subsidiaries (taken as a whole), and (B)&nbsp;does not
relate to (x)&nbsp;a Parent Acquisition Proposal or a Parent Superior Proposal or any inquiry or communications relating thereto, any
matter relating thereto or consequences thereof, and (y)&nbsp; in each case in and of itself, any changes in the market price or trading
volume of shares of Parent Common Stock or the fact that Parent meets, fails to meet or exceeds any internal or published projections,
forecasts or estimates of its revenue, earnings or other financial performance or results of operations for any period (it&nbsp;being
understood, however, that any underlying cause of any of the foregoing may be taken into account unless excluded pursuant to clauses (A)).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<U>Parent
Superior Proposal</U>&rdquo; means any bona fide written Parent Acquisition Proposal (A)&nbsp;on terms which the Parent Board determines
in good faith, after consultation with Parent&rsquo;s outside legal counsel and financial advisors, to be more favorable from a financial
point of view (including taking into account payment by Parent of the Parent Termination Fee) to the holders of shares of Parent Common
Stock than the Merger and the other transactions contemplated by this Agreement (after giving effect to any revisions to the terms of
the Agreement committed to in writing by the Company in response to such Parent Acquisition Proposal pursuant to <B><I><U>&lrm;</U></I></B><U>Section&nbsp;5.5(d)</U>),
taking into account all the terms and conditions of such proposal, including the timing, likelihood of consummation, confidentiality,
legal, financial, regulatory, financing and other aspects of such Parent Acquisition Proposal, and this Agreement and (B)&nbsp;that the
Parent Board believes in good faith, after consultation with the Parent&rsquo;s outside legal counsel and financial advisors, is reasonably
capable of being completed on the terms proposed, taking into account all financial, regulatory, legal and other aspects of such proposal;
<U>provided</U>, that for purposes of the definition of &ldquo;Parent Superior Proposal,&rdquo; the references to &ldquo;20%&rdquo; in
the definition of Parent Acquisition Proposal shall be deemed to be references to &ldquo;50%.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 78; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;5.6</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Preparation
of Form&nbsp;S-4 and Joint Proxy Statement/Prospectus; Stockholders&rsquo; Meetings</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">As
promptly as practicable after the date of this Agreement (and in any event within 40 calendar days after the date hereof; <I>provided</I>,
that such date may be extended by an additional 20 calendar days to the extent mutually agreed by Parent and the Company), the Company
and Parent shall (i)&nbsp;prepare and file with the SEC a joint proxy statement (as amended or supplemented from time to time, the &ldquo;<U>Joint
Proxy Statement/Prospectus</U>&rdquo;) to be sent to the stockholders of the Company relating to the special meeting of the Company&rsquo;s
stockholders (the &ldquo;<U>Company Stockholders Meeting</U>&rdquo;) to be held to consider the adoption of this Agreement and the special
meeting of Parent&rsquo;s stockholders (the &ldquo;<U>Parent Stockholders Meeting</U>&rdquo;) to be held to consider the approval of the
Parent Stock Issuance and (ii)&nbsp;prepare, and Parent shall cause to be filed with the SEC, the Form&nbsp;S-4, in which the Joint Proxy
Statement/Prospectus will be included as a prospectus, in connection with the registration under the Securities Act of the shares of Parent
Common Stock subject to the Parent Stock Issuance. The parties shall consult each other in connection with setting a preliminary record
date for each of the Company Stockholders Meeting and the Parent Stockholders Meeting and shall commence a broker searches pursuant to
Section&nbsp;14a-13 of the Exchange Act in connection therewith. Each of the Company and Parent shall use its reasonable best efforts
to have the Form&nbsp;S-4 declared effective under the Securities Act as promptly as practicable after such filing and to keep the Form&nbsp;S-4
effective as long as is necessary to consummate the Merger and the other transactions contemplated hereby. Parent shall also use its reasonable
best efforts to take any action (other than qualifying to do business in any jurisdiction in which it is not now so qualified or filing
a general consent to service of process) required to be taken under any applicable state securities or &ldquo;blue sky&rdquo; laws in
connection with the Parent Stock Issuance and the Company shall furnish all information concerning the Company and the holders of Company
Shares as may be reasonably requested in connection with any such action. Each of the Company and Parent shall use reasonable best efforts
to cause the Joint Proxy Statement/Prospectus to be mailed to the Company&rsquo;s and Parent&rsquo;s stockholders as promptly as practicable
after the Form&nbsp;S-4 is declared effective under the Securities Act. No filing or mailing of, or amendment or supplement to, the Form&nbsp;S-4
or the Joint Proxy Statement/Prospectus, or any substantive correspondence (including all responses to SEC comments) will be made by Parent
or the Company, as applicable, without providing the other a reasonable opportunity to review and comment thereon (which comments the
receiving party will consider in good faith) and without the other&rsquo;s prior approval (which shall not be unreasonably withheld).
Parent or the Company, as applicable, will advise the other promptly after it receives oral or written notice thereof, of the time when
the Form&nbsp;S-4 has become effective or any amendment or supplement thereto has been filed, the issuance of any stop order, the suspension
of the qualification of the Parent Common Stock issuable in the Parent Stock Issuance for offering or sale in any jurisdiction or any
oral or written request by the SEC for amendment of the Joint Proxy Statement/Prospectus or the Form&nbsp;S-4 or comments thereon and
responses thereto or requests by the SEC for additional information, and will promptly provide the other with copies of any written communication
from the SEC or any state securities commission and a reasonable opportunity to participate in the responses thereto. If at any time prior
to the Effective Time the Company or Parent shall discover or become aware of any information relating to the Company or Parent, or any
of their respective Affiliates, officers or directors that should be disclosed in an amendment or supplement to any of the Form&nbsp;S-4
or the Joint Proxy Statement/Prospectus, so that any of such documents would not contain any misstatement of a material fact or omit to
state any material fact necessary to make the statements therein, in light of the circumstances under which they were made, not false
or misleading, then such party that discovers or becomes aware of such information (A)&nbsp;shall promptly notify the other parties hereto
and an appropriate amendment or supplement describing such information shall promptly be filed with the SEC in accordance with this <B><U>&lrm;</U></B><U>Section&nbsp;5.6</U>
and, to the extent required under applicable Law, disseminated to stockholders of the Company and Parent; <U>provided</U> that the delivery
of such notice and the filing of any such amendment or supplement shall not affect or be deemed to modify any representation or warranty
made by any party hereunder or otherwise affect the remedies available hereunder to any party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 79; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">As
promptly as practicable after the Form&nbsp;S-4 is declared effective under the Securities Act (and in any event within 45 days thereof),
the Company shall cause the Company Stockholders Meeting to be held, and the Company and Parent shall use reasonable best efforts to cause
the Company Stockholders Meeting and the Parent Stockholders Meeting to be held on the same date (and if, notwithstanding such efforts,
either the Parent Stockholders Meeting or the Company Stockholders Meeting is called for a date prior to such other meeting, the party
with the later meeting shall use its reasonable best efforts to cause the Parent Stockholders Meeting or Company Stockholders Meeting,
as applicable, to be held as promptly as reasonably practicable following the date of such earlier meeting), and the Company shall duly
call, give notice of, convene and hold the Company Stockholders Meeting for the purpose of obtaining the Company Stockholder Approval
and, if applicable, the advisory vote required by Rule&nbsp;14a-21(c)&nbsp;under the Exchange Act in connection therewith. The Company
may postpone or adjourn the Company Stockholders Meeting solely (i)&nbsp;with the consent of Parent; (ii)&nbsp;if required by applicable
Law or a request from the SEC, (iii)&nbsp;(A)&nbsp;due to the absence of a quorum necessary to conduct the business of the Company Stockholders
Meeting or (B)&nbsp;if the Company has not received proxies representing a sufficient number of Company Shares for the Company Stockholder
Approval, whether or not a quorum is present, to solicit additional proxies; or (iv)&nbsp;to the extent reasonably necessary to allow
reasonable additional time for the filing and mailing of any supplemental or amended disclosure which the Company Board has determined
in good faith after consultation with Parent and outside legal counsel is necessary under applicable Law and for such supplemental or
amended disclosure to be disseminated and reviewed by the Company&rsquo;s stockholders prior to the Company Stockholders Meeting; <U>provided</U>,
without the prior written consent of Parent (not to be unreasonably withheld, in the cases of clauses (ii)&nbsp;and (iv)), (x)&nbsp;no
single adjournment or postponement permitted hereunder (including by the immediately following sentence) shall be for more than five Business
Days, except as may be required by Law, (y)&nbsp;all such adjournments and postponements together shall not cause the date of the Company
Stockholder Meeting to be more than twenty (20) Business Days after the date for which the Company Stockholder Meeting was originally
scheduled or, in the case of clause (iii)&nbsp;above and the immediately following sentence, less than five (5)&nbsp;Business Days prior
to the Termination Date. In addition to the foregoing, the Company shall, at the request of Parent, to the extent permitted by Law, postpone
or adjourn the Company Stockholders Meeting to a date mutually agreed with Parent (subject to the limitations in the foregoing proviso,
except as may be mutually agreed with Parent) for the absence of a quorum or if the Company has not received proxies representing a sufficient
number of Company Shares for the Company Stockholder Approval; provided, that the Company shall not be required to adjourn the Company
Stockholders Meeting more than two (2)&nbsp;times pursuant to this sentence, and no such adjournment pursuant to this sentence shall be
required to be for a period exceeding ten (10)&nbsp;Business Days. Except in the case of a Company Adverse Recommendation Change specifically
permitted by, and adopted pursuant to the procedures set forth in, <B><U>&lrm;</U></B><U>Section&nbsp;5.4</U>, the Company, through the
Company Board, shall (i)&nbsp;recommend to its stockholders that they adopt this Agreement and the transactions contemplated hereby and
(ii)&nbsp;include such recommendation (including the Company Board Recommendation) in the Joint Proxy Statement/Prospectus. Without limiting
the generality of the foregoing, the Company agrees that, notwithstanding any Company Adverse Recommendation Change, unless this Agreement
is terminated in accordance with its terms, (x)&nbsp;the Company shall use its reasonable best efforts to solicit proxies to obtain the
Company Stockholder Approval and (y)&nbsp;the Company&rsquo;s obligations pursuant to this <B><U>&lrm;</U></B><U>Section&nbsp;5.6(b</U>)&nbsp;shall
not be affected by the commencement, public proposal, public disclosure or communication to the Company or any other Person of any Company
Acquisition Proposal or the occurrence of any Company Adverse Recommendation Change. The Company shall, on a daily basis, during the ten
(10)&nbsp;Business Days prior to the date of the Company Stockholder Meeting, advise Parent as to the aggregate number of Company Shares
entitled to vote at the Company Stockholder Meeting for which proxies have been received by the Company with respect to the Company Stockholder
Approval and the number of such proxies authorizing the holder thereof to vote in favor of the Company Stockholder Approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 80; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">As
promptly as practicable after the Form&nbsp;S-4 is declared effective under the Securities Act (and in any event within 45 days thereof),
Parent shall cause the Parent Stockholders Meeting to be held, and the Company and Parent shall use reasonable best efforts to cause the
Company Stockholders Meeting and the Parent Stockholders Meeting to be held on the same date (and if, notwithstanding such efforts, either
the Parent Stockholders Meeting or the Company Stockholders Meeting is called for a date prior to such other meeting, the party with the
later meeting shall use its reasonable best efforts to cause the Parent Stockholders Meeting or Company Stockholders Meeting, as applicable,
as promptly as reasonably practicable following the date of such earlier meeting), and Parent shall duly call, give notice of, convene
and hold the Parent Stockholders Meeting for the purpose of obtaining the Parent Stockholder Approval and, if applicable, the advisory
vote required by Rule&nbsp;14a-21(c)&nbsp;under the Exchange Act in connection therewith. Parent may postpone or adjourn the Parent Stockholder
Meeting solely (i)&nbsp;with the consent of the Company; (ii)&nbsp;if required by applicable Law or a request from the SEC, (iii)&nbsp;(A)&nbsp;due
to the absence of a quorum necessary to conduct the business of the Parent Stockholders Meeting or (B)&nbsp;if Parent has not received
proxies representing a sufficient number of shares of Parent Common Stock for the Parent Stockholder Approval, whether or not a quorum
is present, to solicit additional proxies; or (iv)&nbsp;to the extent necessary to allow reasonable additional time for the filing and
mailing of any supplemental or amended disclosure which the Parent Board has determined in good faith after consultation with the Company
and outside legal counsel is necessary under applicable Law and for such supplemental or amended disclosure to be disseminated and reviewed
by Parent&rsquo;s stockholders prior to the Parent Stockholders Meeting; <U>provided</U>, without the prior written consent of the Company
(not to be unreasonably withheld, in the cases of clauses (ii)&nbsp;and (iv)), (x)&nbsp;no single adjournment or postponement permitted
hereunder (including by the immediately following sentence) shall be for more than five Business Days, except as may be required by Law,
(y)&nbsp;all such adjournments and postponements together shall not cause the date of the Parent Stockholder Meeting to be more than twenty
(20) Business Days after the date for which the Parent Stockholder Meeting was originally scheduled or, in the case of clause (iii)&nbsp;above
and the immediately following sentence, less than five (5)&nbsp;Business Days prior to the Termination Date. In addition to the foregoing,
Parent shall, at the request of the Company, to the extent permitted by Law, postpone or adjourn the Parent Stockholders Meeting to a
date mutually agreed with the Company (subject to the limitations in the foregoing proviso, except as may be mutually agreed with Parent)
for the absence of a quorum or if Parent has not received proxies representing a sufficient number of shares of Parent Common Stock for
the Parent Stockholder Approval; provided, that Parent shall not be required to adjourn the Parent Stockholders Meeting more than two
(2)&nbsp;times pursuant to this sentence, and no such adjournment pursuant to this sentence shall be required to be for a period exceeding
ten (10)&nbsp;Business Days. Except in the case of a Parent Adverse Recommendation Change specifically permitted by, and adopted pursuant
to the procedures set forth in <B><U>&lrm;</U></B><U>Section&nbsp;5.5</U>, Parent, through the Parent Board, shall (i)&nbsp;recommend
to its stockholders that they approve the Parent Stock Issuance and (ii)&nbsp;include such recommendation (including the Parent Board
Recommendation) in the Joint Proxy Statement/Prospectus. Without limiting the generality of the foregoing, Parent agrees that, notwithstanding
any Parent Adverse Recommendation Change, unless this Agreement is terminated in accordance with its terms, (x)&nbsp;Parent shall use
its reasonable best efforts to solicit proxies to obtain the Parent Stockholder Approval and (y)&nbsp;Parent&rsquo;s obligations pursuant
to this <B><U>&lrm;</U></B><U>Section&nbsp;5.6(c</U>)&nbsp;shall not be affected by the commencement, public proposal, public disclosure
or communication to Parent or any other Person of any Parent Acquisition Proposal or the occurrence of any Parent Adverse Recommendation
Change. Parent shall, on a daily basis, during the ten (10)&nbsp;Business Days prior to the date of the Parent Stockholder Meeting, advise
the Company as to the aggregate number of shares of Parent Common Stock entitled to vote at the Parent Stockholder Meeting for which proxies
have been received by the Parent with respect to the Parent Stockholder Approval and the number of such proxies authorizing the holder
thereof to vote in favor of the Parent Stockholder Approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 81; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;5.7</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Access
to Information; Confidentiality</U>. Upon reasonable prior notice, each party shall, and shall cause each of its Subsidiaries to, afford
to the other parties and their respective Representatives reasonable access during normal business hours, during the period prior to the
Effective Time or the termination of this Agreement in accordance with its terms, to all their respective properties, assets, books, contracts,
commitments, personnel and records and, during such period, each party shall, and shall cause each of its Subsidiaries to, furnish as
promptly as reasonably practicable to the other parties all other information concerning its business, properties and personnel as the
other parties may reasonably request for purposes of completing the Merger or for a bona fide business purpose (including Tax Returns
filed and those in preparation and the work papers of its auditors) <U>provided</U>, <U>however</U>, that the foregoing shall not require
any party to disclose any information (a)&nbsp;if providing such access would unreasonably disrupt such party&rsquo;s operations, (b)&nbsp;that
is a trade secret of a third party, competitively sensitive information, information concerning the valuation of the Company or any of
its Subsidiaries, on the one hand, or Parent or any of its Subsidiaries, on the other hand, as applicable, or personal information that
would expose the Company or Parent, as applicable, to the risk of liability (provided that in each such case the withholding party will
inform the other party of the nature of the information being withheld, and use its reasonable best efforts to make alternative arrangements
that would allow access to such information), (c)&nbsp;would violate the terms of a confidentiality agreement with a third party entered
into prior to the date of this Agreement or entered into after the date of this Agreement in the ordinary course of business (<U>provided</U>,
<U>however</U>, that the withholding party shall use its reasonable best efforts to obtain the required consent of such third party to
such access or disclosure), (d)&nbsp;the disclosure of which would violate any Law applicable to such party or any of its Representatives
(<U>provided</U>, <U>however</U>, that withholding party shall use its reasonable best efforts to make appropriate substitute arrangements
to permit reasonable disclosure not in violation of any Law or duty), or (e)&nbsp;disclosure of which would jeopardize any attorney-client,
attorney work product or other legal privilege (<U>provided</U>, <U>however</U>, that withholding party shall use its reasonable best
efforts to allow for such access or disclosure to the maximum extent that does not result in a loss of any such attorney-client, attorney
work product or other legal privilege, including by means of entry into a customary joint defense agreement that would alleviate the loss
of such privilege); <U>provided</U>, <U>further</U>, that the foregoing shall not require the Company, Parent or any of their respective
Subsidiaries to permit any environmental testing or sampling or subsurface investigations, including surface and subsurface soils and
water, soil gas, air or building materials, on any of the properties owned, leased or operated by it or any of its respective Subsidiaries.
All such information shall be held confidential in accordance with the terms of the Confidentiality Agreement between Parent and the Company,
dated as of November&nbsp;30, 2022 (the &ldquo;<U>Confidentiality Agreement</U>&rdquo;). No investigation pursuant to this <U>&lrm;Section&nbsp;5.7</U>
or information provided, made available or delivered to a party pursuant to this Agreement shall affect any of the representations, warranties,
covenants, rights or remedies, or the conditions to the obligations of, the parties hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 82; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;5.8</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Further
Action; Efforts</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Upon
the terms and subject to the conditions of this Agreement, each of the parties shall use its reasonable best efforts to take, or cause
to be taken, all actions and to do, or cause to be done, and cooperate with each other in order to do, all things necessary, proper or
advisable under applicable Law (including under any Antitrust Law) to consummate the Merger and the other transactions contemplated by
this Agreement at the earliest practicable date, including: (i)&nbsp;causing the preparation and filing of all forms, registrations and
notices required to be filed to consummate the Merger and the taking of such actions as are necessary to obtain any requisite consent
or expiration of any applicable waiting period under the HSR Act or any other Antitrust Law; (ii)&nbsp;using reasonable best efforts to
defend all lawsuits and other proceedings by or before any Governmental Entity challenging this Agreement or the consummation of the Merger;
and (iii)&nbsp;using reasonable best efforts to resolve any objection asserted with respect to the transactions contemplated under this
Agreement under any Antitrust Law raised by any Governmental Entity and to prevent the entry of any court order, and to have vacated,
lifted, reversed or overturned any injunction, decree, ruling, order or other action of any Governmental Entity that would prevent, prohibit,
restrict or delay the consummation of the transactions contemplated by this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">In
furtherance and not in limitation of the provisions of <B><U>&lrm;</U></B><U>Section&nbsp;5.8(a</U>), each of the parties, as applicable,
agrees to prepare and file as promptly as practicable, and in any event by no later than ten (10)&nbsp;Business Days from the date of
this Agreement an appropriate filing of a Notification and Report Form&nbsp;pursuant to the HSR Act. Parent shall pay all filing fees
and other charges for the filings required under the HSR Act by the Company and Parent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
parties shall keep each other apprised with respect to the matters set forth in this <B><U>&lrm;</U></B><U>Section&nbsp;5.8</U> and work
cooperatively in connection with obtaining the approvals of or clearances from each applicable Governmental Entity, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">cooperating
with each other in connection with filings required to be made by any party under any Antitrust Law and liaising with each other in relation
to each step of the procedure before the relevant Governmental Entities and as to the contents of all communications with such Governmental
Entities. In particular, to the extent permitted by Law or Governmental Entity, no party will make any notification in relation to the
transactions contemplated hereunder without first providing the other party with a copy of such notification in draft form and giving
such other party a reasonable opportunity to discuss its content before it is filed with the relevant Governmental Entities, and such
first party shall consider and take account of all reasonable comments timely made by the other party in this respect;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 83; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">furnishing
to the other party all information within its possession that is required for any application or other filing to be made by the other
party pursuant to the applicable Law in connection with the transactions contemplated by this Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">promptly
notifying each other of any material communications from or with any Governmental Entity with respect to the matters set forth in this
<B><I><U>&lrm;</U></I></B><U>Section&nbsp;5.8</U> and ensuring to the extent permitted by Law or Governmental Entity that each of the
parties is entitled to attend any material meetings with or other appearances before any Governmental Entity with respect thereto;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">consulting
and cooperating with one another in connection with all analyses, appearances, presentations, memoranda, briefs, arguments, opinions and
proposals made or submitted by or on behalf of any party hereto in connection with proceedings under or relating to the Antitrust Laws;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">without
prejudice to any rights of the parties hereunder, consulting and cooperating in all respects with the other in defending all lawsuits
and other proceedings by or before any Governmental Entity challenging this Agreement or the consummation of the Merger or the other transactions
contemplated by this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Notwithstanding
anything else in this <B><U>&lrm;</U></B><U>Section&nbsp;5.8</U> all Parties agree that it is Parent&rsquo;s sole right to devise the
strategy for all filings and communications in connection with any filing pursuant to the HSR Act and any other filings and submissions
under applicable Antitrust Laws including material communications and negotiations with the Federal Trade Commission, the Department of
Justice or any other Governmental Entity regarding any of the transactions contemplated by this Agreement, so long as such strategy complies
with the terms and conditions of this Agreement and provided, that, Parent consults and considers in good faith the views of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">In
addition, the Parties shall (i)&nbsp;take, or cause to be taken, all other actions and to do, or cause to be done, all other things necessary,
proper or advisable under all Antitrust Laws and other applicable Laws to consummate the transactions contemplated by this Agreement,
including using its best efforts to obtain the expiration of all waiting periods and obtain all other approvals and any other consents
required to be obtained in order for the parties to consummate the transactions contemplated by this Agreement, and (ii)&nbsp;not enter
into or consummate any Contracts for an acquisition (by stock purchase, merger, consolidation, purchase of assets, license or otherwise)
of any ownership interest, assets or rights in or of any Person to the extent such action would reasonably be expected to prevent or materially
delay the consummation of the Merger and the other transactions contemplated by this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 84; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Notwithstanding
anything to the contrary set forth in this Agreement, the obligations of Parent under this <B><U>&lrm;</U></B><U>Section&nbsp;5.8</U>
shall include Parent committing itself and its Affiliates to: (i)&nbsp;selling, divesting, or otherwise conveying particular assets, categories,
portions or parts of assets or businesses of Parent and its Subsidiaries and Affiliates; (ii)&nbsp;agreeing to sell, divest, or otherwise
convey any particular asset, category, portion or part of an asset or business of the Company and its Subsidiaries contemporaneously with
or subsequent to the Effective Time; (iii)&nbsp;permitting the Company to sell, divest, or otherwise convey any of the particular assets,
categories, portions or parts of assets or business of the Company or any of its Subsidiaries prior to the Effective Time; (iv)&nbsp;licensing,
holding separate or entering into similar arrangements with respect to its respective assets or the assets of the Company or conduct of
business arrangements or terminating any and all existing relationships and contractual rights and obligations and (v)&nbsp;obtain prior
approval or other approval from a Governmental Entity, or submit a notification or otherwise notify any Governmental Entity, prior to
consummating any future transaction (other than the transactions contemplated by this Agreement) as a condition to obtaining any and all
expirations of waiting periods under the HSR Act or other Antitrust Laws or consents from any Governmental Entity necessary to consummate
the transactions contemplated hereby, <I>provided</I>, that, notwithstanding anything to the contrary herein, nothing in this <B><U>&lrm;</U></B><U>Section&nbsp;5.8</U>
shall require any Party or any of its respective Affiliates to agree to any condition, take any measure or action or enter into any agreement
that is not contingent on the Closing, and, <I>provided, further</I>, that notwithstanding anything to the contrary contained in this
Agreement, Parent shall not be required to take any actions that, individually or in the aggregate, would reasonably be expected to have
(A)&nbsp;Company Material Adverse Effect or (B)&nbsp;a Parent Material Adverse Effect, in each case, as determined by Parent in good faith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Notwithstanding
the foregoing, commercially and/or competitively sensitive information and materials of a party will be provided to the other party on
an outside counsel-only basis while, to the extent feasible, making a version in which the commercial and/or competitively sensitive information
has been redacted available to the other party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">For
purposes of this Agreement, &ldquo;<U>Antitrust Law</U>&rdquo; means the Sherman Act, as amended, the Clayton Act, as amended, the HSR
Act, the Federal Trade Commission Act, as amended and all other Laws that are designed or intended to prohibit, restrict or regulate actions
having the purpose or effect of monopolization or restraint of trade or lessening of competition through merger or acquisition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;5.9</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Employment
and Employee Benefits Matters; Other Plans</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">For
purposes of this <B><U>&lrm;</U></B><U>Section&nbsp;5.9</U>, (i)&nbsp;the term &ldquo;<U>Covered Employees</U>&rdquo; shall mean employees
who are actively employed by the Company or any of its Subsidiaries immediately prior to the Effective Time; and (ii)&nbsp;the term &ldquo;<U>Continuation
Period</U>&rdquo; shall mean the period beginning at the Effective Time and ending on the date that is twelve months following the Effective
Time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">During
the Continuation Period or, if sooner, upon the termination of employment of the applicable Covered Employee, Parent shall provide each
Covered Employee with (i)&nbsp;base salaries no less than in effect immediately prior to the Effective Time, (ii)&nbsp;annual cash target
bonus (other than change in control, retention and similar bonuses) and commission opportunities no less than in effect immediately prior
to the Effective Time, and (iii)&nbsp;employee benefits (excluding defined benefit pension plans, plans providing for retiree medical
benefits, plans that provide equity-based compensation and plans that provide for change in control, retention and similar payments or
benefits) which are not less favorable in the aggregate than either (1)&nbsp;those provided to such Covered Employee by the Company immediately
prior to the Effective Time or (2)&nbsp;those Parent provides to its similarly situated employees. In addition, (i)&nbsp;during the Continuation
Period, Parent shall provide each Covered Employee with severance benefits no less favorable in the aggregate than those provided to similarly
situated employees of Parent and its Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 85; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">As
of and after the Effective Time, Parent will, or will cause the Surviving Corporation to, to give Covered Employees full credit for purposes
of eligibility and vesting and benefit accruals (but not for purposes of any retiree welfare plan or for benefit accruals under any defined
benefit pension plans), under the applicable Parent Plan to the same extent recognized by the Company immediately prior to the Effective
Time, except to the extent such credit would result in the duplication of benefits for the same period of service. With respect to each
Parent Plan that is a &ldquo;welfare benefit plan&rdquo; (as defined in Section&nbsp;3(1)&nbsp;of ERISA), Parent and its Subsidiaries
shall&nbsp;use commercially reasonable efforts to (i)&nbsp;cause there to be waived any pre-existing condition or eligibility limitations
and (ii)&nbsp;give effect, in determining any deductible and maximum out-of-pocket limitations, to claims incurred and amounts paid by,
and amounts reimbursed to, Covered Employees under similar plans maintained by the Company and its Subsidiaries immediately prior to the
Effective Time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Unless
otherwise directed by Parent in a writing delivered to the Company following the date hereof and at least three (3)&nbsp;Business Days
prior to the Closing Date, the Company shall take all necessary action (including the adoption of resolutions and plan amendments and
the delivery of any required notices) to terminate, effective as of no later than the day before the Effective Time, the Spectrum Pharmaceuticals,&nbsp;Inc.
401(k)&nbsp;Plan (the &ldquo;<U>Company 401(k)&nbsp;Plan</U>&rdquo;). The Company shall provide Parent with a copy of the resolutions,
plan amendments, notices and other documents prepared to effectuate the termination of the Company 401(k)&nbsp;Plan reasonably in advance
and give Parent a reasonable opportunity to comment on such documents (which comments shall be considered in good faith), and prior to
the Effective Time, the Company shall provide Parent with the final documentation evidencing that the Company 401(k)&nbsp;Plan has been
terminated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Unless
otherwise directed by Parent in a writing delivered to the Company following the date hereof and at least three (3)&nbsp;Business Days
prior to the Effective Time, the Company shall&nbsp;take all necessary action (including the adoption of resolutions and plan amendments
and the delivery of any required notices) to terminate, effective as of no later than the day before the Effective Time, the Spectrum
Pharmaceuticals,&nbsp;Inc. Deferred Compensation Plan&nbsp;(and all other arrangements that would be treated as a single plan with such
plan for purposes of Section&nbsp;409A of the Code) (the &ldquo;<U>Deferred Compensation Plan</U>&rdquo;) in accordance with the requirements
of Department of Treasury Regulation Section&nbsp;1.409A-3(j)(4)(ix)&nbsp;(the &ldquo;<U>Deferred Compensation Plan Termination</U>&rdquo;).
As soon as reasonably practicable following the Effective Time,&nbsp;but in no event later&nbsp;than 30 days after the Closing,&nbsp;the
Company shall distribute&nbsp;to&nbsp;each such&nbsp;participant in the Deferred Compensation Plan his or her entire account balance&nbsp;under
the Deferred Compensation Plan. The Company shall provide Parent with a copy of the resolutions, plan amendments, notices and other documents
prepared to effectuate the Deferred Compensation Plan Termination reasonably in advance and give Parent a reasonable opportunity to comment
on such documents (which comments shall be considered in good faith), and prior to the Effective Time, the Company shall provide Parent
with the final documentation evidencing that the Deferred Compensation Plan has been terminated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 86; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Notwithstanding
anything to the contrary contained in this Agreement, nothing contained in this Agreement shall (i)&nbsp;be treated as an amendment to
any Company Plan or Parent Plan, (ii)&nbsp;obligate Parent or the Surviving Corporation to maintain any particular benefit plan or arrangement,
(iii)&nbsp;prevent Parent or the Surviving Corporation from amending or terminating any benefit plan or arrangement, or (iv)&nbsp;limit
the ability of Parent, the Company or their respective Subsidiaries from terminating the employment of any employee. Nothing herein is
intended to provide any Covered Employee any third party beneficiary rights under this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;5.10</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Takeover
Laws</U>. If any Takeover Law is or becomes applicable to this Agreement, the Merger or any of the other transactions contemplated hereby,
each of the Company and the Company Board shall take all action necessary to ensure that the Merger and the other transactions contemplated
hereby may be consummated as promptly as practicable on the terms contemplated by this Agreement and otherwise to eliminate or minimize
the effect of such Takeover Law on this Agreement, the Merger and the other transactions contemplated hereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;5.11</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Stock
Exchange Listing</U>. Parent shall use its reasonable best efforts to cause the shares of Parent Common Stock to be issued in the Merger,
and such other shares of Parent Common Stock to be reserved for issuance in connection with the Merger, to be approved for listing on
the Nasdaq, subject to official notice of issuance, prior to the Effective Time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;5.12</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Stock
Exchange Delisting</U>. To the extent requested by Parent, prior to the Closing Date, the Company shall cooperate with Parent and use
its reasonable best efforts to take, or cause to be taken, all actions, and do or cause to be done all things, reasonably necessary, proper
or advisable on its part under applicable Laws and rules&nbsp;and policies of Nasdaq to enable the delisting by the Surviving Corporation
of the Company Shares from Nasdaq as promptly as practicable after the Effective Time and the deregistration of the Company Shares under
the Exchange Act at the Effective Time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;5.13</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Indemnification,
Exculpation and Insurance</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Without
limiting any additional rights that any employee may have under any agreement or Company Plan, from the Effective Time through the sixth
anniversary of the date on which the Effective Time occurs, Parent shall, or shall cause the Surviving Corporation to, indemnify and hold
harmless each present (as of the Effective Time) and former officer, director or employee of the Company and its Subsidiaries (the &ldquo;<U>Indemnified
Parties</U>&rdquo;), against all claims, losses, liabilities, damages, judgments, inquiries, fines, amounts paid in settlement and reasonable
fees, costs and expenses, including attorneys&rsquo; fees and disbursements incurred in connection with any pending or threatened Action,
whether civil, criminal, administrative or investigative, arising out of, pertaining to or by reason of (i)&nbsp;the fact that the Indemnified
Party is or was an officer, director, employee, fiduciary or agent of the Company or any of its Subsidiaries or, while a director, officer
or employee of the Company or its Subsidiaries, is or was serving at the request of the Company or any of its Subsidiaries as a director,
officer, employee or agent of another corporation or of another corporation or of a partnership, joint venture, trust, enterprise or nonprofit
entity or (ii)&nbsp;matters existing or occurring at or prior to the Effective Time (including this Agreement and the transactions and
actions contemplated hereby), whether asserted or claimed prior to, at or after the Effective Time, to the fullest extent permitted under
applicable Law and the Company Charter and Company Bylaws as of the date hereof or (iii)&nbsp;in connection with the enforcement of any
Indemnified Party&rsquo;s rights under this <B><U>&lrm;</U></B><U>Section&nbsp;5.13</U> by such Indemnified Party or his or her heirs
or legal representatives. In the event of any such pending or threatened Action, including any such Action to enforce any Indemnified
Party&rsquo;s rights under this <B><U>&lrm;</U></B><U>Section&nbsp;5.13</U>, (A)&nbsp;each Indemnified Party shall be entitled to advancement
of expenses (including attorneys&rsquo; fees and expenses) incurred in connection with such Action from Parent and the Surviving Corporation
to the fullest extent permitted under applicable Law and the Company Charter and Company Bylaws as of the date hereof; <U>provided</U>,
that any Person to whom expenses are advanced provides an undertaking, if and only to the extent required by DGCL or the Company Charter
or Company Bylaws, to repay such advances if it is ultimately determined that such Person is not entitled to indemnification under this
Agreement or any Law, Contract or other source for which indemnification may be available, and (B)&nbsp; the Surviving Corporation shall
cooperate in the defense of any such matter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 87; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Except
as may be required by applicable Law, Parent and the Company agree that all rights to indemnification and exculpation from liabilities
for acts or omissions occurring at or prior to the Effective Time and rights to advancement of expenses relating thereto now existing
in favor of any Indemnified Party as provided in the Organizational Documents of the Company and its Subsidiaries or in any indemnification
agreement in effect as of the date hereof between such Indemnified Party and the Company or any of its Subsidiaries (solely to the extent
such agreement is set forth in <B><U>&lrm;</U></B><U>Section&nbsp;5.13(b)</U>&nbsp;of the Company Disclosure Letter and a copy of which
has been provided to Parent) shall survive the Merger and continue in full force and effect, and shall not be amended, repealed or otherwise
modified in any manner that would adversely affect any right thereunder of any such Indemnified Party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">At
the Company&rsquo;s option, the Company may purchase, prior to the Effective Time, a six-year prepaid &ldquo;tail policy&rdquo; on terms
and conditions (in both amount and scope) providing substantially equivalent benefits as the policies of directors&rsquo; and officers&rsquo;
liability insurance and fiduciary liability insurance maintained by the Company and its Subsidiaries in effect as of the date hereof with
respect to matters arising on or before the Effective Time, covering without limitation the transactions contemplated hereby; <U>provided</U>
that the annual cost of such &ldquo;tail policy&rdquo; may not exceed the 250% of the last annual premium paid by the Company prior to
the date hereof with respect to the Company&rsquo;s existing directors&rsquo; and officers&rsquo; liability insurance and fiduciary liability
insurance policies (the &ldquo;<U>Maximum Annual Premium</U>&rdquo;). If such tail prepaid policy has been obtained by the Company prior
to the Effective Time, Parent shall cause such policy to be maintained in full force and effect, for its full term, and cause all obligations
thereunder to be honored by the Surviving Corporation. If the Company has not purchased such tail policy prior to the Effective Time,
for a period of six years from the Effective Time, Parent shall either cause to be maintained in effect the current policies of directors&rsquo;
and officers&rsquo; liability insurance and fiduciary liability insurance maintained by the Company and its Subsidiaries or cause to be
provided substitute policies or purchase or cause the Surviving Corporation to purchase, a &ldquo;tail policy,&rdquo; in either case of
at least the same coverage and amounts containing terms and conditions that are not less advantageous in the aggregate than such policy
with respect to matters arising on or before the Effective Time; <U>provided</U>, that after the Effective Time, Parent shall not be required
to pay with respect to such insurance policies in respect of any one policy year annual premiums in excess of the Maximum Annual Premium
in respect of the coverage required to be obtained pursuant hereto, but in such case shall purchase as much coverage as reasonably practicable
for such amount; <U>provided further</U>, that if the Surviving Corporation purchases a &ldquo;tail policy&rdquo; and the coverage thereunder
costs more than the Maximum Annual Premium, the Surviving Corporation shall purchase the maximum amount of coverage that can be obtained
for the Maximum Annual Premium.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 88; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Notwithstanding
anything herein to the contrary, if any Action (whether arising before, at or after the Effective Time) is instituted against any Indemnified
Party on or prior to the sixth anniversary of the Effective Time, the provisions of this <B><U>&lrm;</U></B><U>Section&nbsp;5.13</U> shall
continue in effect until the final disposition of such Action.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
indemnification, exculpation and rights to advancement provided for herein shall not be deemed exclusive of any other rights to which
an Indemnified Party is entitled, whether pursuant to Law, Contract or otherwise. The provisions of this <B><U>&lrm;</U></B><U>Section&nbsp;5.13</U>
shall survive the consummation of the Merger and, notwithstanding any other provision of this Agreement that may be to the contrary, expressly
are intended to benefit, and shall be enforceable by, each of the Indemnified Parties and their respective heirs and legal representatives
(and following the Effective Time may not be amended without their prior written consent).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">In
the event that the Surviving Corporation or Parent or any of their respective successors or assigns (i)&nbsp;consolidates with or merges
into any other Person and shall not be the continuing or surviving corporation or entity of such consolidation or merger or (ii)&nbsp;transfers
or conveys all or a majority of its properties and assets to any Person (by merger, consolidation, division, operation of law or otherwise),
then, and in each such case, proper provision shall be made so that the successors and assigns of the Surviving Corporation or Parent,
as the case may be, shall succeed to the obligations set forth in this <B><U>&lrm;</U></B><U>Section&nbsp;5.13</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;5.14</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Rule&nbsp;16b-3</U>.
Prior to the Closing Date, the Company and Parent shall, as applicable, take such steps as may be reasonably necessary or advisable to
cause dispositions of Company equity securities (including derivative securities with respect to such equity securities) and warrants
or acquisitions of Parent Common Stock pursuant to the transactions contemplated by this Agreement by each individual who is a director
or officer of the Company to be exempt under Rule&nbsp;16b-3 promulgated under the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;5.15</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Public
Announcements</U>. The initial press release with respect to this Agreement and the transactions contemplated hereby shall be a joint
release mutually agreed to by the Company and Parent. Thereafter, each of the Company and Parent agrees that no public release, statement,
announcement, or other disclosure concerning the Merger and the other transactions contemplated hereby that is inconsistent with initial
press release (or other release, statement, announcement or other disclosure made in accordance herewith) shall be issued by any party
without (x)&nbsp;consulting with the other party prior to the issuance thereof and (y)&nbsp;providing the other party with a reasonable
opportunity to review and comment upon such communication, except (i)&nbsp;as may be required by applicable Law, court process or by obligations
pursuant to any listing agreement with any national securities exchange or national securities quotation system, the rules&nbsp;or regulations
of any applicable United States securities exchange, or any Governmental Entity to which the relevant party is subject (in which case
the party making such disclosure shall use its reasonable best efforts to provide the other party with a reasonable opportunity to review
and comment on such disclosure in advance, and shall give due consideration to all reasonable additions, deletions or changes suggested
thereto by Parent or the Company, as applicable), (ii)&nbsp;by the Company with respect to any Company Acquisition Proposal or Company
Adverse Recommendation Change, in each case, in compliance with <U>&lrm;Section&nbsp;5.4</U>, or (iii)&nbsp;by Parent with respect to
any Parent Acquisition Proposal or Parent Adverse Recommendation Change, in each case, in compliance with <U>&lrm;Section&nbsp;5.5</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 89; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;5.16</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Obligations
of Merger Sub</U>. Parent shall take all action necessary to cause Merger Sub to perform its obligations under this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;5.17</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Notices
of Certain Events</U>. Subject to applicable Law, the Company shall notify Parent and Merger Sub, and Parent and Merger Sub shall notify
the Company, promptly of: (a)&nbsp;any notice or other communication from any Person alleging that the consent of such Person is or may
be required in connection with the transactions contemplated by this Agreement; (b)&nbsp;any notice or other communication from any Governmental
Entity in connection with the transactions contemplated by this Agreement; and (c)&nbsp;any event, change, or effect between the date
of this Agreement and the Effective Time which individually or in the aggregate causes or is reasonably likely to cause or constitute:
(i)&nbsp;a material breach of any of its representations, warranties, or covenants contained herein, or (ii)&nbsp;the failure of any of
the conditions set forth in <U>&lrm;Article&nbsp;</U>VI of this Agreement to be satisfied; <U>provided</U>, that any failure to give notice
in accordance with the foregoing shall not be deemed to constitute a violation of this <U>&lrm;Section&nbsp;5.16</U> or the failure of
any condition set forth in <U>&lrm;Article&nbsp;VI</U> to be satisfied, or otherwise constitute a breach of this Agreement by the party
failing to give such notice, in each case unless the underlying breach would independently result in a failure of the conditions set forth
in <U>&lrm;Article&nbsp;</U>VI to be satisfied; and <U>provided</U>, <U>further</U>, that the delivery of any notice pursuant to this
<U>&lrm;Section&nbsp;5.16</U> shall not cure any breach of, or noncompliance with, any other provision of this Agreement or limit the
remedies available to the party receiving such notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;5.18</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Stockholder
Litigation</U>. The Company shall promptly advise Parent in writing after becoming aware of, and, upon request from Parent, provide copies
of all pleadings and material correspondence relating to, any Action commenced, or to the Company&rsquo;s knowledge, threatened, against
the Company or any of its directors by any stockholder of the Company (on their own behalf or on behalf of the Company) arising out of
or relating to this Agreement or the transactions contemplated hereby (including the Merger and the other transactions contemplated hereby)
and shall keep Parent reasonably informed on a prompt and current basis regarding any such Action. The Company shall: (a)&nbsp;give Parent
the opportunity to participate in the defense and settlement or compromise of any such Action, (b)&nbsp;keep Parent reasonably apprised
on a prompt and current basis of proposed strategy and other significant decisions with respect to any such Action, and provide Parent
with the opportunity to consult with the Company regarding the defense of any such Action, which advice the Company shall consider in
good faith, and (c)&nbsp;not settle or compromise any such Action without the prior written consent of Parent (which consent shall not
be unreasonably withheld, delayed, or conditioned). Notwithstanding anything to the contrary in this <U>&lrm;Section&nbsp;5.18</U>, any
matters relating to Dissenting Shares shall be governed by <U>&lrm;Section&nbsp;2.3</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 90; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section&nbsp;5.19</FONT><FONT STYLE="color: #010000">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Certain
Tax Matters.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Intended
Tax Treatment</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
parties hereto (A)&nbsp;intend that the Merger will qualify for the Intended Tax Treatment and (B)&nbsp;adopt this Agreement as a &ldquo;plan
of reorganization&rdquo; for purposes of Treasury Regulations Section&nbsp;1.368-2(g)&nbsp;and 1.368-3(a)&nbsp;to which the Parent, Merger
Sub, and the Company are parties under Section&nbsp;368(b)&nbsp;of the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Both
prior to and following the Effective Time, Parent, Merger Sub and the Company shall use their respective commercially reasonable efforts,
and shall cause their respective Subsidiaries to use their commercially reasonable efforts, to take or cause to be taken any action necessary
for the Merger to qualify for the Intended Tax Treatment, including (A)&nbsp;reasonably refraining from any action that is not contemplated
by this Agreement, that such party knows, or is reasonably expected to know, is reasonably likely to prevent the Intended Tax Treatment
and not taking any Tax reporting position inconsistent with the Intended Tax Treatment for U.S. federal (and applicable state, local and
non-U.S.) income Tax purposes, unless otherwise required by a change in applicable Tax Law after the date of this Agreement or a &ldquo;determination&rdquo;
within the meaning of Section&nbsp;1313(a)(1)&nbsp;of the Code (or any similar or corresponding provision of state, local, or non-U.S.
Law). Parent agrees to use commercially reasonable efforts to promptly notify the other party of any challenge to the Intended Tax Treatment
by any Governmental Entity and the parties hereto shall use commercially reasonable efforts to preserve the Intended Tax Treatment during
the course of such challenge.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Parent
shall use commercially reasonable efforts to promptly notify the Company if, at any time before the Effective Time, Parent has knowledge
of any facts, agreements, plans or other circumstances that would reasonably be expected to prevent or impede the Intended Tax Treatment.
The Company shall use commercially reasonable efforts to promptly notify Parent if, at any time before the Effective Time, the Company
has knowledge of any facts, agreements, plans or other circumstances that would reasonably be expected to prevent or impede the Intended
Tax Treatment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Company and Parent shall each reasonably cooperate with one another and their respective counsel and use commercially reasonable efforts
to cause the delivery of the Company Tax Opinion, including by executing and delivering customary Tax representation letters as Company
Tax Counsel may reasonably request; provided that such representation letters shall be (x)&nbsp;consistent with this Agreement, (y)&nbsp;dated
as of the date of such opinion and (z)&nbsp;signed by an officer of the Company or Parent, as applicable. Each of Parent and the Company
shall use its commercially reasonable efforts not to take or cause to be taken any action not contemplated by this Agreement that would
reasonably be expected to cause to be untrue (or fail to take or cause not to be taken any action which would reasonably be expected to
cause to be untrue) any of the covenants, and representations included in the Tax representation letters described in this <B><I><U>&lrm;</U></I></B><U>Section&nbsp;5.19(a)(iv)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Transfer
Taxes</U>. All stock transfer, real estate transfer, documentary, stamp, recording and other similar Taxes incurred in connection with
the consummation of the Merger shall be paid by the party legally responsible for such Taxes under applicable Law. The Parties shall cooperate
in the preparation, execution and filing of all Tax Returns, questionnaires or other documents with respect to such Taxes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 91; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>FIRPTA
Certificate</U>. At the Closing, the Company shall deliver to Parent a certificate and notice prepared in accordance with the requirements
of Treasury Regulations Section&nbsp;1.897-2(h)(2)&nbsp;and 1.1445-2(c)(3)&nbsp;and dated as of the Closing Date, along with written authorization
for Parent to deliver such certificate and notice to the IRS on behalf of the Company upon the Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;5.20</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Governance
Matters</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Subject
to applicable Law and the listing and corporate governance rules&nbsp;and regulations of the Nasdaq that are applicable to Parent, prior
to the Effective Time, the Company shall nominate one member of the Company Board (such individual, the &ldquo;<U>Company Board Designee</U>&rdquo;),
to be appointed to the Parent Board, who shall be selected and designated to the Parent Board upon Parent&rsquo;s consent (such consent
not to be unreasonably withheld, conditioned or delayed), and Parent shall take all necessary action so that such Company Board Designee
shall be appointed to the Parent Board effective as of the Closing in accordance with the Parent Charter and Parent Bylaws. During the
12-month period following the Closing Date, the Parent Board shall not propose to remove the Company Board Designee other than for cause.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">In
the event that the Closing occurs prior to Parent&rsquo;s annual meeting of stockholders for the year in which the Closing takes place,
subject to the Company Board Designee&rsquo;s continued willingness and ability to serve, Parent shall take such actions as may be necessary
to nominate the Company Board Designee for election to the Parent Board at Parent&rsquo;s annual meeting for such year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Company shall cause to be delivered to Parent prior to the Closing resignations, in form and substance reasonably satisfactory to Parent,
executed by each director of the Company in office as of immediately prior to the Effective Time, in each case, conditioned and effective
upon the Effective Time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;5.21</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Term
Loan Credit Facility</U>. The Company shall (x)&nbsp;reasonably cooperate with Parent and (y)&nbsp;obtain not less than two (2)&nbsp;Business
Days prior to the Closing (or such later date as the Parent shall reasonably agree) a fully executed and customary payoff letter (the
 &ldquo;<U>Payoff Letter</U>&rdquo;), with respect to that certain Loan and Security Agreement, dated as of September&nbsp;21, 2022 (as
amended, restated, supplemented or otherwise modified from time to time, the &ldquo;<U>Term Loan Credit Facility</U>&rdquo;), by and among
the Company, Allos Therapeutics,&nbsp;Inc., Talon Therapeutics,&nbsp;Inc., and Spectrum Pharmaceuticals International Holdings, LLC, as
borrowers, and SLR Investment Corp. as collateral agent (the &ldquo;<U>Term Loan Collateral Agent</U>&rdquo;) which shall include provisions
setting forth the aggregate amounts required to satisfy in full all indebtedness evidenced thereunder (other than (i)&nbsp;inchoate indemnity
obligations, and (ii)&nbsp;other obligations that, by their terms survive termination of the Term Loan Credit Facility and the other Loan
Documents, in each case, for which no claim has been made)), and (z)&nbsp;in accordance with the Parent Payoff Source Determination, prior
to or substantially concurrently with the Closing, repay, or cause to be repaid, on behalf of the Company and its Subsidiaries, all amounts
necessary to discharge in full the Term Loan Credit Facility (other than (i)&nbsp;inchoate indemnity obligations, and (ii)&nbsp;other
obligations that, by their terms survive termination of the Term Loan Credit Facility and the other Loan Documents, in each case for which
no claim has been made) and terminate the commitments thereunder in accordance with the Payoff Letter. All parties agree that Parent shall
be responsible for the payment and reimbursement of all principal, interest, fees, costs, expenses (including, without limitation, legal
fees and expenses) and other amounts in connection with the repayment of the Term Loan Credit Facility (provided that, such amounts may
be funded using, at the election of the Parent, the Company&rsquo;s cash or Parent&rsquo;s cash (such election, the &ldquo;<U>Parent Payoff
Source Determination</U>&rdquo;)).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 92; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase; color: #010000"><B>Article&nbsp;VI</B></FONT><B><FONT STYLE="text-transform: uppercase"><BR>
CONDITIONS PRECEDENT</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;6.1</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Conditions
to Each Party&rsquo;s Obligation to Effect the Merger</U>. The obligation of each party to effect the Merger is subject to the satisfaction
or waiver (where permissible pursuant to applicable law) at or prior to the Closing of the following conditions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Stockholder
Approval</U>. Each of the Company Stockholder Approval and the Parent Stockholder Approval shall have been obtained.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>No
Injunctions or Legal Restraints; Illegality</U>. No restraining order, injunction, or other judgment, order or decree issued by any court
of competent jurisdiction or other legal restraint or prohibition shall be in effect, and no Law shall have been enacted, entered, promulgated
or enforced by any Governmental Entity that, in any case, remains in effect and prevents, prohibits or makes illegal the consummation
of the Merger or the other transactions contemplated by this Agreement (any such Law, order, injunction, judgment, order or decree, a
 &ldquo;<U>Relevant Legal Restraint</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>HSR
Act; Antitrust</U>. Any applicable waiting period (and any extension thereof) under the HSR Act relating to the transactions contemplated
by this Agreement shall have expired or been terminated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Parent
Stock Issuance</U>. The Parent Common Stock to be issued in connection with the Merger shall have been approved for listing on Nasdaq,
subject to official notice of issuance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>CVR
Agreement</U>. The CVR Agreement shall have been executed by Parent and the Rights Agent and shall be in full force and effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Effectiveness
of Form&nbsp;S-4</U>. The Form&nbsp;S-4 shall have become effective under the Securities Act and shall not be the subject of any stop
order that remains in effect or any proceedings (commenced or threatened in writing by the SEC) seeking a stop order that have not been
withdrawn.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;6.2</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Conditions
to the Obligations of the Company</U>. The obligation of the Company to effect the Merger is also subject to the satisfaction, or waiver
by the Company, at or prior to the Closing of the following conditions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 93; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Representations
and Warranties</U>. (i)&nbsp;The representations and warranties of Parent and Merger Sub set forth in <B><U>&lrm;</U></B><U>Section&nbsp;4.1,
<B>&lrm;</B>Section&nbsp;4.2(c)</U>-<B><U>&lrm;</U></B><U>(d)</U>, <B><U>&lrm;</U></B><U>Section&nbsp;4.3</U>, <B><U>&lrm;</U></B><U>Section&nbsp;4.4(a)(i)</U>,
<B><U>&lrm;</U></B><U>Section&nbsp;4.20</U> and <B><U>&lrm;</U></B><U>Section&nbsp;4.22</U> shall be true and correct in all material
respects as of the date of this Agreement and as of the Closing Date as if made as of the Closing Date (except to the extent such representations
and warranties expressly relate to an earlier date, in which case as of such earlier date), (ii)&nbsp;the representations and warranties
of Parent and Merger Sub set forth in <B><U>&lrm;</U></B><U>Section&nbsp;4.2(a)-<B>&lrm;</B>(b)</U>&nbsp;shall be true and correct in
all (other than <I>de minimis</I> inaccuracies) respects as of the date of this Agreement and as of the Closing Date as if made as of
the Closing Date (except to the extent such representations and warranties expressly relate to an earlier date, in which case as of such
earlier date), (iii)&nbsp;the representation and warranty of Parent and Merger Sub set forth in <B><U>&lrm;</U></B><U>Section&nbsp;4.8(b)</U>&nbsp;shall
be true and correct in all respects as of the date of this Agreement and as of the Closing Date as if made as of the Closing Date and
(iv)&nbsp;the other representations and warranties of Parent and Merger Sub set forth in this Agreement shall be true and correct in all
respects as of the date of this Agreement and as of the Closing Date as though made as of the Closing Date (except to the extent such
representations and warranties expressly relate to an earlier date, in which case as of such earlier date), except in the case of this
clause (iii)&nbsp;where the failure of such representations and warranties to be so true and correct that, individually or in the aggregate,
has not constituted or resulted in, and would not reasonably be expected to constitute or result in, a Parent Material Adverse Effect;
provided that, for purposes of determining the accuracy of the representations and warranties referenced in this <B><U>&lrm;</U></B><U>Section&nbsp;6.2(a)</U>&nbsp;in
connection with the satisfaction of the condition herein, all materiality, &ldquo;Parent Material Adverse Effect&rdquo; and similar qualifiers
set forth in such representations and warranties shall be disregarded and not given effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Performance
of Obligations of Parent and Merger Sub</U>. Parent and Merger Sub shall have complied with performed in all material respects all obligations
and covenants required to be performed or complied with by them under this Agreement at or prior to the Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>No
Parent Material Adverse Effect</U>. Since the date of this Agreement, there shall not have been any Effect that, individually or in the
aggregate, together with all other Effects, has constituted or resulted in, or would reasonably be expected to constitute or result in,
a Parent Material Adverse Effect that is continuing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Officers&rsquo;
Certificate</U>. The Company shall have received a certificate signed by an executive officer of Parent certifying as to the matters set
forth in <U>Sections <B>&lrm;</B>6.2(b)</U>&nbsp;and <B><U>&lrm;</U></B><U>6.2(c)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Company
Tax Opinion</U>. The Company shall have received, on the Closing Date but before the Effective Time, the Company Tax Opinion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;6.3</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Conditions
to the Obligations of Parent and Merger Sub.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The obligation of Parent and
Merger Sub to effect the Merger is also subject to the satisfaction, or waiver by Parent, at or prior to the Closing, of the following
conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Representations
and Warranties</U>. (i)&nbsp;The representations and warranties of the Company set forth in <B><U>&lrm;</U></B><U>Section&nbsp;3.1<B>&lrm;</B>(a)-<B>&lrm;</B>(b)</U>,
<B><U>&lrm;</U></B><U>Section&nbsp;3.2(c)</U>-<B><U>&lrm;</U></B><U>(d)<B>&nbsp;&lrm;</B>Section&nbsp;3.3</U>, <B><U>&lrm;</U></B><U>Section&nbsp;3.4(a)</U>(i),
<B><U>&lrm;</U></B><U>Section&nbsp;3.22</U>, and <B><U>&lrm;</U></B><U>Section&nbsp;3.24</U> shall be true and correct in all material
respects as of the date of this Agreement and as of the Closing Date as if made as of the Closing Date (except to the extent such representations
and warranties expressly relate to an earlier date, in which case as of such earlier date), (ii)&nbsp;the representations and warranties
of the Company set forth in <B><U>&lrm;</U></B><U>Section&nbsp;3.2(a)</U>-<B><U>&lrm;</U></B><U>(b)</U>&nbsp;shall be true and correct
in all (other than <I>de minimis</I> inaccuracies) respects as of the date of this Agreement and as of the Closing Date as if made as
of the Closing Date (except to the extent such representations and warranties expressly relate to an earlier date, in which case as of
such earlier date), (iii)&nbsp;the representation and warranty of the Company set forth in <B><U>&lrm;</U></B><U>Section&nbsp;3.8(b)</U>&nbsp;shall
be true and correct in all respects as of the date of this Agreement and as of the Closing Date as if made as of the Closing Date, and
(iv)&nbsp;the other representations and warranties of the Company set forth in this Agreement shall be true and correct in all respects
as of the date of this Agreement and as of the Closing Date as though made as of the Closing Date (except to the extent such representations
and warranties expressly relate to an earlier date, in which case as of such earlier date), except in the case of this clause (iv)&nbsp;where
the failure of such representations and warranties to be so true and correct would not, individually or in the aggregate, has not constituted
or resulted in, and would not reasonably be expected to constitute or result in, a Company Material Adverse Effect; <U>provided</U> that,
or purposes of determining the accuracy of the representations and warranties referenced in this <B><U>&lrm;</U></B><U>Section&nbsp;6.3(a)</U>&nbsp;in
connection with the satisfaction of the condition herein, all materiality, &ldquo;Company Material Adverse Effect&rdquo; and similar qualifiers
set forth in such representations and warranties shall be disregarded and not given effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 94; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Performance
of Obligations of the Company</U>. The Company shall have complied with and performed in all material respects all obligations and covenants
required to be performed or complied with by it under this Agreement at or prior to the Effective Time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>No
Company Material Adverse Effect</U>. Since the date of this Agreement, there shall not have been any Effect that, individually or in the
aggregate, together with all other Effects, has constituted or resulted in, or would reasonably be expected to constitute or result in,
a Company Material Adverse Effect that is continuing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Officers&rsquo;
Certificate</U>. Parent shall have received a certificate signed by an executive officer of the Company certifying as to the matters set
forth in <U>Sections&nbsp;<B>&lrm;</B>6.3(a)</U>, <B><U>&lrm;</U></B><U>6.3(b)</U>&nbsp;and <B><U>&lrm;</U></B><U>6.3(c)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;6.4</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Frustration
of Closing Conditions</U>. None of Parent, Merger Sub or the Company may rely on the failure of any condition set forth in this <U>&lrm;Article&nbsp;</U>VI
to be satisfied if such failure was caused by such party&rsquo;s breach of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase; color: #010000"><B>Article&nbsp;VII</B></FONT><B><FONT STYLE="text-transform: uppercase"><BR>
TERMINATION, AMENDMENT AND WAIVER</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;7.1</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Termination</U>.
This Agreement may be terminated and the Merger may be abandoned at any time prior to the Effective Time, whether before or after the
Company Stockholder Approval and/or Parent Stockholder Approval has been obtained except as noted below (with any termination by Parent
also being an effective termination by Merger Sub ):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">by
mutual written consent of Parent and the Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">by
either Parent or the Company:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 95; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">if
the Merger shall not have been consummated on or before the date that is six (6)&nbsp;months after the date hereof (the &ldquo;<U>Termination
Date</U>&rdquo;); <U>provided</U>, <U>further</U>, that if the satisfaction of the last to be satisfied or waived of the conditions set
forth in <B><I><U>&lrm;</U></I></B><U>Article&nbsp;VI</U> (other than those conditions that by their nature are to be satisfied at the
Closing, so long as such conditions are reasonably capable of being satisfied if the Closing were to occur on the Termination Date) occurs
less than two (2)&nbsp;Business Days prior to the Termination Date, the Termination Date shall be deemed extended to the extent necessary
to permit the Closing to occur; <U>provided</U>, <U>further</U>, that neither party shall have the right to terminate this Agreement pursuant
to this <B><I><U>&lrm;</U></I></B><U>Section&nbsp;7.1(b)(i</U>)&nbsp;if any action of such party or failure of such party to perform or
comply with the covenants and agreements of such party set forth in this Agreement shall have materially contributed to the failure of
the Merger to be consummated by the Termination Date and such action or failure to perform constitutes a material breach of this Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">if
any Relevant Legal Restraint permanently restraining, enjoining or otherwise prohibiting or making illegal any of the transactions contemplated
by this Agreement shall have become final and nonappealable; <U>provided</U>, that the party seeking to terminate this Agreement pursuant
to this <B><I><U>&lrm;</U></I></B><U>Section&nbsp;7.1(b)(ii)</U>&nbsp;shall have used reasonable best efforts to contest, appeal and remove
such judgment, order, injunction, rule, decree, ruling or other action in accordance with <B><I><U>&lrm;</U></I></B><U>Section&nbsp;5.8</U>;
and <U>provided</U>, <U>further</U>, that a party shall not be permitted to terminate this Agreement pursuant to this <B><I><U>&lrm;</U></I></B><U>Section&nbsp;7.1(b)(ii)</U>&nbsp;if
such party has failed in any material respect to comply with any of such party&rsquo;s obligations under <B><I><U>&lrm;</U></I></B><U>Section&nbsp;5.8</U>;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">if
the Company Stockholder Approval shall not have been obtained at the Company Stockholders Meeting duly convened therefor or at any adjournment
or postponement thereof at which a vote on the adoption of this Agreement was taken; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">if
the Parent Stockholder Approval shall not have been obtained at the Parent Stockholder Meeting duly convened therefor or at any adjournment
or postponement thereof at which a vote on the approval of the Parent Stock Issuance was taken;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">by
the Company:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">if
Parent or Merger Sub shall have breached or failed to perform any of its representations, warranties, covenants or agreements set forth
in this Agreement, which breach or failure to perform (A)&nbsp;would result in the failure of a condition set forth in <B><I><U>&lrm;</U></I></B><U>Section&nbsp;6.2(a</U>)&nbsp;or
<B><I><U>&lrm;</U></I></B><U>(b)</U>&nbsp;and (B)&nbsp;cannot be cured by the Termination Date; <U>provided</U>, that the Company shall
have given Parent written notice, delivered at least 30 days prior to such termination (or promptly, if such notice is given within 30
days of the Termination Date), stating the Company&rsquo;s intention to terminate this Agreement pursuant to this <B><I><U>&lrm;</U></I></B><U>Section&nbsp;7.1(c)(i)</U>&nbsp;and
the basis for such termination, and the Company may not terminate the Agreement pursuant to this <B><I><U>&lrm;</U></I></B><U>Section&nbsp;7.1(c)(i</U>)&nbsp;unless
such inaccuracy or breach shall remain uncured for the duration of such 30 day period; <U>provided further</U>, that the Company shall
not have the right to terminate this Agreement pursuant to this <B><I><U>&lrm;</U></I></B><U>Section&nbsp;7.1(c)(i</U>)&nbsp;if it is
then in breach of any of its covenants or agreements set forth in this Agreement which breach would give rise to the failure of a condition
set forth in <B><I><U>&lrm;</U></I></B><U>Section&nbsp;6.3(a)</U>&nbsp;or <B><I><U>&lrm;</U></I></B><U>(b)</U>;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 96; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">at
any time prior to obtaining the Company Stockholder Approval if, (A)&nbsp;the Company Board authorizes the Company, to the extent permitted
by and subject to the Company&rsquo;s compliance with the terms of <B><I><U>&lrm;</U></I></B><U>Section&nbsp;5.4</U>, to enter into a
Company Alternative Acquisition Agreement with respect to a Company Superior Proposal, (B)&nbsp;concurrently with the termination of this
Agreement, the Company, subject to complying with the terms of <B><I><U>&lrm;</U></I></B><U>Section&nbsp;5.4(d)</U>, enters into a Company
Alternative Acquisition Agreement providing for a Company Superior Proposal, (C)&nbsp;prior to or substantially concurrently with such
termination, the Company pays to Parent in immediately available funds any fees required to be paid pursuant to <B><I><U>&lrm;</U></I></B><U>Section&nbsp;7.3(b)</U>;
or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">if
prior to receipt of the Parent Stockholder Approval, the Parent Board shall have effected a Parent Adverse Recommendation Change;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">by
Parent:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">if
the Company shall have breached or failed to perform any of its representations, warranties, covenants or agreements set forth in this
Agreement, which breach or failure to perform (A)&nbsp;would result in the failure of a condition set forth in <B><I><U>&lrm;</U></I></B><U>Section&nbsp;6.3(a)</U>&nbsp;or
<B><I><U>&lrm;</U></I></B><U>(b)&nbsp;</U>and (B)&nbsp;cannot be cured by the Termination Date; <U>provided</U>, that Parent shall have
given the Company written notice, delivered at least 30 days prior to such termination (or promptly, if such notice is given within 30
days of the Termination Date), stating Parent&rsquo;s intention to terminate this Agreement pursuant to this <B><I><U>&lrm;</U></I></B><U>Section&nbsp;7.1(d)(i</U>)&nbsp;and
the basis for such termination, and Parent may not terminate the Agreement pursuant to this <B><I><U>&lrm;</U></I></B><U>Section&nbsp;7.1(d)(i</U>)&nbsp;unless
such inaccuracy or breach shall remain uncured for the duration of such 30 day period; <U>provided further</U>, that Parent shall not
have the right to terminate this Agreement pursuant to this <B><I><U>&lrm;</U></I></B><U>Section&nbsp;7.1(d)(i</U>)&nbsp;if Parent or
Merger Sub is then in breach of any of its covenants or agreements set forth in this Agreement which breach would give rise to the failure
of a condition set forth in <B><I><U>&lrm;</U></I></B><U>Section&nbsp;6.2(a</U>)&nbsp;or <B><I><U>&lrm;</U></I></B><U>(b)</U>;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">at
any time prior to obtaining the Parent Stockholder Approval if, (A)&nbsp;the Parent Board authorizes Parent, to the extent permitted by
and subject to Parent&rsquo;s compliance with the terms of <B><I><U>&lrm;</U></I></B><U>Section&nbsp;5.5</U>, to enter into a Parent Alternative
Acquisition Agreement with respect to a Parent Superior Proposal, (B)&nbsp;concurrently with the termination of this Agreement, Parent,
subject to complying with the terms of <B><I><U>&lrm;</U></I></B><U>Section&nbsp;5.5(d)</U>, enters into a Parent Alternative Acquisition
Agreement providing for a Parent Superior Proposal, (C)&nbsp;prior to or substantially concurrently with such termination, Parent pays
to the Company in immediately available funds any fees required to be paid pursuant to <B><I><U>&lrm;</U></I></B><U>Section&nbsp;7.3(c)</U>;
or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">if
prior to receipt of the Company Stockholder Approval, the Company Board shall have effected a Company Adverse Recommendation Change.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The party desiring to terminate
this Agreement pursuant to this <U>&lrm;Section&nbsp;7.1</U> (other than pursuant to <U>&lrm;Section&nbsp;7.1(a</U>)) shall give written
notice of such termination to the other party, specifying the provision of this Agreement pursuant to which such termination is effected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;7.2</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Effect
of Termination</U>. In the event of termination of the Agreement, this Agreement shall forthwith become void and have no effect, without
any liability or obligation on the part of Parent or Merger Sub or the Company or any of its Representatives, except that the Confidentiality
Agreement and the penultimate sentence of <U>&lrm;Section&nbsp;5.7</U>, this <U>&lrm;Section&nbsp;7.2</U>, <U>&lrm;Section&nbsp;7.3</U>
(<I>Fees and Expenses</I>), and <U>&lrm;Article&nbsp;VIII</U> of this Agreement (and any related definitions contained in such Sections
or provisions) shall survive the termination hereof; <U>provided</U>, that none of Parent, Merger Sub or the Company shall be released
from any liabilities or damages arising out of fraud or any Willful Breach of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 97; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;7.3</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Fees
and Expenses</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Except
as otherwise provided in this <B><U>&lrm;</U></B><U>Section&nbsp;7.3</U>, all fees and expenses incurred in connection with this Agreement,
the Merger and the other transactions contemplated hereby shall be paid by the party incurring such fees or expenses, whether or not the
Merger is consummated; <I>provided</I>, Parent and the Company shall each be responsible for paying any fees in connection with the printing
and mailing of the Form&nbsp;S-4 and the Joint Proxy Statement/Prospectus to their respective stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">In
the event that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">(A)&nbsp;this
Agreement is terminated by (1)&nbsp;Parent pursuant to <B><I><U>&lrm;</U></I></B><U>Section&nbsp;7.1(d)(i)</U>&nbsp;or (2)&nbsp;either
Parent or the Company pursuant to <B><I><U>&lrm;</U></I></B><U>Section&nbsp;7.1(b)(iii</U>)&nbsp;(or by the Company or Parent pursuant
to <B><I><U>&lrm;</U></I></B><U>Section&nbsp;7.1(b)(i)</U>&nbsp;at a time when this Agreement could have been terminated pursuant to <B><I><U>&lrm;</U></I></B><U>Section&nbsp;7.1(b)(iii)</U>&nbsp;or
<B><I><U>&lrm;</U></I></B><U>Section&nbsp;7.1(d)(i)</U>), (B)&nbsp;at any time after the date of this Agreement and prior to the taking
of a vote to adopt this Agreement at the Company Stockholders Meeting or any adjournment or postponement thereof (in the case of a termination
pursuant to <B><I><U>&lrm;</U></I></B><U>Section&nbsp;7.1(b)(iii</U>)) or at or prior to the time of the applicable breach by the Company
(in the case of a termination pursuant to <B><I><U>&lrm;</U></I></B><U>Section&nbsp;7.1(d)(i)</U>), a Company Acquisition Proposal shall
have been communicated to the senior management of the Company or the Company Board or shall have been publicly disclosed or announced
or publicly made known to the stockholders of the Company, or any Person shall have publicly announced an intention to make a Company
Acquisition Proposal, and in each case Company Acquisition Proposal or intention to make a Company Acquisition Proposal is not publicly
withdrawn without qualification prior to the date that is five Business Days prior to such vote to adopt this Agreement, and (C)&nbsp;within
12 months after such termination, the Company shall have consummated or entered into a definitive agreement with respect to any Company
Acquisition Proposal (<U>provided</U>, that for purposes of this <B><I><U>&lrm;</U></I></B><U>Section&nbsp;7.3(b)(i</U>), the references
to &ldquo;20% or more&rdquo; in the definition of Company Acquisition Proposal shall be deemed to be references to &ldquo;more than 75%&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">this
Agreement is terminated by the Company pursuant to <B><I><U>&lrm;</U></I></B><U>Section&nbsp;7.1(c)(ii</U>); or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">this
Agreement is terminated by Parent pursuant to <U>Section&nbsp;<B><I>&lrm;</I></B>7.1(d)(iii)</U>;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">then, in any such case, the Company shall pay
Parent a termination fee of $8,300,000 (the &ldquo;<U>Company Termination Fee</U>&rdquo;), less the amount of Parent Expenses previously
paid to Parent (if any) pursuant to <U>&lrm;Section&nbsp;7.3(d)</U>, it being understood that in no event shall the Company be required
to pay the Company Termination Fee on more than one occasion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 98; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">In
the event that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">(A)&nbsp;this
Agreement is terminated by (1)&nbsp;the Company pursuant to <B><I><U>&lrm;</U></I></B><U>Section&nbsp;7.1(c)(i)</U>&nbsp;or (2)&nbsp;either
Parent or the Company pursuant to <B><I><U>&lrm;</U></I></B><U>Section&nbsp;7.1(b)(iv</U>)&nbsp;(or by the Company or Parent pursuant
to <B><I><U>&lrm;</U></I></B><U>Section&nbsp;7.1(b)(i)</U>&nbsp;at a time when this Agreement could have been terminated pursuant to <B><I><U>&lrm;</U></I></B><U>Section&nbsp;7.1(b)(iv</U>)&nbsp;or
<B><I><U>&lrm;</U></I></B><U>Section&nbsp;7.1(c)(i)</U>), (B)&nbsp;at any time after the date of this Agreement and prior to the taking
of a vote to approve the Parent Stock Issuance at the Parent Stockholders Meeting or any adjournment or postponement thereof (in the case
of a termination pursuant to <B><I><U>&lrm;</U></I></B><U>Section&nbsp;7.1(b)(iv)</U>) or at or prior to the time of the applicable breach
by the Company (in the case of a termination pursuant to <B><I><U>&lrm;</U></I></B><U>Section&nbsp;7.1(c)(i))</U>, a Parent Acquisition
Proposal shall have been communicated to the senior management of Parent or the Parent Board or shall have been publicly disclosed or
announced or publicly made known to the stockholders of Parent, or any Person shall have publicly announced an intention to make a Parent
Acquisition Proposal, and, in each case such Parent Acquisition Proposal or intention to make a Parent Acquisition Proposal is not publicly
withdrawn without qualification prior to the date that is 5 Business Days prior to such vote to approve the Parent Stock Issuance, and
(C)&nbsp;within 12 months after such termination, Parent shall have consummated or entered into a definitive agreement with respect to
any Parent Acquisition Proposal (<U>provided</U>, that for purposes of this <B><I><U>&lrm;</U></I></B><U>Section&nbsp;7.3(c)(i</U>), the
references to &ldquo;20% or more&rdquo; in the definition of Parent Acquisition Proposal shall be deemed to be references to &ldquo;more
than 75%&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">this
Agreement is terminated by Parent pursuant to <B><I><U>&lrm;</U></I></B><U>Section&nbsp;7.1(d)(ii</U>); or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">this
Agreement is terminated by the Company pursuant to <B><I><U>&lrm;</U></I></B><U>Section&nbsp;7.1(c)(iii</U>).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">then, in any such case, Parent shall pay the Company
a termination fee of $8,300,000 (the &ldquo;<U>Parent Termination Fee</U>&rdquo;), less the amount of the Company Expenses previously
paid to the Company (if any) pursuant to <U>&lrm;Section&nbsp;7.3(e)</U>, it being understood that in no event shall Parent be required
to pay the Parent Termination Fee on more than one occasion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">In
the event that this Agreement is terminated by the Company or Parent pursuant to <B><U>&lrm;</U></B><U>Section&nbsp;7.1(b)(iii)</U>&nbsp;under
circumstances in which the Company Termination Fee is not then payable pursuant to <B><U>&lrm;</U></B><U>Section&nbsp;7.3(b)(i)</U>, then
the Company shall reimburse Parent and its Affiliates for all of their reasonable and documented out-of-pocket fees and expenses (including
all fees and expenses of counsel, accountants, investment bankers, experts and consultants to Parent and Merger Sub and their Affiliates)
incurred by Parent, Merger Sub and their Affiliates or on their behalf in connection with or related to the authorization, preparation,
investigation, negotiation, execution and performance of this Agreement and the transactions contemplated hereby (the &ldquo;<U>Parent
Expenses</U>&rdquo;), up to a maximum amount of $1,000,000 (the &ldquo;<U>Expense Reimbursement Cap</U>&rdquo;); <I>provided</I>, that
the payment by the Company of the Parent Expenses pursuant to this <B><U>&lrm;</U></B><U>Section&nbsp;7.3(d)</U>, (i)&nbsp;shall not relieve
the Company of any subsequent obligation to pay the Company Termination Fee pursuant to <B>&lrm;</B><U>Section&nbsp;7.3(b)</U>&nbsp;except
to the extent indicated in such Section&nbsp;and (ii)&nbsp;shall not relieve the Company from any liability or damage resulting from a
willful and material breach of any of its representations, warranties, covenants or agreements set forth in this Agreement or fraud.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 99; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">In
the event that this Agreement is terminated by Parent or the Company pursuant to <B>&lrm;</B><U>Section&nbsp;7.1(b)(iv)</U>&nbsp;under
circumstances in which the Parent Termination Fee is not then payable pursuant to <B><U>&lrm;</U></B><U>Section&nbsp;7.3(c)(i)</U>, then
Parent shall reimburse the Company and its Affiliates for all of their reasonable and documented out-of-pocket fees and expenses (including
all fees and expenses of counsel, accountants, investment bankers, experts and consultants to the Company and its Affiliates) incurred
by the Company and its Affiliates or on their behalf in connection with or related to the authorization, preparation, investigation, negotiation,
execution and performance of this Agreement and the transactions contemplated hereby (the &ldquo;<U>Company Expenses</U>&rdquo;), up to
a maximum amount of the Expense Reimbursement Cap; <I>provided</I>, that the payment by Parent of the Company Expenses pursuant to this
<B><U>&lrm;</U></B><U>Section&nbsp;7.3(e)</U>, (i)&nbsp;shall not relieve Parent of any subsequent obligation to pay the Parent Termination
Fee pursuant to <B><U>&lrm;</U></B><U>Section&nbsp;7.3(c)</U>, except to the extent indicated in such Sections and (ii)&nbsp;shall not
relieve Parent from any liability or damage resulting from a willful and material breach of any of its representations, warranties, covenants
or agreements set forth in this Agreement or fraud</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Payment
of the Company Termination Fee or Parent Termination Fee, if applicable, shall be made by wire transfer of immediately available funds
to the account or accounts designated by Parent or the Company, as applicable (i)&nbsp;on the earlier of (A)&nbsp;the consummation of
any transaction contemplated by a Company Acquisition Proposal or Parent Acquisition Proposal, as applicable, and (B)&nbsp;the entry into
a definitive agreement with respect to a Company Acquisition Proposal or Parent Acquisition Proposal, as applicable, in each case, in
the case of a Company Termination Fee or Parent Termination Fee, as applicable, payable pursuant to <B><U>&lrm;</U></B><U>Section&nbsp;7.3(b)(i</U>)&nbsp;or
<B><U>&lrm;</U></B><U>Section&nbsp;7.3(c)(i)</U>, (ii)&nbsp;concurrently with, or prior to, termination, in the case of a Company Termination
Fee or Parent Termination Fee payable pursuant to <B><U>&lrm;</U></B><U>Section&nbsp;7.3(b)(ii)</U>&nbsp;or <B><U>&lrm;</U></B><U>Section&nbsp;7.3(c)(ii)</U>&nbsp;or
(iii)&nbsp;as promptly as reasonably practicable (and in any event within two Business Days) after termination, in the case of a Company
Termination Fee or Parent Termination Fee, as applicable, payable pursuant to <B><U>&lrm;</U></B><U>Section&nbsp;7.3(b)(iii)</U>&nbsp;or
<B><U>&lrm;</U></B><U>Section&nbsp;7.3(c)(iii)</U>. In the event that Parent or its designee or the Company or its designee shall receive
full payment pursuant to <B><U>&lrm;</U></B><U>Section&nbsp;7.3(b)</U>&nbsp;or <B><U>&lrm;</U></B><U>Section&nbsp;7.3(c)</U>, as applicable,
the receipt of the Company Termination Fee or the Parent Termination Fee shall be deemed to be liquidated damages for any and all losses
or damages suffered or incurred by Parent, Merger Sub, any of their respective Affiliates or any other Person, or the Company, any of
its Affiliates or any other Person, as applicable, in connection with this Agreement (and the termination hereof), the transactions herein
(and the abandonment thereof) or any matter forming the basis for such termination, and none of Parent or Merger Sub, any of their respective
Affiliates or any other Person, or the Company, any of its Affiliates or any other Person, as applicable, shall be entitled to bring or
maintain any claim, action or proceeding against the Company or any of its Affiliates, or Parent or any of its Affiliates, as applicable,
arising out of or in connection with this Agreement, any of the transactions contemplated herein or any matters forming the basis for
such termination; <U>provided</U>, that nothing contained herein shall relieve any party from liability resulting from any Willful Breach
or fraud.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Company and Parent each acknowledges that the agreements contained in this <B><U>&lrm;</U></B><U>Section&nbsp;7.3</U> are an integral
part of the transactions contemplated by this Agreement, and that, without these agreements, the Company, Parent and Merger Sub would
not enter into this Agreement; accordingly, if the Company or Parent fails to timely pay any amounts due pursuant to this <B><U>&lrm;</U></B><U>Section&nbsp;7.3</U>,
and, in order to obtain such payment, Parent of the Company commences a suit that results in a judgment against the Company or Parent
for the amounts set forth in this <B><U>&lrm;</U></B><U>Section&nbsp;7.3</U>, the breaching party shall pay to the other party its costs
and expenses (including reasonable attorneys&rsquo; fees and expenses) in connection with such suit, together with interest on the amounts
due pursuant to this <B><U>&lrm;</U></B><U>Section&nbsp;7.3</U> from the date such payment was required to be made until the date of payment
at the prime lending rate as published in The Wall Street Journal in effect on the date such payment was required to be made (which interest
shall be payable in connection with any late payment, regardless of whether any such suit is brought). The parties acknowledge and agree
that the right to receive the Company Termination Fee or the Parent Termination Fee under this Agreement shall not limit or otherwise
affect any party&rsquo;s right to specific performance as provided in <B><U>&lrm;</U></B><U>Section&nbsp;8.10</U>, but for the avoidance
of doubt, under no circumstances shall Parent or the Company, directly or indirectly, be permitted or entitled to receive both a grant
of specific performance that results in the Closing, on the one hand, and the payment of the Company Termination Fee or the Parent Termination
Fee, or any other damages, on the other hand; <U>provided</U>, that nothing contained herein shall relieve any party from liability resulting
from any Willful Breach or fraud.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 100; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;7.4</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Amendment
or Supplement</U>. This Agreement may be amended, modified or supplemented by the parties prior to the Effective Time by written agreement
signed by each of the parties hereto, whether before or after the Company Stockholder Approval has been obtained; <U>provided</U>, that
after the Company Stockholder Approval has been obtained, no amendment may be made that pursuant to applicable Law requires further approval
or adoption by the stockholders of the Company without such further approval or adoption. This Agreement may not be amended, modified
or supplemented in any manner, whether by course of conduct or otherwise, except by an instrument in writing specifically designated as
an amendment hereto, signed on behalf of each of the parties in interest at the time of the amendment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;7.5</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Extension
of Time; Waiver</U>. At any time prior to the Effective Time, the parties may (a)&nbsp;extend the time for the performance of any of the
obligations or acts of the other parties, (b)&nbsp;waive any inaccuracies in the representations and warranties of the other parties set
forth in this Agreement or any document delivered pursuant hereto or (c)&nbsp;unless prohibited by applicable Law, waive compliance with
any of the agreements or conditions of the other parties contained herein; <U>provided</U>, that after the Company Stockholder Approval
has been obtained, no waiver may be made that pursuant to applicable Law requires further approval or adoption by the stockholders of
the Company without such further approval or adoption. Any agreement on the part of a party to any such extension or waiver shall be valid
only if set forth in a written instrument executed and delivered by a duly authorized officer on behalf of such party. No failure or delay
of any party in exercising any right or remedy hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of
any such right or power, or any abandonment or discontinuance of steps to enforce such right or power, or any course of conduct, preclude
any other or further exercise thereof or the exercise of any other right or power.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase; color: #010000"><B>Article&nbsp;VIII</B></FONT><B><FONT STYLE="text-transform: uppercase"><BR>
GENERAL PROVISIONS</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;8.1</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Nonsurvival
of Representations and Warranties and Pre-Closing Covenants</U>. None of the representations, warranties, covenants, obligations or agreements
of the parties in this Agreement or in any instrument delivered pursuant to this Agreement, including any rights arising out of any breach
of such representations, warranties, covenants, obligations or agreements shall survive the Effective Time, other than those covenants
or agreements of the parties which by their terms apply, or are to be performed in whole or in part, after the Effective Time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 101; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;8.2</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Notices</U>.
All notices and other communications hereunder shall be in writing and shall be deemed duly given on (a)&nbsp;the date of delivery if
delivered personally, or if by e-mail, on the date of transmittal (provided no &ldquo;bounce back&rdquo; or similar message of non-delivery
is received with respect thereto), (b)&nbsp;the second Business Day following the date of dispatch if delivered utilizing a next-day service
by a recognized next-day courier or (c)&nbsp;upon confirmed receipt if delivered by registered or certified mail, return receipt requested,
postage prepaid. All notices hereunder shall be delivered to the addresses set forth below, or pursuant to such other instructions as
may be designated in writing by the party to receive such notice:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">if
to Parent, Merger Sub or the Surviving Corporation, to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">Assertio Holdings,&nbsp;Inc.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">100 S. Saunders Rd., Suite&nbsp;300&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">Lake Forest,&nbsp;IL 60045&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">Attention:&nbsp; Legal Department&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">E-mail:&nbsp; Legal@assertiotx.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">with a copy (which shall not constitute notice) to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Latham&nbsp;&amp; Watkins LLP&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">330 N Wabash Ave, Ste 2800&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Chicago,&nbsp;Illinois 60611&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Attention: Zachary Judd; Owen Alexander&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:</FONT>&#9;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">zachary.judd@lw.com;
owen.alexander@lw.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">if
to the Company, to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">Spectrum Pharmaceuticals,&nbsp;Inc.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">2 Atlantic Avenue, 6th Floor&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">Boston, MA 02110&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">Attention: Thomas J. Riga&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">Chief Executive Officer and President&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">E-mail: ir@sppirx.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">with a copy (which shall not constitute notice) to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Gibson, Dunn&nbsp;&amp; Crutcher LLP<BR>
200 Park Avenue<BR>
New York, NY 10166<BR>
Attention: Saee Muzumdar; Branden C. Berns<BR>
E-mail: smuzumdar@gibsondunn.com;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-indent: 0.5in">&#8239;&#8239;&#8239;&#8239;&#8239;bberns@gibsondunn.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 102; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;8.3</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Certain
Definitions</U>. For purposes of this Agreement:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<U>Affiliate</U>&rdquo;
of any Person means any other Person that directly or indirectly, through one or more intermediaries, controls, is controlled by, or is
under common control with, such first Person;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<U>Business
Day</U>&rdquo; means any day other than a Saturday, a Sunday or a day on which the SEC or banks in New York, New York are authorized or
required by applicable Law to be closed;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<U>Company
Material Adverse Effect</U>&rdquo; means any state of facts, circumstance, condition, event, change, development, occurrence, result,
effect, action or omission (each an &ldquo;<U>Effect</U>&rdquo;) that, individually or in the aggregate with any one or more other Effects,
(x)&nbsp;results in a material adverse effect on the business, condition (financial or otherwise) or results of operations of the Company
and its Subsidiaries, taken as a whole or (y)&nbsp;prevents, materially impairs, materially impedes or materially delays the consummation
of the Merger and the other transactions contemplated hereby on a timely basis and in any event on or before the Termination Date; <U>provided</U>,
that with respect to clause (x)&nbsp;only, no Effect to the extent arising out of the following, alone or in combination, shall, to such
extent, be deemed to constitute, or be taken into account in determining whether there has been or would or could be, a Company Material
Adverse Effect: (1)&nbsp;general economic or business conditions or in the financial, debt, banking, capital, credit or securities markets,
or in interest or exchange rates, in each case, generally affecting any of the industries in which the Company or its Subsidiaries operate,
(2)&nbsp;any adoption, implementation, modification, repeal, interpretation, proposal of or other changes in any applicable Laws or any
changes in applicable accounting regulations or principles, or in interpretations of any of the foregoing, (3)&nbsp;any change in the
price or trading volume of the Company&rsquo;s stock, in and of itself (<U>provided</U>, that the facts or occurrences giving rise to
or contributing to such change that are not otherwise excluded from the definition of &ldquo;Company Material Adverse Effect&rdquo; may
be taken into account in determining whether there has been a Company Material Adverse Effect), (4)&nbsp;any failure by the Company to
meet internal or published projections, forecasts or revenue or earnings predictions, in and of itself (<U>provided</U>, that the facts
or occurrences giving rise to or contributing to such failure that are not otherwise excluded from the definition of &ldquo;Company Material
Adverse Effect&rdquo; may be taken into account in determining whether there has been a Company Material Adverse Effect), (5)&nbsp;political,
geopolitical, social or regulatory conditions, including any outbreak, continuation or escalation of any military conflict, declared or
undeclared war, armed hostilities, civil unrest, public demonstrations or acts of foreign or domestic terrorism or sabotage (including
hacking, ransomware or any other electronic attack), or any escalation or worsening of any such conditions, (6)&nbsp;any natural or manmade
disasters or calamities, weather conditions including hurricanes, floods, tornados, tsunamis, earthquakes and wild fires, cyber outages,
or other force majeure events, or any escalation or worsening of such conditions, (7)&nbsp;any epidemic, pandemic or outbreak of disease
(including, for the avoidance of doubt, COVID-19), or any escalation or worsening of such conditions, (8)&nbsp;the announcement of this
Agreement and the transactions contemplated hereby, including the initiation of litigation by any Person with respect to this Agreement,
and including any termination of, reduction in or similar negative impact on relationships, contractual or otherwise, with any customers,
suppliers, distributors, partners or employees of the Company and its Subsidiaries due to the announcement and consummation of the transactions
contemplated hereby or the identity of the parties to this Agreement, or the consummation of the transactions contemplated hereby (<U>provided</U>
that this clause (8)&nbsp;shall not apply to (x)&nbsp;any representation or warranty in <B><U>&lrm;</U></B><U>Section&nbsp;3.4</U> to
the extent that the purpose of such representation or warranty is to address the consequences resulting from the execution and delivery
of this Agreement or the consummation of the Merger, (y)&nbsp;a to the extent related to such representations and warranties identified
in the preceding clause (x), the condition set forth in <B><U>&lrm;</U></B><U>Section&nbsp;6.3(a)</U>, and (z)&nbsp;any action or omission
by the Company, any Subsidiary of the Company or their respective Representatives in order to comply with the Company&rsquo;s obligations
under <B><U>&lrm;</U></B><U>Section&nbsp;5.1</U>), (9)&nbsp;any action taken by the Company, or which the Company causes to be taken by
any of its Subsidiaries, in each case which is expressly required by this Agreement, (10)&nbsp;any actions taken (or omitted to be taken)
at the express written request of Parent; <U>provided</U>, that in the case of clauses (1), (2), (5), (6), and (7), to the extent the
impact of such Effect is not disproportionately adverse to the Company and its Subsidiaries, taken as a whole, as compared to other companies
operating in the industry in which the Company and its Subsidiaries conduct business (and <U>provided further</U>, that in such event,
only the incremental disproportionate adverse impact shall be taken into account when determining whether there has been a &ldquo;Company
Material Adverse Effect&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 103; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<U>Company
Tax Counsel</U>&rdquo; shall mean Gibson, Dunn&nbsp;&amp; Crutcher LLP or such other nationally recognized Tax counsel reasonably acceptable
to the Company and Parent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<U>Company
Tax Opinion</U>&rdquo; shall mean a written opinion from Company Tax Counsel delivered to the Company in connection with the consummation
of the Merger pursuant to <B><U>&lrm;</U></B><U>Section&nbsp;6.2(e)</U>&nbsp;or filed in connection with the Form&nbsp;S-4 and/or the
Joint Proxy Statement/Prospectus, based on the facts, representations, assumptions and exclusions set forth or described in such opinion,
to the effect that, the Merger will qualify for the Intended Tax Treatment. In rendering such opinion, Company Tax Counsel shall be entitled
to rely upon customary assumptions, representations, warranties and covenants reasonably satisfactory to it, including representations
and covenants set forth in the customary Tax representation letters obtained from Parent and the Company pursuant to <B><U>&lrm;</U></B><U>Section&nbsp;5.19(a)(i)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<U>control</U>&rdquo;
(including the terms &ldquo;controlled,&rdquo; &ldquo;controlled by&rdquo; and &ldquo;under common control with&rdquo;) means the possession,
directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through the
ownership of voting securities, by contract or otherwise;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<U>COVID-19</U>&rdquo;
means SARS-CoV-2 or COVID-19, and any variants or evolutions thereof or related or associated epidemics, pandemics or disease outbreaks;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<U>CVR
Agreement</U>&rdquo; means the Contingent Value Rights Agreement in the form attached hereto as <U>Exhibit&nbsp;B</U> to be entered into
between Parent and the Rights Agent, with such revisions thereto requested by the Rights Agent that are not, individually or in the aggregate,
materially detrimental to the holders of CVRs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<U>Encumbrance</U>&rdquo;
means any charge, claim, mortgage, hypothec, lien, option, pledge, imperfection of title, encroachment, lease, license, easement, servitude,
right-of-way, covenant, condition, restriction, adverse claim, other encumbrance or lien, security interest or other restriction of any
kind;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<U>Exchange
Ratio</U>&rdquo; means 0.1783.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 104; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<U>knowledge
of the Company</U>&rdquo; means the actual knowledge, after reasonable inquiry, of the individuals listed on <B><U>&lrm;</U></B><U>Section&nbsp;8.3(j)</U>&nbsp;of
the Company Disclosure Letter;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<U>knowledge
of the Parent</U>&rdquo; means the actual knowledge, after reasonable inquiry, of the individuals listed on <B><U>&lrm;</U></B><U>Section&nbsp;8.3(k)</U>&nbsp;of
the Parent Disclosure Letter;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<U>Organizational
Documents</U>&rdquo; shall mean, with respect to any Person that is not a natural person: (a)&nbsp;if such Person is a corporation, such
Person&rsquo;s certificate or articles of incorporation, by-laws and similar organizational documents, as amended; (b)&nbsp;if such Person
is a limited liability company, such Person&rsquo;s certificate or articles of formation and operating agreement, as amended; and (c)&nbsp;if
such Person is a limited partnership, such Person&rsquo;s certificate or articles of formation and limited partnership agreement, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<U>Parent
Material Adverse Effect</U>&rdquo; means any Effect that, individually or in the aggregate with any one or more other Effects, (x)&nbsp;results
in a material adverse effect on the business, condition (financial or otherwise) or results of operations of Parent and its Subsidiaries,
taken as a whole or (y)&nbsp;prevents, materially impairs, materially impedes or materially delays the consummation of the Merger and
the other transactions contemplated hereby on a timely basis and in any event on or before the Termination Date; <U>provided</U>, that
with respect to clause (x)&nbsp;only, no Effect to the extent arising out of the following (alone or in combination), shall, to such extent,
be deemed to constitute, or be taken into account in determining whether there has been or would or could be, a Parent Material Adverse
Effect: (1)&nbsp;general economic or business conditions or in the financial, debt, banking, capital, credit or securities markets, or
in interest or exchange rates, in each case, generally affecting any of the industries in which Parent or its Subsidiaries operate, (2)&nbsp;any
adoption, implementation, modification, repeal, interpretation, proposal of or other changes in any applicable Laws or any changes in
applicable accounting regulations or principles, or in interpretations of any of the foregoing, (3)&nbsp;any change in the price or trading
volume of Parent&rsquo;s stock, in and of itself (<U>provided</U>, that the facts or occurrences giving rise to or contributing to such
change that are not otherwise excluded from the definition of &ldquo;Parent Material Adverse Effect&rdquo; may be taken into account in
determining whether there has been a Parent Material Adverse Effect), (4)&nbsp;any failure by Parent to meet internal or published projections,
forecasts or revenue or earnings predictions, in and of itself (<U>provided</U>, that the facts or occurrences giving rise to or contributing
to such failure that are not otherwise excluded from the definition of &ldquo;Parent Material Adverse Effect&rdquo; may be taken into
account in determining whether there has been a Parent Material Adverse Effect), (5)&nbsp;political, geopolitical, social or regulatory
conditions, including any outbreak, continuation or escalation of any military conflict, declared or undeclared war, armed hostilities,
civil unrest, public demonstrations or acts of foreign or domestic terrorism or sabotage (including hacking, ransomware or any other electronic
attack), or any escalation or worsening of any such conditions, (6)&nbsp;any natural or manmade disasters or calamities, weather conditions
including hurricanes, floods, tornados, tsunamis, earthquakes and wild fires, cyber outages, or other force majeure events, or any escalation
or worsening of such conditions, (7)&nbsp;any epidemic, pandemic or outbreak of disease (including, for the avoidance of doubt, COVID-19),
or any escalation or worsening of such conditions, (8)&nbsp;the announcement of this Agreement and the transactions contemplated hereby,
including the initiation of litigation by any Person with respect to this Agreement, and including any termination of, reduction in or
similar negative impact on relationships, contractual or otherwise, with any customers, suppliers, distributors, partners or employees
of Parent and its Subsidiaries due to the announcement and consummation of the transactions contemplated hereby or the identity of the
parties to this Agreement, or the consummation of the transactions contemplated hereby (<U>provided</U> that this clause (8)&nbsp;shall
not apply to (x)&nbsp;any representation or warranty in <B><U>&lrm;</U></B><U>Section&nbsp;4.4</U> to the extent that the purpose of such
representation or warranty is to address the consequences resulting from the execution and delivery of this Agreement or the consummation
of the Merger, (y)&nbsp;a to the extent related to such representations and warranties identified in the preceding clause (x), the condition
set forth in <B><U>&lrm;</U></B><U>Section&nbsp;6.2(a)</U>, and (z)&nbsp;any action or omission by Parent, any Subsidiary of Parent or
their respective Representatives in order to comply with Parent&rsquo;s obligations under <B><U>&lrm;</U></B><U>Section&nbsp;5.2</U>),
(9)&nbsp;any action taken by Parent, or which Parent causes to be taken by any of its Subsidiaries, in each case which is expressly required
by this Agreement, (10)&nbsp;any actions taken (or omitted to be taken) at the express written request of the Company; <U>provided</U>,
that in the case of clauses (1), (2), (5), (6), and (7), to the extent the impact of such Effect is not disproportionately adverse to
Parent and its Subsidiaries, taken as a whole, as compared to other companies operating in the industry in which Parent and its Subsidiaries
conduct business (and <U>provided further</U>, that in such event, only the incremental disproportionate adverse impact shall be taken
into account when determining whether there has been a &ldquo;Parent Material Adverse Effect&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 105; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(o)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<U>Permitted
Encumbrance</U>&rdquo; means (i)&nbsp;statutory liens for current Taxes not yet due or payable or the validity or amount of which is being
contested in good faith by appropriate proceedings and for which appropriate reserves have been established in accordance with GAAP, (ii)&nbsp;mechanics&rsquo;,
materialmen&rsquo;s, carriers&rsquo;, workers&rsquo;, repairers&rsquo; and other similar liens arising or incurred in the ordinary course
of business for amounts that are not yet delinquent, or the validity or amount of which is being contested in good faith by appropriate
proceedings and for which appropriate reserves have been established in accordance with GAAP, (iii)&nbsp;zoning, entitlement, conservation
restriction and other land use and environmental regulations promulgated by Governmental Entities which is not violated by the current
occupancy or use of the property; and (iv)&nbsp;all exceptions, restrictions, easements, imperfections of title, charges, rights-of-way
and other Encumbrances that do not or would not materially interfere with the present use, occupancy or value of such asset of the Company
and its Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(p)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<U>Person</U>&rdquo;
means an individual, corporation, partnership, limited liability company, association, trust or other entity or organization, including
any Governmental Entity;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(q)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<U>Prohibited
Person</U>&rdquo; shall mean any Person that is the target of sanctions Laws, including (a)&nbsp;a Person that has been determined by
a Governmental Entity to be the subject of a prohibition on such conduct of any law, regulation, rule&nbsp;or executive order administered
by OFAC; (b)&nbsp;the government, including any political subdivision, agency or instrumentality thereof, of any country against which
the United States maintains comprehensive economic sanctions or embargoes (currently Iran, Syria, Cuba, North Korea, and the Crimea region
of Ukraine); (c)&nbsp;any Person that acts on behalf of or is owned or controlled by a government of a country against which the United
States maintains comprehensive economic sanctions or embargoes; (d)&nbsp;any Person organized or resident in a country or territory subject
to comprehensive sanctions; (e)&nbsp;any Person that has been identified on the OFAC Specially Designated Nationals and Blocked Persons
List (Appendix A to 31 C.F.R. Ch. V), as amended from time to time, or fifty percent (50%) or more of which is owned, directly or indirectly,
by any such Person or Persons, or, where relevant under applicable sanctions Laws, controlled by any such Person or Persons or acting
for or on behalf of such Person or Persons; or (f)&nbsp;any Person that has been designated on any similar list or Order published by
a Governmental Entity in the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 106; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(r)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<U>Public
Health Measures</U>&rdquo; means any quarantine, &ldquo;shelter in place,&rdquo; &ldquo;stay at home,&rdquo; furlough, workforce reduction,
social distancing, shut down, closure, sequester or any other Law, order, directive, guideline or recommendation by any Governmental Entity,
in connection with or in response to COVID-19 or any other epidemic, pandemic or outbreak of disease, or in connection with or in response
to any other public health conditions, in each case, whether such Law, order, directive, guideline or recommendation, or such measures,
are in place currently or adopted or modified hereafter;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(s)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<U>Rights
Agent</U>&rdquo; means the financial institution designated by Parent to act as the rights agent under the CVR Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(t)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<U>Subsidiary</U>&rdquo;
means, with respect to any Person, any other Person of which stock or other equity interests having ordinary voting power to elect more
than 50% of the board of directors or other governing body are owned, directly or indirectly, by such first Person (and notwithstanding
anything to the contrary herein, the Company makes no representation, warranty, covenant or agreement in this Agreement with respect to
any third party equity holder of any joint venture or any securities held by such Person); and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(u)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<U>Willful
Breach</U>&rdquo; means (a)&nbsp;with respect to any material breach of a representation and warranty, that the breaching party had actual
knowledge (as opposed to imputed or constructive knowledge or knowledge that could have been obtained after inquiry, or recklessness or
negligence) of such breach as of the date of this Agreement and (b)&nbsp;with respect to any material breach of a covenant or other agreement,
that is the consequence of an act or omission by a party with the actual knowledge (as opposed to imputed or constructive knowledge or
knowledge that could have been obtained after inquiry, or recklessness or negligence) that the action so taken or omitted to be taken
constituted a material breach of such covenant or agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;8.4</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Interpretation</U>.
When a reference is made in this Agreement to a Section, Article, Exhibit&nbsp;or Schedule such reference shall be to a Section, Article,
Exhibit&nbsp;or Schedule of this Agreement unless otherwise indicated. The table of contents and headings contained in this Agreement
or in any Exhibit&nbsp;or Schedule are for convenience of reference purposes only and shall not affect in any way the meaning or interpretation
of this Agreement. All words used in this Agreement will be construed to be of such gender or number as the circumstances require. Any
capitalized terms used in any Exhibit&nbsp;or Schedule but not otherwise defined therein shall have the meaning as defined in this Agreement.
All Exhibits and Schedules annexed hereto or referred to herein are hereby incorporated in and made a part of this Agreement as if set
forth herein. The word &ldquo;including&rdquo; and words of similar import when used in this Agreement will mean &ldquo;including, without
limitation,&rdquo; unless otherwise specified. The words &ldquo;hereof,&rdquo; &ldquo;herein&rdquo; and &ldquo;hereunder&rdquo; and words
of similar import when used in this Agreement shall refer to the Agreement as a whole and not to any particular provision in this Agreement.
The term &ldquo;or&rdquo; is not exclusive. The word &ldquo;will&rdquo; shall be construed to have the same meaning and effect as the
word &ldquo;shall.&rdquo; The phrase &ldquo;ordinary course of business&rdquo; means an action taken, or omitted to be taken, in the ordinary
course of business, consistent with past practice. References to days mean calendar days unless otherwise specified. If the last day of
a period by which an act is to be done under this Agreement is a non-Business Day, the period in question shall end on the next succeeding
Business Day. Any document or item will be deemed &ldquo;furnished,&rdquo; &ldquo;delivered,&rdquo; &ldquo;provided&rdquo; or &ldquo;made
available&rdquo; within the meaning of this Agreement if such document or item&nbsp;(a)&nbsp;is included in the electronic data room to
which the receiving party has access and is available to such party, or (b)&nbsp;actually delivered or provided to the receiving party
or its representatives, in each case, at least two (2)&nbsp;days prior to the date hereof or the Closing, as applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 107; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;8.5</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Entire
Agreement</U>. This Agreement (including the Exhibits hereto), the Company Disclosure Letter, the CVR Agreement, the Parent Disclosure
Letter and the Confidentiality Agreement constitute the entire agreement, and supersede all prior written agreements, arrangements, communications
and understandings and all prior and contemporaneous oral agreements, arrangements, communications and understandings among the parties
with respect to the subject matter hereof and thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;8.6</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Parties
in Interest</U>. This Agreement is not intended to, and shall not, confer upon any other Person other than the parties and their respective
successors and permitted assigns any rights or remedies hereunder, except (a)&nbsp;with respect to <U>&lrm;Section&nbsp;5.13</U> which
shall inure to the benefit of the Persons benefiting therefrom who are intended to be third party beneficiaries thereof and (b)&nbsp;if
the Effective Time occurs, the right of the Company stockholders to receive the Merger Consideration, any dividends or other distributions
payable pursuant to <U>&lrm;Section&nbsp;2.2(k)</U>&nbsp;and cash in lieu of any fractional shares payable pursuant to <U>&lrm;Section&nbsp;2.5</U>,
in accordance with the terms and conditions of this Agreement. The representations and warranties in this Agreement are the product of
negotiations among the parties hereto. In some instances, the representations and warranties in this Agreement may represent an allocation
among the parties hereto of risks associated with particular matters regardless of the knowledge of any of the parties hereto. Consequently,
Persons other than the parties hereto may not rely upon the representations and warranties in this Agreement or the characterization of
actual facts or circumstances as of the date of this Agreement or as of any other date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;8.7</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Governing
Law</U>. This Agreement and all disputes or controversies arising out of or relating to this Agreement or the transactions contemplated
hereby shall be governed by, and construed in accordance with, the internal laws of the State of Delaware, without regard to the laws
of any other jurisdiction that might be applied because of the conflicts of laws principles of the State of Delaware.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;8.8</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Submission
to Jurisdiction</U>. Each of the parties irrevocably agrees that any legal action or proceeding arising out of or relating to this Agreement
brought by any party or its Affiliates against any other party or its Affiliates shall be brought and determined in the Court of Chancery
of the State of Delaware; <U>provided</U>, that if jurisdiction is not then available in the Court of Chancery of the State of Delaware,
then any such legal action or proceeding may be brought in any federal court located in the State of Delaware or any other Delaware state
court. Each of the parties hereby irrevocably submits to the jurisdiction of the aforesaid courts for itself and with respect to its property,
generally and unconditionally, with regard to any such action or proceeding arising out of or relating to this Agreement and the transactions
contemplated hereby, including the Merger. Each of the parties agrees not to commence any action, suit or proceeding relating thereto
except in the courts described above in Delaware, other than actions in any court of competent jurisdiction to enforce any judgment, decree
or award rendered by any such court in Delaware as described herein. Each of the parties further agrees that notice as provided herein
shall constitute sufficient service of process and the parties further waive any argument that such service is insufficient. Each of the
parties hereby irrevocably and unconditionally waives, and agrees not to assert, by way of motion or as a defense, counterclaim or otherwise,
in any action or proceeding arising out of or relating to this Agreement or the transactions contemplated hereby, including the Merger,
(a)&nbsp;any claim that it is not personally subject to the jurisdiction of the courts in Delaware as described herein for any reason,
(b)&nbsp;that it or its property is exempt or immune from jurisdiction of any such court or from any legal process commenced in such courts
(whether through service of notice, attachment prior to judgment, attachment in aid of execution of judgment, execution of judgment or
otherwise) and (c)&nbsp;that (i)&nbsp;the suit, action or proceeding in any such court is brought in an inconvenient forum, (ii)&nbsp;the
venue of such suit, action or proceeding is improper or (iii)&nbsp;this Agreement, or the subject matter hereof, may not be enforced in
or by such courts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 108; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;8.9</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Assignment;
Successors</U>. Neither this Agreement nor any of the rights, interests or obligations under this Agreement may be assigned or delegated,
in whole or in part, by operation of law or otherwise, by any party without the prior written consent of the other parties, and any such
assignment without such prior written consent shall be null and void. Subject to the preceding sentence, this Agreement will be binding
upon, inure to the benefit of, and be enforceable by, the parties and their respective successors and assigns.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;8.10</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Specific
Performance</U>. The parties agree that irreparable damage would occur in the event that any of the provisions of this Agreement were
not performed in accordance with their specific terms or were otherwise breached. Accordingly, each of the Company (on behalf of itself
and on behalf of the holders of Company Shares as third party beneficiaries under <U>&lrm;Section&nbsp;8.6</U>), Parent and Merger Sub
shall be entitled to specific performance of the terms hereof, including an injunction or injunctions to prevent breaches or threatened
breaches of this Agreement and to enforce specifically the performance of the terms and provisions of this Agreement, this being in addition
to any other remedy to which such party is entitled at law or in equity. Each of the parties hereby further waives (a)&nbsp;any defense
in any action for specific performance that a remedy at law would be adequate and (b)&nbsp;any requirement under any Law to post security
as a prerequisite to obtaining equitable relief.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;8.11</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Currency</U>.
All references to &ldquo;dollars&rdquo; or &ldquo;$&rdquo; or &ldquo;US$&rdquo; in this Agreement refer to United States dollars, which
is the currency used for all purposes in this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;8.12</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Severability</U>.
Whenever possible, each provision or portion of any provision of this Agreement shall be interpreted in such manner as to be effective
and valid under applicable Law, but if any provision or portion of any provision of this Agreement is held to be invalid, illegal or unenforceable
in any respect under any applicable Law or rule&nbsp;in any jurisdiction, such invalidity, illegality or unenforceability shall not affect
any other provision or portion of any provision in such jurisdiction, and this Agreement shall be reformed, construed and enforced in
such jurisdiction as if such invalid, illegal or unenforceable provision or portion of any provision had never been contained herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;8.13</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Waiver
of Jury Trial</U>. EACH OF THE PARTIES TO THIS AGREEMENT HEREBY IRREVOCABLY WAIVES ALL RIGHT TO A TRIAL BY JURY IN ANY ACTION, PROCEEDING
OR COUNTERCLAIM ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY. EACH PARTY TO THIS AGREEMENT CERTIFIES
AND ACKNOWLEDGES THAT: (A)&nbsp;NO REPRESENTATIVE OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD
NOT SEEK TO ENFORCE THE FOREGOING WAIVER IN THE EVENT OF A LEGAL ACTION; (B)&nbsp;SUCH PARTY HAS CONSIDERED THE IMPLICATIONS OF THIS WAIVER;
(C)&nbsp;SUCH PARTY MAKES THIS WAIVER VOLUNTARILY; AND (D)&nbsp;SUCH PARTY HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER
THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS <FONT STYLE="text-transform: uppercase"><U>&lrm;Section&nbsp;8.13</U></FONT>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 109; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;8.14</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Counterparts</U>.
This Agreement may be executed in two or more counterparts, all of which shall be considered one and the same instrument and shall become
effective when one or more counterparts have been signed by each of the parties and delivered to the other parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;8.15</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Facsimile
or .pdf Signature</U>. This Agreement may be executed by facsimile, electronic mail (including any electronic signature covered by the
U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act, the Electronic Signatures and Records Act or other applicable law,
e.g., www.docusign.com) or .pdf signature, and any signature so delivered shall be deemed to have been duly and validly delivered and
be valid and effective, and constitute an original, for all purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;8.16</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>No
Presumption Against Drafting Party</U>. Each of Parent, Merger Sub and the Company acknowledges that each party to this Agreement has
been represented by counsel in connection with this Agreement and the transactions contemplated by this Agreement. Accordingly, any rule&nbsp;of
law or any legal decision that would require interpretation of any claimed ambiguities in this Agreement against the drafting party has
no application and is expressly waived.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000; ">Section&nbsp;8.17</FONT><FONT STYLE="color: #010000; ">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Non-Recourse</U>.
Each party hereto agrees, on behalf of itself and its former, current and future holders of any equity, controlling persons, directors,
officers, employees, agents, attorneys, controlled Affiliates, members, managers, general or limited partners, stockholders and assignees
of it and its controlled Affiliates, that all Action, claims, obligations, liabilities, or causes of action (whether in contract or in
tort, in law or in equity or otherwise, or granted by statute or otherwise, whether by or through attempted piercing of the corporate,
limited partnership, limited liability company or other entity veil or any other theory or doctrine, including alter ego or otherwise)
that may be based upon, in respect of, arise under, out or by reason of, be connected with, or relate in any manner to: (a)&nbsp;this
Agreement or any other agreement referenced herein or contemplated hereby or the transactions contemplated hereunder or thereunder, (b)&nbsp;the
negotiation, execution or performance of this Agreement or any other agreement referenced herein or contemplated hereby (including any
representation or warranty made in, in connection with, or as an inducement to, this Agreement or such other agreement), and (c)&nbsp;any
breach or violation of this Agreement or any other agreement referenced herein or contemplated hereby, in each case, may be made only
against (and are those solely of) the Persons that are expressly identified as parties in the preamble to this Agreement (or any other
agreement referenced herein or contemplated hereby, as applicable) and in accordance with, and subject to the terms of, this Agreement
(or any other agreement referenced herein or contemplated hereby, in each case as applicable).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 110; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[The remainder of this page&nbsp;is intentionally
left blank.]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 111; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the parties
have caused this Agreement to be executed as of the date first written above by their respective officers thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">SPECTRUM PHARMACEUTICALS,&nbsp;INC.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 3%"><FONT STYLE="font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 47%"><FONT STYLE="font-size: 10pt">/s/ Daniel A. Peisert</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">Name: Daniel A. Peisert</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">Title: President and Chief Executive Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">ASSERTIO HOLDINGS,&nbsp;INC.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">/s/ Daniel A. Peisert</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">Name: Daniel A. Peisert</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">Title: President and Chief Executive Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; text-align: left"><FONT STYLE="font-size: 10pt">SPADE
    MERGER SUB 1,&nbsp;INC.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">/s/ Thomas J. Riga</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">Name: Thomas J. Riga</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">Title: President and Chief Executive Officer</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: White">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: White">Signature
Page&nbsp;to Agreement and Plan of Merger</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: White">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: White"></FONT></P>

<!-- Field: Page; Sequence: 112 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: White">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Exhibit&nbsp;A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form&nbsp;of Certificate of Merger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[See attached].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 113 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">FORM&nbsp;OF</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATE OF MERGER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>of</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SPADE MERGER SUB 1,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>with and into</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SPECTRUM PHARMACEUTICALS,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>[&nbsp;&#9679;&nbsp;], 2023</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to Title 8, Section&nbsp;251(c)&nbsp;of
the Delaware General Corporation Law (the &ldquo;<U>DGCL</U>&rdquo;), Spectrum Pharmaceuticals,&nbsp;Inc., a Delaware corporation (the
 &ldquo;<U>Company</U>&rdquo;), hereby certifies the following information relating to the merger of Spade Merger Sub 1,&nbsp;Inc., a Delaware
corporation (&ldquo;<U>Merger Sub</U>&rdquo;), with and into the Company (the &ldquo;<U>Merger</U>&rdquo;):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FIRST</B></FONT><FONT STYLE="font-size: 10pt">:</FONT>&#9;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
name and state of incorporation of each of the constituent corporations (each, a &ldquo;<U>Constituent Corporation</U>&rdquo;) are as
follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="width: 60%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 58%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Name</U></B></FONT></TD>
    <TD STYLE="width: 42%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>State of Incorporation </U></B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Spectrum Pharmaceuticals,&nbsp;Inc.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delaware</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Spade Merger Sub 1,&nbsp;Inc.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delaware</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECOND</B></FONT><FONT STYLE="font-size: 10pt">:</FONT>&#9;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Agreement and Plan of Merger, dated as of April&nbsp;24, 2023 (the &ldquo;<U>Agreement</U>&rdquo;), by and among Assertio Holdings,&nbsp;Inc.
(&ldquo;<U>Parent</U>&rdquo;), a Delaware corporation, Merger Sub, a wholly owned subsidiary of Parent, and the Company, setting forth,
among other things, the terms and conditions of the merger of Merger Sub with and into the Company, with the Company continuing as the
surviving corporation and a wholly owned subsidiary of Parent (the &ldquo;<U>Merger</U>&rdquo;), has been approved, adopted, certified,
executed and acknowledged by each of the Constituent Corporations in accordance with Section&nbsp;251 of the DGCL.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>THIRD</B></FONT><FONT STYLE="font-size: 10pt">:</FONT>&#9;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
name of the surviving corporation of the Merger is [Spectrum Pharmaceuticals,&nbsp;Inc.] (the &ldquo;<U>Surviving Corporation</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FOURTH</B></FONT><FONT STYLE="font-size: 10pt">:</FONT>&#9;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">At
the effective time of the Merger, the certificate of incorporation of the Company, as in effect immediately prior to the Merger, shall
be amended and restated so as to read in its entirety as set forth in <U>Exhibit&nbsp;A</U> hereto and, as so amended and restated, shall
be the Amended and Restated Certificate of Incorporation of the Surviving Corporation until thereafter changed or amended as provided
therein or by applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FIFTH</B></FONT><FONT STYLE="font-size: 10pt">:</FONT>&#9;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">An
executed copy of the Agreement is on file at the principal place of business of the Surviving Corporation located [&nbsp;&#9679;&nbsp;].</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIXTH</B></FONT><FONT STYLE="font-size: 10pt">:</FONT>&#9;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">A
copy of the Agreement will be furnished by the Surviving Corporation, on request and without cost, to any stockholder of any Constituent
Corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>Remainder of Page&nbsp;Intentionally Left Blank</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 114 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>IN
WITNESS WHEREOF</B></FONT>, [Spectrum Pharmaceuticals,&nbsp;Inc.], as the Surviving Corporation in the Merger, has caused this Certificate
of Merger to be executed by a duly authorized officer as of the date first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">SPECTRUM PHARMACEUTICALS,&nbsp;INC.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: White">[<I>Signature
Page&nbsp;to Merger Certificate </I>]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 115 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT&nbsp;A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(See attached)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 116 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Exhibit&nbsp;B</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form&nbsp;of CVR Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM&nbsp;OF CONTINGENT VALUE RIGHTS AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in"><FONT STYLE="background-color: White"><B><I>Form&nbsp;Final</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">THIS CONTINGENT VALUE RIGHTS
AGREEMENT, dated as of [&#9679;], (this &ldquo;<U>Agreement</U>&rdquo;), is entered into by and between Assertio Holdings,&nbsp;Inc.,
a Delaware corporation (&ldquo;<U>Parent</U>&rdquo;), and [RIGHTS AGENT], a [&#9679;], as Rights Agent (the &ldquo;<U>Rights Agent</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>RECITALS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, Parent, Spectrum
Pharmaceuticals,&nbsp;Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;) and Spade Merger Sub 1, a Delaware corporation and
wholly owned subsidiary of the Parent (&ldquo;<U>Merger Sub</U>&rdquo;) have entered into an Agreement and Plan of Merger dated as of
April&nbsp;24, 2023 (as amended, restated, supplemented or otherwise modified from time to time pursuant to its terms, the &ldquo;<U>Merger
Agreement</U>&rdquo;), pursuant to which Merger Sub will merge with and into the Company, with the Company being the surviving corporation
(the &ldquo;<U>Surviving Corporation</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, pursuant to the Merger
Agreement, Parent has agreed to provide to (i)&nbsp;the holders of shares of Company Common Stock, and the holders of the Company Warrants
immediately prior to the Effective Time that are, in each case, validly converted into Merger Consideration (or a portion thereof) and
(ii)&nbsp;the holders of Company Stock Options, Company RSUs and Company SARs (the awards in clause (ii)&nbsp;collectively, &ldquo;<U>Company
Equity Awards</U>&rdquo;) who are entitled to CVRs pursuant to Section&nbsp;2.3 of the Merger Agreement, in each case, pursuant to terms
set forth in the Merger Agreement, the right to receive contingent cash payments and/or Parent Common Stock (as determined in the sole
discretion of Parent) (each, a &ldquo;<U>CVR</U>&rdquo;) as hereinafter described; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, pursuant to this
Agreement, the maximum potential amount payable per CVR is $0.20, without interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, in consideration
of the foregoing and the consummation of the transactions referred to above, Parent and Rights Agent agree, for the equal and proportionate
benefit of all holders of CVRs, as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Article&nbsp;I</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><U>DEFINITIONS;
CERTAIN RULES OF CONSTRUCTION</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt; ">Section&nbsp;1.1</FONT><FONT STYLE="">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Definitions</U>.
Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to them in the Merger Agreement. As used in this
Agreement, the following terms will have the following meanings:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>2024 Annual Net
Sales Milestone</U>&rdquo; means the achievement of Net Sales exceeding $175,000,000 during the 2024 Annual Net Sales Milestone Period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>2024 Annual Net
Sales Milestone Payment</U>&rdquo; means a dollar amount per CVR equal to the lesser of (i)&nbsp;$0.10 and (ii)&nbsp;(A)&nbsp;0.249 <I>multiplied
</I>by (B)&nbsp;(I)&nbsp;the Applicable Parent Stock Price, <I>multiplied by</I> (II)&nbsp;the Exchange Ratio (rounded down to the closest
hundredth of a penny) (<U>provided</U> that such amount shall not be less than $0).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 117 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>2024 Annual Net
Sales Milestone Period</U>&rdquo; means the period commencing on January&nbsp;1, 2024 and ending December&nbsp;31, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>2025 Annual Net
Sales Milestone</U>&rdquo; means the achievement of Net Sales exceeding $225,000,000 for the 2025 Annual Net Sales Milestone Period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>2025 Annual Net
Sales Milestone Payment</U>&rdquo; means a dollar amount per CVR equal to the lesser of (i)&nbsp;$0.10 and (ii)&nbsp;(A)&nbsp;0.249 <I>multiplied
</I>by (B)&nbsp;(I)&nbsp;the Applicable Parent Stock Price, <I>multiplied by</I> (II)&nbsp;the Exchange Ratio, <I>less</I> (III)&nbsp;the
2024 Annual Net Sales Milestone Payment (rounded down to the closest hundredth of a penny) (<U>provided</U> that such amount shall not
be less than $0).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>2025 Annual Net
Sales Milestone Period</U>&rdquo; means the period commencing on January&nbsp;1, 2025 and ending December&nbsp;31, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Acting Holders</U>&rdquo;
means, at the time of determination, Holders of not less than 35% of the outstanding CVRs, as set forth in the CVR Register.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Applicable Parent
Stock Price</U>&rdquo; means the lower of the closing price for Parent Common Stock as reported by Nasdaq (or any national securities
exchange or over the counter trading market on which the Parent Common Stock primarily trades if the Parent Common Stock is no longer
listed on Nasdaq) (A)&nbsp;on the Closing Date, and (B)&nbsp;on the applicable Milestone Payment Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Agreement</U>&rdquo;
has the meaning set forth in the first paragraph hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Annual Net Sales
Milestone</U>&rdquo; means any of the 2024 Annual Net Sales Milestone and the 2025 Annual Net Sales Milestone.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Assignee</U>&rdquo;
has the meaning set forth in <U>Section&nbsp;7.3</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Authorized Officer</U>&rdquo;
means an employee of Parent with the title of President, Vice President, Senior Vice President, Executive Vice President, Secretary, Treasurer
or Assistant Treasurer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Board of Directors</U>&rdquo;
means the board of directors of Parent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Board Resolution</U>&rdquo;
means a copy of a resolution certified by an Authorized Officer to have been duly adopted by the Board of Directors and to be in full
force and effect on the date of such certification, and delivered to the Rights Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Business Day</U>&rdquo;
means any day other than a Saturday, Sunday or a day on which banking institutions in New York, New York are authorized or obligated by
law or executive order to remain closed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Calendar Year</U>&rdquo;
means each respective period of twelve (12) consecutive months beginning on January&nbsp;1 and ending on December&nbsp;31.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 118; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Change of Control</U>&rdquo;
means (a)&nbsp;a sale or other disposition of all or substantially all of the assets of either Parent or the Surviving Corporation on
a consolidated basis (other than to any Subsidiary (direct or indirect) of Parent), (b)&nbsp;a merger or consolidation involving either
Parent or the Surviving Corporation in which Parent or the Surviving Corporation, as applicable, is not the surviving entity, or (c)&nbsp;any
other transaction involving either Parent or the Surviving Corporation in which the stockholders of Parent or the Surviving Corporation,
as applicable, immediately prior to such transaction own less than 50% of the surviving entity&rsquo;s voting power immediately after
the transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Code</U>&rdquo;
shall mean the Internal Revenue Code of 1986, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Combination Product</U>&rdquo;
means any product comprising the Product and at least one other therapeutically active product, compound or pharmaceutical ingredient
that is not the Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Combined Milestone
Cash and Stock Payment</U>&rdquo; has the meaning set forth in <U>Section&nbsp;2.4(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Company</U>&rdquo;
has the meaning set forth in the recitals to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Company Common Stock</U>&rdquo;
means shares of common stock, par value $0.001, of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Company Equity Awards</U>&rdquo;
has the meaning set forth in the recitals to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>CVR</U>&rdquo; has
the meaning set forth in the recitals to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>CVR Register</U>&rdquo;
has the meaning set forth in <U>Section&nbsp;2.3(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>CVR Shortfall</U>&rdquo;
has the meaning set forth in <U>Section&nbsp;4.4(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Diligent Efforts</U>&rdquo;
means, with respect to a particular task related to the Product, the efforts required to carry out such task in a good faith, diligent
and sustained manner without undue interruption, pause or delay, which level is at least commensurate with the level of commercially reasonable
efforts that a pharmaceutical company of comparable size and resources as those of Parent and its Affiliates would devote to a product
of similar commercial potential and stage in development or product life as the Product, taking into account its safety, tolerability,
and efficacy, its proprietary position (including patent coverage) and profitability (including pricing, supply costs and reimbursement
status), the competitiveness of alternative third party products, the regulatory structure involved, the regulatory environment, and technical,
commercial, legal, scientific and/or medical factors. Notwithstanding anything to the contrary herein, Diligent Efforts shall be determined
without regard to any payments hereunder. For the avoidance of doubt, Parent shall not be required to pursue a Combination Product in
order to satisfy its obligation to use Diligent Efforts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>DTC</U>&rdquo; means
The Depository Trust Company or any successor thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Equity Award Holders</U>&rdquo;
means the Holders of CVRs granted with respect to Company Equity Awards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 119; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Fiscal Quarter</U>&rdquo;
means each of the following three (3)-month periods: January&nbsp;1 through March&nbsp;31; April&nbsp;1 through June&nbsp;30; July&nbsp;1
through September&nbsp;30; and October&nbsp;1 through December&nbsp;31.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>GAAP</U>&rdquo;
means the generally accepted accounting principles in the United States as established by the Financial Accounting Standards Board or
any successor entity or other entity generally recognized as having the right to establish such principles in the United States, in each
case, (i)&nbsp;which principals are currently used at the applicable time by Parent in the preparation of the consolidated financial statements
of Parent and (ii)&nbsp;as consistently applied throughout the periods involved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Holder</U>&rdquo;
means a Person in whose name a CVR is registered in the CVR Register at the applicable time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Independent Accountant</U>&rdquo;
means an independent certified public accounting firm of nationally recognized standing designated either (a)&nbsp;jointly by the Acting
Holders and Parent, or (b)&nbsp;if such parties fail to make a designation, jointly by an independent public accounting firm selected
by Parent and an independent public accounting firm selected by the Acting Holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Merger</U>&rdquo; has the meaning set
forth in the recitals to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Merger Agreement</U>&rdquo;
has the meaning set forth in the recitals to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Merger Sub</U>&rdquo;
has the meaning set forth in the recitals to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Milestone Cash Payment</U>&rdquo;
has the meaning set forth in <U>Section&nbsp;2.4(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Milestone Determination
Date</U>&rdquo; means, with respect to any Annual Net Revenue Milestone, the date that is sixty (60) days following the last day of the
applicable Annual Net Sales Milestone Period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Milestone Failure
Notice</U>&rdquo; has the meaning set forth in <U>Section&nbsp;2.4(g)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Milestone Notice</U>&rdquo;
has the meaning set forth in <U>Section&nbsp;2.4(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Milestone Parent
Stock Price</U>&rdquo; means an amount equal to the closing price for Parent Common Stock as reported by Nasdaq (or any national securities
exchange or over the counter trading market on which the Parent Common Stock primarily trades if the Parent Common Stock is no longer
listed on Nasdaq) on the applicable Milestone Payment Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Milestone Payment</U>&rdquo;
means any of the 2024 Annual Net Sales Milestone Payment or the 2025 Annual Net Sales Milestone Payment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Milestone Payment
Amount</U>&rdquo; means, in respect of an Annual Net Sales Milestone, for a given Holder, the product of (a)&nbsp;the Milestone Payment
in respect of such Annual Net Sales Milestone and (b)&nbsp;the number of CVRs held by such Holder as reflected on the CVR Register as
of the close of business on the date of the applicable Milestone Notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 120; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Milestone Payment
Date</U>&rdquo; has the meaning set forth in <U>Section&nbsp;2.4(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Milestone Stock
Payment</U>&rdquo; has the meaning set forth in <U>Section&nbsp;2.4(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Net Sales</U>&rdquo;
means without duplication, the aggregate gross worldwide revenues received (i)&nbsp;by or on behalf of Parent and its Affiliates for the
Product sold to third parties, including to distributors and end-users (other than to Parent or any of its Affiliates), (ii)&nbsp;by or
on behalf of Parent and its Affiliates in the form of any upfront fees, royalty, milestone payments or other consideration received from
any third party to whom rights to the Product have been licensed (such royalty and sales milestone payments described in this clause (ii)&nbsp;collectively,
 &ldquo;<U>Sublicensing Revenue</U>&rdquo;) and (iii)&nbsp;by or on behalf of Sublicensees in respect of sales by such Sublicensees of
the Product&#894; <U>provided</U>, that aggregate gross worldwide revenues received pursuant to clause (i)&nbsp;and clause (ii)&nbsp;of
this definition shall be reduced by the Permitted Deductions incurred by the applicable entity with respect to such sales or licenses,
all as determined in accordance with the applicable entity&rsquo;s usual and customary accounting methods consistent with the treatment
of other branded prescription products sold or licensed by the applicable entity, which shall be in accordance with GAAP, including the
accounting methods for translating gross revenues denominated in foreign currencies into United States dollar amounts. Notwithstanding
the foregoing, if the Product is sold as part of a Combination Product, then Net Sales for such Product shall be determined by multiplying
the Net Sales of the Combination Product (as calculated in accordance with analogous criteria as set forth above for the &ldquo;Net Sales&rdquo;
definition) by the fraction, A / (A+B) where A is the weighted average sale price of such Product when sold separately in finished form,
and B is the weighted average sale price of the other active product(s), compound(s)&nbsp;or ingredient(s)&nbsp;in such Combination Product
sold separately in finished form (the &ldquo;<U>Other Product(s)</U>&rdquo;); <U>provided</U> that (i)&nbsp;if the weighted average sale
price of the Product when sold separately in finished form can be determined but the weighted average sale price of the Other Product(s)&nbsp;cannot
be determined, then Net Sales for such Product shall be calculated by multiplying the Net Sales of such Combination Product (as calculated
in accordance with analogous criteria as set forth above for the &ldquo;Net Sales&rdquo; definition) by the fraction A / C where A is
the weighted average sale price of such Product when sold separately in finished form and C is the weighted average sale price of the
Combination Product; (ii)&nbsp;if the weighted average sale price of the Other Product(s)&nbsp;can be determined but the weighted average
sale price of the Product when sold separately in finished form cannot be determined, Net Sales for such Product shall be calculated by
multiplying the Net Sales of such Combination Product (as calculated in accordance with analogous criteria as set forth above for the
 &ldquo;Net Sales&rdquo; definition) by the following formula: one (1)&nbsp;minus B / C where B is the weighted average sale price of the
Other Product(s)&nbsp;and C is the weighted average sale price of the Combination Product; and (iii)&nbsp;if the weighted average sale
price of both the Product and the Other Product(s)&nbsp;cannot be determined, then Net Sales for such Product shall be calculated by multiplying
the Net Sales of such Combination Product (as calculated in accordance with analogous criteria as set forth above for the &ldquo;Net Sales&rdquo;
definition) by the fraction 1 / D where D is the number of active products, compounds or ingredients in the Combination Product including
the Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Net Sales Statement</U>&rdquo;
means, for a given Annual Net Sales Milestone Period, a written statement of Parent, setting forth with reasonable detail (a)&nbsp;an
itemized delineation and calculation of Net Sales during such Annual Net Sales Milestone Period, (b)&nbsp;an itemized delineation and
calculation of the Permitted Deductions during such Annual Net Sales Milestone Period, (c)&nbsp;an itemized delineation and calculation
of the Sublicensing Revenue, and (d)&nbsp;to the extent that revenues for the Product is recorded in currencies other than United States
dollars during such Annual Net Sales Milestone Period, the exchange rates used for conversion of such foreign currency into United States
dollars.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 121; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Officer&rsquo;s
Certificate</U>&rdquo; means a certificate signed by an Authorized Officer of Parent, in his or her capacity as such an officer, and delivered
to the Rights Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Parent</U>&rdquo;
has the meaning set forth in the first paragraph of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Parent Common Stock</U>&rdquo;
means shares of common stock, par value $0.0001, of Parent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Permitted Deductions</U>&rdquo;
means, to the extent not already excluded from Net Sales, the following deductions that are either included in the billing as part of
the amount charged or invoiced, or otherwise documented as a deduction and accrued in accordance with GAAP specifically attributable to
Net Sales:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(1)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">normal
and customary trade and quantity discounts;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(2)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">accrued
credits, price reductions or discounts by reasons of defects, recalls, returns, rebates or allowances of goods or because of retroactive
price reductions specifically attributable to the Product;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(3)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">chargebacks,
rebates (or the equivalent thereof) and other amounts accrued on sale of the Product, including such amounts mandated by programs of Governmental
Entities;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(4)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">accruals
for rebates (or the equivalent thereof) and administrative fees payable to medical healthcare organizations, commercial payors, group
purchasing organizations or trade customers in line with approved contract terms or other normal and customary understandings and arrangements;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(5)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">accruals
for tariffs, duties, excise, sales, value-added and other Taxes (other than Taxes based on net income) and charges of Governmental Entities;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(6)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">bad
debts, provided that (i)&nbsp;any recovery of bad debts shall be included in Net Sales in the Fiscal Quarter in which recovered and (ii)&nbsp;such
bad debts shall not exceed five percent (5%) of Net Sales;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(7)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">transportation,
freight, postage, importation, insurance and other handling expenses to the extent included in gross amounts invoiced;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(8)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">discounts
pursuant to patient discount programs and any voucher, co-pay assistance and coupon discounts;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(9)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">any
costs associated with effecting a technology transfer with respect to the Product;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 122; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(10)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">accruals
for amounts payable to wholesalers for services related to sales or distribution of the Product; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(11)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">accruals
for distribution and specialty pharmacy provider commissions and fees (including administrative fees and fees related to services provided
pursuant to agreements with specialty pharmacy providers or distribution service agreements with wholesalers, fee-for-service wholesaler
fees and inventory management fees) payable to any third party providing specialty pharmacy or distribution services to Parent, any Assignee
and each of their respective Affiliates, licensees and sublicensees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the avoidance of doubt,
if a single item falls into more than one of the categories set forth in clauses (1)&nbsp;through (10)&nbsp;above, such item may not be
deducted more than once.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">True-ups, changes in estimate,
and other adjustments to Permitted Deduction amounts (whether positive or negative) shall be included in Permitted Deductions in the Fiscal
Quarter as such items are recorded in accordance with GAAP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Permitted Transfer</U>&rdquo;
means: a Transfer of CVRs (a)&nbsp;upon death of a Holder by will or intestacy; (b)&nbsp;made by instrument to an <I>inter vivos </I>or
testamentary trust in which the CVRs are to be passed to beneficiaries upon the death of the trustee; (c)&nbsp;made pursuant to a court
order; (d)&nbsp;made by operation of law (including by consolidation or merger) or without consideration in connection with the dissolution,
liquidation or termination of any corporation, limited liability company, partnership or other Person; (e)&nbsp;in the case of CVRs held
in book-entry or other similar nominee form, from a nominee to a beneficial owner and, if applicable, through an intermediary, or from
such nominee to another nominee for the same beneficial owner, to the extent allowable by DTC; or (f)&nbsp;to Parent as provided in <U>Section&nbsp;2.7</U>,
<U>provided</U>, that with respect to the foregoing clauses (a)&nbsp;&ndash; (e), the transferee in such Transfer of CVRs shall have provided
to Parent a W-8 or W-9, as applicable as soon as practicable following such Transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Product</U>&rdquo;
means the approved product sold as of the Effective Date under the proprietary name ROLVEDON.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Product Transfer</U>&rdquo;
has the meaning set forth in <U>Section&nbsp;4.7</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Qualified Transferee</U>&rdquo;
means (i)&nbsp;any Affiliate of Parent, (ii)&nbsp;any third party acquirer or successor of all or substantially all of the assets Parent
in connection with a Change of Control as specified in clause (a)&nbsp;of the definition of &ldquo;Change of Control&rdquo;, or (iii)&nbsp;any
third party that has net assets of at least $200,000,000 (as shown on its most recently prepared financial statements) at the time of
the applicable Product Transfer or (iv)&nbsp;other person with the prior written consent of the Acting Holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Review Request Period</U>&rdquo;
has the meaning set forth in <U>Section&nbsp;4.4(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Rights Agent</U>&rdquo;
means the Rights Agent named in the first paragraph of this Agreement, until a successor Rights Agent will have become such pursuant to
the applicable provisions of this Agreement, and thereafter &ldquo;Rights Agent&rdquo; will mean such successor Rights Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 123; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Sublicensee</U>&rdquo;
shall mean an authorized or permitted licensee, sublicensee (including at any tier of sublicense) or transferee of Parent or any of its
Affiliates, in each case with respect to rights to the Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Surviving Corporation</U>&rdquo;
has the meaning set forth in the recitals to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading Day</U>&rdquo;
means a day on which Nasdaq (or any national securities exchange or over the counter trading market on which Company primarily trades
if Parent Common Stock is no longer listed on Nasdaq) is open for trading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transfer</U>&rdquo;
means any transfer, pledge, hypothecation, encumbrance, assignment or other disposition (whether by sale, merger, consolidation, liquidation,
dissolution, dividend, distribution or otherwise), the offer to make such a transfer or other disposition, and each contract, arrangement
or understanding, whether or not in writing, to effect any of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt; ">Section&nbsp;1.2</FONT><FONT STYLE="">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Rules&nbsp;of
Construction</U>. When a reference is made in this Agreement to a Section, Article, Exhibit&nbsp;or Schedule such reference shall be to
a Section, Article, Exhibit&nbsp;or Schedule of this Agreement unless otherwise indicated. The table of contents and headings contained
in this Agreement or in any Exhibit&nbsp;or Schedule are for convenience of reference purposes only and shall not affect in any way the
meaning or interpretation of this Agreement. All words used in this Agreement will be construed to be of such gender or number as the
circumstances require. Any capitalized terms used in any Exhibit&nbsp;or Schedule but not otherwise defined therein shall have the meaning
as defined in this Agreement. All Exhibits and Schedules annexed hereto or referred to herein are hereby incorporated in and made a part
of this Agreement as if set forth herein. The word &ldquo;including&rdquo; and words of similar import when used in this Agreement will
mean &ldquo;including, without limitation,&rdquo; unless otherwise specified. The words &ldquo;hereof,&rdquo; &ldquo;herein&rdquo; and
 &ldquo;hereunder&rdquo; and words of similar import when used in this Agreement shall refer to the Agreement as a whole and not to any
particular provision in this Agreement. The term &ldquo;or&rdquo; is not exclusive. The word &ldquo;will&rdquo; shall be construed to
have the same meaning and effect as the word &ldquo;shall.&rdquo; References to days mean calendar days unless otherwise specified. If
the last day of a period by which an act is to be done under this Agreement is a non-Business Day, the period in question shall end on
the next succeeding Business Day. Except as otherwise explicitly specified to the contrary, (a)&nbsp;references to a particular statute
or regulation include all rules&nbsp;and regulations thereunder and any successor statute, rules&nbsp;or regulation, in each case as amended
or otherwise modified from time to time, (b)&nbsp;words in the singular or plural form include the plural and singular form, respectively,
(c)&nbsp;references to a particular Person include such Person&rsquo;s successors and assigns to the extent not prohibited by this Agreement
and (d)&nbsp;all references to dollars or &ldquo;$&rdquo; refer to United States dollars.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Article&nbsp;II</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><U>CONTINGENT
VALUE RIGHTS</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt; ">Section&nbsp;2.1</FONT><FONT STYLE="">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>CVRs</U>.
The CVRs represent the rights of Holders to receive the Milestone Payments in accordance with this Agreement. The initial Holders will
be the holders of Company Shares that are cancelled as of the Effective Time pursuant to the Merger Agreement and the holders of the Company
Warrants immediately prior to the Effective Time that are validly converted into Merger Consideration pursuant to terms set forth in the
Merger Agreement and the holders of Company Equity Awards who are entitled to CVRs pursuant to Section&nbsp;2.3 of the Merger Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 124; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt; ">Section&nbsp;2.2</FONT><FONT STYLE="">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Nontransferable</U>.
The CVRs may not be sold, assigned, Transferred, pledged, encumbered or in any other manner transferred or disposed of, in whole or in
part, other than through a Permitted Transfer. Any attempted Transfer, pledge, encumbrance or disposition of CVRs, in whole or in part,
in violation of this <U>Section&nbsp;2.2</U> shall be void <I>ab initio</I> and of no effect. The CVRs will not be listed on any quotation
system or traded on any securities exchange.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt; ">Section&nbsp;2.3</FONT><FONT STYLE="">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>No
Certificate; Registration; Registration of Transfer; Change of Address</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
CVRs will be issued in book-entry form only and will not be evidenced by a certificate or other instrument.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Rights Agent will keep a register (the &ldquo;<U>CVR Register</U>&rdquo;) for the purpose of registering CVRs and Permitted Transfers
thereof. The CVR Register will initially show one position for Cede&nbsp;&amp; Co. representing all of the Company Shares held by DTC
on behalf of the street holders of the Company Shares held by such holders as of immediately prior to the Effective Time. The Rights Agent
will have no responsibility whatsoever directly to the street name holders with respect to Transfers of CVRs unless and until such CVRs
are Transferred into the name of such street name holders in accordance with <U>Section&nbsp;2.2</U> of this Agreement. With respect to
any payments to be made under <U>Section&nbsp;2.4</U> below, the Rights Agent will accomplish the payment to any former street name holders
of Company Shares by sending one lump payment to DTC. The Rights Agent will have no responsibilities whatsoever with regard to the distribution
of payments by DTC to such street name holders. Parent may receive and inspect a copy of the CVR Register, from time to time, upon written
request made to the Rights Agent. Within two (2)&nbsp;Business Days after receipt of such request, the Rights Agent shall deliver a copy
of the CVR Register, as then in effect, to Parent at the address set forth in <U>Section&nbsp;7.1</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Subject
to the restrictions on transferability set forth in <U>Section&nbsp;2.2</U>, every request made to Transfer a CVR must be in writing and
accompanied by a written instrument of Transfer in a form reasonably satisfactory to the Rights Agent pursuant to its guidelines, duly
executed by the Holder thereof, the Holder&rsquo;s attorney or other personal representative duly authorized in writing or the Holder&rsquo;s
survivor, and setting forth in reasonable detail the circumstances relating to the Transfer. Upon receipt of such written notice, the
Rights Agent will, subject to its reasonable determination that the Transfer instrument is in proper form and the Transfer otherwise complies
with the other terms and conditions of this Agreement (including the provisions of <U>Section&nbsp;2.2</U>), register the Transfer of
the CVRs in the CVR Register. The Rights Agent shall not be obligated to undertake any action with respect to the Transfer of the CVRs
until it shall have been provided with such additional information or material as it may reasonably require to determine that the Transfer
complies with the terms and conditions of this Agreement. Parent and Rights Agent may require payment of a sum sufficient to cover any
stamp or other Tax or governmental charge that is imposed in connection with any such registration of Transfer, unless such Holder has
demonstrated to the reasonable satisfaction of Parent and Rights Agent that any such Tax or charge has been paid or is not applicable.
The Rights Agent shall have no duty or obligation to take any action under any section of this Agreement that requires the payment by
a Holder of applicable Taxes or charges unless and until the Rights Agent is satisfied that all such Taxes or charges have been paid.
All duly Transferred CVRs registered in the CVR Register will be the valid obligations of Parent and will entitle the transferee to the
same benefits and rights under this Agreement as those held immediately prior to the Transfer by the transferor. No Transfer of a CVR
will be valid until registered in the CVR Register in accordance with this Agreement, and any transfer not duly registered in the CVR
Register will be void and invalid.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 125; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">A
Holder may make a written request to the Rights Agent to change such Holder&rsquo;s address of record in the CVR Register. The written
request must be duly executed by the Holder. Upon receipt of such written notice, the Rights Agent will promptly record the change of
address in the CVR Register.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt; ">Section&nbsp;2.4</FONT><FONT STYLE="">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Payment
Procedures; Notices</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">If
an Annual Net Sales Milestone is attained, then, on or prior to the applicable Milestone Determination Date, Parent shall deliver to the
Rights Agent a written notice indicating that the applicable Annual Net Sales Milestone has been achieved and specifying such Annual Net
Sales Milestone (a &ldquo;<U>Milestone Notice</U>&rdquo;). Parent will duly deposit with or transfer to, or cause to be deposited with
or transferred to, the Rights Agent, upon or prior to the delivery of the Milestone Notice, the applicable Milestone Payment Amount to
be made to the Holders, other than any Milestone Payment Amounts to be paid in cash to Equity Award Holders (with respect to which any
such amounts payable shall be retained by Parent for payment pursuant to this <U>Section&nbsp;2.4</U>), in the form of either (A)&nbsp;subject
to the valuation methodology set forth below, solely shares of Parent Common Stock (a &ldquo;<U>Milestone Stock Payment</U>&rdquo;), (B)&nbsp;solely
cash (a &ldquo;<U>Milestone Cash Payment</U>&rdquo;), or (C)&nbsp;a combination of, subject to the valuation methodology set forth below,
shares of Parent Common Stock and cash (a &ldquo;<U>Combined Milestone Cash and Stock Payment</U>&rdquo;). Without limiting Parent&rsquo;s
obligations to pay the Milestone Payments hereunder, Parent shall have the right, in its sole discretion, to elect one of the foregoing
(A), (B), or (C)&nbsp;in paying any Milestone Payment payable hereunder. Such amounts shall be considered paid if on such date the Rights
Agent has received in accordance with this Agreement money or shares of Parent Common Stock sufficient to pay all such amounts required
by <U>Section&nbsp;4.2</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Rights Agent will, within twenty (20) calendar days of receipt of any Milestone Notice (each such date, a &ldquo;<U>Milestone Payment
Date</U>&rdquo;), send each Holder at its registered address a copy of the applicable Milestone Notice. At the time the Rights Agent sends
a copy of such Milestone Notice to each Holder, the Rights Agent will also pay the applicable Milestone Payment Amount to each of the
Holders, with each Holder receiving, subject to <U>Section&nbsp;2.4(c)</U>:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.75in"><FONT STYLE="font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">if
Parent elects the Milestone Stock Payment, the number of shares of Parent Common Stock determined by <I>dividing</I> the applicable Milestone
Payment Amount by the Milestone Parent Stock Price;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.75in"><FONT STYLE="font-size: 10pt">(ii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">if
Parent elects the Milestone Cash Payment, the Milestone Payment Amount; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 126; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.75in"><FONT STYLE="font-size: 10pt">(iii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">if
Parent elects the Combined Milestone Cash and Stock Payment: (A)&nbsp;(1)&nbsp;the applicable Milestone Payment <I>divided</I> by the
Milestone Parent Stock Price, <I>multiplied</I> by (2)&nbsp;the percentage of the Milestone Payment that Parent has elected to pay in
shares of Parent Common Stock (in accordance with the foregoing&nbsp;<U>Section&nbsp;2.4(a)</U>), <I>multiplied</I> by (3)&nbsp;the number
of CVRs held by such Holder as reflected on the CVR Register, <I>plus</I> (B)(1)&nbsp;the applicable Milestone Payment Amount <I>multiplied</I>
by (2)&nbsp;the percentage of the Milestone Payment that Parent has elected to pay in cash (in accordance with the foregoing&nbsp;<U>Section&nbsp;2.4(a)</U>).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Notwithstanding the foregoing,
with respect to any Milestone Payment that is payable in respect of Company Equity Awards, Parent shall, as soon as reasonably practicable
following the Milestone Payment Date (but in any event no later than the second regular payroll date following the Milestone Payment Date,
and, except as described in <U>Section&nbsp;4.4(b)</U>, in all events no later than March&nbsp;15th of the calendar year immediately following
the last day of the applicable Annual Net Sales Milestone Period), or shall cause an Affiliate thereof (including the Surviving Corporation)
to, pay the amount, through Parent&rsquo;s or such Affiliate&rsquo;s payroll system, or, if applicable, issue the number of shares of
Parent Common Stock for distribution by the Rights Agent, in either case, as described in clause (i), (ii)&nbsp;or (iii)&nbsp;of the first
sentence of this <U>Section&nbsp;2.4(b)</U>, to the applicable Equity Award Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Notwithstanding
anything to the contrary herein, with respect to any CVR issued in respect of a Contingent In-the-Money Stock Option, in the event a Milestone
Payment is payable hereunder, the Holder of such CVR shall be entitled to receive an amount equal to (i)&nbsp;such Milestone Payment <I>less</I>
(ii)&nbsp;the amount by which the exercise price of such Contingent In-the-Money Stock Option per share exceeded the value of the Upfront
Consideration. For clarity, the Milestone Payment Amount (or any portion thereof) shall not be paid or payable to any Holder of CVRs issued
in respect of Contingent In-the-Money Stock Options unless the aggregate amount of such Milestone Payment Amounts payable hereunder exceed
the exercise price applicable to such Contingent In-the-Money Stock Options.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">In
the event that any Milestone Payment payable to the Holders under this Agreement includes shares of Parent Common Stock, Parent and the
Rights Agent shall take such actions as are necessary to issue or transfer to each Holder such Holder&rsquo;s shares of Parent Common
Stock, in accordance with applicable Law. Notwithstanding anything to the contrary herein, no fractional shares of Parent Common Stock
shall be issued under this Agreement. In lieu of any fractional share of Parent Common Stock otherwise issuable under this Agreement,
if any, the Holder shall receive a cash payment, rounded to the nearest whole cent and without interest, in an amount equal to the product
of the Milestone Parent Stock Price for the applicable payment and the fraction of a share the Holder would otherwise be entitled to receive.
The shares of Parent Common Stock to be issued to Holders pursuant to the foregoing shall be evidenced by properly authorized share certificates
registered with Parent&rsquo;s stock transfer agent, or, at Parent&rsquo;s discretion, by book-entry registration with Parent&rsquo;s
stock transfer agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Milestone Cash Payment or the cash portion of any Combined Milestone Cash and Stock Payment payable under this Agreement (including any
cash payment in lieu of fractional shares of Parent Common Stock) shall be paid in United States dollars by check mailed to the address
of each Holder as reflected in the CVR Register as of the close of business on the last Business Day prior to such Milestone Payment Date.
The portion of any Milestone Payment Amount payable in cash shall be rounded to the nearest cent. Notwithstanding the foregoing, with
respect to any Milestone Payment that is payable in cash in respect of Company Equity Awards, Parent shall, as soon as reasonably practicable
following the Milestone Payment Date (but in any event no later than the second regular payroll date following the Milestone Payment Date,
and in all events no later than March&nbsp;15th of the year following the year in which the Annual Net Revenue Milestone is attained),
or shall cause the Company or an Affiliate thereof to, pay, through Parent&rsquo;s or any of its Affiliate&rsquo;s (including the Surviving
Corporation&rsquo;s) payroll system, the applicable cash Milestone Payment to the applicable Equity Award Holder in accordance with the
Merger Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 127; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Any
portion of any Milestone Payment Amount delivered to the Rights Agent that remains undistributed to a Holder one year after the date of
the delivery of the Milestone Notice will be delivered by the Rights Agent to Parent, upon demand, and any Holder will thereafter look
only to Parent for payment of such Milestone Payment Amount, without interest, but such Holder will have no greater rights against Parent
than those accorded to general unsecured creditors of Parent under applicable Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(g)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Commencing
with, (i)&nbsp;in the case of the 2024 Annual Net Sales Milestone, the first Fiscal Quarter of the Calendar Year beginning on January&nbsp;1,
2025, and (ii)&nbsp;in the case of the 2025 Annual Net Revenue Milestone, the first Fiscal Quarter of the Calendar Year beginning on January&nbsp;1,
2026, if Parent has not delivered to the Rights Agent a Milestone Notice pursuant to&nbsp;<U>Section&nbsp;2.4(a)</U>&nbsp;with respect
to the achievement of any of such Annual Net Sales Milestones, no later than the forty-fifth (45th) day following the completion of such
Fiscal Quarter, without limiting any of Parent&rsquo;s obligations hereunder (including with respect to payment of any of the Annual Net
Sales Milestones), Parent shall deliver to the Rights Agent (i)&nbsp;written notice indicating that the applicable Annual Net Sales Milestone
was not achieved during the applicable Annual Net Sales Milestone Period (a &ldquo;<U>Milestone Failure Notice</U>&rdquo;) and an Officer&rsquo;s
Certificate certifying the same and (ii)&nbsp;the Net Sales Statement for such Calendar Year. The Rights Agent will promptly, and in any
event within ten (10)&nbsp;Business Days of receipt of a Milestone Failure Notice, send each Holder at its registered address a copy of
such Milestone Failure Notice and Net Sales Statement (which statement may be modified or redacted, at the reasonable request of Parent,
so as to provide only the total amount of gross amounts invoiced by Parent, any Assignee and each of their respective Affiliates, the
total amount of Permitted Deductions).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(h)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Neither
Parent nor the Rights Agent will be liable to any person in respect of any Milestone Payment Amount delivered to a public official pursuant
to any applicable abandoned property, escheat or similar law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Unless
otherwise required by applicable Law, Parent and the Rights Agent agree that for all U.S. federal (and applicable state, local and non-U.S.)
income Tax purposes, (i)&nbsp;amounts payable pursuant to this Agreement may be treated as deferred contingent purchase price for Company
Common Stock; and (ii)&nbsp;if and to the extent such amounts are paid to any Person under this Agreement, a portion of such amounts may
be treated as interest pursuant to Section&nbsp;483 or Section&nbsp;1274 of the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 128; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(j)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Notwithstanding
the foregoing or anything herein to the contrary, Milestone Payments payable to Equity Award Holders will be paid, as, if and when (i.e.,
at the same time) such Milestone Payments are made to the Holders generally, but in no event later than five (5)&nbsp;years following
the Effective Date, in compliance with all requirements of Section&nbsp;409A of the Code, to the extent applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt; ">Section&nbsp;2.5</FONT><FONT STYLE="">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>No
Voting, Dividends or Interest; No Equity or Ownership Interest in Parent</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
CVRs will not have any voting or dividend rights, and interest will not accrue on any amounts payable on the CVRs to any Holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
CVRs will not represent any interest in the capital of, or any equity or ownership interest in, Parent, any constituent company to the
Merger or any of their respective Affiliates. The sole right of each Holder to receive property hereunder is the right to receive the
Milestone Payment Amount, in accordance with the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;2.6</FONT>&#9;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Changes
in Parent Common Stock</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">If
Parent Common Stock is changed into, or exchanged for, a different number of shares or a different class, by reason of any subdivision,
reclassification, reorganization, recapitalization, split, combination, contribution or exchange of shares, or a stock dividend or dividend
payable in any other securities shall be declared with a record date within such period, or any similar event shall have occurred, any
Milestone Stock Payment or the stock portion of any Combined Milestone Cash and Stock Payment shall be correspondingly adjusted to provide
the Holders the same economic effect as contemplated by this Agreement prior to such event; <U>provided</U>, <U>however</U>, that this
sentence shall not be construed to permit Parent to take any action with respect to its securities that is prohibited by the terms of
this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">If,
as a result of any reorganization, recapitalization, reclassification, or other similar change in Parent Common Stock, the outstanding
Parent Common Stock is exchanged for a different kind, class or series of shares or other securities of Parent, an appropriate adjustment
to the kind, class or series of shares or other securities subject to the CVRs and this Agreement shall be made.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;2.7</FONT>&#9;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Ability
to Abandon CVR</U>. A Holder may at any time, at such Holder&rsquo;s option, abandon all of such Holder&rsquo;s remaining rights in a
CVR by transferring such CVR to Parent or a Person nominated in writing by Parent (with written notice thereof from Parent to the Rights
Agent) without consideration therefor, and such rights will be cancelled, with the Rights Agent being promptly notified in writing by
Parent of such Transfer and cancellation. Nothing in this Agreement shall prohibit Parent or any of its Affiliates from offering to acquire
or acquiring any CVRs for consideration from the Holders, in private transactions or otherwise, in its sole discretion. Any CVRs acquired
by Parent or any of its Affiliates shall be automatically deemed extinguished and no longer outstanding for purposes of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 129; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Article&nbsp;III</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><U>THE
RIGHTS AGENT<FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>1</SUP></FONT></U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt; ">Section&nbsp;3.1</FONT><FONT STYLE="">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Certain
Duties and Responsibilities</U>. The Rights Agent will not have any liability for any actions taken or not taken in connection with this
Agreement, except to the extent of its willful misconduct, bad faith or gross negligence. Notwithstanding anything in this Agreement to
the contrary, in no event will the Rights Agent be liable for special, punitive, indirect, incidental or consequential loss or damages
of any kind whatsoever (including, without limitation, lost profits), even if the Rights Agent has been advised of the likelihood of such
loss or damages and regardless of the form of action.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt; ">Section&nbsp;3.2</FONT><FONT STYLE="">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Certain
Rights of Rights Agent</U>. Parent hereby appoints the Rights Agent to act as rights agent for Parent in accordance with the express terms
and conditions hereof and the Rights Agent undertakes to perform such duties and only such duties as are specifically set forth in this
Agreement, and no implied covenants or obligations will be read into this Agreement against the Rights Agent. In addition:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">the
Rights Agent may rely and will be protected and held harmless by Parent in acting or refraining from acting upon any resolution, certificate,
statement, instrument, opinion, report, notice, request, direction, consent, order or other paper or document believed by it to be genuine
and to have been signed or presented by the proper party or parties;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">whenever
the Rights Agent will deem it desirable that a matter be proved or established prior to taking, suffering or omitting any action hereunder,
the Rights Agent may, in the absence of bad faith, gross negligence or willful misconduct on the part of the Rights Agent, rely upon an
Officer&rsquo;s Certificate delivered to the Rights Agent;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">the
Rights Agent may engage and consult with counsel of its selection and the written advice of such counsel or any written opinion of counsel
will be full and complete authorization and protection to the Rights Agent and the Rights Agent shall be held harmless by Parent in respect
of any action taken, suffered or omitted by it hereunder in good faith and in reliance thereon;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">the
permissive rights of the Rights Agent to do things enumerated in this Agreement will not be construed as a duty;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">the
Rights Agent will not be required to give any note or surety in respect of the execution of such powers or otherwise in respect of the
premises;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Parent
agrees to indemnify the Rights Agent for, and hold the Rights Agent harmless against, any loss, liability, claim, demands, suits or expense
arising out of or in connection with the Rights Agent&rsquo;s duties under this Agreement, including the reasonable costs and expenses
of defending the Rights Agent against any claims, charges, demands, suits or loss, unless such loss has been determined by a court of
competent jurisdiction to be a result of the Rights Agent&rsquo;s gross negligence, bad faith or willful misconduct;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>1&nbsp;</SUP> <U>Note to Draft</U>: Subject to review by Rights
Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 130; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(g)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Parent
agrees (i)&nbsp;to pay the fees and expenses of the Rights Agent in connection with this Agreement in accordance with the fee schedule
agreed upon by the Rights Agent and Parent and incorporated herein by reference and (ii)&nbsp;to reimburse the Rights Agent for all Taxes
and governmental charges (other than Taxes imposed on or measured by the Rights Agent&rsquo;s net income and franchise or similar Taxes
imposed on it (in lieu of net income Taxes)). The Rights Agent will also be entitled to reimbursement from Parent for all reasonable and
necessary out-of-pocket expenses paid or incurred by it in connection with the administration by the Rights Agent of its duties hereunder;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(h)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
indemnification provided by Parent to the Rights Agent pursuant to this <U>Section&nbsp;3.2</U> shall survive the resignation, replacement
or removal of the Rights Agent and the termination of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt; ">Section&nbsp;3.3</FONT><FONT STYLE="">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Resignation
and Removal; Appointment of Successor</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Rights Agent may resign at any time by giving written notice thereof to Parent specifying a date when such resignation will take effect,
which notice will be sent at least sixty (60) days prior to the date so specified but in no event will such resignation become effective
until a successor Rights Agent has been appointed. Parent has the right to remove Rights Agent at any time by a Board Resolution specifying
a date when such removal will take effect but no such removal will become effective until a successor Rights Agent has been appointed.
Notice of such removal will be given by Parent to Rights Agent, which notice will be sent at least sixty (60) days prior to the date so
specified.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">If
the Rights Agent provides notice of its intent to resign, is removed pursuant to <U>Section&nbsp;3.3(a)</U>&nbsp;or becomes incapable
of acting, Parent, by a Board Resolution, will promptly appoint a qualified successor Rights Agent who, unless otherwise consented to
in writing by the Acting Holders, shall be a stock transfer agent of national reputation or the corporate trust department of a commercial
bank. The successor Rights Agent so appointed will, forthwith upon its acceptance of such appointment in accordance with <U>Section&nbsp;3.4</U>,
become the successor Rights Agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Parent
will give notice of each resignation and each removal of a Rights Agent and each appointment of a successor Rights Agent by mailing written
notice of such event by first-class mail to the Holders as their names and addresses appear in the CVR Register. Each notice will include
the name and address of the successor Rights Agent. If Parent fails to send such notice within ten (10)&nbsp;days after acceptance of
appointment by a successor Rights Agent in accordance with <U>Section&nbsp;3.4</U>, the successor Rights Agent will cause the notice to
be mailed at the expense of Parent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Rights Agent will reasonably cooperate with Parent and any successor Rights Agent in connection with the transition of the duties and
responsibilities of the Rights Agent to the successor Rights Agent, including the transfer of all relevant data, including the CVR Register,
to the successor Rights Agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 131; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt; ">Section&nbsp;3.4</FONT><FONT STYLE="">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Acceptance
of Appointment by Successor</U>. Every successor Rights Agent appointed pursuant to <U>Section&nbsp;3.3(b)</U>&nbsp;hereunder will execute,
acknowledge and deliver to Parent and to the predecessor Rights Agent an instrument accepting such appointment and a counterpart of this
Agreement, and thereupon such successor Rights Agent, without any further act, deed or conveyance, will become vested with all the rights,
powers, trusts and duties of the predecessor Rights Agent. On request of Parent or the successor Rights Agent, the predecessor Rights
Agent will execute and deliver an instrument transferring to the successor Rights Agent all the rights, powers and trusts of the predecessor
Rights Agent, but such predecessor Rights Agent shall not be required to make any additional expenditure or assume any additional liability
in connection with the foregoing, unless, if requested by Rights Agent, it has been furnished with assurances of repayment or indemnity
satisfactory to it.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Article&nbsp;IV</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><U>COVENANTS</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt; ">Section&nbsp;4.1</FONT><FONT STYLE="">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>List
of Holders</U>. Parent will furnish or cause to be furnished to the Rights Agent in such form as Parent receives from the Company&rsquo;s
transfer agent (or other agent performing similar services for the Company), the names and addresses of the Holders within twenty (20)
Business Days of the Effective Time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt; ">Section&nbsp;4.2</FONT><FONT STYLE="">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Payment
of Milestone Payment Amounts</U>. If an Annual Net Sales Milestone has been achieved in accordance with this Agreement, Parent will, promptly
(but in any event no later than ten (10)&nbsp;Business Days) following the delivery of the applicable Milestone Notice to the Rights Agent,
deposit with or transfer to the Rights Agent, for payment or issuance to the Holders in accordance with <U>Section&nbsp;2.4</U>, the aggregate
amount of cash and or shares of Parent Common Stock necessary to pay the Milestone Payment Amount to each Holder (other than cash payments
to the Equity Award Holders, in respect of which any Milestone Payment Amounts shall be paid in accordance with <U>Section&nbsp;2.4(b)</U>).
For the avoidance of doubt, the Milestone Payment Amount shall only be paid in respect of each given Annual Net Sales Milestone, if at
all, one time under this Agreement, and the maximum aggregate potential amount payable per CVR under this Agreement shall be $0.20.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt; ">Section&nbsp;4.3</FONT><FONT STYLE="">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Books
and Records</U>. Parent shall, and shall cause its Affiliates to, keep true, complete and accurate records in sufficient detail to enable
the Holders and the Independent Accountant to determine the amounts payable hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt; ">Section&nbsp;4.4</FONT><FONT STYLE="">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Audits</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Upon
the reasonable written request of the Acting Holders provided to Parent within forty-five (45) days of the delivery of any Net Sales Statement
pursuant to Section&nbsp;2.4(g)&nbsp;of this Agreement (the &ldquo;<U>Review Request Period</U>&rdquo;), but no more than once following
each respective Annual Net Sales Milestone Period, Parent shall as promptly as reasonably practicable provide the Acting Holders with
reasonable documentation to support its calculation of Net Sales, and shall make its financial personnel reasonably available to a designated
representative of the Acting Holders to discuss and answer the Acting Holders&rsquo; questions regarding such calculations; <U>provided</U>
that (x)&nbsp;the Acting Holders enter into customary confidentiality agreements reasonably satisfactory to Parent with respect to the
confidential information of Parent or its Affiliates to be furnished pursuant to this <U>Section&nbsp;4.4</U>, (y)&nbsp;such access does
not unreasonably interfere with the conduct of the business of Parent or any of its Affiliates and (z)&nbsp;such information or access
would not reasonably be expected to result in the waiver of any attorney-client privilege or violate any applicable Law (<U>provided</U>
that the Parent shall use commercially reasonable efforts to make alternative arrangements with respect to providing such information
or access). If the Acting Holders do not agree with Parent&rsquo;s calculations, the Acting Holders may, no later than twenty (20) Business
Days after the Acting Holders request documentation supporting Parent&rsquo;s calculation, submit a written dispute notice to Parent setting
forth the specific disputed items in the Net Sales Statement and a reasonably detailed explanation thereof (such notice, a &ldquo;<U>Dispute
Notice</U>&rdquo;). If the Acting Holders and Parent fail to agree on the matter under dispute within twenty (20) Business Days after
the Acting Holders deliver the Dispute Notice to Parent, Parent shall permit, and shall use commercially reasonable efforts to cause its
Affiliates to permit, the Independent Accountant (subject to the Independent Accountant&rsquo;s entry into a customary confidentiality
agreement reasonably satisfactory to Parent with respect to the confidential information of Parent or its Affiliates to be furnished pursuant
to this <U>Section&nbsp;4.4</U>) to have access at reasonable times during normal business hours to such of the books and records of Parent
and any of its Affiliates as may be reasonably necessary to verify the accuracy of such Net Sales Statement and the figures underlying
the calculations set forth therein, provided that such information or access (i)&nbsp;does not unreasonably interfere with the conduct
of the business of Parent or any of its Affiliates or (ii)&nbsp;would not reasonably be expected to result in the waiver of any attorney-client
privilege or violate any applicable Law (<U>provided</U> that the Parent shall use commercially reasonable efforts to make alternative
arrangements with respect to providing such information or access). The Independent Accountant, acting as an expert and not as an arbitrator,
shall be charged to come to a final determination solely with respect to those specific items in the Net Sales Statement that the parties
disagree on and submit to it for resolution. All other items in the Net Sales Statement that the parties do not submit, prior to the end
of the Review Request Period, to the Independent Accountant for resolution shall be deemed to be agreed by the parties and the Independent
Accountant shall not be charged with calculating or validating those agreed upon items. If issues are submitted to the Independent Accountant
for resolution, Parent shall, and shall use commercially reasonable efforts to cause its Affiliates, to furnish to the Independent Accountant
such access, work papers and other documents and information related to those disputed issues as the Independent Accountant may reasonably
request and as are available to Parent. The Independent Accountant shall deliver a written report to Parent setting forth its determinations
with respect to the disputed matters, and shall disclose to the Acting Holders whether an Annual Net Sales Milestone was achieved and
such additional information directly related to its findings. The Independent Accountant shall provide Parent with a copy of all disclosures
made to the Acting Holders. The fees charged by such accounting firm shall be paid by Parent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 132; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">If
the Independent Accountant concludes that a Milestone Payment that was properly due was not paid to the Holders, Parent shall pay or transfer,
or cause to be paid or transferred, to the Rights Agent (for further distribution to the Holders) or to each Holder the applicable Milestone
Payment Amount, <I>plus</I> interest on such Milestone Payment Amount at the &ldquo;prime rate&rdquo; as published in the Wall Street
Journal or similar reputable data source from time to time calculated from when the Milestone Payment should have been paid (if Parent
had given notice of achievement of the Annual Net Sales Milestone pursuant to the terms of this Agreement), as applicable, to the date
of actual payment (such amount, including interest, being the &ldquo;<U>CVR Shortfall</U>&rdquo;). The CVR Shortfall shall be paid by
Parent within thirty (30) calendar days of the date the Independent Accountant&rsquo;s written report is provided to Parent. Absent manifest
error, the decision of the Independent Accountant shall be final, conclusive and binding on Parent and the Holders, shall be non-appealable
and shall not be subject to further review. In the event Holders are entitled to Milestone Payment Amounts pursuant to this <U>Section&nbsp;4.4(b)</U>&nbsp;and
such Milestone Payments are made after March&nbsp;15 of the calendar year immediately following the last day of the applicable Annual
Net Sales Milestone Period, the parties hereto intend that such Milestone Payments remain exempt from Section&nbsp;409A of the Code as
 &ldquo;short-term deferrals&rdquo; pursuant to Treasury Regulation Section&nbsp;1.409A-1(b)(4)&nbsp;because payment before such March&nbsp;15
was administratively impracticable and such administrative impracticability was unforeseeable as of the date hereof, as contemplated by
Treasury Regulation Section&nbsp;1.409A-1(b)(4)(ii).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 133; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">If,
upon the expiration of the applicable Review Request Period, the Acting Holders has not requested a review of the Net Sales Statement,
or if the Acting Holders have not delivered a timely Dispute Notice, in each case in accordance with this <U>Section&nbsp;4.4</U>, the
calculations set forth in the Net Sales Statement shall be binding and conclusive upon the Holders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Each
Person seeking to receive information from Parent in connection with a review pursuant to this <U>Section&nbsp;4.4</U> shall enter into,
and shall cause its accounting firm to enter into, a reasonable and mutually satisfactory confidentiality agreement with Parent or any
Affiliate obligating such party to retain all such information disclosed to such party in confidence pursuant to such confidentiality
agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt; ">Section&nbsp;4.5</FONT><FONT STYLE="">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Parent
Stock Issuance</U>. If Parent elects to pay the applicable Milestone Payment as either a Milestone Stock Payment or a Combined Milestone
Cash and Stock Payment, Parent shall use commercially reasonable efforts to cause the shares of Parent Common Stock to be issued in connection
with such payment to be listed on Nasdaq, subject to official notice of issuance, prior to the Milestone Payment Date. Parent shall use
commercially reasonable efforts to take all actions reasonably required to be taken under state securities Laws in connection with the
Milestone Stock Payment or stock portion of the Combined Milestone Cash and Stock Payment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;4.6</FONT>&#9;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Diligent
Efforts</U>. Commencing upon the Closing, subject to <U>Section&nbsp;6.2</U>, and ending at the termination of the 2025 Annual Net Sales
Milestone Period, Parent shall, and shall cause its Affiliates to, (i)&nbsp;use Diligent Efforts to achieve the 2024 Annual Net Sales
Milestone and the 2025 Annual Net Sales Milestone, and (ii)&nbsp;not intentionally take any actions for the primary purpose of frustrating
the payment of the Milestone Payments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;4.7</FONT>&#9;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Product
Transfer</U>. If, at any time on or prior to the termination of the 2025 Net Sales Milestone Period, Parent or its Affiliates, directly
or indirectly, by a sale or swap of assets, merger, reorganization, joint venture, lease, license or any other transaction or arrangement
(other than in connection with a Change of Control as defined in clauses (b)-(c)&nbsp;of the definition of &ldquo;Change of Control&rdquo;),
sells, transfers, conveys or otherwise disposes of (each, a &ldquo;<U>Product Transfer</U>&rdquo;) all or substantially all of its respective
right, title and interest (including all or substantially all Intellectual Property with respect thereto) in and to the Product to any
Qualified Transferee, then Parent shall no longer be liable for any obligations under this Agreement; <U>provided</U>, that (a)&nbsp;such
Qualified Transferee assumes and succeeds to the obligations of Parent set forth in this Agreement (by operation of law or otherwise),
and (b)&nbsp;prior to or simultaneously with the consummation of such Product Transfer any outstanding payments owed to the Holders hereunder
shall have been paid by Parent. Following any Product Transfer to a Person other than a Qualified Transferee, Parent shall remain secondarily
liable for any obligations of Parent set forth in this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 134; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;4.8</FONT>&#9;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Net
Sales Statements</U>. Within forty-five (45) days after the end of each Fiscal Quarter during the 2024 Annual Net Sales Milestone Period
and the 2025 Annual Net Sales Milestone Period, Parent shall compile a Net Sales Statement for each such Fiscal Quarter. Parent shall
keep each such Net Sales Statement in its books and records.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Article&nbsp;V</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><U>AMENDMENTS</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt; ">Section&nbsp;5.1</FONT><FONT STYLE="">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Amendments
without Consent of Holders</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Without
the consent of any Holders, Parent, when authorized by a Board Resolution, at any time and from time to time, may and the Rights Agent
shall, if directed by the Parent, enter into one or more amendments hereto, for any of the following purposes:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">To
evidence the succession of another Person to Parent and the assumption by any such successor of the covenants of Parent herein as provided
in <U>Section&nbsp;7.3</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">(ii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">to
add to the covenants of Parent such further covenants, restrictions, conditions or provisions as Parent and the Rights Agent will consider
to be for the protection of the Holders; provided that, in each case, such provisions do not adversely affect any interests of the Holders;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">(iii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">to
cure any ambiguity, to correct or supplement any provision herein that may be defective or inconsistent with any other provision herein,
or to make any other provisions with respect to matters or questions arising under this Agreement; provided that, in each case, such provisions
do not adversely affect any interests of the Holders;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">(iv)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">as
may be necessary or appropriate to ensure that the CVRs are not subject to registration under the Securities Act of 1933, as amended,
or the Securities Exchange Act of 1934, as amended, and the rules&nbsp;and regulations promulgated thereunder; provided that, in each
case, such provisions do not adversely affect any interests of the Holders;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">(v)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">to
evidence the succession of another Person as a successor Rights Agent and the assumption by any such successor of the covenants and obligations
of the Rights Agent herein in accordance with <U>Sections 3.3</U> and <U>3.4</U>;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">(vi)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">as
may be necessary to comply with or be exempt from the requirements of Section&nbsp;409A of the Code;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">(vii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">to
cancel CVRs in the event that any Holder has abandoned its rights to such CVRs in accordance with <U>Section&nbsp;2.7</U>;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 135; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">(viii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">as
may be necessary to ensure that Parent complies with applicable Law; <U>provided</U> that in each case, such amendments shall not adversely
affect the interests of the Holders; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">(ix)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">any
other amendments hereto for the purpose of adding, eliminating or changing any provisions of this Agreement, unless such addition, elimination
or change is adverse to the interests of the Holders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Promptly
after the execution by Parent and the Rights Agent of any amendment pursuant to the provisions of this <U>Section&nbsp;5.1</U>, Parent
will mail (or cause the Rights Agent to mail, at Parent&rsquo;s expense) a notice thereof by first class mail to the Holders at their
addresses as they appear on the CVR Register, setting forth such amendment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt; ">Section&nbsp;5.2</FONT><FONT STYLE="">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Amendments
with Consent of Holders</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Subject
to <U>Section&nbsp;5.1</U> (which amendments pursuant to <U>Section&nbsp;5.1</U> may be made without the consent of the Holders), with
the consent of the Acting Holders whether evidenced in writing or taken at a meeting of the Holders, Parent, when authorized by a Board
Resolution, and the Rights Agent may enter into one or more amendments hereto for the purpose of adding, eliminating or changing any provisions
of this Agreement, even if such addition, elimination or change is materially adverse to the interest of the Holders; <U>provided</U>,
<U>however</U>, that no such amendment shall, without the consent of the Acting Holders:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">modify
in a manner adverse to the Holders (A)&nbsp;any provision contained herein with respect to the termination of this Agreement or the CVRs,
(B)&nbsp;the time for, and amount of, any payment to be made to the Holders pursuant to this Agreement, or (C)&nbsp;the definition of
any Annual Net Sales Milestone;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">(ii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">reduce
the number of CVRs (except as contemplated by <U>Section&nbsp;5.1(a)(vii))</U>; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">(iii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">modify
any provisions of this <U>Section&nbsp;5.2</U>, except to increase the percentage of Holders from whom consent is required or to provide
that certain provisions of this Agreement cannot be modified or waived without the consent of the Holder of each outstanding CVR affected
thereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Promptly
after the execution by Parent and the Rights Agent of any amendment pursuant to the provisions of this <U>Section&nbsp;5.2</U>, Parent
will mail (or cause the Rights Agent to mail, at Parent&rsquo;s expense) a notice thereof by first class mail to the Holders at their
addresses as they appear on the CVR Register, setting forth such amendment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt; ">Section&nbsp;5.3</FONT><FONT STYLE="">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Execution
of Amendments</U>. In executing any amendment permitted by this <U>Article&nbsp;V</U>, the Rights Agent will be entitled to receive, and
will be fully protected in relying upon, an opinion of counsel selected by Parent stating that the execution of such amendment is authorized
or permitted by this Agreement. The Rights Agent may, but is not obligated to, enter into any such amendment that affects the Rights Agent&rsquo;s
own rights, privileges, covenants or duties under this Agreement or otherwise, including any amendments pursuant to <U>Section&nbsp;5.1(a)(viii)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 136; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt; ">Section&nbsp;5.4</FONT><FONT STYLE="">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Effect
of Amendments</U>. Upon the execution of any amendment under this <U>Article&nbsp;V</U>, this Agreement will be modified in accordance
therewith, such amendment will form a part of this Agreement for all purposes and every Holder will be bound thereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Article&nbsp;VI</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><U>Management
Discretion; no fiduciary duties; remedies of the holders</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt; ">Section&nbsp;6.1</FONT><FONT STYLE="">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Management
of Consumer Business Unit</U>. For the avoidance of doubt, subject to and consistent with its obligations set forth in this Agreement,
management of the Company shall have full discretion in management of its business and the Product in all respects, including without
limitation decisions relating to Taxes, application of US GAAP, selection of auditor, questions of accounting policy decisions/elections,
working capital management, risk management, business opportunities, hiring and terminations of employees and consultants,&nbsp;<I>etc</I>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;6.2</FONT>&#9;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>No
Fiduciary Duties</U>. Neither the Company&rsquo;s officers nor its directors owe fiduciary duties of any kind to the Holders of the CVRs.
Notwithstanding anything to the contrary in this Agreement, the Holders acknowledge that Parent has a fiduciary obligation to operate
its business in the best interests of its stockholders, and any potential obligation to pay the Milestone Payments hereunder will not
create any express or implied obligation to operate Parent&rsquo;s business in any particular manner in order to maximize such Milestone
Payments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;6.3</FONT>&#9;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Event
of Default</U>. An &ldquo;Event of Default&rdquo; with respect to the CVRs, means any of the following events which shall have occurred
and be continuing (whatever the reason for such Event of Default and whether it shall be voluntary or involuntary or be effected by operation
of Law or pursuant to any judgment, decree or order of any court or any order, rule&nbsp;or regulation of any Governmental Entity):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">default
in the payment by Parent pursuant to the terms of this Agreement of all or any part of a Milestone Payment Amount after a period of ten
(10)&nbsp;Business Days after such Milestone Payment Amount shall become due and payable; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">material
default in the performance, or breach in any material respect, of any covenant or warranty of Parent hereunder (other than a payment default
subject to Section&nbsp;6.3(a)), and continuance of such default or breach for a period of thirty (30) days after a written notice specifying
such default or breach and requiring it to be remedied is given, which written notice states that it is a &ldquo;notice of default&rdquo;
hereunder and is sent by registered or certified mail to Parent and the Rights Agent by the Acting Holders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an Event of Default described above occurs
and is continuing (and has not been cured or waived), then, and in each and every such case, the Acting Holders by notice in writing to
Parent and to the Rights Agent, may, in their discretion and at their own expense, commence a legal proceeding to protect the rights of
the Holders, including to obtain payment for any amounts then due and payable. Notwithstanding anything herein to the contrary, damages
directly resulting from and in the event of an Event of Default shall be the sole and exclusive remedy of any and all Holders for any
claims or causes of action (whether in contract, tort or statute) that may be based upon, arise out of or relate to this Agreement or
the CVRs, or the negotiation, execution or performance hereof or thereof or the transactions contemplated hereby, and Parent and its Affiliates
shall not be liable for special, punitive, indirect, incidental or consequential loss or damages of any kind whatsoever (including, without
limitation, lost profits).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 137; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;6.4</FONT>&#9;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Limitations
on Suits by Holders</U>. Except for the rights of the Rights Agent set forth herein, the Acting Holders, will have the sole right, on
behalf of all Holders, by virtue of or under any provision of this Agreement, to institute any action or proceeding with respect to this
Agreement, and no individual Holder or other group of Holders, will be entitled to exercise such rights. Notwithstanding any other provision
in this Agreement, (a)&nbsp;the right of any Holder of any CVR to receive payment of the amounts that a Milestone Notice indicates are
payable in respect of such CVR on or after the applicable due date, or to commence proceedings for the enforcement of any such payment
on or after such due date shall not be impaired or affected without the consent of such Holder and (b)&nbsp;in the event of an insolvency
proceeding of the Parent, individual Holders shall be entitled to assert claims in such insolvency proceeding and take related actions
in pursuit of such claims with respect to any payment that may be claimed by or on behalf of the Parent or by any creditor of the Parent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;6.5</FONT>&#9;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Control
by Acting Holders</U>. The Acting Holders shall have the right to direct the conduct of any proceeding for any remedy available to the
Holders under this Agreement, or exercising any power conferred on the Holders by this Agreement; provided that such direction shall not
be otherwise than in accordance with applicable Law and the provisions of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Article&nbsp;VII</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><U>OTHER
PROVISIONS OF GENERAL APPLICATION</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt; ">Section&nbsp;7.1</FONT><FONT STYLE="">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Notices
to Rights Agent and Parent</U>. All notices and other communications hereunder shall be in writing and shall be deemed duly given on (a)&nbsp;the
date of delivery if delivered personally, or if by e-mail, on the date of transmittal (provided that the transmission of the email is
promptly confirmed by telephone or response email), (b)&nbsp;the second Business Day following the date of dispatch if delivered utilizing
a next-day service by a recognized next-day courier or (c)&nbsp;upon confirmed receipt if delivered by registered or certified mail, return
receipt requested, postage prepaid. All notices hereunder shall be delivered to the addresses set forth below, or pursuant to such other
instructions as may be designated in writing by the party to receive such notice:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">If to the Rights Agent, to it at:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">[&#9679;]&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">[&#9679;]&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><FONT STYLE="font-size: 10pt">Attention:</FONT>
 &#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">[&#9679;]</FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><FONT STYLE="font-size: 10pt">Email:</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">[&#9679;]</FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in">with copies to:&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">[&#9679;]&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"></P>

<!-- Field: Page; Sequence: 138; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">[&#9679;]&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><FONT STYLE="font-size: 10pt">Attention:</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">[&#9679;]</FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><FONT STYLE="font-size: 10pt">Email:</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">[&#9679;]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in">and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Gibson, Dunn&nbsp;&amp; Crutcher LLP&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">200 Park Avenue&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">New York, NY 10166&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><FONT STYLE="font-size: 10pt">Attention:</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Saee
Muzumdar</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-indent: 1in">Branden C. Berns&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><FONT STYLE="font-size: 10pt">Email:</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">SMuzumdar@gibsondunn.com</FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-indent: 1in">BBerns@gibsondunn.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">If to Parent, to it at:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Assertio Holdings,&nbsp;Inc.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><FONT STYLE="font-size: 10pt">Attention:</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">[General
Counsel]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><FONT STYLE="font-size: 10pt">Email:</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">[&#9679;]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><FONT STYLE="font-size: 10pt"></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in">with a copy to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Latham&nbsp;&amp; Watkins LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">330 N Wabash Ave, Suite&nbsp;2800</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Chicago,&nbsp;IL 60613&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><FONT STYLE="font-size: 10pt">Attention:</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Zachary
Judd</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-indent: 1in">Owen Alexander&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><FONT STYLE="font-size: 10pt">Email:</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Zachary.Judd@lw.com</FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-indent: 1in">Owen.Alexander@lw.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Rights Agent or Parent may specify a different
address or facsimile number by giving notice in accordance with this <U>Section&nbsp;7.1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt; ">Section&nbsp;7.2</FONT><FONT STYLE="">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Notice
to Holders</U>. Where this Agreement provides for notice to Holders, such notice will be sufficiently given (unless otherwise herein expressly
provided) if in writing and mailed, first-class postage prepaid, to each Holder affected by such event, at the Holder&rsquo;s address
as it appears in the CVR Register, not later than the latest date, and not earlier than the earliest date, if any, prescribed for the
giving of such notice. In any case where notice to Holders is given by mail, neither the failure to mail such notice, nor any defect in
any notice so mailed, to any particular Holder will affect the sufficiency of such notice with respect to other Holders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt; ">Section&nbsp;7.3</FONT><FONT STYLE="">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Parent
Successors and Assigns</U>. Parent may assign any or all of its rights, interests and obligations hereunder (a)&nbsp;in its sole discretion
and without the consent of any other party (i)&nbsp;to, any controlled Affiliate of Parent, but only for so long as it remains a controlled
Affiliate of Parent, (ii)&nbsp;in connection with a Change of Control, provided that in the case of a Change of Control as defined in
clauses (a)&nbsp;and (b)&nbsp;of the definition of &ldquo;Change of Control&rdquo;, unless otherwise consented to by the Acting Holders,
any applicable Milestone Payment Amount due and payable pursuant to the terms of this Agreement shall be paid solely in cash, or (iii)&nbsp;in
accordance with <U>Section&nbsp;4.7</U> to a Qualified Transferee in connection with a Product Transfer, or (b)&nbsp;with the prior written
consent of the Acting Holders, any other Person; provided, however, that Parent may assign, in its sole discretion, any or all of its
rights, interests and obligations under this Agreement after the Effective Time to any Person, provided that no such assignment shall
relieve Parent of its obligations hereunder except as otherwise provided for in this Agreement. Subject to the preceding sentence, this
Agreement will be binding upon, inure to the benefit of, and be enforceable by, the parties and their respective successors and assigns.
Any attempted assignment of this Agreement or any such rights in violation of this <U>Section&nbsp;7.3</U> shall be void and of no effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 139; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt; ">Section&nbsp;7.4</FONT><FONT STYLE="">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Benefits
of Agreement</U>. Nothing in this Agreement, express or implied, will give to any Person (other than the Rights Agent and its successors
and assigns, Parent, Parent&rsquo;s successors and Assignees, the Holders and the Holders&rsquo; successors and assigns pursuant to a
Permitted Transfer) any benefit or any legal or equitable right, remedy or claim under this Agreement or under any covenant or provision
herein contained, all such covenants and provisions being for the sole benefit of the foregoing. The rights of Holders and their successors
and assigns pursuant to Permitted Transfers are limited to those expressly provided in this Agreement and the Merger Agreement. Notwithstanding
anything to the contrary contained herein, any Holder or Holder&rsquo;s successor or assign pursuant to a Permitted Transfer may agree
to renounce, in whole or in part, its rights under this Agreement by written notice to the Rights Agent and Parent, which notice, if given,
shall be irrevocable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt; ">Section&nbsp;7.5</FONT><FONT STYLE="">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Governing
Law; Jurisdiction; Waiver of Jury Trial</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">This
Agreement, the CVRs and all disputes or controversies arising out of or relating to this Agreement, the CVRs or the transactions contemplated
hereby shall be governed by, and construed in accordance with, the internal laws of the State of Delaware, without regard to the laws
of any other jurisdiction that might be applied because of the conflicts of laws principles of the State of Delaware.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Each
of the parties irrevocably agrees that any legal action or proceeding arising out of or relating to this Agreement brought by any party
or its Affiliates against any other party or its Affiliates shall be brought and determined in the Court of Chancery of the State of Delaware;
<U>provided</U>, that if jurisdiction is not then available in the Court of Chancery of the State of Delaware, then any such legal action
or proceeding may be brought in any federal court located in the State of Delaware or any other Delaware state court. Each of the parties
hereby irrevocably submits to the jurisdiction of the aforesaid courts for itself and with respect to its property, generally and unconditionally,
with regard to any such action or proceeding arising out of or relating to this Agreement and the transactions contemplated hereby, including
the Merger. Each of the parties agrees not to commence any action, suit or proceeding relating thereto except in the courts described
above in Delaware, other than actions in any court of competent jurisdiction to enforce any judgment, decree or award rendered by any
such court in Delaware as described herein. Each of the parties further agrees that notice as provided herein shall constitute sufficient
service of process and the parties further waive any argument that such service is insufficient. Each of the parties hereby irrevocably
and unconditionally waives, and agrees not to assert, by way of motion or as a defense, counterclaim or otherwise, in any action or proceeding
arising out of or relating to this Agreement or the transactions contemplated hereby, including the Merger, (i)&nbsp;any claim that it
is not personally subject to the jurisdiction of the courts in Delaware as described herein for any reason, (ii)&nbsp;that it or its property
is exempt or immune from jurisdiction of any such court or from any legal process commenced in such courts (whether through service of
notice, attachment prior to judgment, attachment in aid of execution of judgment, execution of judgment or otherwise) and (iii)&nbsp;that
(A)&nbsp;the suit, action or proceeding in any such court is brought in an inconvenient forum, (B)&nbsp;the venue of such suit, action
or proceeding is improper or (C)&nbsp;this Agreement, or the subject matter hereof, may not be enforced in or by such courts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 140; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">EACH
OF THE PARTIES TO THIS AGREEMENT HEREBY IRREVOCABLY WAIVES ALL RIGHT TO A TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM ARISING
OUT OF OR RELATING TO THIS AGREEMENT, THE CVRS OR THE TRANSACTIONS CONTEMPLATED HEREBY. EACH PARTY TO THIS AGREEMENT CERTIFIES AND ACKNOWLEDGES
THAT: (i)&nbsp;NO REPRESENTATIVE OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT SEEK TO ENFORCE
THE FOREGOING WAIVER IN THE EVENT OF A LEGAL ACTION; (ii)&nbsp;SUCH PARTY HAS CONSIDERED THE IMPLICATIONS OF THIS WAIVER; (iii)&nbsp;SUCH
PARTY MAKES THIS WAIVER VOLUNTARILY; AND (iv)&nbsp;SUCH PARTY HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE
MUTUAL WAIVERS AND CERTIFICATIONS IN THIS <FONT STYLE="text-transform: uppercase"><U>Section&nbsp;7.5(c)</U>.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt; ">Section&nbsp;7.6</FONT><FONT STYLE="">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Section&nbsp;409A</U>.
For the avoidance of doubt, it is intended that the benefits payable under this Agreement satisfy, to the greatest extent possible, the
exemption from the application of Section&nbsp;409A of the Code provided under Treasury Regulation Section&nbsp;1.409A-1(b)(4)&nbsp;and,
to the extent not so exempt, that the benefits payable under this Agreement constitute &ldquo;transaction-based compensation&rdquo; that
complies with Treasury Regulation Section&nbsp;1.409A-3(i)(5)(iv)(A), and this Agreement shall be interpreted and construed to the greatest
extent possible to be consistent with such intent. Notwithstanding the foregoing, the Parent does not guarantee any particular Tax effect
for income provided to the Holders pursuant to this Agreement and is not responsible for any Taxes owed by Holders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt; ">Section&nbsp;7.7</FONT><FONT STYLE="">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Severability</U>.
Whenever possible, each provision or portion of any provision of this Agreement shall be interpreted in such manner as to be effective
and valid under applicable Law, but if any provision or portion of any provision of this Agreement is held to be invalid, illegal or unenforceable
in any respect under any applicable Law or rule&nbsp;in any jurisdiction, such invalidity, illegality or unenforceability shall not affect
any other provision or portion of any provision in such jurisdiction, and this Agreement shall be reformed, construed and enforced in
such jurisdiction as if such invalid, illegal or unenforceable provision or portion of any provision had never been contained herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt; ">Section&nbsp;7.8</FONT><FONT STYLE="">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Counterparts
and Signature</U>. This Agreement may be executed in two or more counterparts, all of which shall be considered one and the same instrument
and shall become effective when one or more counterparts have been signed by each of the parties and delivered to the other parties. This
Agreement may be executed by facsimile, electronic mail (including any electronic signature covered by the U.S. federal ESIGN Act of 2000,
Uniform Electronic Transactions Act, the Electronic Signatures and Records Act or other applicable law, e.g., www.docusign.com) or .pdf
signature, and any signature so delivered shall be deemed to have been duly and validly delivered and be valid and effective, and constitute
an original, for all purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 141; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt; ">Section&nbsp;7.9</FONT><FONT STYLE="">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Termination</U>.
This Agreement will be terminated and of no force or effect, the parties hereto will have no liability hereunder (other than with respect
to monies due and owing by Parent to Rights Agent) and no payments will be required to be made, upon the earliest to occur of (a)&nbsp;the
mailing by the Rights Agent to the address of each Holder as reflected in the CVR Register the full amount of all potential Milestone
Payment Amounts required to be paid under the terms of this Agreement, (b)&nbsp;the delivery of a written notice of termination duly executed
by Parent and the Acting Holders, (c)&nbsp;expiration of the Review Request Period following the expiration of an Annual Net Sales Milestone
Period (provided no written request is received during such Review Request Period pursuant to <U>Section&nbsp;4.4(a)</U>), (d)&nbsp;if
a written request is received during the Review Request Period immediately following the expiration of an Annual Net Sales Milestone Period,
the decision of the Independent Accountant (and, if applicable, payment of any CVR Shortfall as determined to be owing by the Independent
Accountant) pursuant to <U>Section&nbsp;4.4(a)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt; ">Section&nbsp;7.10</FONT><FONT STYLE="">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Entire
Agreement</U>. This Agreement (including the fee schedule referred to in <U>Section&nbsp;3.2(g)</U>) and the Merger Agreement constitute
the entire agreement, and supersede all prior written agreements, arrangements, communications and understandings and all prior and contemporaneous
oral agreements, arrangements, communications and understandings among the parties hereto with respect to the subject matter hereof and
thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt; ">Section&nbsp;7.11</FONT><FONT STYLE="">&#9;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Legal
Holiday</U>. In the event that a Milestone Payment Date shall not be a Business Day, then, notwithstanding any provision of this Agreement
to the contrary, any payment required to be made in respect of the CVRs on such date need not be made on such date, but may be made on
the next succeeding Business Day with the same force and effect as if made on the applicable Milestone Payment Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;7.12</FONT>&#9;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Force
Majeure</U>. Notwithstanding anything to the contrary contained herein, the Rights Agent shall not be liable for any delays or failures
in performance resulting from acts beyond its reasonable control including, without limitation, acts of God, terrorist acts, shortage
of supply, breakdowns or malfunctions, interruptions or malfunctions of any utilities, communications, or computer facilities, or loss
of data due to power failures or mechanical difficulties with information storage or retrieval systems, labor difficulties, war or civil
unrest.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>Remainder of page&nbsp;intentionally left blank</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 142; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, each of
the parties has caused this Agreement to be executed on its behalf by its duly authorized officers as of the day and year first above
written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">ASSERTIO HOLDINGS,&nbsp;INC.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">[RIGHTS AGENT]</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[Signature Page&nbsp;to Contingent Value Rights
Agreement]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 143; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>tm2313548d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="text-align: right; margin: 0pt"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="margin: 0pt"><IMG SRC="tm2313548d1_ex99-1img01.jpg" ALT="">&nbsp;</P>

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Assertio Holdings,&nbsp;Inc. to Acquire Spectrum
Pharmaceuticals,&nbsp;Inc. in All Stock and CVR Transaction</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Complementary Commercial Growth Platforms Anticipated
to Accelerate ROLVEDON&trade; (eflapegrastim-xnst) Injection Profitability and Diversify Revenue Streams</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Combination of Assertio&rsquo;s Omni-Channel
Digital Sales Capabilities and ROLVEDON In-Person Commercial Team to Enhance Market Access and Growth across All Products</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Transaction Expected to Be Accretive to Assertio&rsquo;s
Adjusted EPS and Operating Cash Flow in 2024</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Spectrum Stockholders Will Receive Upfront Consideration
of 0.1783 ASRT shares per SPPI Share ($1.14 per share) Plus One CVR for Total Potential Consideration of up to $1.34 per Share</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Upfront Consideration Represents a Premium of
65% and the Total Potential Consideration Represents a Premium of 94% to Spectrum&rsquo;s Latest Closing Price</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Assertio Stockholders to Own Approximately 65%
and Spectrum Stockholders to Own Approximately 35% of Combined Company</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Closing of Transaction Expected in Q3 2023</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Assertio and Spectrum to Host Conference Call
Today at 8:30 AM ET</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">LAKE FOREST,&nbsp;Ill., and BOSTON, April&nbsp;25, 2023 (GLOBE NEWSWIRE)
 &ndash; Assertio Holdings,&nbsp;Inc. (Nasdaq: ASRT) (&ldquo;Assertio&rdquo;), a specialty pharmaceutical company offering differentiated
products to patients, and Spectrum Pharmaceuticals,&nbsp;Inc. (Nasdaq: SPPI) (&ldquo;Spectrum&rdquo;), a commercial stage biopharmaceutical
company focused on novel and targeted oncology, today announced that they have entered into a definitive agreement pursuant to which Assertio
will acquire all outstanding shares of Spectrum in an all-stock and contingent value rights (&ldquo;CVR&rdquo;) transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;The addition of Spectrum&rsquo;s commercial
capabilities and ROLVEDON, a novel long-acting G-CSF product recently launched into a blockbuster market in October&nbsp;2022, exemplifies
Assertio&rsquo;s attractiveness as an acquirer of new, accretive assets across diverse therapeutic categories, and ability to continue
their growth and achieve profitable contributions faster and more efficiently than could be achieved on a standalone basis. We intend
to retain the majority of Spectrum&rsquo;s commercial infrastructure, which we believe is synergistic to our digital non-personal platform,
deploying these complementary dual channels to support clinical messaging, reimbursement education and ROLVEDON awareness to further aid
and accelerate its launch,&rdquo; said Dan Peisert, President and Chief Executive Officer of Assertio.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;We are excited to combine with Assertio
in a transaction that will deliver significant value to our stockholders and the opportunity to share in the future upside of ROLVEDON,&rdquo;
said Tom Riga, President and Chief Executive Officer of Spectrum Pharmaceuticals. &ldquo;Our mission at Spectrum has always been to make
a difference in the lives of patients and with Assertio, we have a partner that will enable us to deliver on this promise. Our combined
assets and commercial infrastructure will position us to accelerate ROLVEDON&rsquo;s launch for the benefit of patients, maximize its
potential and drive further growth. We are proud of the launch trajectory our team has achieved with ROLVEDON and look forward to an exciting
new chapter.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Terms of the Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the terms of the agreement, at closing,
Spectrum stockholders will receive a fixed exchange ratio of 0.1783 shares of Assertio common stock for each share of Spectrum common
stock they own, implying an upfront value of $1.14 per Spectrum share (approximately $248 million) based on Assertio&rsquo;s stock price
on April&nbsp;24, 2023 and an initial 65% premium to Spectrum&rsquo;s closing price on such date. Additionally, Spectrum stockholders
will receive one CVR per Spectrum share entitling them to receive up to an additional $0.20 per share in total (approximately $43 million),
payable in cash or stock at Assertio's election, for $1.34 (approximately $291 million), a total potential premium of 94%. Subject to
adjustments, each CVR shall represent the right to receive $0.10 payable upon ROLVEDON net sales (less certain deductions) achieving $175
million during the calendar year ending December&nbsp;31, 2024, and $0.10 payable upon ROLVEDON net sales (less certain deductions) achieving
$225 million during the calendar year ending December&nbsp;31, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Following the close of the transaction, Assertio
stockholders will own approximately 65% of the combined company, and Spectrum stockholders will own approximately 35%, on a fully diluted
basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Transaction Strategic and Financial Rationale</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Strengthened Commercial Infrastructure and
Resources:</B> Assertio&rsquo;s innovative digital non-personal sales model complements Spectrum&rsquo;s in-person commercial infrastructure,
providing greater market access and resources than either company as a standalone entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Expected to Be Accretive to Adjusted EPS and
Operating Cash Flow in 2024:</B> Assertio intends to retain the majority of Spectrum&rsquo;s commercial team and add operating costs of
approximately $60 million annually. The remaining cost synergies are expected to accelerate and enhance the profit opportunities for the
combined company and generate double-digit accretion to adjusted EPS and increased operating cash flow in 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Enhanced IP Portfolio: </B>ROLVEDON&rsquo;s
intellectual property protection is anticipated to extend through 2036, complementing Assertio&rsquo;s portfolio of traditional and non-traditional
IP protection, including assets with protection extending beyond 2040 and plans to secure additional protections on existing assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Improved Strategic Profile:</B> The transaction
enables the combined company to have a more scalable and competitive infrastructure for continuing the development and acquisition of
existing and prospective new commercial- and late development-stage products suited to Assertio&rsquo;s unique omni-channel sales strategy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Platform Diversification: </B>In addition to
Assertio&rsquo;s key assets Indocin, Sympazan and Otrexup, Spectrum&rsquo;s key asset ROLVEDON will represent meaningful further asset
diversification. ROLVEDON is a long-acting growth factor (G-CSF) indicated to decrease the incidence of infection, as manifested by febrile
neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant
incidence of febrile neutropenia.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Access to Capital Markets: </B>With enhanced
scale and greater diversification of revenue generating commercial assets, the combined company is expected to have a more attractive
profile to investors and to benefit from greater access to the capital markets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Approvals and Timing to Close</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The transaction, which has been approved by the
boards of directors of both companies, is expected to close in the third quarter of 2023, subject to approval by Assertio and Spectrum
stockholders and the satisfaction of customary closing conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Conference Call and Investor Presentation Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Assertio and Spectrum will host a conference call
today, at 8:30 am Eastern Time to discuss the transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 31%; border-top: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 2.65pt; padding-left: 2.65pt; text-align: justify"><FONT STYLE="font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="width: 69%; border: black 1pt solid; padding-right: 2.65pt; padding-left: 2.65pt; text-align: justify"><FONT STYLE="font-size: 10pt">April&nbsp;25, 2023</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 2.65pt; padding-left: 2.65pt; text-align: justify"><FONT STYLE="font-size: 10pt">Time:</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 2.65pt; padding-left: 2.65pt; text-align: justify"><FONT STYLE="font-size: 10pt">8:30 a.m.&nbsp;Eastern Time</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1pt; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 2.65pt; padding-left: 2.65pt; text-align: justify"><FONT STYLE="font-size: 10pt">Webcast (live and archive) and Presentation:</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 2.65pt; padding-left: 2.65pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>http://investor.assertiotx.com/overview/default.aspx</U></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>https://investor.sppirx.com/events-and-presentations</U><B>&nbsp;</B></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 2.65pt; padding-left: 2.65pt; text-align: justify"><FONT STYLE="font-size: 10pt">Dial-in numbers:</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 2.65pt; padding-left: 2.65pt; text-align: justify"><FONT STYLE="font-size: 10pt">1-929-201-5912 </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 2.65pt; padding-left: 2.65pt; text-align: justify"><FONT STYLE="font-size: 10pt">Conference number:</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 2.65pt; padding-left: 2.65pt; text-align: justify"><FONT STYLE="font-size: 10pt">9687947</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Please connect at least 15 minutes prior to the
live webcast to ensure adequate time for any software download that may be needed to access the webcast. The replay will be available
approximately two hours after the call on the investor websites.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Advisors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Guggenheim Securities, LLC is acting as financial
advisor to Spectrum, and Gibson, Dunn&nbsp;&amp; Crutcher LLP is serving as legal counsel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SVB Securities and H.C. Wainwright&nbsp;&amp;
Co. are acting as financial advisors to Assertio, and Latham&nbsp;&amp; Watkins LLP is serving as legal counsel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Assertio</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Assertio is a specialty pharmaceutical company
offering differentiated products to patients utilizing a non-personal promotional model. We have built and continue to build our commercial
portfolio by identifying new opportunities within our existing products as well as acquisitions or licensing of additional approved products.
To learn more about Assertio, visit <U>www.assertiotx.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>About&nbsp;Spectrum</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Spectrum is a commercial
stage biopharmaceutical company, with a strategy of acquiring, developing, and commercializing novel and targeted oncology therapies.
We have an in-house clinical development organization with regulatory and data management capabilities, in addition to commercial infrastructure
and a field based sales force for our marketed product, ROLVEDON&trade; (eflapegrastim-xnst) Injection. For additional information on
Spectrum please visit<FONT STYLE="color: #646464">&nbsp;</FONT><U>www.sppirx.com<FONT STYLE="color: #0563C1">.</FONT></U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The statements in this communication include forward-looking
statements concerning Assertio and Spectrum, the proposed transactions and other related matters. Forward-looking statements may discuss
goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based
on current beliefs and involve numerous risks and uncertainties that could cause actual results to differ materially from expectations.
Forward-looking statements speak only as of the date they are made or as of the dates indicated in the statements and should not be relied
upon as predictions of future events, as there can be no assurance that the events or circumstances reflected in these statements will
be achieved or will occur. Forward-looking statements can often, but not always, be identified by the use of forward-looking terminology
including &ldquo;believes,&rdquo; &ldquo;expects,&rdquo; &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;should,&rdquo; &ldquo;seeks,&rdquo;
 &ldquo;intends,&rdquo; &ldquo;plans,&rdquo; &ldquo;pro forma,&rdquo; &ldquo;estimates,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;designed,&rdquo;
or the negative of these words and phrases, other variations of these words and phrases or comparable terminology. These forward-looking
statements involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the statements,
including: failure to obtain applicable regulatory or stockholder approvals in a timely manner or otherwise; failure to satisfy other
closing conditions to the proposed transactions; risks that the new businesses will not be integrated successfully or that the combined
company will not realize estimated cost savings, value of certain tax assets, synergies and growth, or that such benefits may take longer
to realize than expected; failure to realize anticipated benefits of the combined operations; risks relating to unanticipated costs of
integration; demand for the combined company&rsquo;s products; the growth, change and competitive landscape of the markets in which the
combined company participates; expected industry trends, including pricing pressures and managed healthcare practices; variations in revenues
obtained from commercialization agreements, including contingent milestone payments, royalties, license fees and other contract revenues,
including non-recurring revenues, and the accounting treatment with respect thereto; Assertio&rsquo;s and Spectrum&rsquo;s abilities to
obtain and maintain intellectual property protection for their respective products and operate their respective businesses without infringing
the intellectual property rights of others; the commercial success and market acceptance of Assertio&rsquo;s and Spectrum&rsquo;s products;
the entry and sales of generics of Assertio&rsquo;s products including the Indocin products which are not patent protected and may face
generic competition at any time; the outcome of, and Assertio&rsquo;s intentions with respect to, any litigation or investigations, including
antitrust litigation, opioid-related investigations, opioid-related litigation and related claims for negligence and breach of fiduciary
duty against Assertio&rsquo;s former insurance broker, and other disputes and litigation, and the costs and expenses associated therewith;
and the ability of Assertio&rsquo;s and Spectrum&rsquo;s third-party manufacturers to manufacture adequate quantities of commercially
salable inventory and active pharmaceutical ingredients for each of their respective products, and Assertio&rsquo;s and Spectrum&rsquo;s
abilities to maintain their respective supply chains. For a discussion of additional factors that could cause actual results to differ
materially from those contemplated by forward-looking statements, see the sections captioned &ldquo;Risk Factors&rdquo; in Assertio&rsquo;s
and Spectrum&rsquo;s Annual Reports on Form&nbsp;10-K for the year ended December&nbsp;31, 2022 and other filings with the Securities
and Exchange Commission (the &ldquo;SEC&rdquo;). Many of these risks and uncertainties may be exacerbated by the COVID-19 pandemic and
any worsening of the global business and economic environment as a result. Assertio and Spectrum do not assume, and hereby disclaim, any
obligation to update forward-looking statements, except as may be required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About ROLVEDON&trade;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ROLVEDON&trade; (eflapegrastim-xnst) injection
is a long-acting granulocyte colony-stimulating factor (G-CSF) with a novel formulation. Spectrum has received an indication to decrease
the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive
anti-cancer drugs associated with clinically significant incidence of febrile neutropenia. ROLVEDON is not indicated for the mobilization
of peripheral blood progenitor cells for hematopoietic stem cell transplantation. The BLA for ROLVEDON was supported by data from two
identically designed Phase 3, randomized, open-label, noninferiority clinical trials, ADVANCE and RECOVER, which evaluated the safety
and efficacy of ROLVEDON in 643 early-stage breast cancer patients for the management of neutropenia due to myelosuppressive chemotherapy.
In both studies, ROLVEDON demonstrated the pre-specified hypothesis of non-inferiority (NI) in mean duration of severe neutropenia (DSN)
and a similar safety profile to pegfilgrastim. ROLVEDON also demonstrated non-inferiority to pegfilgrastim in the mean DSN across all
four cycles (all NI p&lt;0.0001) in both trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Please see the Important Safety Information below
and the full prescribing information for ROLVEDON at <U>www.rolvedon.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Indications and Usage</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ROLVEDON is indicated to decrease the incidence
of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer
drugs associated with clinically significant incidence of febrile neutropenia.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Limitations of Use</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ROLVEDON is not indicated for the mobilization
of peripheral blood progenitor cells for hematopoietic stem cell transplantation.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Important Safety Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Contraindications</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;</TD><TD STYLE="text-align: justify">ROLVEDON is contraindicated in patients with a history of serious allergic reactions to eflapegrastim,
pegfilgrastim or filgrastim products. Reactions may include anaphylaxis.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Warnings and Precautions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Splenic Rupture</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">Splenic rupture, including fatal cases, can occur following the administration of recombinant human granulocyte
colony-stimulating factor (rhG-CSF) products. Evaluate patients who report left upper abdominal or shoulder pain for an enlarged spleen
or splenic rupture.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Acute Respiratory Distress Syndrome (ARDS)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">ARDS can occur in patients receiving rhG-CSF products. Evaluate patients who develop fever, lung infiltrates,
or respiratory distress. Discontinue ROLVEDON in patients with ARDS.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Serious Allergic Reactions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">Serious allergic reactions, including anaphylaxis, can occur in patients receiving rhG-CSF products. Permanently
discontinue ROLVEDON in patients who experience serious allergic reactions.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Sickle Cell Crisis in Patients with Sickle
Cell Disorders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">Severe and sometimes fatal sickle cell crises can occur in patients with sickle cell disorders receiving
rhG-CSF products. Discontinue ROLVEDON if sickle cell crisis occurs.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Glomerulonephritis</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">Glomerulonephritis has occurred in patients receiving rhG-CSF products. The diagnoses were based upon
azotemia, hematuria (microscopic and macroscopic), proteinuria, and renal biopsy. Generally, events of glomerulonephritis resolved after
dose-reduction or discontinuation. Evaluate and consider dose reduction or interruption of ROLVEDON if causality is likely.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Leukocytosis</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">White blood cell (WBC) counts of 100 x 10<SUP>9</SUP>/L or greater have been observed in patients receiving
rhG-CSF products. Monitor complete blood count (CBC) during ROLVEDON therapy. Discontinue ROLVEDON treatment if WBC count of 100 x 10<SUP>9</SUP>/L
or greater occurs.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Thrombocytopenia</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">Thrombocytopenia has been reported in patients receiving rhG-CSF products. Monitor platelet counts.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Capillary Leak Syndrome</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">Capillary leak syndrome has been reported after administration of rhG-CSF products and is characterized
by hypotension, hypoalbuminemia, edema and hemoconcentration. Episodes vary in frequency and severity and may be life-threatening if treatment
is delayed. If symptoms develop, closely monitor and give standard symptomatic treatment, which may include a need for intensive care.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Potential for Tumor Growth Stimulatory Effects
on Malignant Cells</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">The granulocyte colony-stimulating factor (G-CSF) receptor through which ROLVEDON acts has been found
on tumor cell lines. The possibility that ROLVEDON acts as a growth factor for any tumor type, including myeloid malignancies and myelodysplasia,
diseases for which ROLVEDON is not approved, cannot be excluded.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Myelodysplastic Syndrome (MDS) and Acute Myeloid
Leukemia (AML) in Patients with Breast and Lung Cancer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">MDS and AML have been associated with the use of rhG-CSF products in conjunction with chemotherapy and/or
radiotherapy in patients with breast and lung cancer. Monitor patients for signs and symptoms of MDS/AML in these settings.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Aortitis</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">Aortitis has been reported in patients receiving rhG-CSF products. It may occur as early as the first
week after start of therapy. Consider aortitis in patients who develop generalized signs and symptoms such as fever, abdominal pain, malaise,
back pain, and increased inflammatory markers (e.g., c-reactive protein and white blood cell count) without known etiology. Discontinue
ROLVEDON if aortitis is suspected.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Nuclear Imaging</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">Increased hematopoietic activity of the bone marrow in response to growth factor therapy has been associated
with transient positive bone imaging changes. This should be considered when interpreting bone imaging results.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Adverse Reactions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">The most common adverse reactions (&ge;20%) were fatigue, nausea, diarrhea, bone pain, headache, pyrexia,
anemia, rash, myalgia, arthralgia, and back pain.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">Permanent discontinuation due to an adverse reaction occurred in 4% of patients who received ROLVEDON.
The adverse reaction requiring permanent discontinuation in 3 patients who received ROLVEDON was rash.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>To report SUSPECTED ADVERSE REACTIONS, contact
Spectrum Pharmaceuticals,&nbsp;Inc. at 1-888-713-0688 or FDA at 1800FDA1088 or <U>www.fda.gov/medwatch</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">SPECTRUM PHARMACEUTICALS,&nbsp;INC.&reg;
is a registered trademark of&nbsp;Spectrum Pharmaceuticals,&nbsp;Inc.&nbsp;and its affiliates. REDEFINING CANCER CARE&trade; and ROLVEDON&trade;
are the Spectrum Pharmaceuticals&rsquo; logos and trademarks owned by&nbsp;Spectrum Pharmaceuticals,&nbsp;Inc.&nbsp;Any other trademarks
are the property of their respective owners.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>No Offer or Solicitation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This communication is not intended to and does
not constitute an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for
any securities or the solicitation of any vote in any jurisdiction pursuant to the proposed transactions or otherwise, nor shall there
be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offer of securities shall be
made except by means of a prospectus meeting the requirements of Section&nbsp;10 of the Securities Act of 1933, as amended. Subject to
certain exceptions to be approved by the relevant regulators or certain facts to be ascertained, the public offer will not be made directly
or indirectly, in or into any jurisdiction where to do so would constitute a violation of the laws of such jurisdiction, or by use of
the mails or by any means or instrumentality (including without limitation, facsimile transmission, telephone and the internet) of interstate
or foreign commerce, or any facility of a national securities exchange, of any such jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Important Additional Information Will be Filed
with the SEC</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Assertio will file with the SEC a Registration
Statement on Form&nbsp;S-4, which will include a joint proxy statement and prospectus of both Assertio and Spectrum (the &ldquo;joint
proxy statement/prospectus&rdquo;). <B>INVESTORS AND STOCKHOLDERS ARE URGED TO READ THE JOINT PROXY STATEMENT/PROSPECTUS, AND OTHER RELEVANT
DOCUMENTS TO BE FILED WITH THE SEC,&nbsp;IN THEIR ENTIRETY CAREFULLY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION
ABOUT ASSERTIO, SPECTRUM, THE PROPOSED TRANSACTIONS AND RELATED MATTERS.</B> Investors and stockholders will be able to obtain free copies
of the joint proxy statement/prospectus and other documents filed with the SEC by Assertio and Spectrum through the website maintained
by the SEC at www.sec.gov. In addition, investors and stockholders will be able to obtain free copies of the joint proxy statement/prospectus
and other documents filed with the SEC by Assertio and Spectrum by contacting Investor Relations at Assertio Holdings,&nbsp;Inc., 100
South Sanders Rd., Suite&nbsp;300, Lake Forest,&nbsp;IL 60045 (for documents filed by Assertio) or Investor Relations at Spectrum Pharmaceuticals,&nbsp;Inc.
by email at ir@sppirx.com or by phone at (949) 788-6700 (for documents filed by Spectrum).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Participants in the Solicitation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Assertio and Spectrum and their respective directors
and executive officers may be deemed to be participants in the solicitation of proxies from their respective stockholders in respect of
the proposed transactions contemplated by the joint proxy statement/prospectus. Information regarding the persons who are, under the rules&nbsp;of
the SEC, participants in the solicitation of the stockholders of Assertio and Spectrum in connection with the proposed transactions, including
a description of their direct or indirect interests, by security holdings or otherwise, will be set forth in the joint proxy statement/prospectus
when it is filed with the SEC. Information regarding Assertio&rsquo;s directors and executive officers is contained in its Annual Report
on Form&nbsp;10-K for the year ended December&nbsp;31, 2022 and its Proxy Statement on Schedule 14A, dated April&nbsp;3, 2023, which are
filed with the SEC. Information regarding Spectrum&rsquo;s directors and executive officers is contained in its Annual Report on Form&nbsp;10-K
for the year ended December&nbsp;31, 2022 and its Proxy Statement on Schedule 14A, dated April&nbsp;27, 2022, which are filed with the
SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Assertio Investor Contact</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Matt Kreps</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Darrow Associates</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">M: 214-597-8200</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>mkreps@darrowir.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Spectrum Investor Contacts</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Nora Brennan</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">Chief Financial Officer/Investor
Relations<BR>
949-788-6700<FONT STYLE="color: #646464"><BR>
</FONT><FONT STYLE="text-decoration: underline">InvestorRelations@sppirx.com</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Lisa Wilson<FONT STYLE="color: #646464"><BR>
</FONT>In-Site Communications,&nbsp;Inc.<FONT STYLE="color: #646464"><BR>
</FONT><FONT STYLE="background-color: white">212-452-2793</FONT><FONT STYLE="color: #646464"><BR>
</FONT><FONT STYLE="text-decoration: underline">lwilson@insitecony.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>asrt-20230424.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWaWE2bOdzZR+uYkxtmBxbQl6TyYt5hVRgC28LfP2wUQK -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:ASRT="http://assertiotx.com/20230424" elementFormDefault="qualified" targetNamespace="http://assertiotx.com/20230424">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://assertiotx.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="asrt-20230424_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="asrt-20230424_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" />
    <import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
    <import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>asrt-20230424_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>asrt-20230424_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://assertiotx.com/role/Cover" xlink:href="asrt-20230424.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://assertiotx.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>tm2313548d1_ex99-1img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2313548d1_ex99-1img01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  X 5X# 2(  A$! Q$!_\0
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M/XUWOC;Q7_8G@]=2T^53-=E%M7(R/F&[=@_[(/XD4Y8.I%P7\VQ,<73DI/\
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139629666782560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Apr. 24, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Apr. 24,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39294<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ASSERTIO HOLDINGS,&#160;INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001808665<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">85-0598378<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">100
South Saunders Rd<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite
300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Lake Forest<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">IL<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">60045<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">224<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">419-7106<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ASRT<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>tm2313548d1_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="asrt-20230424.xsd" xlink:type="simple"/>
    <context id="From2023-04-24to2023-04-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808665</identifier>
        </entity>
        <period>
            <startDate>2023-04-24</startDate>
            <endDate>2023-04-24</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2023-04-24to2023-04-24">0001808665</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2023-04-24to2023-04-24">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2023-04-24to2023-04-24">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2023-04-24to2023-04-24">2023-04-24</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2023-04-24to2023-04-24">ASSERTIO HOLDINGS,&#160;INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2023-04-24to2023-04-24">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2023-04-24to2023-04-24">001-39294</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2023-04-24to2023-04-24">85-0598378</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2023-04-24to2023-04-24">100 South Saunders Rd</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2023-04-24to2023-04-24">Suite 300</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2023-04-24to2023-04-24">Lake Forest</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2023-04-24to2023-04-24">IL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2023-04-24to2023-04-24">60045</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2023-04-24to2023-04-24">224</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2023-04-24to2023-04-24">419-7106</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2023-04-24to2023-04-24">true</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2023-04-24to2023-04-24">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2023-04-24to2023-04-24">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2023-04-24to2023-04-24">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2023-04-24to2023-04-24">Common Stock, $0.0001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2023-04-24to2023-04-24">ASRT</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2023-04-24to2023-04-24">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2023-04-24to2023-04-24">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M$I,D>7HP8%U+A0L9E6/3AU]U!1\W\4#&(A1&I!OR#:I;"1;7XN J3=,0K;H
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M='@//GL?)=-[*CG_5U/\!%!+ P04    " !$2YE6EXJ[',     3 @  "P
M %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=
MOZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'
MTD!$VV-#L%HL/D N&6:WO606IW.D5XA<UYVE/=LO3T%O@*\Z3'%":4A+,P[P
MS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T
M>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0    ( $1+F5:JQ"(6,P$
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M'EKG5LJ]AU>RY1AQ_)[E#U!+ P04    " !$2YE6)!Z;HJT   #X 0  &@
M 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSM9$]#H,P#(6O$N4 -5"I0P5,
M75@K+A %\R,2$L6N"K<OA0&0.G1ALIXM?^_)3I]H%'=NH+;S)$9K!LIDR^SO
M *1;M(HNSN,P3VH7K.)9A@:\TKUJ$)(HND'8,V2>[IFBG#S^0W1UW6E\./VR
M./ /,+Q=Z*E%9"E*%1KD3,)HMC;!4N++3):BJ#(9BBJ6<%H@XLD@;6E6?;!/
M3K3G>1<W]T6NS>,)KM\,<'AT_@%02P,$%     @ 1$N95F60>9(9 0  SP,
M !,   !;0V]N=&5N=%]4>7!E<UTN>&ULK9--3L,P$(6O$F5;)2XL6*"F&V +
M77 !8T\:J_Z39UK2VS-.VDJ@$A6%3:QXWKS/GI>LWH\1L.B=]=B4'5%\% )5
M!TYB'2)XKK0A.4G\FK8B2K636Q#WR^6#4,$3>*HH>Y3KU3.T<F^I>.EY&TWP
M39G 8ED\C<+,:DH9HS5*$M?%P>L?E.I$J+EST&!G(BY84(JKA%SY'7#J>SM
M2D9#L9&)7J5CE>BM0#I:P'K:XLH90]L:!3JHO>.6&F,"J;$#(&?KT70Q32:>
M,(S/N]G\P68*R,I-"A$YL01_QYTCR=U59"-(9*:O>"&R]>S[04Y;@[Z1S>/]
M#&DWY(%B6.;/^'O&%_\;SO$1PNZ_/[&\UDX:?^:+X3]>?P%02P$"% ,4
M" !$2YE6!T%-8H$   "Q    $               @ $     9&]C4')O<',O
M87!P+GAM;%!+ 0(4 Q0    ( $1+F59 :J(][P   "L"   1
M  "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( $1+F5:97)PC
M$ 8  )PG   3              "  <T!  !X;"]T:&5M92]T:&5M93$N>&UL
M4$L! A0#%     @ 1$N95@H9<)UH!   (!$  !@              ("!#@@
M 'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( $1+F5:?H!OP
ML0(  .(,   -              "  :P,  !X;"]S='EL97,N>&UL4$L! A0#
M%     @ 1$N95I>*NQS     $P(   L              ( !B \  %]R96QS
M+RYR96QS4$L! A0#%     @ 1$N95JK$(A8S 0  (@(   \
M ( !<1   'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( $1+F58D'INBK0
M /@!   :              "  =$1  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN
M<F5L<U!+ 0(4 Q0    ( $1+F59ED'F2&0$  ,\#   3              "
M ;82  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(    4
!  $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm2313548d1_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://assertiotx.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="tm2313548d1_8k.htm">tm2313548d1_8k.htm</File>
    <File>asrt-20230424.xsd</File>
    <File>asrt-20230424_lab.xml</File>
    <File>asrt-20230424_pre.xml</File>
    <File>tm2313548d1_ex2-1.htm</File>
    <File>tm2313548d1_ex99-1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "tm2313548d1_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2021q4": 23
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "tm2313548d1_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "asrt-20230424_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "asrt-20230424_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "asrt-20230424.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021q4": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "ASRT",
   "nsuri": "http://assertiotx.com/20230424",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm2313548d1_8k.htm",
      "contextRef": "From2023-04-24to2023-04-24",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://assertiotx.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm2313548d1_8k.htm",
      "contextRef": "From2023-04-24to2023-04-24",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://assertiotx.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://assertiotx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://assertiotx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://assertiotx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://assertiotx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://assertiotx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://assertiotx.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://assertiotx.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://assertiotx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://assertiotx.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://assertiotx.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://assertiotx.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://assertiotx.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://assertiotx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://assertiotx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://assertiotx.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://assertiotx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://assertiotx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://assertiotx.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://assertiotx.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://assertiotx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://assertiotx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://assertiotx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://assertiotx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://assertiotx.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://assertiotx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://assertiotx.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://assertiotx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://assertiotx.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://assertiotx.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://assertiotx.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://assertiotx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://assertiotx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://assertiotx.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://assertiotx.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://assertiotx.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://assertiotx.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://assertiotx.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://assertiotx.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://assertiotx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://assertiotx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://assertiotx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://assertiotx.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://assertiotx.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://assertiotx.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://assertiotx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://assertiotx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://assertiotx.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://assertiotx.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://assertiotx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://assertiotx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://assertiotx.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://assertiotx.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://assertiotx.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://assertiotx.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://assertiotx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://assertiotx.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://assertiotx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r10": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r11": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r12": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r13": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r14": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r15": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r16": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r19": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r9": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001104659-23-049365-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-23-049365-xbrl.zip
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M8MQM6QS5_R*V#61Y:33M7%,M_P!02P,$%     @ 1$N95FSRHQK_"@  ;(<
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M>+#V_EUB5V#T&]: P,H@0.FU9P(C \91+0(5(2B/\8_./$TW1+P)($N()XQ
M\P!,+7V(2$$F>\$J GWSM2#11O:7N^G1\C[)J.W$LRUQUC\!YJK>R4@/@@_
ME,E#GH;X YH>_7GY%Z2C/"!PS>\%5HO:+G;K):? 2EA6E2L0.BQJ%BR2('"
M?9E$7'-42E&A];525L.PI4A&NBL(K+9T]3<2@ZAXFZ-6(]"H;X_-_\4V>I3&
M"##9P2YSW0W83)I=05T3! 8=QEHG*Z44::VOR0[[+FS5/RA8>1L4K'H&!:L0
M!P6KH8."E==!@=YUL4R);*-NEC1986#1Q$ZU:S Z+)N,6*1!X0+[ ]N.*@3M
M8WRLMIDONZ9>)2#6N8=+^<%24D#G;+W-+IO5@ILV41"<=#EK+;E9+(17$R.E
M]L'&)DXR$A>&+A.&691@6BW=:+MZWA_BC)B!YBMX>O1A<#3,9 NI(DROL5@%
M[I?A]''9O7B(XQ="Z4^,O[(%P2EG)"ZNM]CN+G7KW3YUTV.[^> -( X"J2$.
M@<=O5-#X244A'59>+?-&TU=.-RS#(I_#+FPM%*!S2P]@LTF-(0J(%KLS@))*
MC JUOTGAQ>H5U<"K>&<26$A([GB*>*=I8Z:X51L0-YT&H7GCY9HC^_%R$>5Q
M.F=&U+LNDA?R&6>X] >6&9*[GL#99=J<N6G3!H11IT%PKF85HY:KP9HKK\O6
MB)D<?JUXQ]/GALK]XC4MB^WU:RI)0(C8?'6L8B.0UGKC8;'&E'[:I DC*=PI
M&2JW/%@M-GEH2 +BP>8+X"&7(JWUQL/%FHB5[.Y^%/PU>RS7D 7+!ZC=\M%I
MN<F)51H0+UW^ &YT""IB]+*__@#:[A= +U: A$MKD3I&!S1K<-/2A00-9*Y%
M#"61NAYSS3-TS]&7E*#LD:"+\K5Z]97KBWQ\OB4EBM2$BV*TSF(L;!AUB9V_
M,04TW'IO2DL9!$R]]N!WJ%012(=X(.=&LBSJYWBYD7E&UN!,BOX05Q0--:]9
MZM,'0=1 DR97>5CSQ#L/1"K2]ZI*]07YX6%?0^1XM&PQ: R6:XH@. %M04/E
M^OL-_*WGMUG2)+JD',-781H:QZOXM>T9"_CM!0%1T'8%+=N7"U&N],; )\R>
MQ.8YBW:W@D>$J*>UTJKEZKM&-S#:+3=O*E*3J$&A ;'V%K\ A?LL4"V/#[7>
MR_<%/_4PNEIACD=/BT<L#^+-)DM5CRK-P5?,.X,<WXH84 #CAD1'1$#X#; )
MW9S((U$>^@$5P:@6[?&\+=VO3DCB3[L[\D"$FM-P3[;9)[FSIXXSCP&QKL_J
M!A?'/,GK#0P"Q+>ZA4X!4U3/ "W5<V9E%NA7E0G*<[&]I[V^Z4I^DIOU)OEK
MB5,BM_P74$L#!!0    ( $1+F58XW_M65@<  ,58   5    87-R="TR,#(S
M,#0R-%]P<F4N>&ULS9S?<]HX$,??;^;^!Q_W# 22WC4TN4Y"0X=IVN0";>_N
MI2-L 9K($I7D /_]23:F_+#DS4LW>4B(O9+V^UDA>RW)%V]7*8^>J-),BLM&
MIW72B*B(9<+$[++Q>=2\&O6'PT:D#1$)X5+0RX:0C;=__?I+9'\N?FLVHP&C
M/.E%[V3<'(JI?!-](BGM1>^IH(H8J=Y$7PC/W!$Y8)RJJ"_3!:>&VA-%P[WH
M5:OSFD3-)J#>+U0D4GU^&&[KG1NST+UV>[E<MH1\(DNI'G4KEBFLPI$A)M/;
MVDY6)YN?HO@%9^*QYWY-B*:1Y25T;Z799<.UNVEV>=J2:M;NGIQTVO]\O!W%
M<YJ2)A..6TP;92E72U6YSOGY>3L_6YH>6:XFBI=MG+9+=[8UV[,L8+_CB68]
MG;MW*V-B\K#7-A-Y+=Q_S=*LZ0XU.]WF::>UTDFCA)\35)+3!SJ-W%\;O6VK
M1&NJK!]FY4+6=J?;?6F[I/4U+SA7='K9(%H96W_W].2L>^9J_WW/R*P7MFMJ
MYGI6(VKOM;Q05%-A<K&W]L!>$;HRMD/1I*S(M0_WS3#CS#<=IA,U7>_*4MN:
M_5A8;EPIG>$RWFN?NRC( [%EC\Y9:QJW9O*IG5!FF7<[W\_<QV;Q,2=A__V6
M-W8UT4:1V)2U<3*A/&_CF[4Y,&G_),]*(F-;:[5C^Q:'?NV&[TK%D50)599Y
M61=1\5[0CCOIQJ*](,I6U(SGC&_C/54R]1':T) >1W=AV29^'M$KZT/B_!AP
M,JM&>F "9-K!@%JI!I/J.ZICQ1:.30W</4L@XRXJXPIM"*C+[]$#G3'GLW/'
M78:I.Q@>(SQ%@/!/,4>-H%K$*%P)D1'^0!=2U<#?MP0R/\-D7J4-$?7?&5&&
M*KZ&T#XR!@)_A0G<HQ"1^5@1H9EC!(%^; VD_@?J#8E'(R+VT9QR[E(](D"]
MO<H>B/Y/3/1^G2\$_LV3N^[;RPV<_TX18 A>OY00'*E%C,(]54PF]E*O /R/
MC('DSS')>Q2B,[\1"93XUA2<(^$#/Y"'B'O =$QXX=7 'M-AY!7F4.PHN6FM
M3'3T_U*BP.!WC*'84=+5&HD(T/N94GL.!4<8OS44.TJB6B<2@?N-,,RLW;S!
MIRR=_'CPNL_[V K*&24Y]8E"XUL^F1#&38F$&!]:0CFCY*0A<6BL^U:3(GPH
M$KKZ0-<AV$>F4-HHN6A0'AKN>\52HM8C%M</(,>V4. H&6A8(!KQ,5D-$ZN,
M35DQP5@/WEL$RA\E_03)10O#4,12+>3.X^:^S.QW<]V727"(KRD(#0E*7OH,
MZ6B!N4H2BTQO_MPR03NA<%2:@^>:\((0D/F"T'>?A[X+1X^2K];*?$'H3Y^'
M_A2.'B5GK96)C;YO/]ZIL5QZ9K6]QE#L*#EKC41LZ/G5YT[=*_G$BO57=>2/
M2D#Q(Z:R8;'8,=A<_"&]OK2$,D=,:ZO%8;.^E]H0_A];U-UE5MM#N2,FN"&A
M& \FB_B[AQR^Y4H')E#&*#EMI1P,K"[2BA)_-]ZW@$)%252KQ" PO95N#F4N
M1?!9[K$5E"U*QND3A3$0NZ7,VCL,[)P&KY9#&68/92"@_*J8L5[T99IF8O-<
MQS/#YC&%(D9)$X/R$'"/)&<Q,TS,/MH[2,4(KV9=90<%C9(4^H4A4+Y7U$6<
MVEOS?,V8V_>@[J93WT@<LH=21\D)ZX7BTQ]JG5'UW!A4E()& B4]A(K&&'-H
MG-EA<-WI3L9N%X]GQ#FR@O)&20U]HA#X?I)C1=P^PM$ZG4CNWZI2:0BEC)((
M!J0A@-[SI1KQ@0D4+DH&6"D'<7RX6<5S(F;4OS*BVA(*&24C#(E#'8MGH+%X
M]LRQ&"4S](E"Y%NL3[??KKL)9S/BW^$6+ #>]X-)/2 58V]AO@W)[3I7:>[+
MP'ZH1N\QA4+'V<(9DH>!.TN8H4GAUH )(F*;>FWWW'DR^?I2T"#@[/$$BD:;
M(OA*.?\@Y%*,*-%2T*1(!T*S!-XBT$@@SDG6R$4+PQ?),TM*Y0M0E>>[X#&%
M8D><B_3(PUOO62RJWEZ/BM>-A*C[2D#A(TY*AL4BKH4SU/G-GN@[8LC&RU ,
M?"6@,4"<H R+15W#K_KV8C23X;GX T,H<<0EN)72T$"/4L+Y=::9H#HXSAP8
M0D$CKK6ME(8&^B:E:F8'N?=*+LU\L_\T!-Q3  H><45M4"I> %8_]KT7>_."
M]"NLP6]40$3O%8GYRI X=@LUBBN\2(CRD _90]FC;OST"T6@?V?F5.W>6^4.
M#6U^%UI045\*&@F4M!8J&N]ZN_/V@>#E=L\.RAPQ@:T2AK>/*YMP%@^X),'[
M]CTS*&/$;+5"%AKB:R(>5;8P\?I>R9A2-PVCM]\\0-($K  :%L0\]EDH\!XM
MR#1U&YQD_#B:6^'Z+C/YFUJMC\$'#,%RT/!@;C(%"$>\.](_-J#1Y'K]0*=4
MN2408[HRU[:QQ_#-$J X-$:H;T8"8Z@(U47[2->M/>#>QUN<<;_<.V?MD?\!
M4$L#!!0    ( $1+F58,PI.QJS8  )X: 0 2    =&TR,S$S-30X9#%?.&LN
M:'1M[7UI=QK)DNAWG:/_D$_OWCGR/$" %FMQ:P9+V*9;6X/<;O<7GX)*1%E%
M%:Y%"/_Z%Q&Y5-:&0$;>KN=.6U)55BZ1L4=DY(O_N1^[[(X'H>-[OVTT:O4-
MQKV!;SO>S6\;<32L[F_\S_'ZVHM1!.V@K1?^MC&*HLGAUM9T.JU-MVM^<+/5
M.#@XV+K'-ANBT>%]8;MFO=[8^OO\K#<8\;%5=;PPLKP!UQ^YCG=;WC^^U4W[
M@>NDFN(3-<CV5JYK>&LG'YB-][;$RU33J+#IKF@:J:9.Z.\T&\_GS4.TT!_<
ME[5MX)QAA?SOE]VSI'E4W#YINA4%EA<._6!L1;"'V--NM=ZL-O>,3JHA'Z0Z
M@K]K-_[=@_WL5[<;JI_<YJ17BJ_[5J@A;O,,N-68\ *^:#8^[:BF 1^6=KRW
M!6]5PSBLWEC61#<>6F&?&LH7U&^UWC!F#6\"W^5AX3?TIN"C@1][43 KGK]\
M29^I#\(@R@\ #POZ;O6ZU[JM%88\ 'A'][6!/\;6V_6=YLX&D1RW;/C)\/]>
M1$[D\N,76^(GO!WSR&+82Y5_BIV[WS9.?"_B7E2]GDU@#P;BK]\V(GX?;0G*
MW,+OMF2W+_Y/M<I>.=RU#UF/1T?LPAKS0W9OWQ^QSBG]\J'>;'UXV_MW\_1U
MJW4%/W QK%I=].OM^@=<[(?T(C^H12[1T\Z._NHQG^^^_, !ZV %\/]M#V X
M.P'@!);;\6Q^_P>??:@#9]JO[^_M[2[3[X'1;VO,/1O^BUZYULV'H>6&?(FN
M]EX"I$\_-#Y(AB'ZA$?+]-'\T!M9 0\_-#\0?Q2=A/1LF7Y.<2Y7LJ_MW)1*
M.^_[]HR%T<SEOVT, 0$/6:,^B=BU,X8F%WS*NO[8\BKB004F$#A#0G7;N5/?
MV4XX<:W9(?-\C]-+Y_X0<98'2 STEV/;W"/2P#^AX44\AKX& NOOHR[RDU>!
M/T9<J=9WJLV=R$]^WV >K!J&XLYA(39L'"?H\&(K-<1J1DWARL8Q(4OA0%NI
MY>*XP UY "*:AZ(%LMW#D.0I3("1D#P<$4>U@ %5%;G4[D-[0[Z.@$7\MA$Z
MXXG+!5N00Z4[%\.%?ARHT: 9[?VA7#)S[+E+5NQ+?<8)VOJI?N[8^&;H\(#1
M4GBAL#KI_)'>F>S'R7!;A>/)T28 7]_.SP(TAB ZM2)^G"Q!]92\RWT&6UGR
MD7J3G59J NJA!&D:SK'G"" #V>6@.>96& ?\6-+G(;11G:E7Z2&PMY+^!;&7
M#B&!0(T>/4;"5'+C  . ;<S#%K\E@K B/S!>+P^#[!R+>C4&/>6>/W:\AX9]
M&"[9<8LZ5N]34,@!5%*H08^"/2C>^&(+OH>?^+\7$\5/QU9PXWB'K+YQ_%__
MM[%7/WJQ-3DN;;+82T.(=&.75Z^L&Y)U)A^?.G8T0@%0__=&ZD7?#V"^U<B?
M'+*7KC6X94V0$:'O.O81DR_[?A3Y8_6^D;Q'J5(-G<\@L^!ILB1<N?S7F-Q6
M:G8+PB7=3(JQ_8?$V!'3'4+3^A%#6JY:KG,#CP; AW@ 8.@?O[WH7+=/6>^Z
M==WNO=CJ%T!\U4/VVB=ONYWK3KO'6A>GK/WWR9O6Q>LV.[D\/^_T>IW+B[GS
M>%""+SJ/=U8X K,R\N'[T]I)C37KNSL'7V'L,KQ?-:!?77;/Y5CAQ/*(YZ%"
M=5!ODYY8K9[Z@QC%/NKH'P9:I4V4V\^-?TYW#\*]X,UKT N^6,\PQ]LXWJ_^
MD54R7FSA3(]7N@D/ GQE& 5XW6U?7+-N^^JR>_WM,6EE"[N*@S"VO(A%/GPX
M0(.<-;:9'[#&[J;]C/E#%HWXUR%;&#\.G,B!GMKW@Y'E 3=M#2*<0^-@>^<G
M@GJ6:O<R5'M%:EM;*'7%Y/OJX_.(3]]-SX>[CR9?X8/Y;<.YCPYM&&D,WXUL
M:S;CH&5X1>2=FMC&<6L2."YK[E08=OLU2+X4I#@AQ)0NG_A!Q#;5W[ 4%S J
M8OP.&K. 7G/[63*KU;.A1;06T4/5Y4,8THHC7W5:#9R;D7XFE9OFP[K-D^@N
M3\28FT]&24U)2<+:[O(;)T1W8X3>AV)">M\(7LZF[ZY&Y_T-<Y82@#C5%<C'
MHOD _?1Z[>YUYY*]N3P[[5R\[E4$W#H7)[5O2DV;[7L+."_.'XDHT/-F5LC"
M"1^@%6PS!T ?A>MKP*R!J()G3RO=?Y%5%B*1U7<Y[)OK FX,*))2WZ"_)Y9M
MJ[^7'M2PJ+2A-/!=UYJ$L';U&[G,(F5;OHAL-= =^F 'EJOP"J"I^]QN_GMI
MJ2AHI^,-_ "8-P4->A&P]Q/A'C_Q[1+2_N35=^N.LW?R>F<5,A)C&^B>B?@D
M\.^0-M)"<H%Y;AR?<M>:@GB=2]Z1_3!4A>6:H/*_$^Q8Y//5;,HKQ^6P@CX/
M2K04?QI=Q->_U]U5&!G9,=%'UZAN'S0/=GX.<%Y;]QWI8QP0_LR#;>?<[YW9
MIU?G!X_7 +.P+9D 6'2[U?KNP?[V\_V'( W_!$MQAC(11+2#EL@E6" !^QUL
M@]!VA(GB#U_T ^E/9BQ%<L^6W7,:3>WUHI_.G?F)/QX[(0:ZS5DBWC(!S^]@
MCIUNC[7'$]>? 6Q3P$SM?V[":GNW2/:L0GU^C"G6]UU[B9&$0(?F^H'R^]&S
M0AAE"/55BE!;MAWP,)0_SAR/-XJ)],USMWG&]ULOWP\%_:^&3@O&WS@&>;V^
MUO/C:,1Z5NR!U Y9U\[3:U_3;/^X5F'9E9X\L-)F\4J=[<;UU:C?.#AU5\:.
M"@;?..[%3L37U[;K]7FLJ'^LL3J[P$;1 D_@U\O@VI]ZQ<NS_YY\]F_L/WEW
MN.KE)4-O')]9MYR]\N%Q-']U^7UK%RV+F.AE< 4*B^,-2O0D?UQ_=7VZOW<V
M>;R>5+*VS/@;QYVSAW9MD65=^:"'N?\XDW+E+S[G;T[_VH]_M_BJ%Y4:?>-X
MKU[?R45OG\!<.ZC7]G:18^+OC5+&!<Q=SA--MTD <'<FELOX/1_$D7.'%AVP
M=QX^8YNP!H:+6+7EEI%63VBN@H$"9MI- #JVC4:*'QRRZ<A![Q1"H@R;D.9:
M ;?*\>?^ZG<OM%Y/;EY;*\ ?<[R-XV:S3&%]EL/_'3GC,Q]$^]7(]^8JW/SC
MN?_VGZN=]]L?5S#K[)@;QSN-@^KS1GWO6WDG'MCNQ,'R7_]WO]EX?A1"'RZ?
MX!*81VNH," (-T;KF($=9@%85H__7\N1?+'5^DH.(9!)L-.4Q8,ZN?Q3,AJ
MZ9"=D,?>9CUD].S,"B/IC/W.@;MDN'E)#]/NC^UA>D2')@9]C$.P)6;E>KB$
M6;U(,=\X/AEQ !"8?\R:3 (?9!F:A'W_GO6YZT\1Z_ E(B/;K_ZQOC9T7*1K
M)P0BCSBHP#8&MD)G'+N1Y7$_#MT9"\&R"8<S^E1^X/=AOI8T+>F%X?(D59I9
MWDR]&_HNC([?H2/(04,O/'PB&I00?&*6HD<1TL=T@P^ML>/.#MD[6"\RS7"I
M1HD<>R[EV+O B6!KT$:./6EEAB4B^+0WN0TO#MQ68R4QKK[ONQQV-(BY*>4*
M9T0 ;R+ 2P2=^4/L3=F_LG^8LCG ^MK$B+TB*8O6.\U=B7&(:D9,%$.AFXWG
M[.15EP&$:M#PV0^&=.+?6G/7\4KX!#UT//1!'+*J:/J46+DKL;('#'@ </9N
MSH'% )]Q2TRE^W@/C(HWX=GCS< "E*2\3!,G\_,1F[&_&$+F82&E2CT1*V7_
MRBZ2&:ROC>4<6#'*-G:L:J-I8&TJ?*]Q=J=>$RU_H>V7HNU+B;97 4>VA8FT
ME'V#(B^X' [+S(/F;CVT#MQ/.U?-)T7?\GE];32&F50'QE0R7+@4H^UJ<[/_
M3/RU$&*+#WZA]I>B=K,8M3MA&//@002_""\OMOGK67=H?TT$S\WN!T'S;5[=
MV1PL@>;R@]6A^:HM#K3+%G+[;YCY9D+;YP'8"PI2ZVM)2IR$5L(1I"$ X%F=
MWO]=1O?GQ)8V\A&H(G^-&125\U96WVYM!_=&/14F-3TDG\,UGD 38U BUV#$
M!JX5AN41,"-XNT"\;,YLFWO+SS:P;%*6<)3>;-SWW<UP3J!O97/=WE]ZKNC%
M20.6*XH'"W@Z<N!)0A(%H=TO1XME)ERFLPOZG36:?4*58HG0[EY^'F]'?UIW
MHQ5X1+-C;ARC& "@]2)_<%MA_ZK7\-P0+"1@=Y8;E^=YF+L\-]7@"Z%G' YY
M-(=:8?Q4DHD@D.(=B_9//KX?79]]_F,5B0VI 3'E#O.W2_9DLLR^++P'Q0"Z
M!OF1!5(]@]E*#I=G+UI7\>_[\?#Z_'-_92E.R ORV4U%<]H 3A+:UJ<2@+(3
M:^)$8#:>6\$MCXKS!WX@9;EDE(YGHY[%67_&!N2QA*]N@8UR2ES)>!.=D,&>
M@Y*&'8.XN G\:31"?6V"+D8K9#8?.I[(KD15C>W4=Y7G,>,.$IGQVVP3%_K\
MB+Q"JC&, QLUP;1,=-A33\"UJLU\7^MK1?GVNE?4^Y(/C7YK/YBQ4S)*6^X%
M2V_%?+T[_R][.IMH.Q4#5_-]3=,]$;,M$7ZWC4_7+__\L_]Q)>RAU!R:,['E
M+*&? J$Z0Y/$,VB%\<="?B&"&>MK!J\8 3?@+M@@P T\GXRW..1$O3"NC&]@
M-0V'0A?BM"]N& WFSG#TJ0-C(V?Q8$GP)N!W3@C? 8^QO $Z]:P!%9K QEC*
MQ+8"&[W3&-JP#8.(Y>RA[4TK;0^9;*3VU:A%X=>3(-*CLM"7.))J1/\*CZ0:
M1U:_@^C@=V7V+Q#%Q>4?0?M/,3I&H%L!"]+D\MM2>AC8U((;S0(U>(_LE/R1
M7W.;)L?JW'1N^(!;M]4^!\*%.4YHSN:0>P4CXC26'=+$CN\N;)S/(.I$?"PY
M30U,JC8FT6-<UV<64U$1=HK*DD-I3:V;@)/SJ_9])QR42(U+C]%Y.C&:.E17
M82U9U(:]\5WB>.J0D#>H50 4ZD0!,Y*@U]<VD1]C$DQ3'1(VS4F;#V3+0Q&V
MP>),9,NBB-)13?BZ<?2LPLAD(8T4@>\ED(8_;';E6A0V/P=Y!_KNHT:6W^J.
M<U, 68EC66!K@]*,0YPH>=H#FXNKT7MQGS46@!#U-AWYKCMC_A35[3#NAX[M
M6(&.\\L14!%^U&I@+MEUK*_AN+T)R-$@'K.KD07*U8#'Y$599&>7GXP:+ =2
M4["3SZ>",/@(K?$) @!V?1R**8.V:#O"EQSR"'4,4"O0ON$.8+L!_*GCN@Q5
M'ZY4#XDW>M%?@""Y-= 0NN<P#NZ<.S*KPG@P4M,"+<I:<*]_$I/FA:-P\ 1V
M#-0X 5'0P7\2%?NMCE5D.0<03B0TY.$0M540#)$CCC$:S3=)U5X6"=NZ2YQQ
MGDVB)Y5*M.!H ^$8#(5C4#L$A8NP@<JZ:%O!QE]&'/IKX8Q<7R-O9&9^S,$@
ME4T$Z<<1J?J4+#4><QL3JX Z0/Z B2"I/[U:MNE+=P;,:=.1BG\44 V:F5@*
M[.&FHUXAYQ1/U]?,%9H.4S8";8393@#O8/C^+,5W82H&8\%Y0^^J>UD/;'[/
M)#5F#$@?8+6^!CP 4[8 ]#"8S0'W[)!2RRPG!%T"^B*V(;MV/&%&.5C>47(:
MT_YI[FE?BN;4K[D'M.;"5!*.?69-GPFVV$=6[J'3G-OK:\05R3N$'D2$.H"!
M([PW6W*1]5KC^?[VXY!"&V-=?)=%!IBXQ88QLL2)Y0BL .N\BB7TPI B3QE,
M!IY:B,HY7$Z)SB]00U+[F9T_S)>R3F'W7)"=,-\*&UCA"'?-=7@,$UE?&P86
M[1=LB,)/0\*1NTU_3AL\$BK6XZ;]=C(,@,EE66Z&21 :OU1VLT<8@;8WQY"C
M *O ATUK><#]U<U+2(KFP/(!_P(^ 2"@WE:(=L0?'9?#/L.\KJP9\M,0)I+X
M)"GO\IGBL:"($2L7,E[F1@9CIGT'Z(J0+V!NAMZ8[Y-M8NA1,!QW)B4[?E@(
MU@I[O!*QOC9OAWX2#: 5%?#P2L(K29D6* #[A]@'>IUT-0'75.V$\O?%%-T5
MX[1N\JJ]X(QD82CC+J$(9A $3E.CSZ/8BHF!!8JYP%U@8()DT%$?12#2468*
MI_W]R.D[6CO.:QXW/O!V#QF(UIYUA!5&K[&V_(U1O4"@-&HHQ)/0II%M&21I
MP6;?.^.8YA5-?1,VQ.Y@>[;\@!6Q3&#4@H(K(JH0#@*GK^BMHK1S@"HLX ;]
MD6HH CH);6#PS;IH"BH#)57CT33!Q0Q6"K0>BY.Y2/$XD0"+Q:+-:+)57(-U
M#ZO>1)"@B;,T!6?94WX?G6R2]EA]$^*!#P8C._R.VU\[8SM)YS#3-[+I'5^6
MSK%0WLO#\?N2Z+/."9-CZF0P"NPM^4VI9U=%:@%\^]M'9KQ\_A#D=[\ V[1G
M(6%MIB-I.1%$*M"_&L]W$3]<ROP/V-@'!+'C0)&P]*C+S"I\^KOEQ6 V2K\4
M^6AVB!JX)](_3H%R\9R1:+&MFB WD8A7$5IF#I4%)QR@; HCH:#9F(T3H-<C
MAO>H9A'S^!2#1B.Y$'02PG-HKI5RH-I&77#N1!TW=,KFS@$#"Q$/13B@_@"
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M-"34FPJ1K:]-K8#*!7Y9[9!WHI<<7U=EX4$.*7^,;(J4?*63R8629:M<:=2
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M2FD1J),<!<.Z,RL\T :&3I0VAI!H<D9Z4D% TAUV*3BN]&,)BU'UD\41(JR
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MY34H(]U'C;7S%D6Z8WW@D]8H]5GN\CN+LE1%GG-:<4"24XF8Y>H<<6'5@6+
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MAV *GFL^V]P <=7\6TEM7@?)KRR9B)S82M<F('7X)F;E#;%J\R(_TU!JP4D
M<\+[LGNYZXT%6L#1YD88 Y\(FDP!C#%-,GP<$FD:T+@/[T:D D@7T@P+^"8
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M;?>?3U8>?!6$8A<,ZUN9K9]HV=67@D>>AW/=^D+1_*:>D<OS\^I$/I)N"ME
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M56@?^)19%->JM!ET5:I*_ @SRZB4NQ2U(^NN%%6*,6--&,DWBL"*+1F-EK(
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MN_:G6=]I-KW'T\Q9JLFJY%+_)!M1H4UV #=>E;DG@1E ,-"?5F5!KGM!QP4
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MI,UX60=)1+BF+!DXRZ84+#3SE,/$JE$V2GIXN29-UY-S:V_X5'SY^%AX$6S
M$YN5=-W:3'GYCT3VD>K5\X(!=)GJF9MD#07*/C47@H42!"5(NI*V\NC6! 69
MUHY8'UR4.&6DJ4**M6M*\Z>TQ?/9A*9 +A76+L/9OP)/]AMK'(2K$14E0N/
ME_@6GN@65&$=XI!PLL$-4'?"+OY-H!8.F9INO;%K?UINAN&6D&&Y8-)S@0C;
M+AND:$;(%V.SE!R-?OS'N^/(JZ GCFLO[./T5%_Z/)!S*HZ=GYVESMTX9;?C
M[-0[230!6:V\M+E;D[Z.2B4$6W99 ^+>[[H=:S&+<NYKQ6R)]6!5ZB$D!9H9
M.EV0GO='_[5;;O[@*JNRLW7<1=?XV0RYMBE874_J^V-C>P5SY&#)@2'IL4"T
MEE+.D$N;PH&C;7 F%>8V9GU9>"X_RM[7E/\7YF$T7XK058I\SS\S+J *BR05
MN$MHRHSE5QYV+NQM5 C8F!WMFQ'F:I/[D0(5P)YN%%4]YR7OQG/RY,7CI+JD
M*IVFM"B#9+8J*[Q)K7(H5054%%&8P5/83CSF)?VM7=SK(=H,=M8=P<S Q+$C
MZB24J!1+WE#:?))YRL7E5:0[MS<FN]_A\Y&*%[8.3E2&>?$?MQP:E@\?UQD+
M#S@3X^P%BG.RV:2VYI.6.$9:( 6/2VBC#MHH'M_HIOGRD-B4)#(R^H/;TY0>
M@DLO:S/>N0,13^KC'4ZXFJ/2V,/6[GGGL1%J1(2E@*K>=9$CG!AX5/]EC4C#
MMB.CAK3UX<'&7'Y/R>$#AW _8QY:A8=!-LL-%7]8UM]<\D]ZA[C[9F'+'/79
M-Y:C?KS/47^UI\[5O9\Z8EY6I?<S^@W80#O&)HC2%H6X0#GC3%.'-3P:!2>[
M-"^GK?'^[$..AVO,PAFL1U]+%J=M_'??]MW'XBQV@L(C(@#>)H/![QGM/VD2
M"%/1\1.[0& *Z"2-(5.9D>8&".Z!(Z73'EZ[6:&TP)%D)$S_:B9 S'G14&49
M1)SZ33YU>_TE2MSR&:VD<IU;M'@$//D<JO/#;A@%GEQXYTQS*@\6AI5RBE0'
M,,\^17^V>W>XBUF4@ITA,4@;K?.3LG5Y77UB]NN%.SA'MYZ[0@"UXCFAYR*E
MN) F_8,. NZLIY_Z(8.;][U[>WDM'6)O9\QV_Z,+1U<(RL3/<FX;&C+>\6V;
M?"G*!<[0/'U&6.Y'U!?X*'GR[.SE67+T(5^X>[H+"R#Y-*6VB+. 4<]",]%2
MVKA:ZNSTS&^65\6HD;M&(,_#@S;*LX?BN@S$_W0TS]G+S\=M0G/.GD5AN5A2
M*&!Y#@]VLV>WLIQ3LUP)D.Q7JRP&:KD)*X VB" ]+#X(">8)OS",:6QC]_Y\
M0]O_[DS5W@;WV>!_W7-F62!Z+N 4N'@3X'N:R.6:(;R$MK&:%(+Q8O)3;8"I
MRZ*YZD""AA@L+F]C61(#+JHVW"%59H<;N":F3$;?"U\S7]):R>!S0WL>#U[5
M_KDW,_+])D(^5%1;O(#PF)8Q,>!&RC[.CVUZQ-Y7Z_%J2:3Y4I3.]O?"U(3'
M"!@UO"8P5N R CKS0GNA\4>S"Z1<@5!F2=]UAN,KD+&Z#P/Q:;><M#_)1[/.
MS6WP;C@)'IU?;?\F^CL\'$Z\YTW4 -S;@4M-EP,=N&FK/=KVKE[0\'H;8%-)
M*77S^E%[BB+GI94IE=ZF5DM3!*$1GFD+J6!AO0Z-ET^ T<T;AD.@]@R4")MQ
M^O5^^_5MO]DWN?T4$W5=P(8K-(5ZH)D&"/H"7A)(P1H>]*/'(D,.-D08_&&0
M)0 _A9W;*1Z[;;,9T-UIP7_\^&F6&N8A+[4XU%W<WIE>%MG7IFVKB]N5ODE"
MMB5_[_?<E\G/)FA8_XHI?[S-\IB*\1Q>!FE8!PIJ2PVXK(UOL_@P*A#*PM#>
MS)[^/@YAXQ66;%I@$X#4BM%5I(LQ"BGQ@2%1J7"+(?'2B$IZ9V?N2!CN$^?>
M>NK1#^VS?@GI*C'6__#@)R8*E5L^#*/[!W,.=1B'SD\W,P[][GQ#KUU03(4S
MM* ^XA+P WAW#Y1=:,L2' 4VUV[7@E-(>J>KVK98!49O)ISU% R1ED<MV$,U
M,NXOJ= &DK1QMJ#C046=E/5=?R(V(X%99>[VHP*X6SK?4L&2C(6@U\5)G_!#
M*JR%^(. +F^I:MR,*'?&:O><OSP\F%'O"X+'TIUF9/S8<-J4#XF-43>[R*(M
M\UF^N*)S1^49<Q=*S\('+HO9K#4+J=K4Z'=CZN"K@U"1ZE[K=7F60R_XB>AX
M>B2I^\QU[FP^':_R.\&_^$N4,Z*_L=_@5CG[*]Y:;]_Y1S@\N*RK&[S*JX(Z
MV-!7#C"D_*Q=:J9!T;]1=ZR[BU,B1+*#S!:)T%WO*BY!F S)%+:_0F?3Q@_Q
M M,_MDX8JIAH<ZUQ1\18)>\M"LV4LM_IM0V]B\UH*GY^4K$^)TU&<P7X4-+W
M75FSULO9*)Y*9A5(NU)(VT(5'2D($7='3LB]+/=2_SLK5UE]*^>SO-CST_-3
M^48A?D-OS@)0*T^?_5.;RX=I5CHL U5M=C[J!'V/G_(:H<JK6T06JI4F-_DE
MX.&46IE7ER E,Z*H<D].H6LCB<=:I];NH)E61L:,!L(#-2+<?;3WH'1&^S:%
MS4_FU# XY< R[/ (P18)&NAH4LT1A540\O=BH5"MZ)^5EO" ,JZM&#_JO/?H
M0N$U6+:;WN4V2(]V>-!:=W$:OV]?1)G\G3_9MX1*G']C4(DG>ZC$5^LXWC?#
M1OY9R"_(>YB1TR(%2'<"P^3TL[<KY=(_\GJ:UZS4X*RET6A0]5?/AA&(H4TI
MV,.#@0&3,T3"XCY[]9VQTU*4888^8>MP7^532[,6$X7LQ9IF1+<@]$>]PI)]
MAO<[:\X[=#-,5TTS%>,X#*4TO%9GJ8N:O5IJL6;>*D+X>\2_IY\&%[B<B3@5
MS!.TS@2E'J?:C>^0UYJUD5R( @%_1Q5;@(<5R/9]SQAH%JZ*2QDO./M)BF#H
MA))CB9]K]X^5;XSCI(/R]YUPK9*C+X@5/C"C7W&J4PNB%N]MG5KKR?CMWK=:
MX$+Y(9CBI;_]K=Q\R+U-!T48ET3:2+TNSI<$A2C]"^PK]30KB_]DTL0Y=U\!
M+MFM]%E6JNLY9JSRB-E/!2P6F+J\K1-)V %W;9I1^Y^4=$8(DV@8JW*6W4Q6
M,V;3RU;+JZIFAI>1<)F!29/T+E*C1$G1^S+7)H4QR9VL1D) XWON&"IS>TF?
M<P'QIU061HA\LX0V<36_ <T=/L0P-#<\-XTGU>1$Z+X.#^3/4$A((XD$GQ1\
M6_*#=0#!QEYKP,[($XY'61>\%$H6XO_%#\ZP?FI:D0GW96H,,&1[@L2\79E;
M<2[W(.GB%4T+/X"OQUR6\ZNQ,Q=[_-VN$1B\19O:S!]20&*V7YL&>SWN1]HI
M&1'FX2AHRX4F8$';!]@(_LBYBI&;Y\K9*^;A;E;SN%ZUO@-!DU@XJ8,K9'JT
MV.$A<TEW1Y\M.AQ2[8Z"424K*S0YQ.,ZIB4-)TR(?Z,&+^:@TL="@XX(07F!
M=(O80BG#MUF%[J=T$ S3>KQM0&4]L-S^-@(NE$0.&[RB$;=6LG_K7Z+,Z\/8
MNW^^+,+YV;W((KQBEF)/#\Y""+UG0;F&8TO_II3[Z6 ].:S8A:C*,?;3-\=W
MNN&J'JGKJZP93H\?9;(D!<H!N\*ZW :7:):X5\2&$R31%D%831.F-$_:  D0
M#^[B=8.MZ]6"*'0E"1?*?<^?Q^4^^MJO_Z.HU8@,5QYUX4Q?+L2](*>%?0EE
M9N0A320VDIM+:J]9+P30)4A;E_P"\D6>#DYGFZP4!O7RV$2P%%.E7N LJ $9
M5XWNL0JRAQ-FC^N\]Z'E-J$ZA?<#X69*#UMC_,-I,6';YG^#C!*M]X!W]LO1
M?TAG,:JF4&Y3V A9,"&87@KTOCL\"(<*08^BYP?4*)Z #!I<\1V!0Y3U1"4B
M=]2!2C;8_>07VE6@":*CPE+MAN]BL?@OAX%K48J,?4;1]+24CM:AZ6_/>Q3(
MN\N[!<; 30*ZV_ G/!N+E:$)L2HCL:BL:?+EMG>]-E,KYR;37"QS>JG$:L?'
MZV55?6J$3*2J_5.%N*W_!M=W?'677#;S;U#IU.TK=5<QORC*R6S%OH*\;O-'
M)7%.!E>C>ET+\6+@VS,D= '^\JB8B#UY[=]40$<  0?5,D["TQ>,DB"679Y)
MJ2[H=PK4I 8%9O2'21KZW+D[ND[\2[(;$X)IM,Y2,#)$O,B(9&4SQF03J384
M\+1[ U=9I<= F2Z5SL#9PX_>??*D]>!<Z>'Y>"<I&_<I<:KN?!PR.)\N*9C<
M1=80<-5Y4K=Y)A$17,)@- $FT4 .>]B'>+&3.,R*ZP7K_('&?#"HG73.LI9E
MYU,E\H[=*,GO[Z$QJ%I]O;[!H+])?YK57H9TT]BX?-;]D+,DEM7(I#>&'N91
M\F%=!?#L19J4=WRQF!&_OD-RP>VV:D9"&G5\+ASKONUE_.S1S]4^Z*+F7F<N
M*%+315\7AHD[PHQ%S!&!PYOXC2"VB(4&"QES)_1/8? $>HXAXP>X:<E)CB 8
M*3V?E)I+B^'4?S3-@[SC&I7*^/"*KQ(H:+'L[54.#_0R<$(]P1$[[\D<;3TX
M![G#2M5FX[; YN'T0#_^Q@I[3_>%O8<<*I_?2ZB,)L3#@X_.(R1;HUT &C%7
M:BI)CH55:-K@G#E+112K>?LODBD'7":WLAD&P>,)\\FVR2 8(#J(FO%C[01M
MN?.?EYZ@6.P>*]+ #Q"_Y=<2?A >G</*6XXH;5$S%0_[?]_',M4F+QRY6GUB
MU5(7I7_OOM7=T6WQ^%ZVA==J=UO#O&7>%6^XW<Y[N<[M#8VWSD50BB3\3\_S
M_/KW3F6APXT4N:S(#'CA1RG4"K*)O!%@!C6N]TUQJO/>2&,:G&^ODP$'!H(W
M.$4RN##Y9ZGK1@PJ;UXEKZ5]SOFKN%:+J-[SK/I>.%KUV(!C[[_#\Q]I#<:(
M:[2HWOFKA+=*!(]PG6OFC0'[/!&=G)I1KA?OKS,7'G]PR>Q7R6HA,?86"9IH
M]Q>U;_*^YI(X!8_Z,4D#<"]S5!C2D%,C6_^'$'ZJ6/3VPT(MB@-B#_+W%[:A
ML&=9DZDCKV!: ?C0%U4DYZ?G9WO3]86FZ\F]F*[OZ^J3:O\>'K@3_!*_4'H[
MG&.768E?38HR*]'0D8VO"RBR=RI+$DHZZ_#C:NI"'+?TYUHG R[RIY]>I;3W
M<J6[D\W']U58":F4T;L(O^C>W4-0_"A"5V#N^1Y8 J)'VV3]F8P-59!6IS_.
MF:<8)B"K:]**X$0,8N$-U,O#&[++"LRQ];6+]#5[S6"8PP.5QF QC*CG>%0M
ML+LG@#GP[F;'A"8#U6^9G&#H+_/EC=;D//I81NJ'V*YK'W,M??CM[@W %QJ
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M4_UKG%#>LZJ]OY$ET]K%TB>K10JRFY.;*Q(RJ?R9[IP7>>RB] X>Q'+=A6G
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M:[XPY_@(\I?5HRLBS62.+)* =%X\F-VO\YD+64F+,+O,B9,A,6?PF.HGHT]
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MM^9T,7@T4#P[66,[,;+-D56N<LND(<W)KW+.&G,_C4?;8$BI7Y8E;5SBD<!
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M<"6]SO C_'I^A968!$DUT^Z6);*2JOM(R\=F.0?+Q$P/8.KY.%X2[WIU<E_
M;.Y7/T;DQ&DH@K@1O2-%AS6!(;B-^1]2R5U%>]@1<?O]_\W>C)2]?+1'9]E%
M6:'N9Q <>_UPL$(<2+,W+@JSP(K',E9(L,JNB 34Q^,)K-A/JG7KU]R8JWPL
MR#G25%Y@ I+U>%,;,!G1C)X5Z %P'2)#?F$-!/4V!Z#3\(>"MIDP4JK@LTD&
MNKM1JU-:0BC 7>/0V-83J^T@9/#6DBXO&:E3N/BC8H$'^KSXG,^+<Y!+\Q.4
MQL7"N7$:Q,X, ^4O=4*4"M9:"1XH?\S9*R9_19"@GO#>O/C>JGH&@AQO(<K&
MV+Q#?O&U,#9B>ZRH/5),X[KB+C.O22?5I"0>\JGTC/K5-VF\6L>L:,O<TJC:
MYU76^:4Y.J) =3,\W)'(TLK]-)\AB249MZP^VS$)1&]29!2:_\GT*>6GQJ&4
M:PK>U?XC.O=)/%@9?="+)__YF)]T\ =QSR3-LP>6I'EQ3-)\,SOOR>W:>2^-
M=IN7U4_)_W[R](GYOY?)_PK/KA>R+?4CF[_ZK__=S^R+W*QA_1FU]WMI+#Z-
M\&Q/[;N1S]U'DB+;G[W^JS%)^92(@SF:,[$@&\?XE>:$K^3@HM@'%.K"ZUF;
M\<+,W-3##VC>\]I@A(P$R34&6:V:(!QG@%BEO< E7]#Q+&@!BD]9$/V+M87P
MC^3WN'U$S"9")K+HKJG"S[E%,F8(ST!T1 67P;5QT65;(<+\V'DJJ.LI!JF,
MU0,%GC74 ^M/"N!7QLB ^TQ8M7./4SO7SLI8>)JPX$<5SYRH@ \&H&-U>0&2
M92K!%"H@2HF@"&OS4HLVKM"?P<0C,4L5P0\X5V4;2CX^8EO3$W,"0FL52T=;
MS,O5/-GV$S3<L>4=AQ'PF<$P/1(S<XFN0(R27^_,6[_#!CC!;(KFK=_RRENR
M7E':^AA7NOB&S<<%-<2WRUJ?;".MMWDX"FI]%<+Z9 >^>@C#?C7">BIY[ECQ
M.%T]%4=LY:N/J-8&5?TM*D>:J6M3U2>WS%0_'&RAJN^<]MLDJF<B<XF@[$92
MG_3GJ.]\(:S]O@%'?7)-BGJ%!M3(BA*R=&]Z^N9PU[?$3D^ZIF/^V@#P>Y/3
M2Z/L=EYZL@G[$-/K0H#;YZ7':&!_8OIC<]*#( Y_@2X3HNUL)PYGH;\EWO N
MP^B :,-?7(LV_$6#-ES:$]NL(-\S*G=F#.?IW *O8$2F)8I,O_\&/.%B+!&#
MB16J/="$>T'O/HV>>HX[01J"4W(KQK/XS72"?FM><,U,([3@9B3?G!<\:=*"
M#P?P"]?U__4IP55R;$<R\!<>L5'(">YW4(;V7H=9U<T%WJ5%6ZG 45EO-<6O
M2P6^D]WE&].W2QK=,9 &![B1=\V'[9?_*+;?[43@KO*T3=6[XQ5)H^$X7Q,6
M!]R&>C1!)=GLGMV?]M7TL]>M#.);8@^[\(<K>.HR1B"NZ^>!1=RR.EL"\4YW
M9GWN+((M0C <W*(4,'&X7NX(>WC'+8:#6V</3T+R\&U[W,,+!SO_-LC#DQMR
MA\/Q?D/R<$\>5)\S=CCK)=O"'3X<W!IY^%9YB%.'>T SNQ"(;XL!-/NP^].'
M(WQW_B#XP[]__L 2TM\=$])W-L!P5_G#V3S^!7@ /<9P]T5^$G*$]R5/FSJ*
M<./=*XYPS^^]/D5XA*B[#T.XG2G6[C=B!N]+2>X]S\V!0)A=DP\\.NRM=.!=
M^29MN^S,!DXEB\Z \M;YFES@QEB[%AGXELSEKE3@B-$[Z<T%WO7HFS*!#P=F
MF$\L%?@N-."W15/--I9$R+XI2_4$-<I)P %N$RM2 Z&VVRY,X(E'!-ZYC#$>
M\%OG6;_A!!L7\-HS# Y%-PUXU_Z.L(!C"*-) ZX8LV2^NV X-&O6RPX.\*T^
M/9X#^?7XOY.O0?\]'%R?_SOYFO3?+T9C%4_/B?Z;F82:_-^[W;-)_]VUZ49-
M:1D.MAY4WXS\&ZL"6MB_^[Q>V<;]+8&<?J3?03=LTP+TF+^;-N M<'UK!2PH
MPT1;G,0)OY,^>_](]WVD^]Y:SKB%[KO3^E7<2=^8Z/L%P9J ]1"G^&Z>N-TD
M%4W+H<E1T;GG+&F=3^^MX)S[,GOW=2@:*18";FQ--UZ?UWNZE=<["6F]P93Z
MVKS>?73@X>.G](SOO7A@\;WOC_&]N]Q8O&=6[WZU(IT-AS<M%U&<WEU&;#0(
M\\T9O7O7?1P)O>\HOHMM@A<_L(7+6_M"-R/T;I7EK\;GW;7/VB.>UV7S[O2\
M;TKF_=6YO#N+!FZ%RKNW'7M[3-ZM(K='(N_6,7T3'N\M)-X-9A_OX&SG]>EC
M>A-C]=?D[YYNX^]&EXHV4/\TS:[TW3U#,20C7XN]>]J#O3NB^6].EJ3/BX Q
M27_5H$T:#C1OTJX4WEO.EOX,WAXZQ4U(EWIKNQ86;UF<N.G7F\2[=V!P_=4H
MO*<!A;>G4KX.@W>(9>8T=!N-=U /=^3ROEO848?*Y=TFZWNE\NYV*G>FH?*R
MQ9T/Z&+SWN[I$DI>A,Q[!Q7W=;F\.P[=(Y?W->.<WSVP..</QSCGG4T/WF&J
M^+[IP0Z.>%;#38;AR%'XE9-OFA\^\>GA_2:\>T\/_^#"_7'^[C[2$M!WWS!E
MH.A!&7CQ!NS=K5NKA;R[7V;ZVMS=MY<=& Y\ZFZO ::=M?OZ06F!WVXR=V/C
MY36HN]O6Q@9AF\S=_0L'^A-W]W%-=HOKF3.DGY;M0=?=<P-VA9^&@Z\:?VJG
M[4X\UFXBC^@31TIN(XP4<'?K91,EU_LTC!!WMPKO-9W?(V'W 1_*=RL^TQTL
M_!9\W=V:_69Q$K6W=]['1\KN0W#V]DC9+;F!:[-UZ]-I-\KNK6A[-V?L=JT'
MO<FZ];T$"J<767</,(G^7-V)1]4-37MQKN[>S=37HNK>LD378^K>,N2V6S9Y
MNOWB^F_(UMW S\%T])&M>YN:NUMLW4YW-(R'(T_W/GBZ@ZK):U!TZT5LM^YL
MJ.7(T!UAZ.YE5MZ4H+M'T]H]8^;^_H'EIGX\YJ;N[#E^YYBY^V6D DKNX+@)
MG >&Y&YAY-[:\KP3(7??EC7;,W?X6O%(PGTDX3[4Q8KTM>^!@]N/JP!BA>78
MO"]$W*PE^W%P"ZRH1[^MNRZ&@VO3;W< B/9@WO9>"]C.LKTP;P=OX?.U'TFW
M'UJ:I*G%OB+G-J/V]F3>QO1X@XK:B[!\.^)MU*H,W/H-B;>;;VO1T#I+EKIH
MM[MPD'LS;DOC$]Q0,6YO 4OI*+HMK\6W/1P0X7;CVV_.MST<$.%V0D!XE7<<
MF1-Z 8A@L%9-^FV^Z':8MVG7-*FWQ;WX1LS;G->+46\GWXQYNSY2;Q]J^T3S
MW+DV\W9G%VP'\79+N5UOWNW>[?E[H-R6R((79^A!MMVBN<SJH.JZ-5/P>MS;
ME,I3C6SMW-O;NJNZA.:Z_-LO[B/_=@]T[#[TV]YFNP[[]HUVV_TEWVY%$+@Y
M]W8G'.N#IM[^X6%E8;Y_<LS"W&/J[>_V0KW]OLH!U9*J'(RV^=7X&S2BCX^>
MH^K<!C7]TO-]I<"07>#Z;J1]'QB!-R0X; DATF& N<@P%]L '-M+#I\8'W(.
MQ05 CFOAH(,H5*Q8PH&CXH5A/S9F^C0&RFGX)+_<?[%9;ZBTD3!=%#HE&\IL
MDIZD^B]"D?0:46Q-Q@JW2<Z6S3QW!M''MZ^-K_ 7;I(5;A)7E@&-YEAK0_#2
M]69ES!OX)N>J).R @\&;_])8G$.&^PX+^%HVG@?/2R=_G3N\&J_BAFT7QR+C
MJB[Q6J F,Q.[H%T;7"[6WG#@W3- >9)[QR)AD:&>FY/" ^? V#Q@\,=#A[:V
MCX8*H,]VK%VU1BU85#<9)!-!1M'<DW<U."T,W:,HR4B (FP_'@^U$:VI)ULD
M%9Y6QNR \Y^5?@;_L"DGQ)9,M>$4HL&XXLJ1!;15C!E;NJC7##7E:M,^VIP'
M5J=)M6;@LR*:B@NWJ8ZE,&QJY^QQ\LE\!1C.2 9WSL2]B!%+>7:&\FB,MLZ%
ME=9,]!Q\-$A, 3< M,N@5@%;7E<B=,FKE;8.<5'86,(5@ 4!Y6>H>\VS:@)]
M1LJ)-:NC3_RGS[-'3Y_):+QZ/_\%,60*;_DX>1L9?T.@A!5;-;.-H327NZ@P
M<DVX*Z%D&3=B,L^@EH\B ="@T;KL>&YTG2'<Y#&W\UDZ.BOOL=C@Q8\S=X+6
M(03IKSU67^=DY]>)?< DCJ\>^U.5S>LR,E] D>DFS,.MY42I1B1C=A-6I]/2
MY3OYE/S+3%L]+23%RGNWL W*R_(2\"GH/@6=%31OT(EWEB_S2M(@I-[KO+HH
MJ/_:+ %,T8DKPR1-0H%:KE:$<;N*1>HH=(E+>!PKR+'QII+Z\Y5XI//LLD:W
M-*8=VM6>%D^::&:&3(@K+DHF&,IT$!*SA_1'TC-9+7:"RMTX,HN(C@A@AW?8
M35T[B=7W^79.%@DV9JCD_696>W:YY\>/L_9=)WRWS5U=U+ML[,>)<3=YVR+_
M(?]SE@:EP]J@P3Q:9&-SDF4K78WDG2Q')((-5A0OG*)N55%7YB?'4").*QAA
MI(379BO(>8<UK-;XLX.QK5@A4HL1DG*S9G0H$4F.'&D9*%<KL_R;94$\[A G
M-68_!1(77(\+MJY1$[3596AD+A!>)58*(%L!#M=:&%XLCE#]9&!V.%8T*/%J
M#9*1;G%FV@# 9+3[ _F7C$US\MA:+5LGQ6\>HNEP(LA<E([]$KJ*DB8DJ,W[
M\7Y#R_?R/.>0ER^PQ(V E1].7EE"6@60$XZ65P%M*1+*0I23=(2LRQ4!!-+W
M]<;(X;(6'Q@^8F4LQ=9> -^S:_#>(!7%LD,KSJ2P2#A/LGD>/1ZDTC^<1NFO
MX9@Z"/PLK.3OI83*F(;@-*_(*,JND3R05;O+7$+7-F"%@W$>FL= 33*LB4Z%
MD=9)5(0X4U[=2T /!^0X\6-%;81'&J8DJ"$+8> ZMN_*D07+&C;>&GE>&Z@E
MM@;@K1723^C0^<5@WG$"'0G"@L(BGEUFE17-MMZXZ#U3)RZX^CZ)^JL9:'%(
M.L.N,[*,)VGEFD$IQEV?"QJ$=$NP>]^AZW6.^+H:'Q"Y) TM 7D'^2J-Y&LI
M$L;K8$VM=XV]*[:B O/XL,N Q B,;9()CWX4K_%L2DM:8V_+:UXL?30.N&92
M5&9X<#Y-;!>Z]<.NJ" %SIP4QSTSQB5!GYI1 PN\X/XRH_N*J6J0#H.$HG92
M43NQ:/2NV&QJ0!^L&'Y93;,G14),\0U85S@OC 3C_+2LL<*Z:#P_>&S4;XWU
MBO0OD?[.LGJD06S'FKEQ;GFH<<P)Y6W:Z(MJ-?4:7-V)A6$0O%'<8AJA5$Q4
ML914KV';G+IS.:-$*ZZVRMTP%R)%:%RI.AT+1AR,<[/&6ANR:[#J Z4(%I@F
MQ&?ZD>HP4&GF&2 +CLK:_8@W--[K\(.U/;-#/SZP[-#38W;HSN8"QH>>"[B)
M0]F1,7C!X7NF4D_])G$O/KHM8N<"MHXM_#I.?2(^O3^6:T<)52"9BQIJLW,I
MT4$3,T-[08/XT3'" S*3TN0 CC[*=^7BUP#7FYD!2$!@(2B.P];OXG,9T5YJ
M6-<<DKUB#&CXF\@Y)0+?*^R8>+&2+:_1]0IF/@(?54UQ$!Y1KJ^6ZTB)M)SN
M>5;-"_=N)TUA8CM^0Q4L\WD*U5.YF 7@XAJ+U4@YF0@P^.VK(OA@7&N"%9YC
ML'K#P)@F-'W%;C_;20!>J"<%TRE8>7,%G0FY,YV"_O7LT>G3T81-RI8.]-:(
M]">=/X. G!"J*C[5[>]OSM(<T$PT9S69W!STM%F%ERJG8MY8OU, +D>%SA:E
M0WF-'@&S-::G&PN.E8UKBV^9_&M35IM%(Q0]W;!E9:.]'7F%X4 )MRW+*OP?
M"'^=Y3.!="+H4&L+4H:CWH S5\"T+#>+,7&MVJ=2='36K@N& Q&<U*+&(S[+
MVKTLD/32(U,"3T;.9>W@\]A>X@M9ING05K>[SYN];(Y884I1:'X+\*!E^"I[
MX.*0;&B+6<U%ZYQF52 $+D4FLQ #O0OJ3+>4F;:C;OOIBIAW0LGCDA,CP0N8
M3=Q\ U)LGD\#]Z" 8P-;*AXP]GHSNC9APPE*2>%+Y-$'56QLS&0$$D0CCL8<
M+>3#).-J.L=I[*!VIBA-)XJL8@F^O!D?B@GJ$W&M1-40"X!@%RB_1H6,>:J*
M!;A!9B:QT4-. 7@3V/ GKJ!N)JUIF.+QH,J& \":3 4402<BG#(B=$OI;T N
M(W0-W1M0K%^_ YR19[0AG:OHSDS-;^VR(4V&:UW43)7"E^;F1KN>/CE)8H3=
M]N;PTLU=$WL$] R556&L9BBT, O$).N0N_(6VJVS!ZD$4/GV9.U>%"CCK&NU
M#J,74?)Q/R2GBZS?F%L_3MZY$A)+Z2/M#5X="$T^HA23YTPGB)7T,"3A)$_6
M7185HS^]#T'$I:("F*" 12N@49!(AV3WFEM!>-Y=UP91,9=@0H;"VO&,$ZM_
M8P<AM7#=[. :#JYS<EF+IT'LW+3/./NALZ*1A?#VCUL)O75*!\6Z1K=.EZ5C
M1,L)*@BTH+5H7=7Z$ZMOX#3T\K=DG7-/#[4>H8P8U3MZ^B2V 1Z#Q<8H+7KW
M979FMJ# 0&$-9#QP0VNAIA?#VIR@OX?.A7)B]CZLG89K2OM%^IX[>A@%D5B5
MF[-SRI9Y9W<:UF55\BI1!">1C2L:?-)24K2M:(!2(<KNI#H:6N?*G\R1WR[@
M6Q[^Q)_(2FV+E3]._LGG,&YV"Z;)E0$*&*Y%H>$6I^EH^IIP02\)2:75RY]&
M8T#5CELCRIX""X.E_.I8;V[9'@ZD&**B8" ?A7Z2+RLQG>$W',;,)@WSU-BQ
M_<+6HS$VGJCH/($2CB46ZXPVJ1DBJC%&1G1=)TT&^; 5,Y(5<FQ'@EHPT\L;
MAT:0L$$3U[^75'@NH!R=".HW-1;[E4#Z,<@R;C=(^K8H,=]<C5@\,6LDE02U
MV.BV(#0[.P/\17.7MO/&G(P K<@5&>@G!^=)S/QQAI)((A948=[9GH)!^U-(
MTKW5/;/ZR8U=NE;PD<*^+?/*8UQ+MS>_CMD<V-K6-9'RR/L2_/_AR0,+_I\>
M@_]W-O@_.0;_.?@?JXON'5Z_I;!_JR7QK</^# _I<>CL(^QOT_K#P5[#_D%E
M&F8!OD:LWR_7V9C;=4;YJ:K"AOF[WG!KE+_Y8\]\[8SQ _#%UPKR"S)&1WB_
M.707\^X3W5<2W"O$GUPOPF_C0S<*\6\18QW@YTO#$ FJW=[!_6X@DX!<)B8]
MK9%^=-YN(=3?C.\G.X7W(7=T_?A^%Z=-O^B^%Q/Z6C'^V$ML"?$KF,@>X?T.
MN6Q&]Y->P7UO8KY>B#_9)<(_''SM$'_2,\)OIN2KA?@CV[D[P&\&LV.$O^,1
M?H _N4Y\GS;2+0?X1=1WC._[MF4LMN]'('L&^+>?@GYXGUO1HK%W;<-=*\C?
M%->N&#\"5&T)\K<<7CLEIK>>76T&;GNTW[/0M@3ZNU;$"_/#[OGZ<?ZP32L>
MYC=3<ITX?S^P=Q7F3[9'^:W!U!+FWXE#U.;/7( _0/EO"^_C,+KB^R@K32>C
MK1UWAQ"^S[QV:R'\9&L$7Z*9'<%[0B_M2;$7"]XGUXK=ATZUL2)O$+??YO:X
MJ'T(/A0)V+.\]H_83\*(?7)+ 7M,_C8B]@'6>"18OP6[,1ZJ[Q0!(9;TFU^W
M1^G;-%![D+[=H) 8O5]5V1VI[SXZVN+V'49-(VQO+,G6N+U &$?"]ML$=N>@
M/<Y*9]2^XY'W)FC_]($%[9\=@_;W&,_I^[W@.;V:3+!$S>B1=ZYEZZ51G1XF
M(<(R)7^N2H_SF/2Z\"4C6 :%@,5K<H@7Z/$)G$8#OQAA@>'XGUK[T>](8RWI
M-RR&]!PZ@H2O)>?3$MYK[L)RR'3HG5YL4>N#:C@(VC3Y,%TK3[().]-M$5&P
MJ_DF8!;D%:'"$^1[:M12^;G&L/$:PM-0UT_ F1@72&'(-41?YQP @H?6%/;5
M#,7"D7K#U;& #$$&J"6*'E]$\RA!9(E".L"399%2-2D4%G'ORXWQ_MW!AVU"
M.S0@&1DS4A:>44$ 00-=*X=3:Z5%PN_*SO^4?3'2MS9S8J:#FAE)0DN"HUXY
ME#1[P%^6U6<SV!5W%L*[9N9NT%A[T@RVF0\L'YB%E_3]>&=]LI-(UCWWB2HR
ML[!/V)++%3,%7L!0%[AOJ)O6B]F9NU6;U5KUHCJ[VH)+&YM_K#!$,5J<(=0V
M=EM7N3#(G1< C YW27%%S(+ 1H#($336XZ;P>L([0$",2;/QVN[#"I<9^1L!
MQP_Y$A"4.<=-XSJO[>]BO*)+)=CTPZ"[!.0-1=5O:T]H0FAF\R\H4<%@Q=UM
MMJM@[*FH/\.8YH4Q#] %'#FF>V:+PRU,Y&_"!8JQ5F, ^O@14,4.0PMVJ74K
MC7Y39.+Z-0AYU45P0;Q[Y/2(MGB.,.@$W /=J6<4Y&1$-YH;R@:P($JR48T
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ML7V2JNR.LKAXFL"-E4,)Z6DYZ C@\V=+,_<-)V6[Y41VO"4CBY0F\5Q*F%^
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MD_'M8.6' R@9)2KC=R1&\A4!W5$?5FX,I[P.V ECS84.7D9U@6WK;N:>E>%
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M1IY*FG#O$8$V(*X6]8F(E($OA]_9M6_K=*)=348]RH8W\0ZCVBY ,>L071E
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M:"% N:&0*M?YC[,:[8FSK(KA0T2D3YF8"LF?%BB(TEG"A&;_.X[<P?R@?;&
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MJ]5HE(%OX>5.M?]IFZL[B&_,D-U%VVXN6.I1*'4J@PDR<ZISE%[7_*#?OM<
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M&?16B? %?57*JA H"ES9 </B2&OL+>@&(E=_%]H)H8PD3_\E(&)ZM5HA\*K
M_4F3%^LZB[FR9:*J?&:F&%WQ'6COOT.5[38X*.)8W%+[5@U:'$NPI _=8FT\
M+<ZQ=$^-(-%BF(*!/ @1TX@;U>FZK=E'9NQ^G18UL15P[3BL+;!!+(^!L8--
MXKXGAD+JLS:2%L0/HMK;8T:,,M)A>(F(CK#_C#HKF74D,!?5&68^]:B62?\(
MPY@N#A_GZH9,5.&>11&(191FL2,<<93/PTLZ0I%!MSYCNL6"^<9;+(&4DHXJ
M,*O20<LK5TS5?LH9>;3'G)&<LQPM(&*E!LG%/^D^9C[/L[KS"(2 V19HQ+;3
MSPQDR_&7" (Q-X$>A?L@TYY_$+)>S05^$:289G,9BBW1N\$QZR&D>+!]C&IU
MD6L /Q8;^A%R]&6U:$&AP#$& &*R6,9!-F'0PK&N)I@RVE=I#R=\9Z,C1QD\
MP(2IQJMD3,Q>LH>M/0U_:;Q9]P29U2"<]T,POGW:Z=F!IIVBMN']8;OAA6[F
MTMQ[#P<^$_A-TVJN,J$KH98V,FKH7[J4VEV>]6.R8UNL36O776./SQX_]2+)
M\<AROQS#LS[YD%]8AN(IE6<[9$&>818$OC7SU7N$I\+^URL-8G[P_)@&N=TT
MR,W$52)I;2+6*Q5"I-][3X6XZ=AO*@0J'Z,+NT,JY&:K>I@)D/0F&9#6"=DQ
M[V'?-8;E_NWR'M]6J;3G/1*;]KC060]**=Y:VL-F*7KD/I)(ZH.YH6\W]R'2
MU);\"(GO*:R%0SF %,BS;Y "V3)#QQS(C<O:GC^PLK;OCF5M=];3.^@46[1$
M-Q)W\U-<V!&X<THM\3)JX*'LD%(KUKT3:O<1\.[^Y=6V')(/,[&V95*.F;5[
MDEGSP!!OEE33#M[U,FN\WEYZ3<SDMA 87-$W ??L7B7@OGV>Y?E>\BR_0HLU
MD12AX2 .NLN_"*;",G?9!X_8F?O]13J)APYT[S*L#B0D!?&OFG$*D2L/M0B>
M_X]W FU/+AN8# 6[W7+_2]#9X*WC/G)DQQ;9!NQD@1'1I\M=$]C]0DC="$/J
MT]L/?W_W^RM D4J35W]_^_L;\___G[UW;6[;2K9 O[.*_P&5,S,EU845/^,D
MGN,ZLBPGRG%L7TE.SMRI^0"2H(28!#@ (47SZV^O[MXO *0H6[*H1]4Y$XL$
M-_:S=S]6KSZ,MM^]CG[?WOMM=_^>4.HSY<?S:R*4.@QI_[B\;*"Y*ZF[XT:P
M6<\J0O2!9$"?"\.U5TMV*4GVZ;%H<8H%0#*K*<;M%,]%-$'?NH) G8]8[DM#
M#V3<A.)_@Y1))\5IM*&FTEG S&DCJ4B"J""YI#B)E]O;>-P3J)OKGY=XQV*I
M@[-^;UK/43' U)<R=4\6UB!]<;^(Z^4FP2*F&4L,7;%0<UG_4[>BV_39'7.;
M/K]WF][DNN+7)Q$R30X,*'Q"]Y(E.H,7*!>J)XL\' D/MCAKJNS/:.,[#1-R
MI:?*Z2/RJ%!2=7'?JR* H@OSH*97*\X6XX-Q74*.R=_2@?'"B-8DJ4PM+F<]
M&=#7J!7W:KD07BTIWMSBE_WX,H YS(^+*FB;.VNIS6G4,-U0;:W902&U)CW.
MH,Y(B^(JCTD5F5)CIE'\WJ^#D<R8)(Q&)GI78#3Z8>C35-[,-9:,P>JM!\>I
M-[4$4[]W3LF,J%TQH]E6W/FI%]J#UCR24/C(52K3T'A8&8D94L-:468HJ^Z:
M7.]#(6[U_%0<F@4K$?? XWP/='O#RZH0S0M5^B:#A92!C0S/&.+\L5_6W(35
MI6]:&-V/MUNV60TI1*@MP!$%KX* 2^UAN(+I>M5HY7S,!$^+"7Y(P8)YF0UJ
MKYZ<ZV @5F1G^X)$V4M:VT J$=FB6/Z@O6$ZSS(-RL5C%KDWKEP/O;_,O,OL
MFF\SG)]%W)<L,))<2FQX!*D@%_VC,%RI7@T;RULJ7TP3)GHR-*!XE=X=GTN@
MJ'Q7XRQ7ZMZ<)/ALEB83R.\.(6:+XYE3*]Q35RVCLA;,C[O/OD9[[V X=-&2
M@4]RI-(0T)SK3LB8M%@%:C8J!JY!9QIRG:)@:6SI3>DO?WV,A.BHM+'Z\)YM
M?8^O7PBZ:K4;(PGN"B4?DYO(2,+S5B*ZG(7(#))0.@1_#82E1JK9$1U&JF5)
MW/6@&[C#4^Q'LR4<??%)77MC\KH$Y!KH^TM]@UU6@/4!FMJ<[08JNNZEEN2H
M%O7@A&GS.'(-8@"X)\6SF8S^*&KA:!:\7%'-9T4NIV2N1@(]*^#%)#HIN'RP
MX.=&Q<PI]\'Y0@ $=37S%_2N^^W7O?U.KG_WG<]-OWSS=?S^ZVP]T\F@OE 4
M\NEZN_!V;,';@\B!__-&N3OOI#_*N::[&2_$S!,/CNH[GFVH.DW&5!8!FCCV
MH,2Q9Q9#-CBKV-K!G+321&&)5#"&9J=QNK%M@/**CU+<4PL*L @(L+JFQ40W
MGOL YO_27[>@+!NO]*?#)%=5=EB7BPWT919)@*8$0Q&ME8"R=45-X$@XOF.O
M:G&"8JQPTCUY&(T"%Q+KIGZ@<$/*24QG9,/%%@*AM.&T6/)&J+<TE4\>]GO<
MGE=T+G!LQ1$*F=H2](T:<:B;EYM"0%>EU0\-LZ!=%1%2@Z3**E>6.R@CV0BT
M<009RQ?6)KS4+GK;K,XGS._,_;))6^RATI-ABM^";9GL!]E2IG+AJ!:TC34]
M9-&UDD&PPZ*V^=6QTZRR<#&?W>5,1@99$X$@C-[.YJAS0WFRZ%QQT^%V"X2-
M2!/L;AJBU/]<+% :N147D2AAWDAQCN&G F7]-9T5 X??W;' X??W@<.;K*A=
MHZ:6S,77&H*4Q%)KW*?=AEXVCIVNY#_]JDA*4@GJ^7%1T@LKOZFX$0^R?C?V
MLTKT("!Z:)5]Y7R+L"JOE!<F"7H1']=3O9,**4P%7:% "28SBNV)U@TG@;T]
M_'>=5:+J>>*]4;#=H>(/:KX+R^A#69!]BA*^3E'K+!/=JHF,"RG,'G!3Z$V1
M> ,Y$/AELV&YEWDV*IT.\T[JR[G3(7>^UBX_9S)V=#+<OCN_FK:PB09JE+_K
M9E 3J2755>G6S*;3=)21 D$M)"=TS[*+&X6'*[[9N1QR,[<GR4:!@G$1W<(@
MS5_ ,;'V-^H=]9[:+<>)#+-YER^H(>IB_P&1;GX-+<9#<D*$/F)R8?93J40R
MDG.]<YSD=-/>CHUQ>_)@X%22A;OW)ZVE/ZEE,7Y5-Y*QZX+K>-W<2$VC[WPW
MDLM,N4PW4BM=K-\3?XZ_AFOM1I(1?%T/TBCT2*SL0=+9OF+GT6B-G$?!_J(Q
MJY?RJ_B-1BV_D75T!S1V&1L\U^9)XARX*_%-WQ)/TKVIWV7J+POIMBS]0!7V
M#'V36KG QH^@:C5L_(:\O33S_EFG>6\U=&?-HECO:M:]F:++,.[]F)3.6E!/
M];+L^F<+[/KV//A6O:?KM,SZ);/PN59]>+/I"V#/6^)4HSI<CU4_O+?J;ZI5
MO\R#&?J/EMGUUB>XS+"_:4G8YY+V"BIQE%99V82H0C\]1[?2L]5.\6WD5P3'
M<L&/5!'9U.5AU4>M"(X>:L7IEI&@TJ-P&0*DZ)- 5^H)AN%"O%7=<#2_:Z*!
MM=Y SYM]LG4K%OXKIGM?3S582<%F+;F9^1WMB:&:GFA:;.OB3D-&GPY4.&O:
MP@4ET/"3(I.$<2TFK/LEYNNOJ%4U(YUGD(&;C_'1'EMV;L'B7IYN"*UIL%=H
M162U-GP"Y1,LEV&L=+'X?)QA"P@WH'_U&Y3"+,WK"2F/G.<#/2*7\]9Y7)]M
M/3<&VV(Q\-CBL[N^94[C?F^#KN@WN,W1C]T_J1=5RD2SF\I'W,6U\=O>GN1P
MM8_S!N?/Y(9P<T2B;4P*L,/\"T;1<!D:UAE!&1HQ41DA5-7E2::VI[]/!(&X
MR$&2KTQ"8A.JJ+=I4B%"-BX+<6R9W<+4J2 !G29'F"<R!QEB7_-F&9=)/3+;
MX?=L,AG7D^C5C:4061$!\/R.(0!^N$< W.([\GI*5T#JBJ7NQ.YMH<6Z19P>
MNWR5"\^UG_(FWM,+L T_-V4$6(,Q5VZJ:T\ML='.3;9)B -G1I V:O0'U?87
MI=CQE3GP;CPVUS7R($:(]( 3H9DP*Y6+S_30$>G0A^P*1]ZUJR#B9:Z^ &^]
MNYCW7EJ'0Q.3*=WAVY)OX6I&K63L;(!"D A[G?$X=$X->]M @'@DIVF:9)(#
M)[KDFZ*<R@(</'AJW_]+@4S'#V7Q)\Q6ZC,F]EOZFUU1M:'+RTKCG8(64GEI
M//?G=,UH6_9R.19B5T /O(\TKUVDV7-P!\%>CN<XZB\22QN/]$GCJ?Q,QZ*$
ME$*PKF5D$%H#/YDB #M]]BLY!]6/8R&0JK+6LR ;0V-'[,5?Y,/BD7C+ 8C3
MX[05WQIR2,LEC'D3_J5#O4A<?/$";7I.?I_=K4&/TEUB(N#3F',.ND;I.#D-
M#GGD1+9^ND*FIEIW7E)<M"@G;J-1'2+QS=9^[U*VU*8FZC69KGFN]-9+9K-)
M-I1T<S%&P^V' B)+>GH9QVW3+P_AAW],,"/(@5$6G>FTSIGKUK)E5&F>,:M
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M"O5]!E!DZ#<IR=!I,2(I+'*[LC]- \K$+*W"U!JAO898QXQQ9$#+,%F-G-0
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M@$A=HV,EB$RA>;*HVAP6!2)TT*W%#F!R<HS@.)L9QP]]53?T_]B9(4/29NB
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M1Z6J_&&GCUTBI@JH.2TLB>C0:R!F,\_Q$/EYM)E@(I#A:2 'G$CKF'0]F/X
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M881Y\:,+YT*&>EG_X:"2,!PF0%9%UVK2U8*:P\NQPK7AZ9I[B<%^J9(@73-
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MK4_RYH#-S" V?#CZYOKV?M4C]=W]D;K91ZKIZ7]U:S)8?MN/O/#\S1R0ERW
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M+4G+(,H_]!;$3(8]\7+ZV!'IO]=?T8RO-N05I:4K^1,\[2)?<L$ C693$-1
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MA->K"G1!%*.RN=:%GR2KO(IV2!UJ=$N4HW8A3UYFR/TP'C,]86O>B: IHMD
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MG_T G(=Q*BQ^>WM[7X/ OGV0JS83<!R?O!WV>T=[;]Z>' >#-\.#D^8!/HW
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M2?\#^5W4UZP[:R2(F1&_E*8[06Q-+S=@>EQ6/VAVW7K#)VM6;_CB>[WA*@7
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M#*;2"E36OXLZ>]3%[^P$JN'\&IQB:IBJ%5L2G:"1$3Y5])0FQ/D:=5F],<=
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M#8%E@H2J+JT!<  K3_]!K!*TS<*TQIF$!C? \U<6>22$<+MA(7F(8Q',^$N
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M9]O/Z/=%^_C8__[FCU[K,)O@H]L_%\IGD$213"VHB?ZO9Z3=O1WT_ >N$*0
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M61)6XQO[#;7$![0#2DK59>!&8*91L7,I6R%$EW,VF=OI__5R'_]?HAI;9$S
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M<^O]^?&OA!B?!J<G[_X?4$L! A0#%     @ 1$N95I84"\ \ P  ^PL  !$
M             ( !     &%S<G0M,C R,S T,C0N>'-D4$L! A0#%     @
M1$N95FSRHQK_"@  ;(<  !4              ( !:P,  &%S<G0M,C R,S T
M,C1?;&%B+GAM;%!+ 0(4 Q0    ( $1+F58XW_M65@<  ,58   5
M      "  9T.  !A<W)T+3(P,C,P-#(T7W!R92YX;6Q02P$"% ,4    " !$
M2YE6#,*3L:LV  ">&@$ $@              @ $F%@  =&TR,S$S-30X9#%?
M.&LN:'1M4$L! A0#%     @ 1$N95L14&S(G) ( U;\. !4
M ( ! 4T  '1M,C,Q,S4T.&0Q7V5X,BTQ+FAT;5!+ 0(4 Q0    ( $1+F5;\
MXP?X7"@  /W(   6              "  5MQ @!T;3(S,3,U-#AD,5]E>#DY
<+3$N:'1M4$L%!@     &  8 C $  .N9 @    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
